Insufficent data points (0) to generate a histogram of RSD values

( Species:Human)
ANOVA results for this metabolite where p-value <=0.05

Name	Study_id	Analysis_id	ANOVA p-Value	FDR	Experimental Conditions (factors)
isohydroxybutyric acid	ST000092	AN000146	3.930E-230	7.460E-229	Solution Added;N/A;None;Urease;Water
Nicotine-1-N-oxide	ST001048	AN001716	3.070E-167	2.260E-165	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-Glutamic Acid / N-Methyl-D-aspartic acid	ST001048	AN001716	3.810E-154	1.870E-152	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
glucosylglycerol	ST000092	AN000146	2.800E-139	3.550E-138	Solution Added;N/A;None;Urease;Water
Disaccharide	ST000589	AN000904	3.570E-126	1.800E-125	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Indolelactic acid	ST000589	AN000904	7.810E-121	3.550E-120	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
OH-MiNP (7-OH-(Mono-methyl-octyl) phthalate / Mono-(4-methyl-7-hydroxyloctyl) phthalate)	ST001048	AN001717	3.460E-118	2.940E-116	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Methyl eicosatrienoate	ST000589	AN000904	3.390E-116	1.260E-115	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Phenylglycine	ST001048	AN001716	9.020E-109	2.040E-107	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	1.990E-105	1.890E-103	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	4.610E-101	2.190E-99	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
GAB-13C0	ST000114	AN000194	1.430E-94	9.960E-93	Oxygen Condition;hypoxia;normoxia
GAB-ALL	ST000114	AN000194	1.430E-94	9.960E-93	Oxygen Condition;hypoxia;normoxia
6-Deoxyhexose	ST000589	AN000904	3.150E-80	8.530E-80	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
glycodeoxycholate/glycochenodeoxycholate	ST001142	AN001876	7.320E-81	2.160E-79	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
glucosylglycerol	ST000092	AN000146	1.440E-79	2.740E-78	Volume Urine (µL);100;10;25;50;5
isohydroxybutyric acid	ST000092	AN000146	2.000E-77	2.840E-76	Volume Urine (µL);100;10;25;50;5
cis/trans-hydroxyproline	ST001142	AN001875	2.010E-74	1.030E-73	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
cis-Cyclo[L-ala-L-Pro]	ST000974	AN001595	3.890E-75	3.020E-73	REGION;AHRI;MRC;SUN
2-Ketoleucine	ST000589	AN000904	3.070E-72	7.600E-72	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	4.770E-70	4.530E-68	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	1.690E-68	8.050E-67	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
BOC-ALA-OH	ST000016	AN000033	1.210E-67	3.030E-65	Material;Cells;Media
Ovothiol A-cysteine disulfide	ST001201	AN001998	9.400E-65	3.680E-62	cell_type;iRBC;unRBC
2-Ketovaline	ST000589	AN000904	9.360E-62	2.060E-61	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Methyl palmitate	ST000589	AN000904	6.410E-61	1.390E-60	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Trisaccharide	ST000589	AN000904	7.830E-61	1.670E-60	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
gamma-thiomethyl glutamate	ST001202	AN002000	9.020E-59	1.820E-56	cell_type;iRBC;unRBC
Asp-Val-Pro-Ser	ST001201	AN001999	1.260E-56	4.500E-55	cell_type;iRBC;unRBC
Mevalolactone	ST001048	AN001716	4.310E-56	6.330E-55	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
psicoselysine	ST001201	AN001998	7.260E-57	9.460E-55	cell_type;iRBC;unRBC
2-chloro-3-methyl-maleylacetate	ST001201	AN001998	4.340E-56	3.390E-54	cell_type;iRBC;unRBC
Trp-Trp-Tyr-Tyr	ST001202	AN002000	8.160E-56	1.100E-53	cell_type;iRBC;unRBC
3-Pyridinebutanoic acid	ST000356	AN000583	1.940E-53	1.110E-51	Diagnosis;breast cancer;control
methylsuccinoylcarnitine (1)	ST000974	AN001595	2.270E-53	1.130E-51	REGION;AHRI;MRC;SUN
ZEATIN [ISTD] (M+H)+	ST000842	AN001357	3.400E-53	3.940E-51	Sample type;Muscles;Plasma;Pooled sample
glucosylglycerol	ST000092	AN000146	1.500E-51	5.710E-50	Gender;N/A;Female;Male
D/L N-Acetylglucosamine / D/L N-Acetylgalactosamine / D/L N-Acetylmannosamine	ST001048	AN001716	5.780E-51	7.720E-50	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Tartronic acid	ST000589	AN000904	4.310E-50	8.090E-50	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
2-oxo-5-methylthiopentanoic-acid	ST001201	AN001998	2.050E-50	6.680E-49	cell_type;iRBC;unRBC
L-Valine/Methyl 4-Aminobutyrate	ST001317	AN002192	8.944E-50	1.252E-48	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
L-Valine/Methyl 4-Aminobutyrate	ST001317	AN002192	8.944E-50	1.252E-48	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
HEPES	ST001202	AN002001	1.250E-49	7.990E-48	cell_type;iRBC;unRBC
glucosylglycerol	ST000092	AN000146	3.050E-49	1.160E-47	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
methiin	ST001202	AN002000	3.350E-49	1.500E-47	cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphate	ST001201	AN001999	5.200E-48	6.980E-47	cell_type;iRBC;unRBC
L-Zeatine	ST000614	AN000939	3.870E-48	2.980E-46	Diagonsis;Benign;Cancer;Normal
hexoses (HILIC neg)	ST001142	AN001876	3.470E-47	4.100E-46	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
L-methioninamide	ST001204	AN002005	3.860E-48	5.120E-46	cell_type;iRBC;unRBC
Ala-Ala-Asp-Tyr	ST001201	AN001999	4.300E-47	5.320E-46	cell_type;iRBC;unRBC
L-Zeatine	ST000614	AN000939	2.100E-47	1.620E-45	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
C8-Ceramide m+13	ST000644	AN000976	2.330E-46	9.470E-45	tracer;13C-glucose;13C-glutamine;No label
hexoses (HILIC neg)	ST001142	AN001876	7.600E-46	4.480E-44	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
C8-Ceramide m+15	ST000644	AN000976	1.790E-45	6.340E-44	tracer;13C-glucose;13C-glutamine;No label
L-cysteine sulfinate	ST001201	AN001999	4.040E-44	4.200E-43	cell_type;iRBC;unRBC
5-Amino-6-ribitylamino uracil	ST000356	AN000583	1.610E-44	4.580E-43	Diagnosis;breast cancer;control
hexoses (HILIC pos)	ST001142	AN001875	3.470E-43	1.340E-42	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
gamma-thiomethyl glutamate	ST001201	AN001998	2.430E-43	5.580E-42	cell_type;iRBC;unRBC
C8-Ceramide m+11	ST000644	AN000976	2.320E-42	6.590E-41	tracer;13C-glucose;13C-glutamine;No label
Biflorin	ST000356	AN000583	3.570E-42	7.620E-41	Diagnosis;breast cancer;control
3-Phosphonopyruvate	ST001201	AN001999	1.020E-41	9.100E-41	cell_type;iRBC;unRBC
Hexose Monophosphate Pool	ST000450	AN000706	2.610E-42	1.460E-40	gender;Female;Male
Allothreonine/L-Threonine	ST001317	AN002192	1.776E-41	1.658E-40	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Allothreonine/L-Threonine	ST001317	AN002192	1.776E-41	1.658E-40	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
biphosphoglyceric acid	ST000608	AN000931	9.730E-42	1.670E-40	Sample_Type;blotter;serum
L-Glutamyl 5-phosphate	ST001201	AN001998	1.290E-41	2.650E-40	cell_type;iRBC;unRBC
Gluconic acid or similar sugar acid	ST000586	AN000901	1.190E-41	4.470E-40	Plasma Volume;0 uL;150 uL;700 uL
FA oxo(21:0)	ST001201	AN001998	2.710E-41	5.290E-40	cell_type;iRBC;unRBC
methylhexadecanoic acid	ST000385	AN000620	7.320E-41	6.180E-40	Organ;Plasma;Serum;Serum or Plasma
N2-(D-1-Carboxyethyl)-L-arginine	ST001202	AN002000	1.500E-40	2.630E-39	cell_type;iRBC;unRBC
Ala-Lys-Asp-Gly	ST001201	AN001998	4.530E-40	8.430E-39	cell_type;iRBC;unRBC
Crotanecine	ST001202	AN002000	1.500E-39	2.420E-38	cell_type;iRBC;unRBC
C8-Ceramide m+9	ST000644	AN000976	1.830E-39	3.460E-38	tracer;13C-glucose;13C-glutamine;No label
melibionate	ST001202	AN002001	4.960E-39	1.270E-37	cell_type;iRBC;unRBC
deacetylcolchicine	ST001202	AN002000	2.500E-38	3.600E-37	cell_type;iRBC;unRBC
Ala-Asp-Cys-Ser	ST001202	AN002000	5.710E-38	7.430E-37	cell_type;iRBC;unRBC
3-deoxy-D-galactose	ST001201	AN001998	4.830E-38	8.580E-37	cell_type;iRBC;unRBC
Allopregnanalone sulfate	ST000566	AN000869	5.090E-38	1.120E-36	Time point;Post;Pre;Baseline
2-Ketoleucine/ketoisoleucine	ST000586	AN000901	2.300E-37	1.960E-36	Plasma Volume;0 uL;150 uL;700 uL
nonulose 9-phosphate	ST001202	AN002001	9.490E-38	2.020E-36	cell_type;iRBC;unRBC
Aldopentoses	ST000589	AN000904	2.110E-36	3.340E-36	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Disaccharide	ST000586	AN000901	5.980E-37	4.570E-36	Plasma Volume;0 uL;150 uL;700 uL
2-Methylmaleate/Itaconate	ST001317	AN002193	5.539E-37	5.601E-36	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-Methylmaleate/Itaconate	ST001317	AN002193	5.539E-37	5.601E-36	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Myoinositol-2-phosphate	ST000589	AN000904	5.880E-36	9.210E-36	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
L-Erythrulose	ST001201	AN001999	3.350E-36	2.630E-35	cell_type;iRBC;unRBC
[13C]-PROLINE	ST000016	AN000033	1.060E-36	2.780E-35	Material;Cells;Media
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001202	AN002000	3.320E-36	3.530E-35	cell_type;iRBC;unRBC
Cohibin C	ST001202	AN002000	5.620E-36	5.660E-35	cell_type;iRBC;unRBC
Methyl palmitate	ST000586	AN000901	1.720E-35	1.100E-34	Plasma Volume;0 uL;150 uL;700 uL
Benzyl tetradecyl dimethylammonium cation (disinfectant)	ST000089	AN000141	2.130E-35	1.900E-34	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
m-hydroxybenzoic acid	ST001325	AN002207	2.036E-35	2.300E-34	Sample type;batch pool;chear plasma;master pool;red cross pl...
tartrazine	ST001202	AN002001	1.910E-35	3.490E-34	cell_type;iRBC;unRBC
13C-aminoadipic	ST000947	AN001555	3.560E-34	3.560E-34	Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
Pyroglutamate/Oxoproline	ST001317	AN002192	5.592E-35	3.914E-34	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pyroglutamate/Oxoproline	ST001317	AN002192	5.592E-35	3.914E-34	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
glycine-d5 deuterated	ST000865	AN001390	3.090E-35	4.540E-34	RACE;AA;Asian;EA;Hisp;Other;-
Gluconic acid or similar sugar acid 2	ST000586	AN000901	9.870E-35	5.810E-34	Plasma Volume;0 uL;150 uL;700 uL
glycine-d5 deuterated	ST000865	AN001390	2.310E-35	6.470E-34	Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001204	AN002004	1.280E-35	1.240E-33	cell_type;iRBC;unRBC
3-(4-hydroxyphenyl)propionate	ST000974	AN001595	4.120E-35	1.440E-33	REGION;AHRI;MRC;SUN
Galactose-N-acetylgalactosamine-SL	ST001104	AN001796	9.310E-34	2.330E-33	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
NMMA	ST001237	AN002055	3.030E-35	3.100E-33	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
C8-Ceramide m+7	ST000644	AN000976	4.830E-34	4.570E-33	tracer;13C-glucose;13C-glutamine;No label
[13C]-VALINE	ST000016	AN000033	2.750E-34	6.550E-33	Material;Cells;Media
Galactose-N-acetylgalactosamine	ST001104	AN001796	4.990E-33	7.630E-33	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
IS Ceramide;[M-H20]+	ST000661	AN001009	1.000E-33	7.770E-33	Study;CHOICE;CSU-143;POOLED
IS Ceramide;[M-H20]+	ST000661	AN001009	1.000E-33	7.770E-33	Type;Clinical;Preclinical;POOLED
Ala-Glu-Glu-His	ST001201	AN001998	1.660E-33	2.410E-32	cell_type;iRBC;unRBC
alloxanoic acid	ST000608	AN000931	7.420E-33	3.190E-32	Sample_Type;blotter;serum
6-Deoxyhexose	ST000586	AN000901	6.940E-33	3.420E-32	Plasma Volume;0 uL;150 uL;700 uL
D-erythro-L-galacto-Nonulose	ST001202	AN002001	2.540E-33	3.430E-32	cell_type;iRBC;unRBC
L-Ala-L-Glu	ST001202	AN002001	4.390E-33	5.110E-32	cell_type;iRBC;unRBC
Aniline-2-Sulfonate	ST001048	AN001716	1.130E-32	6.240E-32	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Asn-Lys-Gly-Pro	ST001201	AN001998	7.230E-33	9.430E-32	cell_type;iRBC;unRBC
isohydroxybutyric acid	ST000092	AN000146	1.320E-32	1.070E-31	Gender;N/A;Female;Male
Ala-Met-Asp-Tyr	ST001202	AN002001	1.860E-32	1.980E-31	cell_type;iRBC;unRBC
Ala-Ala-Ala-Ser	ST001202	AN002000	2.710E-32	2.060E-31	cell_type;iRBC;unRBC
Cys-Leu-Cys-Tyr	ST001202	AN002001	2.310E-32	2.360E-31	cell_type;iRBC;unRBC
Deoxyribose phosphate	ST000450	AN000706	1.510E-32	3.070E-31	gender;Female;Male
16a-Hydroxyestrone-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+Na]+	ST000142	AN000225	4.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.330E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C1[+QDA adduct+Na]+	ST000142	AN000225	8.660E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C3[+QDA adduct+Na]+	ST000142	AN000225	4.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Dehydro-xylonate-13C0[+H]+	ST000142	AN000225	8.530E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C0[+H]+	ST000142	AN000225	8.630E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Oxo-8-methylthiooctanoate-13C0[+Na]+	ST000142	AN000225	7.960E-33	6.130E-31	Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C0[+QDA adduct+Na]+	ST000142	AN000225	2.340E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C1[+QDA adduct+Na]+	ST000142	AN000225	7.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C2[+QDA adduct+Na]+	ST000142	AN000225	6.480E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Deoxy-glycero-galacto-2-nonulosonic acid-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.830E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Hydroxyethylbacteriochlorophyllide a-13C0[+Na]+	ST000142	AN000225	2.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Iodo-4-hydroxyphenylpyruvate-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.910E-32	6.130E-31	Treatment;13C-Glc;unlabeled
4-Ketoanhydrochlortetracycline-13C0[+H]+	ST000142	AN000225	2.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
4-Keto-ATC-13C0[+13CD3 QDA]+	ST000142	AN000225	4.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
4-Sulfobenzaldehyde-13C0[+Na]+	ST000142	AN000225	7.600E-32	6.130E-31	Treatment;13C-Glc;unlabeled
5-Methyl-2-furaldehyde-13C0[+QDA adduct]+	ST000142	AN000225	1.840E-32	6.130E-31	Treatment;13C-Glc;unlabeled
6-Azaequilenin-13C0[+H]+	ST000142	AN000225	7.200E-32	6.130E-31	Treatment;13C-Glc;unlabeled
6-Hydroxykynurenate-13C0[+Na]+	ST000142	AN000225	2.680E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C0[+Na]+	ST000142	AN000225	4.060E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C2[+Na]+	ST000142	AN000225	3.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C4[+Na]+	ST000142	AN000225	7.430E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+QDA adduct]+	ST000142	AN000225	5.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Aloinoside A-13C0[+13CD3 QDA]+	ST000142	AN000225	6.210E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Aquayamycin-13C0[+13CD3 QDA]+	ST000142	AN000225	2.660E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Atheroline-13C1[+H]+	ST000142	AN000225	3.130E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Atheroline-13C6[+H]+	ST000142	AN000225	8.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Bacteriochlorophyllide a-13C0[+QDA adduct]+	ST000142	AN000225	4.230E-32	6.130E-31	Treatment;13C-Glc;unlabeled
B-Norcholest-4-en-3-one-13C0[+Na]+	ST000142	AN000225	5.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
C-132-Carboxypyropheophorbide a-13C0[+QDA adduct+Na]+	ST000142	AN000225	7.880E-33	6.130E-31	Treatment;13C-Glc;unlabeled
Candletoxin A-13C0[+13CD3 QDA]+	ST000142	AN000225	6.320E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Chalcomycin-13C0[+QDA adduct]+	ST000142	AN000225	1.950E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Chalcomycin-13C1[+QDA adduct]+	ST000142	AN000225	6.120E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C0[+QDA adduct]+	ST000142	AN000225	1.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cinncassiol C1-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+Na]+	ST000142	AN000225	2.290E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+QDA adduct]+	ST000142	AN000225	5.160E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C1[+QDA adduct]+	ST000142	AN000225	3.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C20[+QDA adduct]+	ST000142	AN000225	2.810E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+13CD3 QDA]+	ST000142	AN000225	1.970E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+Na]+	ST000142	AN000225	2.850E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C1[+H]+	ST000142	AN000225	6.630E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dehydropantoate-13C0[+Na]+	ST000142	AN000225	2.530E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C1[+QDA adduct+Na]+	ST000142	AN000225	5.610E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Deoxycarminomycin-13C0[+QDA adduct]+	ST000142	AN000225	7.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydrocarminomycin-13C0[+13CD3 QDA]+	ST000142	AN000225	6.170E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydrogossypetin-13C0[+13CD3 QDA]+	ST000142	AN000225	6.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
dihydro-keto-PGF2a-13C0[+Na]+	ST000142	AN000225	6.970E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxanthommatin-13C0[+13CD3 QDA]+	ST000142	AN000225	3.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C0[+H]+	ST000142	AN000225	8.780E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C1[+H]+	ST000142	AN000225	8.300E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Divinylprotochlorophyllide-13C0[+QDA adduct]+	ST000142	AN000225	6.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Epothilone C-13C0[+H]+	ST000142	AN000225	6.420E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Flavonol 3-O-beta-glucosyl-(1->2)-beta-glucoside-13C0[+QDA adduct]+	ST000142	AN000225	8.050E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C0[+13CD3 QDA]+	ST000142	AN000225	9.430E-33	6.130E-31	Treatment;13C-Glc;unlabeled
GQ1c (34:1)-13C0[+13CD3 QDA]+	ST000142	AN000225	3.610E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydrocortisone sodium succinate-13C0[+13CD3 QDA]+	ST000142	AN000225	3.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C4[+H]+	ST000142	AN000225	2.140E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C8[+H]+	ST000142	AN000225	2.480E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyamoorstatin-13C0[+QDA adduct]+	ST000142	AN000225	5.380E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+	ST000142	AN000225	5.910E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct]+	ST000142	AN000225	3.570E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.120E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxy-naphthoquinone-13C0[+H]+	ST000142	AN000225	2.770E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyretinal-13C0[+H]+	ST000142	AN000225	2.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxystreptomycin-13C0[+H]+	ST000142	AN000225	7.880E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isophenoxazine-13C0[+H]+	ST000142	AN000225	5.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isophenoxazine-13C10[+QDA adduct+Na]+	ST000142	AN000225	5.620E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C6[+QDA adduct]+	ST000142	AN000225	6.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Ketoetiocholanolone-13C0[+Na]+	ST000142	AN000225	5.390E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Kolanone-13C0[+H]+	ST000142	AN000225	6.620E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Lankamycin-13C0[+QDA adduct]+	ST000142	AN000225	4.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Melengestrol acetate-13C0[+Na]+	ST000142	AN000225	8.110E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+Na]+	ST000142	AN000225	2.650E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C0[+QDA adduct]+	ST000142	AN000225	6.680E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C1[+QDA adduct]+	ST000142	AN000225	2.700E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C6[+QDA adduct]+	ST000142	AN000225	6.950E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C0[+H]+	ST000142	AN000225	8.310E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C1[+H]+	ST000142	AN000225	6.150E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+Na]+	ST000142	AN000225	4.090E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.090E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C1[+QDA adduct+Na]+	ST000142	AN000225	6.600E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Naphthoquinone-13C0[+H]+	ST000142	AN000225	8.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nigakilactone K-13C0[+13CD3 QDA]+	ST000142	AN000225	2.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nigakilactone M-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.520E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nitrophenyl-ketovalidamine-13C0[+H]+	ST000142	AN000225	5.450E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N-Methyl-2-oxoglutaramate-13C0[+Na]+	ST000142	AN000225	2.340E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N-tert-Butyloxycarbonyl-deacetyl-leupeptin-13C0[+13CD3 QDA]+	ST000142	AN000225	5.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oleoylglycerone phosphate-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.230E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxalomalate-13C0[+H]+	ST000142	AN000225	7.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxalomalate-13C1[+H]+	ST000142	AN000225	2.920E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxo-4-phosphonobutanoate-13C0[+QDA adduct]+	ST000142	AN000225	6.860E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxononanoate-13C8[+QDA adduct]+	ST000142	AN000225	2.010E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C1[+QDA adduct+Na]+	ST000142	AN000225	5.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C4[+QDA adduct+Na]+	ST000142	AN000225	2.580E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C5[+QDA adduct+Na]+	ST000142	AN000225	4.840E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+H]+	ST000142	AN000225	8.300E-32	6.130E-31	Treatment;13C-Glc;unlabeled
PD116740-13C0[+QDA adduct]+	ST000142	AN000225	7.770E-32	6.130E-31	Treatment;13C-Glc;unlabeled
PD116740-13C1[+QDA adduct]+	ST000142	AN000225	7.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C0[+QDA adduct]+	ST000142	AN000225	8.640E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C12[+QDA adduct]+	ST000142	AN000225	3.270E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C1[+QDA adduct]+	ST000142	AN000225	4.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C6[+QDA adduct]+	ST000142	AN000225	7.140E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C0[+13CD3 QDA]+	ST000142	AN000225	6.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C19[+13CD3 QDA]+	ST000142	AN000225	7.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C20[+13CD3 QDA]+	ST000142	AN000225	3.170E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prednisolone 21-all-cis-farnesylate-13C0[+QDA adduct]+	ST000142	AN000225	7.370E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prephenate-13C0[+H]+	ST000142	AN000225	6.440E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+H]+	ST000142	AN000225	2.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Propiomazine hydrochloride-13C0[+13CD3 QDA]+	ST000142	AN000225	5.850E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+H]+	ST000142	AN000225	6.030E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rehmaionoside C-13C0[+Na]+	ST000142	AN000225	7.870E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C0[+13CD3 QDA]+	ST000142	AN000225	7.020E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C1[+13CD3 QDA]+	ST000142	AN000225	6.260E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C2[+13CD3 QDA]+	ST000142	AN000225	8.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rifamycin S-13C0[+QDA adduct]+	ST000142	AN000225	2.520E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sedoheptulose phosphate-13C0[+Na]+	ST000142	AN000225	2.130E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sethoxydim-13C0[+H]+	ST000142	AN000225	8.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sialyllactosamine-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sodium equilin sulfate-13C0[+13CD3 QDA]+	ST000142	AN000225	5.060E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Stanolone benzoate-13C0[+Na]+	ST000142	AN000225	4.070E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Tepraloxydim-13C0[+13CD3 QDA]+	ST000142	AN000225	4.220E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Testosterone isocaproate-13C9[+Na]+	ST000142	AN000225	6.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Triamcinolone diacetate-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.050E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Trinexapac-ethyl-13C0[+Na]+	ST000142	AN000225	8.640E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Uracil 5-carbaldehyde-13C1[+QDA adduct]+	ST000142	AN000225	6.390E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C0[+Na]+	ST000142	AN000225	3.150E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C1[+Na]+	ST000142	AN000225	2.720E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C9[+Na]+	ST000142	AN000225	3.510E-32	6.130E-31	Treatment;13C-Glc;unlabeled
YC-17-13C0[+Na]+	ST000142	AN000225	6.070E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Demethylmenaquinone-13C0[+Na]+	ST000142	AN000225	8.830E-32	6.150E-31	Treatment;13C-Glc;unlabeled
AminoDHS-13C0[+H]+	ST000142	AN000225	9.200E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Hinokitiol glucoside-13C0[+H]+	ST000142	AN000225	8.870E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C1[+13CD3 QDA]+	ST000142	AN000225	9.220E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+Na]+	ST000142	AN000225	8.930E-32	6.150E-31	Treatment;13C-Glc;unlabeled
SC-1271-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.850E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Spectinomycin dihydrochloride-13C0[+QDA adduct+Na]+	ST000142	AN000225	9.010E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Hydroxy-carboxybenzalpyruvate-13C0[+H]+	ST000142	AN000225	9.320E-32	6.180E-31	Treatment;13C-Glc;unlabeled
Testosterone decanoate-13C0[+13CD3 QDA]+	ST000142	AN000225	9.330E-32	6.180E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C19[+QDA adduct]+	ST000142	AN000225	9.490E-32	6.250E-31	Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C0[+H]+	ST000142	AN000225	9.470E-32	6.250E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C9[+QDA adduct]+	ST000142	AN000225	9.560E-32	6.280E-31	Treatment;13C-Glc;unlabeled
Alisol A-13C0[+13CD3 QDA]+	ST000142	AN000225	9.600E-32	6.300E-31	Treatment;13C-Glc;unlabeled
GD1b (36:2)-13C0[+13CD3 QDA]+	ST000142	AN000225	1.030E-31	6.620E-31	Treatment;13C-Glc;unlabeled
Aminomuconic acid semialdehyde-13C0[+Na]+	ST000142	AN000225	1.060E-31	6.700E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C3[+H]+	ST000142	AN000225	1.050E-31	6.700E-31	Treatment;13C-Glc;unlabeled
5-Chloro-2-hydroxymuconic semialdehyde-13C0[+Na]+	ST000142	AN000225	1.090E-31	6.860E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+H]+	ST000142	AN000225	1.110E-31	6.910E-31	Treatment;13C-Glc;unlabeled
Phosphohydroxypyruvate-13C0[+H]+	ST000142	AN000225	1.100E-31	6.910E-31	Treatment;13C-Glc;unlabeled
Geranylchrysin-13C0[+13CD3 QDA]+	ST000142	AN000225	1.150E-31	7.100E-31	Treatment;13C-Glc;unlabeled
Hydroxymuconic semialdehyde-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.170E-31	7.200E-31	Treatment;13C-Glc;unlabeled
Cinncassiol C2-13C0[+13CD3 QDA]+	ST000142	AN000225	1.210E-31	7.410E-31	Treatment;13C-Glc;unlabeled
SLC1G	ST001104	AN001796	7.640E-31	7.640E-31	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
Hygromycin A-13C0[+QDA adduct]+	ST000142	AN000225	1.300E-31	7.850E-31	Treatment;13C-Glc;unlabeled
FA oxo(19:0)	ST001201	AN001998	7.550E-32	8.440E-31	cell_type;iRBC;unRBC
Hydroxyanthraquinone-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.590E-31	9.480E-31	Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C1[+H]+	ST000142	AN000225	1.910E-31	1.130E-30	Treatment;13C-Glc;unlabeled
4-Hydroxyphenylacetylglycine	ST001202	AN002001	2.120E-31	1.940E-30	cell_type;iRBC;unRBC
IS Ceramide;[M-H20]+	ST000661	AN001009	3.620E-31	2.710E-30	Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
SDMA/ADMA	ST001142	AN001875	5.730E-31	3.680E-30	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Ala-Asp-Asp-Cys	ST001202	AN002000	6.480E-31	4.150E-30	cell_type;iRBC;unRBC
DIHEXOSE	ST000016	AN000033	2.330E-31	5.060E-30	Material;Cells;Media
5?-Androstan-3?-ol-17-one sulfate - 8.185043	ST000566	AN000869	7.010E-31	6.170E-30	Time point;Post;Pre;Baseline
Asn-Gly-Pro-Pro	ST001201	AN001998	6.000E-31	6.380E-30	cell_type;iRBC;unRBC
taurodeoxycholate/taurochenodeoxycholate	ST001142	AN001876	7.860E-31	7.730E-30	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Alanine / D-Alanine	ST001048	AN001716	1.750E-30	8.180E-30	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
isohydroxybutyric acid	ST000092	AN000146	1.360E-30	1.190E-29	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
HEPES	ST001201	AN001999	3.490E-30	2.080E-29	cell_type;iRBC;unRBC
IS SM 35:1;[M+H]+	ST000661	AN001009	5.210E-30	2.960E-29	Study;CHOICE;CSU-143;POOLED
IS SM 35:1;[M+H]+	ST000661	AN001009	5.210E-30	2.960E-29	Type;Clinical;Preclinical;POOLED
2-chloro-3-methyl-maleylacetate	ST001204	AN002004	1.120E-30	3.980E-29	cell_type;iRBC;unRBC
AC1MIY4G	ST000842	AN001361	1.870E-29	5.350E-29	Sample type;Muscles;Plasma;Pooled sample
Aldopentoses	ST000586	AN000901	1.750E-29	7.450E-29	Plasma Volume;0 uL;150 uL;700 uL
Asp-Trp-Gly-Gly	ST001204	AN002005	3.370E-30	7.580E-29	cell_type;iRBC;unRBC
Asp-Gly-Pro-Ser	ST001201	AN001999	1.360E-29	7.990E-29	cell_type;iRBC;unRBC
Hydroxyprolines	ST000589	AN000904	7.190E-29	1.040E-28	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Pyridinebutanoic acid	ST000356	AN000583	1.920E-30	1.100E-28	stage;-;2;3
Arg-Phe-Phe-Arg	ST001201	AN001999	2.250E-29	1.290E-28	cell_type;iRBC;unRBC
Pregnanolone sulfate	ST000567	AN000871	6.830E-30	1.950E-28	Time point;Post;Pre;Baseline
succinate/methylmalonate	ST001142	AN001876	2.420E-29	2.380E-28	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
IS SM 35:1;[M+H]+	ST000661	AN001009	5.690E-29	3.440E-28	Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
Lyso-PAF C-18	ST000089	AN000141	1.340E-28	4.630E-28	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Cinchonain 1a	ST001204	AN002004	2.120E-29	6.870E-28	cell_type;iRBC;unRBC
Ala-Leu-Asn-Pro	ST001201	AN001998	8.510E-29	7.080E-28	cell_type;iRBC;unRBC
IS Ceramide;[M-H20]+	ST000661	AN001009	1.630E-28	1.110E-27	Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
Pentonic acids	ST000589	AN000904	1.050E-27	1.510E-27	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-methyladipate/pimelate	ST001142	AN001876	2.100E-28	1.630E-27	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
cyclo-Dopa-glucuronylglucoside	ST000567	AN000871	7.360E-29	1.750E-27	Time point;Post;Pre;Baseline
Montecristin	ST001202	AN002000	4.030E-28	2.030E-27	cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphate	ST001202	AN002001	3.590E-28	2.490E-27	cell_type;iRBC;unRBC
PIPES	ST001202	AN002001	3.860E-28	2.600E-27	cell_type;iRBC;unRBC
Ala-Thr-Ala-Ser	ST001202	AN002000	5.630E-28	2.770E-27	cell_type;iRBC;unRBC
Ethanol diglycine (EDTA decomposition product)	ST000586	AN000901	7.510E-28	2.800E-27	Plasma Volume;0 uL;150 uL;700 uL
2-oxo-4-methylvaleric acid	ST000356	AN000582	2.670E-28	3.370E-27	Diagnosis;breast cancer;control
C8-Ceramide m+8	ST000644	AN000976	5.670E-28	4.020E-27	tracer;13C-glucose;13C-glutamine;No label
DG(36:2)>DG(18:1_18:1_0:0)	ST001325	AN002206	7.228E-28	4.437E-27	Sample type;batch pool;chear plasma;master pool;red cross pl...
Glu-Glu-Gln-His	ST001201	AN001998	6.800E-28	5.120E-27	cell_type;iRBC;unRBC
Methylnoradrenaline	ST000356	AN000583	6.850E-28	6.890E-27	Diagnosis;breast cancer;control
Benzyl dodecyl dimethylammonium cation (disinfectant)	ST000089	AN000141	2.450E-27	7.240E-27	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N5-acetyl-N5-hydroxy-L-ornithine	ST001202	AN002000	1.940E-27	8.890E-27	cell_type;iRBC;unRBC
3-methoxytyramine sulfate	ST000974	AN001595	3.490E-28	9.040E-27	REGION;AHRI;MRC;SUN
Hexadeceylamin	ST001202	AN002000	2.270E-27	1.030E-26	cell_type;iRBC;unRBC
2-oxo-3-methylvaleric acid	ST000356	AN000582	1.610E-27	1.800E-26	Diagnosis;breast cancer;control
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001201	AN001999	3.960E-27	2.120E-26	cell_type;iRBC;unRBC
Tolylacetonitrile	ST001202	AN002000	2.530E-26	1.040E-25	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	1.260E-27	1.190E-25	Country;Ethiopia;Tanzania;Botswana
C8-Ceramide m+17	ST000644	AN000976	2.590E-26	1.750E-25	tracer;13C-glucose;13C-glutamine;No label
L-pyroglutamic acid/ glutamic acid	ST000865	AN001390	4.180E-26	1.800E-25	Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
Bile salt	ST001202	AN002001	5.240E-26	2.690E-25	cell_type;iRBC;unRBC
CerH2O(d18:1/26:1)	ST000608	AN000929	1.870E-26	3.280E-25	Sample_Type;blotter;serum
Ala-Leu-Thr-Ala	ST001202	AN002000	8.570E-26	3.350E-25	cell_type;iRBC;unRBC
Ala-Leu-Lys-Asp	ST001202	AN002000	1.050E-25	4.040E-25	cell_type;iRBC;unRBC
deacetylcolchicine	ST001201	AN001999	9.260E-26	4.660E-25	cell_type;iRBC;unRBC
Biflorin	ST000356	AN000583	2.050E-26	5.020E-25	stage;-;2;3
5-Amino-6-ribitylamino uracil	ST000356	AN000583	2.910E-26	6.220E-25	stage;-;2;3
[13C]-LYSINE	ST000016	AN000033	5.440E-26	7.770E-25	Material;Cells;Media
CL 76:9 (18:0/20:4/18:1/20:4) [M-2H](2-)	ST001111	AN001806	2.700E-27	8.950E-25	Sample;Benign;Cancer;Metastasis
CerH2O(d18:1/16:0)	ST000608	AN000929	5.650E-26	9.290E-25	Sample_Type;blotter;serum
IS SM 35:1;[M+H]+	ST000661	AN001009	2.030E-25	1.030E-24	Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
C8-Ceramide m+10	ST000644	AN000976	1.750E-25	1.100E-24	tracer;13C-glucose;13C-glutamine;No label
Cys-Gly-Pro-Ser	ST001202	AN002001	2.450E-25	1.140E-24	cell_type;iRBC;unRBC
Ala-Asp-Gly-Tyr	ST001202	AN002000	3.130E-25	1.150E-24	cell_type;iRBC;unRBC
Laurencione diacetate	ST000567	AN000871	6.200E-26	1.270E-24	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	4.320E-26	1.370E-24	Country;Ethiopia;Tanzania;Botswana
Asn-Leu-Pro-Pro	ST001201	AN001998	2.170E-25	1.410E-24	cell_type;iRBC;unRBC
2-Benzothiazolesulfonamide	ST001201	AN001999	3.060E-25	1.470E-24	cell_type;iRBC;unRBC
Octulose-monophosphate	ST000450	AN000706	2.010E-25	1.600E-24	gender;Female;Male
Ala-Phe-Arg-His	ST001204	AN002004	7.830E-26	1.690E-24	cell_type;iRBC;unRBC
CL 76:9 (18:0/16:0/22:5/20:4) [M-2H](2-)	ST001111	AN001806	2.150E-26	1.780E-24	Sample;Benign;Cancer;Metastasis
5?-Androstan-3?-ol-17-one sulfate - 7.7291727	ST000566	AN000869	2.700E-25	1.830E-24	Time point;Post;Pre;Baseline
Cys-Cys-Pro-Ser	ST001201	AN001998	3.690E-25	2.330E-24	cell_type;iRBC;unRBC
psicoselysine	ST001204	AN002004	1.390E-25	2.700E-24	cell_type;iRBC;unRBC
L-pyroglutamic acid/ glutamic acid	ST000865	AN001390	7.370E-25	2.750E-24	RACE;AA;Asian;EA;Hisp;Other;-
4-Hydroxy-4-(3-pyridyl)butanoic acid	ST001317	AN002192	2.629E-24	7.362E-24	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-(3-pyridyl)butanoic acid	ST001317	AN002192	2.629E-24	7.362E-24	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
MES	ST001202	AN002000	2.390E-24	7.640E-24	cell_type;iRBC;unRBC
Marinobufagenin	ST000567	AN000871	7.610E-25	1.360E-23	Time point;Post;Pre;Baseline
octulose 8-phosphate	ST001201	AN001999	3.580E-24	1.700E-23	cell_type;iRBC;unRBC
Ala-Val-Asp-Ser	ST001202	AN002000	6.450E-24	2.030E-23	cell_type;iRBC;unRBC
Sulfate	ST001202	AN002001	5.520E-24	2.210E-23	cell_type;iRBC;unRBC
Asp-Val-Gly-Ser	ST001202	AN002000	7.810E-24	2.440E-23	cell_type;iRBC;unRBC
Ala-Lys-Ala-Ala	ST001201	AN001999	6.090E-24	2.760E-23	cell_type;iRBC;unRBC
glycodeoxycholate/glycochenodeoxycholate	ST001142	AN001876	6.990E-24	3.170E-23	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
hexoses (HILIC pos)	ST001142	AN001875	9.570E-24	3.350E-23	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000450	AN000706	5.060E-24	3.530E-23	gender;Female;Male
Ala-Asp-Cys-Ser	ST001201	AN001998	6.320E-24	3.740E-23	cell_type;iRBC;unRBC
PC(18:0/9:0(CHO))	ST000608	AN000929	3.670E-24	4.190E-23	Sample_Type;blotter;serum
PC(16:0/11:0(CHO))	ST000608	AN000929	4.250E-24	4.650E-23	Sample_Type;blotter;serum
Avenic acid A	ST001202	AN002001	1.470E-23	5.530E-23	cell_type;iRBC;unRBC
4-amino-4-deoxy-L-arabinose	ST001201	AN001998	9.770E-24	5.700E-23	cell_type;iRBC;unRBC
FA methyl (8:1)	ST001202	AN002001	1.540E-23	5.710E-23	cell_type;iRBC;unRBC
[13C]-THREONINE	ST000016	AN000033	4.970E-24	6.210E-23	Material;Cells;Media
Elaidate / Oleate /Petroselinate	ST001048	AN001717	1.250E-23	6.660E-23	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Tetrasaccharide	ST000589	AN000904	7.160E-23	9.520E-23	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001202	AN002000	4.120E-23	1.200E-22	cell_type;iRBC;unRBC
FA methyl(6:0)	ST001202	AN002001	3.720E-23	1.320E-22	cell_type;iRBC;unRBC
Phenolsulfonphthalein	ST001202	AN002001	4.920E-23	1.700E-22	cell_type;iRBC;unRBC
Asn-Met-Thr-Asp	ST001201	AN001999	4.440E-23	1.930E-22	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M+Cl)-	ST000842	AN001356	4.840E-23	3.230E-22	Sample type;Muscles;Plasma;Pooled sample
Anthranilate/4-Aminobenzoate	ST001317	AN002193	6.526E-23	3.959E-22	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Anthranilate/4-Aminobenzoate	ST001317	AN002193	6.526E-23	3.959E-22	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Asp-Leu-Lys-Asp	ST001202	AN002000	1.750E-22	4.740E-22	cell_type;iRBC;unRBC
4-Amino-4-deoxychorismate	ST001202	AN002001	1.800E-22	5.830E-22	cell_type;iRBC;unRBC
Sulfate	ST001204	AN002005	5.160E-23	6.330E-22	cell_type;iRBC;unRBC
Molybdenum cofactor (sulfide)	ST000241	AN000373	3.530E-24	6.640E-22	Concentration (uM);0;500
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001204	AN002004	8.410E-23	1.380E-21	cell_type;iRBC;unRBC
N-Acetyl-O-acetylneuraminate	ST001204	AN002004	8.490E-23	1.380E-21	cell_type;iRBC;unRBC
a Cysteine adduct	ST001204	AN002005	1.310E-22	1.410E-21	cell_type;iRBC;unRBC
MOPS	ST001202	AN002000	6.460E-22	1.660E-21	cell_type;iRBC;unRBC
D-Galacturonate	ST001202	AN002001	5.920E-22	1.740E-21	cell_type;iRBC;unRBC
2-S-Glutathionyl acetate	ST001201	AN001998	3.450E-22	1.800E-21	cell_type;iRBC;unRBC
Ala-Thr-Ala-Asp	ST001202	AN002000	7.080E-22	1.800E-21	cell_type;iRBC;unRBC
L-a-glutamyl-L-Lysine	ST001201	AN001998	3.910E-22	2.010E-21	cell_type;iRBC;unRBC
Decosahexaenoic acid	ST000356	AN000582	2.700E-22	2.280E-21	Diagnosis;breast cancer;control
CMP-N-trimethyl-2-aminoethylphosphonate	ST001202	AN002000	1.290E-21	3.210E-21	cell_type;iRBC;unRBC
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	3.070E-22	4.100E-21	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
MEVALOLACTONE	ST000105	AN000173	1.480E-23	6.090E-21	Sampling;After SWS onset;Morning fasting
5?-Androstan-3?-ol-17-one sulfate	ST000567	AN000871	7.040E-22	8.390E-21	Time point;Post;Pre;Baseline
taurodeoxycholate/taurochenodeoxycholate	ST001142	AN001876	2.810E-21	8.730E-21	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
acetophenone NIST	ST000385	AN000620	4.190E-21	1.030E-20	Organ;Plasma;Serum;Serum or Plasma
Hexose Diphosphate Pool	ST000450	AN000706	2.950E-21	1.400E-20	gender;Female;Male
Asn-Thr-Asn-Asn	ST001202	AN002000	6.110E-21	1.490E-20	cell_type;iRBC;unRBC
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	2.720E-21	2.470E-20	Material;Cells;Media
CL 74:9 (18:0/20:4/18:2/18:3) [M-2H](2-)	ST001111	AN001806	1.440E-21	3.410E-20	Sample;Benign;Cancer;Metastasis
octulose 8-phosphate	ST001202	AN002001	1.650E-20	4.440E-20	cell_type;iRBC;unRBC
CerH2O(d18:1/26:0);CerH2O(d20:1/24:0)	ST000608	AN000929	9.130E-21	5.580E-20	Sample_Type;blotter;serum
C9 / C14:1-OH	ST000544	AN000827	9.930E-22	6.360E-20	Sample Type;Control;Replicate
PC(16:0/5:0(CHO))	ST000608	AN000929	1.080E-20	6.470E-20	Sample_Type;blotter;serum
L(-)-Nicotine pestal	ST000241	AN000373	1.010E-21	7.610E-20	Concentration (uM);0;500
5?-Androstan-3?-ol-17-one sulfate	ST000566	AN000869	2.100E-20	1.230E-19	Time point;Post;Pre;Baseline
Asn-Thr-Asn-Asn	ST001204	AN002004	1.170E-20	1.300E-19	cell_type;iRBC;unRBC
Ala-Leu-Trp-Ser	ST001201	AN001998	3.340E-20	1.430E-19	cell_type;iRBC;unRBC
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000089	AN000141	7.590E-20	1.510E-19	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
D-glycero-L-galacto-Octulose	ST001202	AN002001	6.430E-20	1.630E-19	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	5.160E-21	1.630E-19	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
Asp-Leu-Gln-Pro	ST001202	AN002000	7.290E-20	1.660E-19	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	7.320E-21	1.740E-19	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
L-Isoleucine / Norleucine	ST001048	AN001716	9.370E-20	2.400E-19	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Steryl sulfate	ST000566	AN000869	5.390E-20	2.960E-19	Time point;Post;Pre;Baseline
6-diazo-5-oxonorleucine	ST001202	AN002000	1.430E-19	3.200E-19	cell_type;iRBC;unRBC
DMGV	ST001237	AN002055	5.980E-20	5.110E-19	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
8-Amino-7-oxononanoate	ST001202	AN002000	2.410E-19	5.260E-19	cell_type;iRBC;unRBC
Asn-Leu-Pro-Pro	ST001202	AN002000	2.860E-19	6.160E-19	cell_type;iRBC;unRBC
Progtaglandin F2a	ST001229	AN002042	3.460E-19	6.910E-19	Sample Source;Feces;Serum;Tissues
5-hydroxymethyl-2-furoylcarnitine*	ST000974	AN001595	3.900E-20	7.380E-19	REGION;AHRI;MRC;SUN
Asp-Val-Pro-Ser	ST001204	AN002004	7.500E-20	7.890E-19	cell_type;iRBC;unRBC
[13C]-GLUTAMATE	ST000016	AN000033	1.100E-19	8.850E-19	Material;Cells;Media
Ala-Asp-Gly-Arg	ST001201	AN001998	2.320E-19	9.340E-19	cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerate	ST001202	AN002001	3.890E-19	9.570E-19	cell_type;iRBC;unRBC
2-oxo-4-methylvaleric acid	ST000356	AN000582	6.850E-20	9.880E-19	stage;-;2;3
Ala-Cys-Pro-Ser	ST001202	AN002001	4.120E-19	9.950E-19	cell_type;iRBC;unRBC
2-S-Glutathionyl acetate	ST001204	AN002004	1.190E-19	1.220E-18	cell_type;iRBC;unRBC
6-Acetyl-D-glucose	ST001202	AN002000	7.530E-19	1.540E-18	cell_type;iRBC;unRBC
16-Feruloyloxypalmitate	ST000567	AN000871	2.230E-19	1.990E-18	Time point;Post;Pre;Baseline
Coproporphyrin	ST000356	AN000583	3.960E-19	2.260E-18	Diagnosis;breast cancer;control
Gln-Leu-Lys-Tyr	ST001202	AN002001	1.070E-18	2.440E-18	cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamate	ST001202	AN002000	1.500E-18	2.980E-18	cell_type;iRBC;unRBC
Ala-Asn-Gln-Gln	ST001204	AN002005	4.090E-19	3.250E-18	cell_type;iRBC;unRBC
2-oxo-3-methylvaleric acid	ST000356	AN000582	2.980E-19	3.770E-18	stage;-;2;3
PC(18:0/9:0(COOH))	ST000608	AN000929	8.220E-19	3.860E-18	Sample_Type;blotter;serum
Albendazole sulfone	ST001204	AN002005	5.040E-19	3.890E-18	cell_type;iRBC;unRBC
Dihydrogenphosphate	ST001204	AN002005	5.260E-19	3.950E-18	cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitine	ST001201	AN001998	1.260E-18	4.890E-18	cell_type;iRBC;unRBC
Methylnoradrenaline	ST000356	AN000583	6.060E-19	6.480E-18	stage;-;2;3
Asn-Asn-Gly-His	ST001202	AN002000	3.410E-18	6.670E-18	cell_type;iRBC;unRBC
Cholic acid or similar bile acid	ST000589	AN000904	5.310E-18	6.870E-18	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Arg-Asp-Asp-Gly	ST001204	AN002004	8.910E-19	7.530E-18	cell_type;iRBC;unRBC
N5-formyl-N5-hydroxy-L-ornithine	ST001201	AN001999	2.250E-18	8.240E-18	cell_type;iRBC;unRBC
O-Acetylneuraminic acid	ST001202	AN002000	4.790E-18	9.290E-18	cell_type;iRBC;unRBC
3-deoxy-D-galactose	ST001204	AN002005	1.580E-18	1.150E-17	cell_type;iRBC;unRBC
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)	ST001317	AN002193	3.375E-18	1.228E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)	ST001317	AN002193	3.375E-18	1.228E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
CL 74:10 (16:1/22:5/20:4/16:0) [M-2H](2-)	ST001111	AN001806	7.520E-19	1.360E-17	Sample;Benign;Cancer;Metastasis
acetyl-galactosamine	ST001237	AN002055	2.020E-18	1.480E-17	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Beta-alanine methyl ester	ST001317	AN002192	6.364E-18	1.485E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Beta-alanine methyl ester	ST001317	AN002192	6.364E-18	1.485E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-Hydroxyphenylacetate	ST001317	AN002193	4.515E-18	1.522E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-Hydroxyphenylacetate	ST001317	AN002193	4.515E-18	1.522E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
N-Butyl-beta-carboline-3-carboxylate	ST001202	AN002001	9.270E-18	2.010E-17	cell_type;iRBC;unRBC
FA hydroxy(10:0)	ST001202	AN002001	1.390E-17	2.980E-17	cell_type;iRBC;unRBC
[13C]-TYROSINE	ST000016	AN000033	4.790E-18	3.470E-17	Material;Cells;Media
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000842	AN001356	9.570E-18	3.990E-17	Sample type;Muscles;Plasma;Pooled sample
Arg-Leu-Val-Asn	ST000539	AN000819	8.810E-20	4.720E-17	Cell type;Mature erythrocyte;Reticulocyte
3-deoxy-D-galactose	ST001202	AN002001	2.310E-17	4.840E-17	cell_type;iRBC;unRBC
Cotinineglucuronide	ST000241	AN000373	2.240E-18	5.270E-17	Concentration (uM);0;500
fumarate/maleate/alpha-ketoisovalerate	ST001142	AN001876	1.800E-17	5.300E-17	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
diacetylspermine	ST001237	AN002055	9.340E-18	5.980E-17	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Glucosamine/Galactosamine	ST000614	AN000939	4.400E-18	6.780E-17	Diagonsis;Benign;Cancer;Normal
C9 / C14	ST000544	AN000827	4.120E-18	7.910E-17	Sample Type;Control;Replicate
Paraxanthine / Theobromine /Theophylline	ST001048	AN001716	3.790E-17	8.430E-17	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
urobilin - targeted	ST000923	AN001513	9.370E-19	8.800E-17	Diagnosis;CD;nonIBD;UC
5-aminovaleric acid lactame	ST000420	AN000662	7.540E-19	9.490E-17	Group;nonsmoker;smoker
Glu-Lys-Lys-Phe	ST001202	AN002001	5.360E-17	1.110E-16	cell_type;iRBC;unRBC
Pseudo uridine penta-tms	ST000978	AN001602	1.140E-18	1.110E-16	Competitive_RRTvsDeath;.;N;RRT;DEATH
4-Pyrodixic acid / Xanthurenate	ST001048	AN001716	5.470E-17	1.170E-16	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	8.130E-19	1.400E-16	Cox_RRT;.;N;Y
Glucosamine/Galactosamine	ST000614	AN000939	1.670E-17	1.830E-16	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	2.900E-18	2.120E-16	Competitive_RRTvsDeath;.;N;RRT;DEATH
Aminocaproate/Adenine	ST001317	AN002192	1.375E-16	2.800E-16	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Aminocaproate/Adenine	ST001317	AN002192	1.375E-16	2.800E-16	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-Adenosylmethionimine	ST000241	AN000373	1.420E-17	3.870E-16	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Sulforaphane	ST001202	AN002001	3.780E-16	7.440E-16	cell_type;iRBC;unRBC
C16-OH Sulfatide	ST000567	AN000871	1.030E-16	7.760E-16	Time point;Post;Pre;Baseline
Decosahexaenoic acid	ST000356	AN000582	8.270E-17	8.360E-16	stage;-;2;3
CL 76:11 (16:0/18:1/22:6/20:4) [M-2H](2-)	ST001111	AN001806	5.450E-17	9.050E-16	Sample;Benign;Cancer;Metastasis
z dioctylphtalate	ST000054	AN000092	1.740E-17	9.070E-16	treatment;Basal ;DCIS ;HER2 ;LumA ;LumB ;Reduction ;Total Po...
Kyn/Trp	ST001237	AN002055	1.650E-16	9.640E-16	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Pseudo uridine penta-tms	ST000978	AN001602	1.340E-17	9.810E-16	Cox_RRT;.;N;Y
gamma-thiomethyl glutamate	ST001204	AN002004	1.840E-16	1.170E-15	cell_type;iRBC;unRBC
L-beta-aspartyl-L-phenylalanine	ST000356	AN000583	3.470E-16	1.690E-15	Diagnosis;breast cancer;control
cotinine1	ST000614	AN000941	2.830E-16	1.700E-15	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
FA methyl(18:0)	ST001202	AN002001	9.430E-16	1.830E-15	cell_type;iRBC;unRBC
Molybdenum cofactor (sulfide)	ST000241	AN000373	1.180E-16	2.220E-15	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Sucrose and similar disaccharides	ST000586	AN000901	8.950E-16	2.450E-15	Plasma Volume;0 uL;150 uL;700 uL
alloxanoic acid NIST	ST000392	AN000628	2.630E-16	2.590E-15	Organ;Plasma;Serum;Serum or Plasma
(R)-2-Ethylmalate	ST001202	AN002000	1.660E-15	2.870E-15	cell_type;iRBC;unRBC
C38:5 PC	ST001142	AN001877	7.780E-16	2.890E-15	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
D-O-Phosphoserine	ST001202	AN002000	1.800E-15	3.100E-15	cell_type;iRBC;unRBC
CTAB	ST001202	AN002000	2.130E-15	3.640E-15	cell_type;iRBC;unRBC
MCPP (Mono (3-carboxpropyl) phthalate)	ST001048	AN001717	8.880E-16	3.770E-15	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
CL 74:10 (16:0/22:5/16:1/20:4) [M-2H](2-)	ST001111	AN001806	4.400E-16	5.840E-15	Sample;Benign;Cancer;Metastasis
L-a-glutamyl-L-Lysine	ST000539	AN000818	2.030E-17	5.890E-15	Cell type;Mature erythrocyte;Reticulocyte
Coproporphyrin	ST000356	AN000583	9.540E-16	6.270E-15	stage;-;2;3
2-deoxytetronic acid NIST	ST000385	AN000620	3.320E-15	6.390E-15	Organ;Plasma;Serum;Serum or Plasma
6-deoxy-5-ketofructose-1-phosphate	ST001201	AN001998	1.860E-15	6.620E-15	cell_type;iRBC;unRBC
diacetylspermine	ST001237	AN002055	1.060E-16	6.790E-15	OS_Censor (1 means the time is a censoring time and 0 means ...
NMMA	ST001237	AN002055	1.320E-16	6.790E-15	OS_Censor (1 means the time is a censoring time and 0 means ...
CL 74:9 (18:2/20:3/18:3/18:1) [M-2H](2-)	ST001111	AN001806	5.670E-16	7.230E-15	Sample;Benign;Cancer;Metastasis
Asparaginyl-Hydroxyproline	ST001202	AN002000	4.400E-15	7.380E-15	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate - 7.5459185	ST000566	AN000869	1.700E-15	7.880E-15	Time point;Post;Pre;Baseline
NMMA	ST001142	AN001875	3.410E-15	7.960E-15	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Acetylpseudotropine	ST001202	AN002000	6.310E-15	1.050E-14	cell_type;iRBC;unRBC
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	1.090E-15	1.060E-14	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
P-DPD	ST001204	AN002005	2.190E-15	1.180E-14	cell_type;iRBC;unRBC
BOC-HIS-OH	ST000016	AN000033	2.440E-15	1.450E-14	Material;Cells;Media
[13C]-LEUCINE	ST000016	AN000033	2.880E-15	1.680E-14	Material;Cells;Media
trihydroxypyrazine NIST	ST000369	AN000603	1.160E-15	1.750E-14	Organ;Plasma;Serum
PC(18:0/8:0(COOH))	ST000608	AN000929	1.040E-14	2.690E-14	Sample_Type;blotter;serum
PYRIDINE CARBOXYLIC ACID	ST000016	AN000033	7.130E-16	2.720E-14	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
C8-Ceramide m+6	ST000644	AN000976	7.860E-15	3.020E-14	tracer;13C-glucose;13C-glutamine;No label
Bis(glycerophospho)-glycerol	ST000403	AN000642	2.860E-16	3.380E-14	Cell type;Mature erythrocyte;Reticulocyte
5-Deoxy-5-aminoshikimic acid	ST000403	AN000643	1.550E-16	3.490E-14	Cell type;Mature erythrocyte;Reticulocyte
Theobromine /Theophylline/ Paraxanthine	ST001317	AN002192	2.012E-14	3.521E-14	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Theobromine /Theophylline/ Paraxanthine	ST001317	AN002192	2.012E-14	3.521E-14	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
dihomocitrate	ST000403	AN000643	3.880E-16	3.790E-14	Cell type;Mature erythrocyte;Reticulocyte
sinapoyltyramine	ST000403	AN000643	4.210E-16	3.790E-14	Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/7:0(CHO))	ST000608	AN000929	1.520E-14	3.850E-14	Sample_Type;blotter;serum
Glutaminolysis	ST000544	AN000826	2.320E-15	3.950E-14	Sample Type;Control;Replicate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	3.880E-16	4.790E-14	KD#1;no;yes;Pooled melanoma
2-deoxyglucose-6-phosphate	ST001201	AN001999	1.690E-14	5.490E-14	cell_type;iRBC;unRBC
FA methyl(16:1)	ST001202	AN002001	3.220E-14	5.520E-14	cell_type;iRBC;unRBC
PC 34:2 (17:2(9Z.12Z)/17:0) [M-Ac-H]-	ST001111	AN001806	6.350E-15	6.200E-14	Sample;Benign;Cancer;Metastasis
Arg-Leu-Val-Asn	ST000403	AN000643	9.310E-16	6.290E-14	Cell type;Mature erythrocyte;Reticulocyte
L(-)-Nicotine pestal	ST000241	AN000373	4.800E-15	6.450E-14	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-(1-Pyrrolidinyl)-2-pentanone	ST001202	AN002000	3.990E-14	6.480E-14	cell_type;iRBC;unRBC
ADMA / Arg	ST000544	AN000826	6.110E-15	6.930E-14	Sample Type;Control;Replicate
Ala-Asp-Cys-Ser	ST000539	AN000818	9.050E-16	7.530E-14	Cell type;Mature erythrocyte;Reticulocyte
Galabiosylceramide (d18:1/26:0)	ST000241	AN000373	6.080E-15	7.880E-14	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
P-DPD	ST001202	AN002001	5.420E-14	9.060E-14	cell_type;iRBC;unRBC
C8-Ceramide m+12	ST000644	AN000976	2.500E-14	9.210E-14	tracer;13C-glucose;13C-glutamine;No label
Asp-Met-Cys-Cys	ST000403	AN000643	1.710E-15	9.270E-14	Cell type;Mature erythrocyte;Reticulocyte
[Fv] Desmosdumotin C	ST000539	AN000818	1.650E-16	9.540E-14	timepoint;1 hour;20 hours
tetrahydro-beta-carboline-carboxylic acid	ST001000	AN001878	3.160E-15	1.120E-13	Diagnosis;CD;Control;UC
Pentonic acids	ST000586	AN000901	4.330E-14	1.120E-13	Plasma Volume;0 uL;150 uL;700 uL
Methyl methoxyacetate	ST000614	AN000941	3.760E-14	1.350E-13	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
S-Methyl-5-thio-D-ribose 1-phosphate	ST001204	AN002005	2.750E-14	1.370E-13	cell_type;iRBC;unRBC
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST000403	AN000643	2.890E-15	1.410E-13	Cell type;Mature erythrocyte;Reticulocyte
F1P/F6P/G1P/G6P	ST001142	AN001876	6.960E-14	1.420E-13	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	1.160E-15	1.440E-13	KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	1.180E-15	1.460E-13	Condition;no;Pooled melanoma;yes
3-nitro-2-pentanol	ST001202	AN002000	9.710E-14	1.550E-13	cell_type;iRBC;unRBC
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE	ST000016	AN000033	2.920E-14	1.550E-13	Material;Cells;Media
trihydroxypyrazine NIST	ST000386	AN000621	9.980E-15	1.640E-13	Organ;Plasma;Serum
Asp-Leu-Lys-Lys	ST000403	AN000643	3.990E-15	1.660E-13	Cell type;Mature erythrocyte;Reticulocyte
FA methyl(8:0)	ST001202	AN002001	1.110E-13	1.820E-13	cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitine	ST001204	AN002004	3.480E-14	1.850E-13	cell_type;iRBC;unRBC
4-Hydroxypyridine	ST000589	AN000904	1.590E-13	1.880E-13	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
di-n-Undecylamine	ST000403	AN000642	4.980E-15	2.260E-13	Cell type;Mature erythrocyte;Reticulocyte
C9 / C16:1-OH	ST000544	AN000827	1.600E-14	2.360E-13	Sample Type;Control;Replicate
Ala-Asp-Cys-Ser	ST000403	AN000642	6.390E-15	2.510E-13	Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminate	ST000403	AN000643	6.630E-15	2.560E-13	Cell type;Mature erythrocyte;Reticulocyte
1-deoxyxylonojirimycin	ST000539	AN000818	5.460E-15	2.870E-13	Cell type;Mature erythrocyte;Reticulocyte
IS D31-TAG	ST000523	AN000800	8.330E-15	3.640E-13	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	1.020E-14	4.270E-13	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
3-(ADP)-2-phosphoglycerate	ST001201	AN001998	1.340E-13	4.580E-13	cell_type;iRBC;unRBC
Asp-Leu-Lys-Lys	ST000539	AN000819	8.390E-15	6.420E-13	Cell type;Mature erythrocyte;Reticulocyte
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	2.810E-14	7.390E-13	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
FA methyl(14:0)	ST001202	AN002001	4.720E-13	7.470E-13	cell_type;iRBC;unRBC
1-deoxyxylonojirimycin	ST000403	AN000642	4.600E-14	8.870E-13	Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-Gly	ST000403	AN000642	4.660E-14	8.870E-13	Cell type;Mature erythrocyte;Reticulocyte
3-phosphoglucarate	ST001202	AN002001	5.990E-13	9.350E-13	cell_type;iRBC;unRBC
3-(ADP)-glycerate	ST001201	AN001999	2.990E-13	9.430E-13	cell_type;iRBC;unRBC
Ala-Trp-Gly-Gly	ST001202	AN002000	6.160E-13	9.480E-13	cell_type;iRBC;unRBC
C38:5 PC	ST001142	AN001877	3.600E-14	1.070E-12	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Bisacurone epoxide	ST001202	AN002000	7.010E-13	1.070E-12	cell_type;iRBC;unRBC
Asp-Met-Gln-Gln	ST001204	AN002004	2.280E-13	1.110E-12	cell_type;iRBC;unRBC
Sphinganine-phosphate (d18:0)	ST000553	AN000845	1.120E-13	1.210E-12	Sample type;Plasma;Urine
Dihomo-?-Linolenic Acid	ST000553	AN000846	1.740E-13	1.280E-12	Sample type;Plasma;Urine
IS SM 35:1;[M+H]+	ST000661	AN001009	7.300E-13	1.280E-12	Species;Homo sapiens;Rattus
4-Imidazolone-5-propanoate	ST001202	AN002000	8.720E-13	1.330E-12	cell_type;iRBC;unRBC
4-Imidazolone-5-propanoate	ST000403	AN000642	9.030E-14	1.370E-12	Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphate	ST000539	AN000819	2.410E-14	1.440E-12	Cell type;Mature erythrocyte;Reticulocyte
8-iso-15-keto-PGE2	ST000241	AN000373	1.530E-13	1.480E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-(4-sulfophenyl)butyrate	ST001202	AN002000	1.090E-12	1.660E-12	cell_type;iRBC;unRBC
CL 82:11 (18:0/20:0/22:6/22:5) [M-2H](2-)	ST001111	AN001806	2.060E-13	1.670E-12	Sample;Benign;Cancer;Metastasis
Arg-Asp-Asp-Gly	ST001202	AN002000	1.140E-12	1.730E-12	cell_type;iRBC;unRBC
Myoinositol-2-phosphate	ST000586	AN000901	7.020E-13	1.790E-12	Plasma Volume;0 uL;150 uL;700 uL
F1P/F6P/G1P/G6P	ST001142	AN001876	4.930E-13	1.820E-12	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose	ST001202	AN002001	4.520E-14	1.930E-12	treatment_duration_(h);-;1.5;3;6;9
Mesaconate	ST001202	AN002001	1.280E-12	1.940E-12	cell_type;iRBC;unRBC
Ganglioside GA1 (d18:1/24:0)	ST001202	AN002000	1.350E-12	2.030E-12	cell_type;iRBC;unRBC
vanilylmandelic acid	ST000420	AN000662	1.530E-13	2.140E-12	Group;nonsmoker;smoker
Ala-Ala-Ala-Ser	ST001204	AN002004	5.740E-13	2.630E-12	cell_type;iRBC;unRBC
CL 78:13 (18:1/20:4/18:2/22:6) [M-2H](2-)	ST001111	AN001806	3.740E-13	2.820E-12	Sample;Benign;Cancer;Metastasis
HWESASXX	ST000553	AN000846	4.720E-13	2.830E-12	Sample type;Plasma;Urine
(5-Amino-1H-tetraazol-1-yl)acetic acid	ST000356	AN000582	7.490E-13	3.150E-12	Diagnosis;breast cancer;control
5-hydroxymethyl-2-furoic acid nist	ST000420	AN000662	2.880E-13	3.630E-12	Group;nonsmoker;smoker
Tetrahydroneopterin	ST000356	AN000583	8.300E-13	3.640E-12	Diagnosis;breast cancer;control
N-acetyl -D- glucosaminitol	ST001202	AN002001	1.010E-13	3.710E-12	treatment_duration_(h);-;1.5;3;6;9
Asp-Met-Cys-Cys	ST000539	AN000819	9.280E-14	3.820E-12	Cell type;Mature erythrocyte;Reticulocyte
sinapoyltyramine	ST000539	AN000819	1.310E-13	3.910E-12	Cell type;Mature erythrocyte;Reticulocyte
5-6-Dihydrouridine	ST001201	AN001998	1.220E-12	3.940E-12	cell_type;iRBC;unRBC
Lys-Lys-Trp-Pro	ST001204	AN002005	9.230E-13	4.080E-12	cell_type;iRBC;unRBC
PC(24:1(15Z)/P-18:1(11Z))	ST000241	AN000373	4.830E-13	4.220E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-Phosphonopyruvate	ST001202	AN002001	3.090E-12	4.540E-12	cell_type;iRBC;unRBC
nicotinamide guanine dinucleotide	ST001201	AN001999	1.490E-12	4.600E-12	cell_type;iRBC;unRBC
SALICYLATE #2 (M-H)-	ST000748	AN001172	1.580E-12	4.630E-12	Sample type;Cells;Culture Media
L-beta-aspartyl-L-phenylalanine	ST000356	AN000583	8.850E-13	4.880E-12	stage;-;2;3
trans-Hexadec-2-enoylcarnitine	ST000539	AN000818	1.960E-13	5.670E-12	Cell type;Mature erythrocyte;Reticulocyte
plasmenyl-PC 40:2 (18:0/22:2(13Z.16Z)) [M+Na]+	ST001111	AN001805	8.150E-13	5.670E-12	Sample;Benign;Cancer;Metastasis
L-a-glutamyl-L-Lysine	ST000403	AN000642	5.470E-13	5.860E-12	Cell type;Mature erythrocyte;Reticulocyte
PIP(16:0/20:1(11Z))	ST000241	AN000373	7.200E-13	5.890E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Butanoyl-PAF	ST000553	AN000845	6.650E-13	5.980E-12	Sample type;Plasma;Urine
Bis(glycerophospho)-glycerol	ST000539	AN000818	2.390E-13	6.300E-12	Cell type;Mature erythrocyte;Reticulocyte
Ala-Met-Pro-Tyr	ST000403	AN000642	6.500E-13	6.730E-12	Cell type;Mature erythrocyte;Reticulocyte
CMP-N-trimethyl-2-aminoethylphosphonate	ST000403	AN000642	6.780E-13	6.900E-12	Cell type;Mature erythrocyte;Reticulocyte
PC(14:1(9Z)/P-18:1(11Z))	ST000241	AN000373	9.260E-13	6.960E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N2-(D-1-Carboxyethyl)-L-arginine	ST001204	AN002004	1.710E-12	7.390E-12	cell_type;iRBC;unRBC
dibenzothiophene-5-oxide	ST001202	AN002000	5.880E-12	8.590E-12	cell_type;iRBC;unRBC
3-Butynoate	ST001202	AN002000	3.650E-13	8.640E-12	treatment_duration_(h);-;1.5;3;6;9
IDP-D-mannose	ST001201	AN001999	2.860E-12	8.780E-12	cell_type;iRBC;unRBC
Asn-Leu-Asn-Tyr	ST000539	AN000818	4.180E-13	9.310E-12	Cell type;Mature erythrocyte;Reticulocyte
4-hydroxypyridine	ST000420	AN000662	9.750E-13	1.020E-11	Group;nonsmoker;smoker
6-Acetyl-D-glucose	ST000539	AN000819	5.090E-13	1.050E-11	Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucose 2	ST000539	AN000819	5.090E-13	1.050E-11	Cell type;Mature erythrocyte;Reticulocyte
Eicosapentaenoyl PAF C-16	ST000553	AN000846	2.740E-12	1.210E-11	Sample type;Plasma;Urine
Marinobufagenin	ST000566	AN000869	3.080E-12	1.230E-11	Time point;Post;Pre;Baseline
5-6-Dihydrouridine	ST001202	AN002000	6.290E-13	1.410E-11	treatment_duration_(h);-;1.5;3;6;9
N-hydroxyisoleucine	ST000403	AN000643	1.220E-12	1.470E-11	Cell type;Mature erythrocyte;Reticulocyte
Eicosapentaenoyl PAF C-16	ST000553	AN000845	2.900E-12	1.570E-11	Sample type;Plasma;Urine
CerH2O(d19:1/24:0)	ST000608	AN000929	8.300E-12	1.670E-11	Sample_Type;blotter;serum
1-thio-beta-D-glucose	ST001204	AN002005	3.940E-12	1.690E-11	cell_type;iRBC;unRBC
Ala-Phe-Tyr-Tyr	ST001201	AN001999	6.290E-12	1.840E-11	cell_type;iRBC;unRBC
Ala-Phe-Tyr-Tyr	ST001204	AN002005	4.420E-12	1.860E-11	cell_type;iRBC;unRBC
D/L Glucosamine / D/L Galactosamine / D-Mannosamine	ST001048	AN001716	1.190E-11	1.950E-11	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Putrescine / Orn	ST000544	AN000826	2.420E-12	2.060E-11	Sample Type;Control;Replicate
hydrogen iodide	ST000403	AN000643	2.040E-12	2.250E-11	Cell type;Mature erythrocyte;Reticulocyte
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)	ST000403	AN000643	2.240E-12	2.420E-11	Cell type;Mature erythrocyte;Reticulocyte
BOC-PRO-OH	ST000016	AN000033	8.260E-13	2.430E-11	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
Lactosylceramide(d18	ST001202	AN002000	1.770E-11	2.540E-11	cell_type;iRBC;unRBC
3-Butynoate	ST001201	AN001998	8.210E-12	2.570E-11	cell_type;iRBC;unRBC
Asn-Leu-Asn-Tyr	ST000403	AN000642	3.160E-12	2.620E-11	Cell type;Mature erythrocyte;Reticulocyte
omega-Cyclohexylundecanoic acid	ST000539	AN000819	1.720E-12	2.800E-11	Cell type;Mature erythrocyte;Reticulocyte
farnesol	ST000568	AN000874	1.660E-11	2.850E-11	Genotype;AA;AC;CC
IS SM 35:1;[M+H]+	ST000661	AN001009	9.430E-12	2.960E-11	Sample_Source;Plasma;POOLED;Mammary gland
Methylprednisone	ST000567	AN000871	5.880E-12	3.000E-11	Time point;Post;Pre;Baseline
PE(14:1(9Z)/P-16:0)	ST000241	AN000373	2.680E-12	3.250E-11	Concentration (uM);0;500
BOC-PRO-OH	ST000016	AN000033	1.520E-12	3.310E-11	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
CL 82:11 (18:0/20:0/22:5/22:6) [M-2H](2-)	ST001111	AN001806	5.690E-12	3.570E-11	Sample;Benign;Cancer;Metastasis
dXMP	ST000403	AN000643	3.910E-12	3.710E-11	Cell type;Mature erythrocyte;Reticulocyte
5-Taurinomethyl-2-thiouridine	ST000241	AN000373	6.310E-12	3.760E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-Imidazolone-5-propanoate	ST000539	AN000818	2.430E-12	3.810E-11	Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfone	ST000403	AN000642	4.960E-12	3.840E-11	Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Asn-His	ST000403	AN000642	5.150E-12	3.900E-11	Cell type;Mature erythrocyte;Reticulocyte
3-Phosphonopyruvate	ST000403	AN000643	4.440E-12	4.140E-11	Cell type;Mature erythrocyte;Reticulocyte
Cotine	ST000614	AN000943	4.370E-12	4.260E-11	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
2-O-ethyl PAF C-16	ST000553	AN000845	1.140E-11	4.390E-11	Sample type;Plasma;Urine
C4 / C5	ST000544	AN000827	3.530E-12	4.520E-11	Sample Type;Control;Replicate
Arg-Asn-Pro-His	ST000403	AN000642	6.410E-12	4.720E-11	Cell type;Mature erythrocyte;Reticulocyte
HEPES	ST000539	AN000819	3.360E-12	4.860E-11	Cell type;Mature erythrocyte;Reticulocyte
D-Galacturonate	ST000403	AN000643	5.830E-12	5.260E-11	Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-glycerate	ST000403	AN000643	6.160E-12	5.460E-11	Cell type;Mature erythrocyte;Reticulocyte
4-oxo-Retinoic acid	ST000241	AN000373	9.630E-12	5.570E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
1-Oleoyl Lysophosphatidic Acid	ST000553	AN000846	1.430E-11	5.590E-11	Sample type;Plasma;Urine
glucosylglycerol	ST000092	AN000146	9.150E-12	6.130E-11	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
undecanedionate	ST001000	AN001880	2.230E-12	6.230E-11	Diagnosis;CD;Control;UC
Cyclo(leucylprolyl)	ST000553	AN000845	1.890E-11	6.380E-11	Sample type;Plasma;Urine
Taurine Dimer	ST000380	AN000614	8.550E-12	6.600E-11	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Met-Trp-OH	ST000242	AN000375	4.610E-12	6.640E-11	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
PC(18:0/P-18:1(11Z))	ST000539	AN000818	4.990E-12	6.720E-11	Cell type;Mature erythrocyte;Reticulocyte
SDMA/ADMA	ST001142	AN001875	3.570E-11	7.220E-11	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
3-Butynoate	ST000403	AN000642	1.050E-11	7.380E-11	Cell type;Mature erythrocyte;Reticulocyte
epibrassinolide+HCOOH	ST001325	AN002207	7.898E-12	7.437E-11	Gender;-;female;male
Methylhippurate	ST000553	AN000847	2.750E-11	7.880E-11	Sample type;Plasma;Urine
Ala-Met-Pro-Tyr	ST000539	AN000818	7.510E-12	8.390E-11	Cell type;Mature erythrocyte;Reticulocyte
Vanilloylglycine	ST000292	AN000467	1.970E-12	8.460E-11	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Trihexosylceramide (d18:1/9Z-18:1)	ST000241	AN000373	1.590E-11	8.670E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholine	ST000403	AN000642	1.290E-11	8.880E-11	Cell type;Mature erythrocyte;Reticulocyte
Cotinineglucuronide	ST000241	AN000373	1.750E-11	9.140E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000403	AN000643	1.170E-11	9.150E-11	Cell type;Mature erythrocyte;Reticulocyte
Clitidine 5-phosphate	ST000539	AN000819	8.300E-12	9.670E-11	Cell type;Mature erythrocyte;Reticulocyte
IS Ceramide;[M-H20]+	ST000661	AN001009	6.530E-11	9.870E-11	Species;Homo sapiens;Rattus
Ala-Leu-Lys-Pro	ST000403	AN000642	1.580E-11	1.070E-10	Cell type;Mature erythrocyte;Reticulocyte
Total DMA / Arg	ST000544	AN000826	1.430E-11	1.080E-10	Sample Type;Control;Replicate
Asn-Cys-Pro-Ser	ST000403	AN000642	1.650E-11	1.090E-10	Cell type;Mature erythrocyte;Reticulocyte
HWESASXX	ST000553	AN000845	3.470E-11	1.100E-10	Sample type;Plasma;Urine
octulose 8-phosphate	ST001204	AN002004	2.890E-11	1.150E-10	cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphate	ST000403	AN000643	1.650E-11	1.260E-10	Cell type;Mature erythrocyte;Reticulocyte
CL 82:11 (18:0/22:5/20:0/22:6) [M-2H](2-)	ST001111	AN001806	2.120E-11	1.280E-10	Sample;Benign;Cancer;Metastasis
3-Methylglutarate/Adipate	ST001317	AN002193	6.165E-11	1.368E-10	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-Methylglutarate/Adipate	ST001317	AN002193	6.165E-11	1.368E-10	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-methyladipate/pimelate	ST001142	AN001876	4.270E-11	1.400E-10	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-Deoxyinosine	ST000553	AN000847	5.700E-11	1.470E-10	Sample type;Plasma;Urine
D/L Glucosamine / D/L Galactosamine	ST001048	AN001716	9.910E-11	1.540E-10	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
dXMP	ST000539	AN000819	1.580E-11	1.590E-10	Cell type;Mature erythrocyte;Reticulocyte
5-hydroxynorvaline NIST	ST000385	AN000620	1.060E-10	1.600E-10	Organ;Plasma;Serum;Serum or Plasma
3-(ADP)-glycerate	ST001202	AN002001	1.150E-11	1.640E-10	treatment_duration_(h);-;1.5;3;6;9
Methyl Guanine	ST000614	AN000943	2.650E-11	1.720E-10	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Beta-alanine methyl ester	ST000553	AN000847	7.090E-11	1.740E-10	Sample type;Plasma;Urine
IS Ceramide;[M-H20]+	ST000661	AN001009	6.350E-11	1.760E-10	Sample_Source;Plasma;POOLED;Mammary gland
5-Ureido-4-imidazole carboxylate	ST000292	AN000466	7.700E-13	1.790E-10	Treatment ;Baseline plasma;Plasma after drinking apple juice...
PC 24:2 (2:0/22:2(13Z.16Z)) [M+HCOO]-	ST001111	AN001806	3.190E-11	1.860E-10	Sample;Benign;Cancer;Metastasis
D-Galacturonate	ST000539	AN000819	2.110E-11	2.060E-10	Cell type;Mature erythrocyte;Reticulocyte
MUFA (PC) / SFA (PC)	ST000545	AN000830	2.270E-12	2.170E-10	Sample Type;Control;Replicate
ribitol (likely)	ST000420	AN000662	4.220E-11	2.210E-10	Group;nonsmoker;smoker
Kyn/Trp	ST001237	AN002055	3.260E-12	2.230E-10	Time point;baseline;week 4;week 8
Asn-Lys-Gly-Pro	ST001204	AN002004	6.050E-11	2.380E-10	cell_type;iRBC;unRBC
(S)-Methylmalonate semialdehyde	ST000539	AN000819	5.900E-13	3.160E-10	Glucose labelling;C13 glucose;unlabelled
PUFA (PC) / SFA (PC)	ST000545	AN000830	5.060E-12	3.220E-10	Sample Type;Control;Replicate
DMGV	ST001237	AN002055	2.960E-11	3.370E-10	OS_Censor (1 means the time is a censoring time and 0 means ...
1-O-Methyl-myo-inositol	ST001204	AN002005	9.040E-11	3.440E-10	cell_type;iRBC;unRBC
dihomocitrate	ST000539	AN000819	3.710E-11	3.480E-10	Cell type;Mature erythrocyte;Reticulocyte
A-Ketoglutaricacidoxime	ST000539	AN000819	4.150E-11	3.830E-10	Cell type;Mature erythrocyte;Reticulocyte
3-dimethylsulfoniopropionaldehyde	ST000539	AN000819	1.450E-12	3.880E-10	Glucose labelling;C13 glucose;unlabelled
20cooh AA	ST000916	AN001491	5.140E-12	3.960E-10	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
p-Toluic acid-M+0	ST001167	AN001930	7.990E-11	4.020E-10	Time points;0.25h;0h;12h;24h;4h;6days
hydrogen iodide	ST000539	AN000819	4.480E-11	4.070E-10	Cell type;Mature erythrocyte;Reticulocyte
Unknown_742.54(-)@6.25	ST000818	AN001298	2.110E-10	4.500E-10	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Dimethylallylaminopurine	ST000553	AN000846	1.920E-10	4.880E-10	Sample type;Plasma;Urine
CMP-N-acetylneuraminate	ST000539	AN000819	5.770E-11	4.910E-10	Cell type;Mature erythrocyte;Reticulocyte
di-n-Undecylamine	ST000539	AN000818	6.430E-11	5.390E-10	Cell type;Mature erythrocyte;Reticulocyte
Asn-Asp-Asp-Pro	ST000539	AN000819	7.460E-11	6.060E-10	Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Asn-His	ST000539	AN000818	7.940E-11	6.390E-10	Cell type;Mature erythrocyte;Reticulocyte
melibionate	ST000539	AN000819	8.950E-11	7.060E-10	Cell type;Mature erythrocyte;Reticulocyte
gamma-Muricholic acid	ST000553	AN000846	3.000E-10	7.080E-10	Sample type;Plasma;Urine
m-hydroxybenzoic acid	ST001325	AN002207	9.617E-11	7.245E-10	Gender;-;female;male
DL-Methionine sulfone	ST001202	AN002000	5.570E-11	7.480E-10	treatment_duration_(h);-;1.5;3;6;9
o-toluidene2	ST000614	AN000941	4.200E-10	7.550E-10	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
nonulose 9-phosphate	ST000403	AN000643	1.100E-10	7.600E-10	Cell type;Mature erythrocyte;Reticulocyte
2-Ketovaline	ST000586	AN000901	3.340E-10	7.630E-10	Plasma Volume;0 uL;150 uL;700 uL
Ganglioside GT3 (d18:1/18:1(11Z))	ST000241	AN000373	1.830E-10	7.660E-10	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
CL 72:10 (18:3/14:0/20:3/20:4) [M-2H](2-)	ST001111	AN001806	1.580E-10	7.820E-10	Sample;Benign;Cancer;Metastasis
Asn-Asp-Asp-Pro	ST000403	AN000643	1.240E-10	8.360E-10	Cell type;Mature erythrocyte;Reticulocyte
4-amino-4-deoxy-L-arabinose	ST001202	AN002000	6.470E-11	8.420E-10	treatment_duration_(h);-;1.5;3;6;9
CMP-N-trimethyl-2-aminoethylphosphonate	ST000539	AN000818	1.090E-10	8.460E-10	Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-Glu	ST000403	AN000643	1.320E-10	8.580E-10	Cell type;Mature erythrocyte;Reticulocyte
Hexose Pool	ST000450	AN000706	3.650E-10	8.670E-10	gender;Female;Male
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucoside	ST001202	AN002000	6.560E-10	8.720E-10	cell_type;iRBC;unRBC
gamma-Muricholic acid	ST000553	AN000845	3.390E-10	8.720E-10	Sample type;Plasma;Urine
nicotinamide guanine dinucleotide	ST001202	AN002001	7.590E-11	8.830E-10	treatment_duration_(h);-;1.5;3;6;9
Docosahexaenoyl PAF C-16	ST000553	AN000845	3.720E-10	9.140E-10	Sample type;Plasma;Urine
MANDELIC ACID #2 (M-H)-	ST000842	AN001356	5.800E-10	9.350E-10	Sample type;Muscles;Plasma;Pooled sample
z dioctylphtalate	ST000054	AN000092	2.330E-11	1.030E-9	pool aliquot;no;yes
plasmenyl-PE 34:1 (16:0/18:1(11E)) [M+H]+	ST001111	AN001805	2.650E-10	1.050E-9	Sample;Benign;Cancer;Metastasis
1-AG b	ST000096	AN000154	8.250E-11	1.070E-9	Timepoint;18 hours;4 hours;NA
N-acetylglycine NIST	ST000385	AN000620	8.230E-10	1.200E-9	Organ;Plasma;Serum;Serum or Plasma
Asp-Leu-Lys-Lys	ST001202	AN002000	9.150E-10	1.210E-9	cell_type;iRBC;unRBC
Methyl deoxyadenosine	ST000614	AN000943	3.230E-10	1.260E-9	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
1-arachidonoylglyercophosphate	ST000974	AN001595	1.190E-10	1.280E-9	REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (3)*	ST000974	AN001595	1.190E-10	1.280E-9	REGION;AHRI;MRC;SUN
n-acetyl-d-hexosamine	ST001322	AN002198	3.197E-11	1.321E-9	treatment;expecting 2 month - human breast milk;expecting 2 ...
ribose-5-P/ribulose5-P	ST001142	AN001876	9.640E-10	1.350E-9	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
trans-Hexadec-2-enoylcarnitine	ST000403	AN000642	2.680E-10	1.440E-9	Cell type;Mature erythrocyte;Reticulocyte
dibenzothiophene-5-oxide	ST001202	AN002000	1.330E-10	1.460E-9	treatment_duration_(h);-;1.5;3;6;9
PC(18:0/P-18:1(11Z))	ST000403	AN000642	2.770E-10	1.470E-9	Cell type;Mature erythrocyte;Reticulocyte
Threonine /Homoserine	ST000553	AN000847	7.040E-10	1.510E-9	Sample type;Plasma;Urine
Asp-Thr-Cys-Cys	ST001201	AN001998	5.370E-10	1.520E-9	cell_type;iRBC;unRBC
mildronate	ST000539	AN000818	2.150E-10	1.540E-9	Cell type;Mature erythrocyte;Reticulocyte
epibrassinolide+HCOOH	ST001325	AN002207	4.327E-10	1.577E-9	Sample type;batch pool;chear plasma;master pool;red cross pl...
Tris(2-chloroethyl)phosphate	ST000566	AN000869	4.530E-10	1.590E-9	Time point;Post;Pre;Baseline
Azythromycin	ST000241	AN000374	6.490E-10	1.640E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Amino-3-methyl-1-butanol	ST000242	AN000375	1.860E-10	1.670E-9	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
PE(16:1(9Z)/P-18:1(11Z))	ST000241	AN000373	4.310E-10	1.710E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-Nitrophenyl-3-ketovalidamine	ST000403	AN000643	3.260E-10	1.890E-9	Cell type;Mature erythrocyte;Reticulocyte
N-dimethylethanolamine	ST001202	AN002000	1.470E-9	1.930E-9	cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphate	ST001204	AN002005	5.480E-10	2.000E-9	cell_type;iRBC;unRBC
4-Phosphopantothenoylcysteine	ST000241	AN000373	5.210E-10	2.020E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ovothiol disulfide	ST001202	AN002000	1.590E-9	2.060E-9	cell_type;iRBC;unRBC
FMLP	ST000403	AN000642	5.010E-10	2.570E-9	Cell type;Mature erythrocyte;Reticulocyte
Theobromine /Theophylline	ST000553	AN000847	1.330E-9	2.680E-9	Sample type;Plasma;Urine
(5-Amino-1H-tetraazol-1-yl)acetic acid	ST000356	AN000582	7.550E-10	2.930E-9	stage;-;2;3
Dolichyl beta-D-mannosyl phosphate	ST000241	AN000373	8.010E-10	2.980E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N-hydroxyisoleucine	ST000539	AN000819	4.350E-10	3.030E-9	Cell type;Mature erythrocyte;Reticulocyte
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	9.220E-10	3.340E-9	Material;Cells;Media
Pentosidine	ST000355	AN000581	1.370E-10	3.400E-9	Diagnosis;Breast cancer;Control
4-Aminobenzoate / Anthranilate	ST001048	AN001716	2.360E-9	3.460E-9	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Met-Trp-Trp-Tyr	ST000403	AN000642	5.900E-12	3.480E-9	Glucose labelling;C13 glucose;unlabelled
FKGK 11	ST000242	AN000375	5.550E-10	3.630E-9	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	1.980E-9	3.760E-9	Gender;N/A;Female;Male
Cysteinyl-Hydroxyproline	ST001202	AN002000	4.210E-10	3.950E-9	treatment_duration_(h);-;1.5;3;6;9
SB N-(hexadecanoyl)-sphing-4-enine (d18:1(4E)/16:0) [M-H]-	ST001111	AN001806	9.140E-10	4.100E-9	Sample;Benign;Cancer;Metastasis
Sertraline	ST000356	AN000583	1.090E-9	4.250E-9	Diagnosis;breast cancer;control
PAF C-18	ST000553	AN000845	2.050E-9	4.250E-9	Sample type;Plasma;Urine
Sphinganine-phosphate (d18:0)	ST000553	AN000846	2.200E-9	4.400E-9	Sample type;Plasma;Urine
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)	ST000539	AN000819	7.170E-10	4.740E-9	Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-Gly	ST000539	AN000818	7.570E-10	4.760E-9	Cell type;Mature erythrocyte;Reticulocyte
[6]-Paradol	ST001202	AN002001	3.620E-9	4.780E-9	cell_type;iRBC;unRBC
Benzyl dodecyl dimethylammonium cation	ST000077	AN000123	3.660E-9	4.910E-9	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Ala-Lys-Asp-Pro	ST001204	AN002004	1.420E-9	4.920E-9	cell_type;iRBC;unRBC
NMMA	ST001142	AN001875	2.820E-9	5.050E-9	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Disialyllacto-N-tetraose	ST000241	AN000373	1.430E-9	5.060E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-Phosphonopyruvate	ST001202	AN002001	5.500E-10	5.420E-9	treatment_duration_(h);-;1.5;3;6;9
4-AMINOBUTANOATE (GABA);2-AMINO-2-METHYLPROPANOATE;3-AMINOISOBUTANOATE	ST000956	AN001568	3.600E-10	5.560E-9	Treatment;Condition-1;Condition-2;Condition-3;Control
Ala-Glu-Glu-His	ST001204	AN002004	1.690E-9	5.770E-9	cell_type;iRBC;unRBC
IS SM 35:1; [M+H]+	ST000523	AN000800	7.780E-10	5.810E-9	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Ala-Asp-Cys-Ser	ST001204	AN002004	1.720E-9	5.830E-9	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M+CL)-	ST000748	AN001172	3.110E-9	6.040E-9	Sample type;Cells;Culture Media
1-Hexadecylpyridinium cation	ST000089	AN000141	5.230E-9	6.570E-9	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
C8-Ceramide m+14	ST000644	AN000976	2.780E-9	6.630E-9	tracer;13C-glucose;13C-glutamine;No label
SC-514	ST000567	AN000871	1.690E-9	6.710E-9	Time point;Post;Pre;Baseline
2-C-Methyl-D-erythritol 4-phosphate	ST001201	AN001999	2.780E-9	7.280E-9	cell_type;iRBC;unRBC
[FA methyl(14:0)] 12-methyl-tetradecanoic acid	ST000539	AN000819	1.120E-9	7.330E-9	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (M-H)-	ST000748	AN001172	4.000E-9	7.450E-9	Sample type;Cells;Culture Media
ZEATIN [ISTD] (M+CL)-	ST000726	AN001138	2.250E-9	7.500E-9	Timepoint;-;270;120;30;90
N-Stearoyl-4-sphingenyl-1-O-phosphorylcholine	ST000089	AN000141	6.750E-9	8.450E-9	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphate	ST000539	AN000819	1.340E-9	8.540E-9	Cell type;Mature erythrocyte;Reticulocyte
Arg-Phe-Phe-Arg	ST001202	AN002001	6.640E-9	8.720E-9	cell_type;iRBC;unRBC
5-iPF2a-VI	ST001214	AN002025	9.870E-10	8.960E-9	BMI group;lean;obese;overweight
methylhexadecanoic acid	ST000368	AN000602	1.210E-9	9.110E-9	Organ;Plasma;Serum;Serum or Plasma
N-ACETYL-L-ALANINE;3-AMINO-5-HYDROXYBENZOIC ACID	ST000956	AN001568	8.720E-10	9.320E-9	Treatment;Condition-1;Condition-2;Condition-3;Control
Cotinine-good	ST000614	AN000943	3.160E-9	9.490E-9	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
MG(18:0e/0:0/0:0)	ST000241	AN000373	2.910E-9	9.670E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ala-Asp-Asp-Gln	ST000539	AN000818	1.810E-9	9.710E-9	Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerate	ST001202	AN002001	8.470E-9	1.110E-8	cell_type;iRBC;unRBC
Kanokoside D	ST000242	AN000375	2.860E-9	1.140E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Docosahexaenoyl PAF C-16	ST000553	AN000846	6.510E-9	1.260E-8	Sample type;Plasma;Urine
Arachidonoyl PAF C-16	ST000553	AN000846	7.090E-9	1.340E-8	Sample type;Plasma;Urine
hydrogen iodide	ST001202	AN002001	1.050E-8	1.350E-8	cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001202	AN002000	1.160E-8	1.480E-8	cell_type;iRBC;unRBC
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))	ST001202	AN002001	1.180E-8	1.510E-8	cell_type;iRBC;unRBC
DIHEXOSE	ST000105	AN000174	7.890E-11	1.510E-8	Sampling;After SWS onset;Morning fasting
Boc-Asn	ST000403	AN000642	3.390E-9	1.530E-8	Cell type;Mature erythrocyte;Reticulocyte
Malyngamide J	ST000242	AN000375	4.670E-9	1.530E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000974	AN001595	1.530E-9	1.570E-8	REGION;AHRI;MRC;SUN
Phosphatidyl glycerol	ST000242	AN000377	4.150E-10	1.590E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000974	AN001595	1.610E-9	1.630E-8	REGION;AHRI;MRC;SUN
mildronate	ST000403	AN000642	3.930E-9	1.760E-8	Cell type;Mature erythrocyte;Reticulocyte
DIHEXOSE	ST000105	AN000173	1.710E-10	1.760E-8	Sampling;After SWS onset;Morning fasting
Hydroxyibuprofen	ST000566	AN000869	5.680E-9	1.850E-8	Time point;Post;Pre;Baseline
metabolite 2	ST000539	AN000819	2.780E-10	1.860E-8	Glucose labelling;C13 glucose;unlabelled
Galactinoldihydrate	ST000403	AN000643	3.700E-9	1.870E-8	Cell type;Mature erythrocyte;Reticulocyte
melibionate	ST000403	AN000643	3.670E-9	1.870E-8	Cell type;Mature erythrocyte;Reticulocyte
3-dimethylsulfoniopropionaldehyde	ST000403	AN000643	7.120E-11	1.930E-8	Glucose labelling;C13 glucose;unlabelled
5?-Androstan-3?-ol-17-one sulfate - 8.185043	ST000566	AN000869	1.360E-9	1.990E-8	group;Old-Curcumin;Old-Placebo;young
Lyso-PAF C18	ST001223	AN002036	1.530E-9	1.990E-8	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
PAF C-16	ST000553	AN000845	1.110E-8	2.000E-8	Sample type;Plasma;Urine
Triterpenoid	ST000241	AN000373	6.640E-9	2.030E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Digitoxigenin bisdigitoxoside	ST000242	AN000375	6.820E-9	2.040E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
GC(18:2/16:0)	ST000450	AN000705	5.570E-9	2.170E-8	gender;Female;Male
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	9.540E-10	2.200E-8	Type;Cath;Non-invasive
FA hydroxy(16:0)] hexadecanoic acid	ST001202	AN002001	1.750E-8	2.210E-8	cell_type;iRBC;unRBC
Tetrahydroneopterin	ST000356	AN000583	5.290E-9	2.260E-8	stage;-;2;3
DOCOSAPENTAENOATE (*)	ST000106	AN000176	4.020E-10	2.320E-8	Sampling time;0 min;60 min
PE(16:0/P-18:1(11Z))	ST000241	AN000373	7.990E-9	2.420E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(14:1(9Z)/P-16:0)	ST000241	AN000373	8.460E-9	2.510E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Asp-Gly-Arg 2	ST000539	AN000818	5.020E-9	2.570E-8	Cell type;Mature erythrocyte;Reticulocyte
L-Arabinonate	ST000539	AN000819	4.330E-9	2.580E-8	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m0	ST000644	AN000976	1.180E-8	2.610E-8	tracer;13C-glucose;13C-glutamine;No label
Erythrulose 1-phosphate	ST000403	AN000642	6.160E-9	2.620E-8	Cell type;Mature erythrocyte;Reticulocyte
L-Aspartyl-4-phosphate	ST000241	AN000373	9.100E-9	2.650E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
o-toluidene	ST000614	AN000943	9.800E-9	2.730E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
ethanedisulfonate	ST000539	AN000819	4.700E-9	2.770E-8	Cell type;Mature erythrocyte;Reticulocyte
Phe-Ala-Phe-Ala	ST000553	AN000845	1.670E-8	2.830E-8	Sample type;Plasma;Urine
Xylobiose	ST001201	AN001999	8.800E-11	2.830E-8	treatment;DHA;DMSO;OZ277;OZ439
succinate/methylmalonate	ST001142	AN001876	1.080E-8	2.890E-8	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-(Acetamidomethylene)succinate	ST000403	AN000643	5.950E-9	2.900E-8	Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Lys-Asp	ST001204	AN002004	9.370E-9	2.960E-8	cell_type;iRBC;unRBC
5-?-Hydroxybutyl Hydantoin	ST000567	AN000871	8.440E-9	3.020E-8	Time point;Post;Pre;Baseline
nonulose 9-phosphate	ST000539	AN000819	5.380E-9	3.070E-8	Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphate 2	ST000539	AN000819	5.380E-9	3.070E-8	Cell type;Mature erythrocyte;Reticulocyte
Dihydro Cer (d18:0/16:0)	ST000553	AN000846	1.990E-8	3.120E-8	Sample type;Plasma;Urine
benzi(ghi)perylene	ST000614	AN000943	1.200E-8	3.120E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
tetranor 12-HETE	ST000916	AN001491	8.660E-10	3.330E-8	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
2-Hydroxyiminodibenzyl glucuronide	ST000242	AN000375	1.220E-8	3.370E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
plasmenyl-PC 37:0 (20:0/17:0) [M+Na]+	ST001111	AN001805	1.140E-8	3.470E-8	Sample;Benign;Cancer;Metastasis
4-Hydroxy-4-methylglutamate	ST000539	AN000818	7.380E-9	3.650E-8	Cell type;Mature erythrocyte;Reticulocyte
beta-Nicotinamide adenine dinucleotide	ST001211	AN002017	5.470E-10	3.760E-8	Group;Control;Methotrexate
Arg-Asn-Pro-His	ST000539	AN000818	7.740E-9	3.800E-8	Cell type;Mature erythrocyte;Reticulocyte
HEPTADECENOATE (*)	ST000106	AN000176	1.070E-9	4.310E-8	Sampling time;0 min;60 min
CerH2O(d18:2/22:0)	ST000608	AN000929	2.710E-8	4.340E-8	Sample_Type;blotter;serum
Na-methylhistamine	ST000553	AN000847	2.390E-8	4.360E-8	Sample type;Plasma;Urine
Epoxomicin	ST000567	AN000871	1.250E-8	4.370E-8	Time point;Post;Pre;Baseline
dibenzothiophene-5-oxide	ST001204	AN002004	1.580E-8	4.930E-8	cell_type;iRBC;unRBC
N-BOC-D-GLUCOSAMINE	ST000016	AN000033	1.540E-8	5.010E-8	Material;Cells;Media
Unknown_742.54(-)@6.25	ST000818	AN001298	1.050E-8	5.050E-8	Country;Ethiopia;Tanzania;Botswana
ArachidonoylPAF-C16	ST000553	AN000845	3.110E-8	5.090E-8	Sample type;Plasma;Urine
AC1MIY4G	ST000842	AN001360	5.020E-8	5.220E-8	Sample type;Muscles;Plasma;Pooled sample
1-OG b	ST000096	AN000154	1.230E-8	5.310E-8	Timepoint;18 hours;4 hours;NA
trans-Hexadec-2-enoylcarnitine	ST001202	AN002000	8.190E-9	5.410E-8	treatment_duration_(h);-;1.5;3;6;9
CL 82:12 (20:1/18:0/22:5/22:6) [M-2H](2-)	ST001111	AN001806	1.480E-8	5.660E-8	Sample;Benign;Cancer;Metastasis
Fibrinopeptide B (1-9)**	ST000974	AN001595	6.390E-9	5.880E-8	REGION;AHRI;MRC;SUN
N-acetyl-D-hexosamine	ST000412	AN000652	1.640E-9	6.370E-8	Collection Time;1 Hr;2 Hr;3 Hr;-
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-Gluc	ST000241	AN000373	2.600E-8	6.890E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ala-Asp-Asp-Gln	ST000403	AN000642	1.850E-8	7.370E-8	Cell type;Mature erythrocyte;Reticulocyte
D-Erythronic acid ?-lactone	ST000614	AN000943	3.050E-8	7.420E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
melibionate	ST001201	AN001999	2.950E-8	7.550E-8	cell_type;iRBC;unRBC
isohydroxybutyric acid	ST000092	AN000146	1.990E-8	7.830E-8	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
Asparaginyl-Hydroxyproline	ST001202	AN002000	1.260E-8	7.840E-8	treatment_duration_(h);-;1.5;3;6;9
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000713	AN001113	1.660E-9	7.930E-8	malignant transformation;No;yes;Yes
Phenylacetonitrile	ST001201	AN001998	3.100E-8	8.030E-8	cell_type;iRBC;unRBC
Unknown_742.54(-)@5.61	ST000818	AN001298	4.840E-8	8.070E-8	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Sertraline	ST000356	AN000583	1.960E-8	8.160E-8	stage;-;2;3
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	4.530E-8	8.470E-8	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
L-Erythrulose	ST000403	AN000643	2.060E-8	8.490E-8	Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxy-4-methylglutamate	ST001202	AN002000	1.410E-8	8.620E-8	treatment_duration_(h);-;1.5;3;6;9
heptadecanoic acid NIST	ST000385	AN000620	6.370E-8	8.650E-8	Organ;Plasma;Serum;Serum or Plasma
Estriol 3-sulfate 16-glucuronide	ST000241	AN000373	3.370E-8	8.730E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Butanoyl-PAF	ST000553	AN000846	6.370E-8	8.950E-8	Sample type;Plasma;Urine
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine	ST000403	AN000643	2.250E-8	9.220E-8	Cell type;Mature erythrocyte;Reticulocyte
Pseudo uridine penta-tms	ST000978	AN001602	9.440E-10	9.220E-8	Cox_Composite_DeathRRT;.;N;Y
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE;BETAINE	ST000956	AN001568	1.330E-8	9.260E-8	Treatment;Condition-1;Condition-2;Condition-3;Control
Benzyl dodecyl dimethylammonium cation	ST000077	AN000123	3.160E-8	9.430E-8	Treatment;100uM Met ;370uM Hcy ;quality check
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001201	AN001998	3.780E-8	9.720E-8	cell_type;iRBC;unRBC
2-(Acetamidomethylene)succinate	ST000539	AN000819	1.910E-8	9.860E-8	Cell type;Mature erythrocyte;Reticulocyte
Met-Trp-Trp-Tyr	ST000539	AN000818	1.780E-10	1.030E-7	Glucose labelling;C13 glucose;unlabelled
3-nitro-2-pentanol	ST001202	AN002000	1.700E-8	1.030E-7	treatment_duration_(h);-;1.5;3;6;9
Erucate	ST001317	AN002193	5.968E-8	1.073E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Erucate	ST001317	AN002193	5.968E-8	1.073E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
N-Acetyl-D-glucosaminate	ST000539	AN000819	2.220E-8	1.120E-7	Cell type;Mature erythrocyte;Reticulocyte
beta-mannosylglycerate	ST000385	AN000620	8.300E-8	1.120E-7	Organ;Plasma;Serum;Serum or Plasma
SB N-(15Z-tetracosenoyl)-sphing-4-enine (d18:1(4E)/24:1(15Z)) [M-H]-	ST001111	AN001806	3.190E-8	1.150E-7	Sample;Benign;Cancer;Metastasis
(S)-Methylmalonate semialdehyde	ST000403	AN000643	1.300E-9	1.170E-7	Glucose labelling;C13 glucose;unlabelled
Se-Methylselenocysteine	ST000356	AN000583	3.580E-8	1.180E-7	Diagnosis;breast cancer;control
HETE	ST001223	AN002036	2.760E-8	1.200E-7	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	3.970E-8	1.220E-7	Material;Cells;Media
ketoconazol	ST000403	AN000642	3.180E-8	1.230E-7	Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Lys-Asp	ST001201	AN001998	4.920E-8	1.250E-7	cell_type;iRBC;unRBC
EPC(d33:1)	ST001202	AN002000	2.220E-8	1.280E-7	treatment_duration_(h);-;1.5;3;6;9
4aminobenzaldehyde1	ST000614	AN000941	8.690E-8	1.300E-7	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
nocardicin G	ST000403	AN000643	3.450E-8	1.350E-7	Cell type;Mature erythrocyte;Reticulocyte
Methylpicolinate	ST000553	AN000847	8.070E-8	1.360E-7	Sample type;Plasma;Urine
KG M+5	ST000507	AN000776	2.890E-8	1.380E-7	Time (incubation);24 hours;72 hours
6-Acetyl-D-glucose	ST001202	AN002000	2.570E-8	1.400E-7	treatment_duration_(h);-;1.5;3;6;9
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000974	AN001595	1.670E-8	1.430E-7	REGION;AHRI;MRC;SUN
Laurencione diacetate	ST000567	AN000871	3.070E-9	1.460E-7	groups;Old-Curcumin;Old-Placebo;young
4-(Trimethylammonio)but-2-enoate	ST001201	AN001998	1.120E-9	1.460E-7	treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-Ser	ST001204	AN002004	4.910E-8	1.490E-7	cell_type;iRBC;unRBC
Trisaccharide	ST000586	AN000901	8.180E-8	1.580E-7	Plasma Volume;0 uL;150 uL;700 uL
Mesaconate	ST001202	AN002001	2.310E-8	1.600E-7	treatment_duration_(h);-;1.5;3;6;9
N-(octanoyl)-L-homoserine	ST000403	AN000642	4.270E-8	1.610E-7	Cell type;Mature erythrocyte;Reticulocyte
4Alpha-hydroxymethyl-5alpha-cholesta-8-en-3beta-ol	ST000241	AN000373	7.190E-8	1.800E-7	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
5-6-Dihydrouridine	ST001202	AN002000	1.510E-7	1.830E-7	cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001202	AN002000	3.560E-8	1.860E-7	treatment_duration_(h);-;1.5;3;6;9
C-glycosyltryptophan	ST000899	AN001464	1.220E-9	1.890E-7	Type;Control;Crohn disease;Ulcerative Colitis
6-Acetyl-D-glucose	ST000403	AN000643	5.010E-8	1.900E-7	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	1.920E-8	2.090E-7	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
PAF C-18	ST000553	AN000846	1.650E-7	2.100E-7	Sample type;Plasma;Urine
SDMA / Arg	ST000544	AN000826	3.530E-8	2.180E-7	Sample Type;Control;Replicate
Unknown_742.54(-)@6.25	ST000818	AN001298	9.880E-8	2.210E-7	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Methylpicolinate	ST001317	AN002192	1.629E-7	2.225E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Methylpicolinate	ST001317	AN002192	1.629E-7	2.225E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
sulfate of piperine metabolite C16H19NO3 (2)*	ST000974	AN001595	2.720E-8	2.260E-7	REGION;AHRI;MRC;SUN
Dehydro-L-(+)-ascorbic acid dimer	ST000567	AN000871	6.820E-8	2.270E-7	Time point;Post;Pre;Baseline
17?-Ethinyl estradiol	ST000553	AN000846	1.860E-7	2.320E-7	Sample type;Plasma;Urine
3-methyladipate-pimelate	ST001000	AN001879	1.660E-8	2.420E-7	Diagnosis;CD;Control;UC
C12 / C10	ST000544	AN000827	2.610E-8	2.790E-7	Sample Type;Control;Replicate
Ovothiol disulfide	ST000539	AN000818	6.860E-8	2.880E-7	Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerate	ST001202	AN002001	4.520E-8	2.890E-7	treatment_duration_(h);-;1.5;3;6;9
acetyl-galactosamine	ST001237	AN002055	4.080E-8	2.980E-7	OS_Censor (1 means the time is a censoring time and 0 means ...
Benzyl tetradecyl dimethylammonium cation	ST000077	AN000123	2.750E-7	3.060E-7	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Phenolsulfonphthalein	ST000403	AN000643	8.450E-8	3.130E-7	Cell type;Mature erythrocyte;Reticulocyte
3-Methylglutaconic acid	ST000356	AN000583	1.110E-7	3.460E-7	Diagnosis;breast cancer;control
Allopregnanalone sulfate	ST000566	AN000869	3.980E-8	3.500E-7	group;Old-Curcumin;Old-Placebo;young
CerH2O(d18:2/23:0)	ST000608	AN000929	2.340E-7	3.570E-7	Sample_Type;blotter;serum
Boc-Asn	ST000539	AN000818	8.790E-8	3.660E-7	Cell type;Mature erythrocyte;Reticulocyte
D-Erythronic acid ?-lactone	ST000614	AN000943	3.870E-8	3.770E-7	Diagonsis;Benign;Cancer;Normal
2-amino-2-deoxyglucitol-6-phosphate	ST001204	AN002004	1.360E-7	3.920E-7	cell_type;iRBC;unRBC
L-Ascorbate 6-phosphate	ST001204	AN002005	1.350E-7	4.110E-7	cell_type;iRBC;unRBC
FA hydroxy(18:0)	ST001202	AN002001	3.520E-7	4.210E-7	cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphate	ST001202	AN002001	3.610E-7	4.300E-7	cell_type;iRBC;unRBC
Glu-Cys-Cys 2	ST000539	AN000819	9.280E-8	4.400E-7	Cell type;Mature erythrocyte;Reticulocyte
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	9.840E-8	4.570E-7	Organ;Plasma;Serum;Serum or Plasma
[PR] 9-Hydroxy-helminthosporol	ST000403	AN000643	1.300E-7	4.620E-7	Cell type;Mature erythrocyte;Reticulocyte
2-deoxytetronic acid nist	ST000420	AN000662	1.670E-7	4.790E-7	Group;nonsmoker;smoker
L-beta-aspartyl-L-leucine	ST001204	AN002004	1.700E-7	4.840E-7	cell_type;iRBC;unRBC
FA oxo(18:0)	ST001202	AN002001	4.220E-7	4.980E-7	cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphate	ST001202	AN002001	9.320E-8	5.300E-7	treatment_duration_(h);-;1.5;3;6;9
Flavonol 3-O-xylosylglycoside-13C1[+QDA adduct]+	ST000148	AN000235	1.250E-10	5.430E-7	Treatment;13C-Glc;unlabeled
5-HETrE	ST001214	AN002025	1.140E-7	5.890E-7	BMI group;lean;obese;overweight
Se-Methylselenocysteine	ST000356	AN000583	1.660E-7	6.310E-7	stage;-;2;3
Pentosidine	ST000355	AN000581	2.550E-8	6.320E-7	Stage;1;2;3;4;-
(-)-jasmonoyl-L-valine	ST000403	AN000643	1.880E-7	6.500E-7	Cell type;Mature erythrocyte;Reticulocyte
Oxonitine	ST000242	AN000376	1.670E-7	6.660E-7	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Methyl eicosatrienoate	ST000586	AN000901	3.530E-7	6.670E-7	Plasma Volume;0 uL;150 uL;700 uL
4-Nitrophenyl-3-ketovalidamine	ST000539	AN000819	1.470E-7	6.740E-7	Cell type;Mature erythrocyte;Reticulocyte
Crotetamide	ST000913	AN001483	5.870E-9	6.810E-7	Diagnosis;MECFS;MS;ND
4-Amino-4-deoxychorismate	ST001204	AN002005	2.350E-7	6.900E-7	cell_type;iRBC;unRBC
2-O-methyl PAF C-16	ST000553	AN000846	6.290E-7	7.410E-7	Sample type;Plasma;Urine
N-(5-Methyl-3-oxohexyl)alanine	ST001202	AN002000	6.190E-7	7.420E-7	cell_type;iRBC;unRBC
C4 N O4 S	ST000566	AN000870	5.760E-8	7.450E-7	Time point;Post;Pre;Baseline
C7 N O6 S	ST000566	AN000870	8.060E-8	7.450E-7	Time point;Post;Pre;Baseline
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acid	ST000403	AN000643	2.190E-7	7.510E-7	Cell type;Mature erythrocyte;Reticulocyte
3-hydroxyacyl group of bacterial toxin	ST000539	AN000819	1.670E-7	7.590E-7	Cell type;Mature erythrocyte;Reticulocyte
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphate	ST000403	AN000643	2.350E-7	7.960E-7	Cell type;Mature erythrocyte;Reticulocyte
glyoxalurea NIST	ST000386	AN000621	1.320E-7	7.960E-7	Organ;Plasma;Serum
4-hydroxy-3-methylacetophenone	ST001237	AN002055	2.350E-8	8.010E-7	Time point;baseline;week 4;week 8
13C-aminoadipic	ST000947	AN001555	2.680E-7	8.040E-7	Group;control;PCOS
G3P	ST000301	AN000479	8.830E-8	8.240E-7	Cell Line;L229;LN18;Pooled glioblastoma;U-138
PC(18:0/5:0(COOH))	ST000608	AN000929	5.650E-7	8.540E-7	Sample_Type;blotter;serum
Cyclopiazonic Acid	ST000242	AN000375	4.050E-7	8.580E-7	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
para-toluidene	ST000614	AN000943	5.340E-7	9.060E-7	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Asn-Leu-Pro-Pro	ST001204	AN002004	3.270E-7	9.150E-7	cell_type;iRBC;unRBC
C12 / C10	ST000545	AN000830	7.060E-8	9.800E-7	Sample Type;Control;Replicate
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000105	AN000174	2.070E-8	9.870E-7	Sampling;After SWS onset;Morning fasting
Hydroxyprolines	ST000586	AN000901	5.510E-7	1.020E-6	Plasma Volume;0 uL;150 uL;700 uL
Methyl methoxyacetate	ST000614	AN000941	1.750E-7	1.050E-6	Diagonsis;Benign;Cancer;Normal
Clitidine 5-phosphate	ST000403	AN000643	3.150E-7	1.060E-6	Cell type;Mature erythrocyte;Reticulocyte
1-LG b	ST000096	AN000154	4.250E-7	1.110E-6	Timepoint;18 hours;4 hours;NA
3-hydroxyoxyisovaleric acid	ST000356	AN000582	4.060E-7	1.140E-6	Diagnosis;breast cancer;control
Erythrotetrofuranose	ST000356	AN000582	4.360E-7	1.190E-6	Diagnosis;breast cancer;control
2-Amino-3-methyl-1-butanol	ST000566	AN000870	2.430E-7	1.220E-6	Time point;Post;Pre;Baseline
7b-Hydroxydehydroepiandrosterone	ST000356	AN000583	4.100E-7	1.250E-6	Diagnosis;breast cancer;control
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000016	AN000033	4.600E-7	1.260E-6	Material;Cells;Media
Tolylacetonitrile	ST001202	AN002000	3.260E-7	1.260E-6	treatment_duration_(h);-;1.5;3;6;9
3-Sulfolactate	ST000403	AN000643	3.860E-7	1.280E-6	Cell type;Mature erythrocyte;Reticulocyte
Senecivernine	ST000566	AN000870	2.910E-7	1.330E-6	Time point;Post;Pre;Baseline
N-Succinyl-L-diaminopimelic acid	ST000242	AN000376	4.500E-7	1.350E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Benzylserine	ST000553	AN000847	9.400E-7	1.400E-6	Sample type;Plasma;Urine
4-(Trimethylammonio)but-2-enoate	ST001202	AN002000	1.200E-6	1.410E-6	cell_type;iRBC;unRBC
Tyrphostin B44 (-)	ST000242	AN000376	5.890E-7	1.410E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Malyngamide J	ST000242	AN000377	8.870E-8	1.420E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
OLEANANOICACIDACETATE	ST000046	AN000076	2.520E-8	1.430E-6	Cognitive Status;AD;CN;MCI
Digitoxigenin bisdigitoxoside	ST000242	AN000377	1.140E-7	1.490E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hydroxytetrabenazine glucuronide	ST000242	AN000377	1.160E-7	1.490E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000077	AN000123	1.410E-6	1.530E-6	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Phenolsulfonphthalein	ST000539	AN000819	3.570E-7	1.580E-6	Cell type;Mature erythrocyte;Reticulocyte
GLUCARIC/GULARIC/SACCHARIC ACID	ST000016	AN000033	5.850E-7	1.580E-6	Material;Cells;Media
omega-Cyclohexylundecanoic acid	ST000403	AN000643	5.130E-7	1.660E-6	Cell type;Mature erythrocyte;Reticulocyte
Trihexosylceramide (d18:1/24:0)	ST000241	AN000373	7.560E-7	1.680E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
D-glycero-L-galacto-Octulose	ST001202	AN002001	3.810E-7	1.690E-6	treatment_duration_(h);-;1.5;3;6;9
D-O-Phosphoserine	ST001202	AN002000	4.550E-7	1.710E-6	treatment_duration_(h);-;1.5;3;6;9
Ethylmalonate/Methyl Malonate	ST000614	AN000939	1.140E-6	1.720E-6	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	9.180E-8	1.810E-6	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
Asymmetrical dimethylarginine	ST001040	AN001702	5.170E-8	1.830E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
Antheridiogen-An	ST001204	AN002004	6.890E-7	1.860E-6	cell_type;iRBC;unRBC
C4 N O4 S	ST000567	AN000872	9.850E-8	1.860E-6	Time point;Post;Pre;Baseline
C7 N O6 S	ST000567	AN000872	4.500E-8	1.860E-6	Time point;Post;Pre;Baseline
Hydromorphone (anesthetic)	ST000089	AN000141	1.660E-6	1.870E-6	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Total lysoPC	ST000545	AN000830	2.360E-7	1.880E-6	Sample Type;Control;Replicate
FA oxo(16:0)	ST001202	AN002001	1.630E-6	1.910E-6	cell_type;iRBC;unRBC
POV-PC	ST000553	AN000845	1.410E-6	2.000E-6	Sample type;Plasma;Urine
2-Aminomalonate semialdehyde	ST000539	AN000819	4.620E-7	2.010E-6	Cell type;Mature erythrocyte;Reticulocyte
2-hydroxymethanesulfonate	ST000539	AN000819	4.850E-7	2.100E-6	Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Pro-Ser	ST000403	AN000642	6.650E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/P-18:1(11Z))	ST000403	AN000642	6.570E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
Tyr-OEt	ST000403	AN000642	6.600E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
Diphenylmethylphosphine	ST000567	AN000871	6.890E-7	2.140E-6	Time point;Post;Pre;Baseline
Very low density lipoprotein	ST001038	AN001699	6.960E-7	2.200E-6	Placenta_Surface;Fetal;Maternal
glyoxalurea NIST	ST000369	AN000603	4.070E-7	2.210E-6	Organ;Plasma;Serum
Steryl sulfate	ST000566	AN000869	2.790E-7	2.230E-6	group;Old-Curcumin;Old-Placebo;young
nocardicin G	ST000539	AN000819	5.290E-7	2.270E-6	Cell type;Mature erythrocyte;Reticulocyte
4-Imidazolone-5-propanoate	ST001202	AN002000	6.530E-7	2.350E-6	treatment_duration_(h);-;1.5;3;6;9
saccharic acid	ST000412	AN000652	7.370E-7	2.380E-6	Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
Assymetrical dimethylarginine	ST000553	AN000847	1.730E-6	2.430E-6	Sample type;Plasma;Urine
3-Indolelactic acid/tryptophan	ST000586	AN000901	1.420E-6	2.530E-6	Plasma Volume;0 uL;150 uL;700 uL
Heptadecanoic acid/Octadecanol 2	ST000586	AN000901	1.530E-6	2.630E-6	Plasma Volume;0 uL;150 uL;700 uL
PE(14:0/P-18:1(11Z))	ST000241	AN000373	1.200E-6	2.630E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-Butynoate	ST000539	AN000818	7.200E-7	2.740E-6	Cell type;Mature erythrocyte;Reticulocyte
N-HISTIDYL-2-AMINONAPHTHALENE(betaNA)	ST000046	AN000076	6.580E-8	2.850E-6	Cognitive Status;AD;CN;MCI
Dimethylarsinous acid	ST000241	AN000373	1.330E-6	2.860E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Methylbutanal	ST000567	AN000872	3.780E-7	2.890E-6	Time point;Post;Pre;Baseline
Ganglioside GM3 (d18:0/16:0)	ST000241	AN000373	1.360E-6	2.910E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[13C]-HISTIDINE	ST000016	AN000033	3.800E-7	2.920E-6	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
HYDROXYACETAMINOPHEN SULFATE (*)	ST000106	AN000176	1.350E-7	3.030E-6	Sampling time;0 min;60 min
5-Formiminotetrahydrofolic acid	ST000566	AN000870	9.050E-7	3.060E-6	Time point;Post;Pre;Baseline
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE;L-2-Aminoadipic Acid	ST000956	AN001568	6.230E-7	3.090E-6	Treatment;Condition-1;Condition-2;Condition-3;Control
[PR] Citronellyl acetate	ST000403	AN000643	1.030E-6	3.220E-6	Cell type;Mature erythrocyte;Reticulocyte
L-Glutamic acid n-butyl ester + 1.5990624	ST000566	AN000870	1.050E-6	3.340E-6	Time point;Post;Pre;Baseline
L-Glutamic acid n-butyl ester	ST000566	AN000870	1.160E-6	3.590E-6	Time point;Post;Pre;Baseline
C29 N O20 S2	ST000567	AN000872	5.290E-7	3.620E-6	Time point;Post;Pre;Baseline
ribose-5-P/ribulose5-P	ST001142	AN001876	1.850E-6	3.640E-6	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Furmecyclox	ST000567	AN000871	1.210E-6	3.700E-6	Time point;Post;Pre;Baseline
Flavonoid or short-chain cholesterol ester	ST000586	AN000901	2.210E-6	3.710E-6	Plasma Volume;0 uL;150 uL;700 uL
[13C]-ARGININE	ST000016	AN000033	1.460E-6	3.740E-6	Material;Cells;Media
Kyn/Trp	ST001237	AN002055	6.290E-7	3.790E-6	OS_Censor (1 means the time is a censoring time and 0 means ...
N-Glycolyl-D-mannosamine	ST001201	AN001998	1.680E-6	3.840E-6	cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001202	AN002001	1.000E-6	3.880E-6	treatment_duration_(h);-;1.5;3;6;9
7?-Hydroxy-3-oxo-4-cholestenoate	ST000567	AN000872	6.540E-7	4.050E-6	Time point;Post;Pre;Baseline
4-hydroxy-3-methylacetophenone	ST001000	AN001878	5.060E-7	4.130E-6	Diagnosis;CD;Control;UC
HBA	ST000567	AN000872	7.050E-7	4.160E-6	Time point;Post;Pre;Baseline
2-Aminomalonate semialdehyde	ST000403	AN000643	1.360E-6	4.210E-6	Cell type;Mature erythrocyte;Reticulocyte
L-Erythrulose	ST000539	AN000819	1.020E-6	4.290E-6	Cell type;Mature erythrocyte;Reticulocyte
MethoxsalenMetabolite	ST000047	AN000083	5.660E-8	4.540E-6	Cognitive Status;AD;CN;MCI
PC(16:0/5:0(CHO))	ST000403	AN000642	1.480E-6	4.550E-6	Cell type;Mature erythrocyte;Reticulocyte
C12 / C8	ST000544	AN000827	4.990E-7	4.560E-6	Sample Type;Control;Replicate
Citiolone	ST000242	AN000375	2.550E-6	4.590E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000077	AN000123	2.290E-6	4.590E-6	Treatment;100uM Met ;370uM Hcy ;quality check
Asp-Gly-Pro-Ser	ST000403	AN000642	1.540E-6	4.700E-6	Cell type;Mature erythrocyte;Reticulocyte
Istamycin C	ST000242	AN000377	4.540E-7	4.840E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-ACETYL-HEXOSAMINE	ST000475	AN000739	6.130E-7	4.910E-6	Treatment;-;MDH inhib
N2-Acetyl-L-aminoadipate 2	ST000539	AN000819	1.240E-6	4.990E-6	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	3.330E-7	4.990E-6	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
Myxothiazol Z	ST000566	AN000870	1.830E-6	5.050E-6	Time point;Post;Pre;Baseline
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	2.590E-7	5.180E-6	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Elaidate / Oleate /Petroselinate	ST001040	AN001703	6.700E-7	5.360E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
PUFA	ST001223	AN002036	2.500E-6	5.420E-6	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000713	AN001114	2.910E-7	5.500E-6	malignant transformation;No;yes;Yes
Mono-N-depropylprobenecid	ST000421	AN000664	1.400E-8	5.570E-6	treatment;ND;T1D poor glycemic control
Adrenaline(Epinephrine)	ST001040	AN001702	2.240E-7	5.670E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
8-HETrE	ST001214	AN002025	1.820E-6	5.830E-6	BMI group;lean;obese;overweight
N(alpha)-t-Butoxycarbonyl-L-leucine	ST000567	AN000872	1.230E-6	6.070E-6	Time point;Post;Pre;Baseline
2(alpha-D-Mannosyl)-D-glycerate	ST001202	AN002001	1.690E-6	6.080E-6	treatment_duration_(h);-;1.5;3;6;9
8-Amino-7-oxononanoate	ST001202	AN002000	2.130E-6	6.100E-6	treatment_duration_(h);-;1.5;3;6;9
Galactinoldihydrate	ST000539	AN000819	1.590E-6	6.250E-6	Cell type;Mature erythrocyte;Reticulocyte
Asn-Cys-Pro-Ser	ST000539	AN000818	1.740E-6	6.360E-6	Cell type;Mature erythrocyte;Reticulocyte
N-Methylalanine/2-Aminobutanoic acid/N-Ethylglycine	ST000586	AN000901	3.900E-6	6.490E-6	Plasma Volume;0 uL;150 uL;700 uL
Hydroxyglutaric acid	ST000356	AN000582	2.620E-6	6.620E-6	Diagnosis;breast cancer;control
2-deoxycytidine	ST001142	AN001875	4.440E-6	6.840E-6	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
3-methyladipate/pimelate	ST000923	AN001514	7.130E-7	6.840E-6	Diagnosis;CD;nonIBD;UC
Total SM-OH	ST000545	AN000830	1.400E-6	6.860E-6	Sample Type;Control;Replicate
Adenosine 35-diphosphate	ST001091	AN001777	3.740E-6	7.180E-6	Sample.Matrix;Colon Mucosal Tissue;Plasma
4-Amino-4-deoxychorismate	ST001202	AN002001	2.080E-6	7.200E-6	treatment_duration_(h);-;1.5;3;6;9
Penicilloic G acid	ST000242	AN000376	4.330E-6	7.430E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
MUFA (PC)	ST000545	AN000830	1.860E-6	7.970E-6	Sample Type;Control;Replicate
Total SM	ST000545	AN000830	1.960E-6	7.970E-6	Sample Type;Control;Replicate
Total SM-non OH	ST000545	AN000830	1.920E-6	7.970E-6	Sample Type;Control;Replicate
URACIL;Uracil	ST000956	AN001568	1.700E-6	8.170E-6	Treatment;Condition-1;Condition-2;Condition-3;Control
lysoPC a C16:0 / lysoPC a C16:1	ST000545	AN000830	2.270E-6	8.290E-6	Sample Type;Control;Replicate
PUFA (PC)	ST000545	AN000830	2.420E-6	8.290E-6	Sample Type;Control;Replicate
Total PC ae	ST000545	AN000830	2.340E-6	8.290E-6	Sample Type;Control;Replicate
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000475	AN000739	1.300E-6	8.480E-6	Treatment;-;MDH inhib
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000748	AN001172	6.440E-6	8.550E-6	Sample type;Cells;Culture Media
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	1.050E-6	8.560E-6	Country;Ethiopia;Tanzania;Botswana
GQ1 d18:1 N18:0	ST000362	AN000594	7.670E-7	8.820E-6	Gender;1;2
Total PC	ST000545	AN000830	3.140E-6	8.880E-6	Sample Type;Control;Replicate
Total PC aa	ST000545	AN000830	3.250E-6	8.880E-6	Sample Type;Control;Replicate
Total (PC+SM)	ST000545	AN000830	2.900E-6	8.880E-6	Sample Type;Control;Replicate
Total SM / Total PC	ST000545	AN000830	3.210E-6	8.880E-6	Sample Type;Control;Replicate
4-Hydroxy-4-methylglutamate	ST001204	AN002004	3.460E-6	8.970E-6	cell_type;iRBC;unRBC
[Fv] Ovalitenin A	ST000539	AN000818	8.120E-8	9.410E-6	timepoint;1 hour;20 hours
SARCOSINE/BETA-ALANINE	ST000475	AN000740	1.370E-6	9.790E-6	Treatment;-;MDH inhib
ketodeoxycholate	ST001000	AN001880	2.460E-6	9.860E-6	Diagnosis;CD;Control;UC
N-(octanoyl)-L-homoserine	ST000539	AN000818	2.910E-6	1.030E-5	Cell type;Mature erythrocyte;Reticulocyte
Ethylmalonate/Methyl Malonate	ST000614	AN000939	6.340E-6	1.060E-5	Diagonsis;Benign;Cancer;Normal
BOC-ASN	ST000016	AN000033	4.550E-6	1.130E-5	Material;Cells;Media
D-2-Amino-hexano-6-lactam	ST000567	AN000872	2.680E-6	1.130E-5	Time point;Post;Pre;Baseline
C18:0e MAG	ST001000	AN001881	3.710E-7	1.140E-5	Diagnosis;CD;Control;UC
Pantathonicacid	ST000614	AN000942	6.430E-6	1.160E-5	Diagonsis;Benign;Cancer;Normal
S-Budesonide	ST001317	AN002193	7.378E-6	1.164E-5	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-Budesonide	ST001317	AN002193	7.378E-6	1.164E-5	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Desmethylmianserin glucuronide	ST000566	AN000870	5.590E-6	1.200E-5	Time point;Post;Pre;Baseline
PC aa C40:5 / PC aa C42:5	ST000545	AN000830	4.960E-6	1.210E-5	Sample Type;Control;Replicate
2-keto-l-gluconic acid	ST000092	AN000146	8.360E-6	1.220E-5	Gender;N/A;Female;Male
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000721	AN001128	2.190E-6	1.260E-5	Injury;1 month;3 months
2E-Eicosenoic acid	ST001191	AN001983	1.280E-6	1.310E-5	Treatment;Control;QC;Sample
DL-Methionine sulfone	ST000539	AN000818	3.750E-6	1.320E-5	Cell type;Mature erythrocyte;Reticulocyte
3-ureidoacrylate	ST001201	AN001999	6.250E-6	1.380E-5	cell_type;iRBC;unRBC
4-(Trimethylammonio)but-2-enoate	ST001201	AN001998	6.350E-6	1.400E-5	cell_type;iRBC;unRBC
GLYCERALDEHYDE/LACTATE	ST000475	AN000740	3.080E-6	1.400E-5	Treatment;-;MDH inhib
Urethane	ST000403	AN000642	5.350E-6	1.540E-5	Cell type;Mature erythrocyte;Reticulocyte
PUFA (PC) / MUFA (PC)	ST000545	AN000830	7.370E-6	1.550E-5	Sample Type;Control;Replicate
Total SM / Total (SM+PC)	ST000545	AN000830	7.360E-6	1.550E-5	Sample Type;Control;Replicate
1-stearoyl-rac-glycerol	ST000356	AN000582	6.550E-6	1.580E-5	Diagnosis;breast cancer;control
azelate	ST001000	AN001880	4.340E-6	1.620E-5	Diagnosis;CD;Control;UC
Plasmalogen(20:4/p18:1)	ST000450	AN000706	9.850E-6	1.620E-5	gender;Female;Male
D-Arabino-Hexonic acid	ST001037	AN001698	2.800E-7	1.640E-5	Description ;Blank;Reagent Blank;Serum Sample;Solvent
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST000403	AN000642	5.780E-6	1.650E-5	Cell type;Mature erythrocyte;Reticulocyte
3-phosphoglucarate	ST001202	AN002001	5.350E-6	1.690E-5	treatment_duration_(h);-;1.5;3;6;9
5?-Androstan-3?-ol-17-one sulfate - 7.7291727	ST000566	AN000869	2.730E-6	1.720E-5	group;Old-Curcumin;Old-Placebo;young
metabolite 3	ST000539	AN000818	9.090E-8	1.750E-5	Glucose labelling;C13 glucose;unlabelled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.520E-7	1.770E-5	Treatment response;No;Yes;Pooled
Ginsenoside Re	ST001191	AN001983	2.220E-6	1.780E-5	Treatment;Control;QC;Sample
ALANINE/SARCOSINE	ST000475	AN000739	5.190E-6	1.780E-5	Treatment;-;MDH inhib
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000741	AN001155	1.220E-7	1.790E-5	subject type;Healthy control;Mild disease;POOLED;Severe dise...
Asp-Leu-Lys-Lys	ST001202	AN002000	6.940E-6	1.820E-5	treatment_duration_(h);-;1.5;3;6;9
Octonyl Carnitine	ST000614	AN000939	1.340E-5	1.840E-5	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
(-)-Medicocarpin	ST000403	AN000643	6.330E-6	1.860E-5	Cell type;Mature erythrocyte;Reticulocyte
C36:5 PC plasmalogen-A	ST001000	AN001881	8.270E-7	1.860E-5	Diagnosis;CD;Control;UC
2(alpha-D-Mannosyl)-D-glycerate	ST000539	AN000819	4.830E-7	1.990E-5	Glucose labelling;C13 glucose;unlabelled
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE	ST000010	AN000026	2.840E-6	2.000E-5	FCS;FCS;NO_FCS
N-(5-Methyl-3-oxohexyl)alanine	ST001202	AN002000	7.990E-6	2.040E-5	treatment_duration_(h);-;1.5;3;6;9
delta-Guanidinovaleric acid	ST000567	AN000872	6.660E-6	2.060E-5	Time point;Post;Pre;Baseline
Fructoselysine	ST000403	AN000642	2.200E-7	2.170E-5	Glucose labelling;C13 glucose;unlabelled
Lys-Ser-Ser-Ser	ST000403	AN000642	1.860E-7	2.170E-5	Glucose labelling;C13 glucose;unlabelled
Total AC-DC / Total AC	ST000545	AN000830	1.100E-5	2.190E-5	Sample Type;Control;Replicate
acetophenone NIST	ST000385	AN000620	1.910E-6	2.230E-5	Health State;Adenocarcinoma;Healthy;NA
Octonyl Carnitine	ST000614	AN000939	1.430E-5	2.240E-5	Diagonsis;Benign;Cancer;Normal
3-deoxy-D-galactose	ST001205	AN002006	5.070E-8	2.310E-5	treatment_duration_(h);1;5;3
N-Acetyl-D-glucosamine 6-phosphate	ST001202	AN002001	8.070E-6	2.400E-5	treatment_duration_(h);-;1.5;3;6;9
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	1.020E-5	2.430E-5	Material;Cells;Media
2-Dehydro-D-xylonate	ST000403	AN000643	8.500E-6	2.450E-5	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	4.240E-7	2.470E-5	Treatment response;No;Yes;Pooled
PAF C-16	ST000553	AN000846	2.400E-5	2.510E-5	Sample type;Plasma;Urine
IS Ceramide; [M-H2O]+	ST000523	AN000800	1.000E-5	2.540E-5	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
MOPS	ST001202	AN002000	1.020E-5	2.560E-5	treatment_duration_(h);-;1.5;3;6;9
3-Methoxyanthranilate	ST000403	AN000642	9.590E-6	2.590E-5	Cell type;Mature erythrocyte;Reticulocyte
1-docosapentaenoylglycerophosphocholine (22:5n3)*	ST000975	AN001596	1.600E-6	2.650E-5	GENDER;F;M
Sulforaphane	ST001202	AN002001	8.990E-6	2.650E-5	treatment_duration_(h);-;1.5;3;6;9
1-3-7-trimethylurate	ST001000	AN001879	3.930E-6	2.670E-5	Diagnosis;CD;Control;UC
Methylbutyric aid / Valeric / Isovaleric	ST001000	AN001879	3.820E-6	2.670E-5	Diagnosis;CD;Control;UC
Ala-Leu-Lys-Pro	ST000539	AN000818	8.160E-6	2.680E-5	Cell type;Mature erythrocyte;Reticulocyte
SALICYLATE #2 (M-H)-	ST000523	AN000799	2.030E-6	2.710E-5	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
P-DPD	ST001202	AN002001	9.650E-6	2.810E-5	treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerate	ST000539	AN000819	8.120E-6	2.830E-5	Cell type;Mature erythrocyte;Reticulocyte
(Z)-N-(2-hydroxyethyl)hexadec-7-enamide	ST000566	AN000870	1.410E-5	2.910E-5	Time point;Post;Pre;Baseline
Ac-Tyr-OEt	ST000403	AN000642	1.110E-5	2.990E-5	Cell type;Mature erythrocyte;Reticulocyte
Sulfate	ST001202	AN002001	1.070E-5	3.010E-5	treatment_duration_(h);-;1.5;3;6;9
Xylobiose	ST000403	AN000643	9.020E-7	3.050E-5	Glucose labelling;C13 glucose;unlabelled
2-Oxo-7-methylthioheptanoic acid	ST000567	AN000872	1.150E-5	3.050E-5	Time point;Post;Pre;Baseline
MEVALOLACTONE	ST000016	AN000033	3.840E-6	3.050E-5	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
protocatechualdehyde	ST001201	AN001998	1.470E-5	3.170E-5	cell_type;iRBC;unRBC
1-stearoyl-rac-glycerol	ST000356	AN000582	1.140E-5	3.190E-5	stage;-;2;3
delta-Guanidinovaleric acid	ST000567	AN000872	7.390E-7	3.200E-5	groups;Old-Curcumin;Old-Placebo;young
Pantathonicacid	ST000614	AN000942	2.170E-5	3.250E-5	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Sucrose / Trehalose	ST001048	AN001716	2.700E-5	3.290E-5	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Trp-Trp-Tyr-Tyr	ST000539	AN000818	1.070E-5	3.400E-5	Cell type;Mature erythrocyte;Reticulocyte
Asp-Leu-Gln-Pro	ST001202	AN002000	1.400E-5	3.400E-5	treatment_duration_(h);-;1.5;3;6;9
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE	ST000009	AN000024	5.500E-6	3.500E-5	AFTER_MEAL_TIME;30_MIN;NO_WAIT
SALICYLATE #2 (M-H)-	ST000713	AN001113	2.000E-6	3.580E-5	level of dysplasia;HGD;HGD & PDA;LGD;N/A
PC(22:0/P-18:1(11Z))	ST000241	AN000373	1.980E-5	3.600E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Succcinate	ST001038	AN001699	1.250E-5	3.640E-5	Timepoint;15 min;1 hr;24 hr;30 min;<5 min
Convallasaponin A	ST000437	AN000687	2.380E-5	3.760E-5	Sample type;Spiked;Unknown
Ginsenoside Rg3	ST001191	AN001983	6.790E-6	3.920E-5	Treatment;Control;QC;Sample
2-deoxycytidine	ST001142	AN001875	3.170E-5	4.010E-5	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Hexose Disaccharide Pool	ST000450	AN000706	2.540E-5	4.020E-5	gender;Female;Male
phe-FMDP	ST001201	AN001999	1.930E-5	4.060E-5	cell_type;iRBC;unRBC
C4 / C5	ST000545	AN000830	2.180E-5	4.120E-5	Sample Type;Control;Replicate
2-Deoxymugineic acid	ST000539	AN000819	1.230E-5	4.150E-5	Cell type;Mature erythrocyte;Reticulocyte
3-hydroxyoxyisovaleric acid	ST000356	AN000582	1.550E-5	4.220E-5	stage;-;2;3
Total AC-OH / Total AC	ST000545	AN000830	2.280E-5	4.240E-5	Sample Type;Control;Replicate
N-Didesethylquinagolide	ST000047	AN000082	3.420E-7	4.270E-5	Cognitive Status;AD;CN;MCI
Unknown_742.54(-)@5.61	ST000818	AN001298	2.650E-5	4.310E-5	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
2-Oxo-10-methylthiodecanoic acid	ST000566	AN000870	2.280E-5	4.430E-5	Time point;Post;Pre;Baseline
Benzyl tetradecyl dimethylammonium cation	ST000077	AN000123	2.640E-5	4.460E-5	Treatment;100uM Met ;370uM Hcy ;quality check
Asp-Leu-Ser-His	ST000403	AN000642	6.180E-7	4.560E-5	Glucose labelling;C13 glucose;unlabelled
azelate	ST000923	AN001514	6.440E-6	4.630E-5	Diagnosis;CD;nonIBD;UC
2-oxo-3-methylvaleric acid	ST000566	AN000870	2.520E-5	4.640E-5	Time point;Post;Pre;Baseline
Ala-Leu-Lys-Asp	ST001202	AN002000	2.040E-5	4.770E-5	treatment_duration_(h);-;1.5;3;6;9
3-Methyglutarate	ST001048	AN001717	3.270E-5	4.880E-5	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
3-(ADP)-2-phosphoglycerate	ST000403	AN000642	1.860E-5	4.880E-5	Cell type;Mature erythrocyte;Reticulocyte
acetophenone NIST	ST000385	AN000620	3.230E-6	4.920E-5	Gender;F;M;NA
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	1.820E-5	4.940E-5	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Ala-Asp-Gly-Tyr	ST001202	AN002000	2.150E-5	4.990E-5	treatment_duration_(h);-;1.5;3;6;9
DIMETHYLCAFFEIC ACID	ST000421	AN000664	2.570E-7	5.100E-5	treatment;ND;T1D poor glycemic control
Arg-Trp-Asp-Cys	ST001204	AN002005	7.570E-7	5.110E-5	treatment_duration_(h);-;3;6;9
6-Hydroxy flavin adenine dinucleotide	ST000241	AN000373	6.150E-6	5.140E-5	Concentration (uM);0;500
[PR] Citronellyl acetate	ST000539	AN000819	1.560E-5	5.150E-5	Cell type;Mature erythrocyte;Reticulocyte
phthalate ester	ST000420	AN000662	2.430E-5	5.280E-5	Group;nonsmoker;smoker
acetophenone NIST	ST000385	AN000620	3.190E-6	5.400E-5	Smoking Status;Current;Former;NA
2-OG b	ST000096	AN000154	2.510E-5	5.430E-5	Timepoint;18 hours;4 hours;NA
L-Arabinonate	ST000403	AN000643	1.990E-5	5.450E-5	Cell type;Mature erythrocyte;Reticulocyte
lysoPC a C20:4 / lysoPC a C20:3	ST000545	AN000830	3.020E-5	5.450E-5	Sample Type;Control;Replicate
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	2.240E-6	5.470E-5	Cox_Composite_DeathRRT;.;N;Y
Asp-Leu-Lys-Asp	ST001202	AN002000	2.410E-5	5.470E-5	treatment_duration_(h);-;1.5;3;6;9
2(alpha-D-Mannosyl)-D-glycerate	ST001201	AN001999	1.040E-6	5.590E-5	treatment;DHA;DMSO;OZ277;OZ439
Total lysoPC / Total PC	ST000545	AN000830	3.160E-5	5.630E-5	Sample Type;Control;Replicate
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)	ST000105	AN000174	3.270E-6	5.680E-5	Sampling;After SWS onset;Morning fasting
Adenosylcobimide-GDP	ST000241	AN000373	3.240E-5	5.790E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[FA methyl(14:0)] 12-methyl-tetradecanoic acid	ST000403	AN000643	2.180E-5	5.920E-5	Cell type;Mature erythrocyte;Reticulocyte
DG(36:2)>DG(18:1_18:1_0:0)	ST001325	AN002206	2.022E-5	5.999E-5	Gender;-;female;male
[13C]-ASPARTIC ACID	ST000016	AN000033	1.080E-5	6.010E-5	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
3-Sulfolactate	ST000539	AN000819	1.840E-5	6.010E-5	Cell type;Mature erythrocyte;Reticulocyte
Diethyl adipate	ST000539	AN000819	1.120E-7	6.010E-5	timepoint;1 hour;20 hours
azelate	ST000923	AN001515	1.000E-5	6.070E-5	Diagnosis;CD;nonIBD;UC
N-hydroxyisoleucine	ST001202	AN002000	5.440E-5	6.180E-5	cell_type;iRBC;unRBC
Galacto-N-biose	ST001211	AN002017	5.240E-6	6.260E-5	Group;Control;Methotrexate
ALANINE/SARCOSINE	ST000956	AN001568	1.550E-5	6.340E-5	Treatment;Condition-1;Condition-2;Condition-3;Control
O-PHOSPHONOHEXOPYRANOSE	ST000016	AN000033	2.890E-5	6.440E-5	Material;Cells;Media
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	1.290E-6	6.460E-5	Treatment response;No;Yes;Pooled
D-glycero-L-galacto-Octulose	ST001205	AN002007	6.310E-7	6.650E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
bOHbutyrate-13C0	ST000114	AN000194	1.440E-6	6.660E-5	Treatment;None;Tetracycline
cis Aconitate M0	ST000507	AN000776	2.560E-5	7.230E-5	Time (incubation);24 hours;72 hours
isodeoxytetronic acid	ST000396	AN000633	6.810E-7	7.350E-5	Sex;Male;Female
Xylobiose	ST000539	AN000819	1.920E-6	7.360E-5	Glucose labelling;C13 glucose;unlabelled
3-Methylglutaconic acid	ST000356	AN000583	2.460E-5	7.640E-5	stage;-;2;3
Istamycin C1	ST000242	AN000377	1.010E-5	7.770E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
5?-Androstan-3?-ol-17-one sulfate	ST000566	AN000869	1.460E-5	8.030E-5	group;Old-Curcumin;Old-Placebo;young
Cys-Thr-Cys-Cys	ST000539	AN000818	2.800E-5	8.280E-5	Cell type;Mature erythrocyte;Reticulocyte
Westiellamide	ST000242	AN000375	5.420E-5	8.300E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
4-Methylene-L-glutamate	ST000403	AN000643	3.370E-5	8.930E-5	Cell type;Mature erythrocyte;Reticulocyte
Uscharidin	ST000242	AN000377	1.210E-5	8.960E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
8-Amino-7-oxononanoate	ST001205	AN002006	7.190E-7	9.120E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
Avenic acid A	ST001205	AN002006	1.000E-6	9.120E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
Sucrose monopalmitate	ST001205	AN002007	1.750E-6	9.200E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
11-Hydroxyeicosatetraenoate glyceryl ester	ST000241	AN000373	5.360E-5	9.230E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Hydroxyglutaric acid	ST000356	AN000582	3.590E-5	9.300E-5	stage;-;2;3
C8-Ceramide m+1	ST000644	AN000976	5.500E-5	9.300E-5	tracer;13C-glucose;13C-glutamine;No label
a Cysteine adduct	ST001202	AN002000	4.380E-5	9.350E-5	treatment_duration_(h);-;1.5;3;6;9
Pregnanolone sulfate	ST000567	AN000871	7.860E-6	9.360E-5	groups;Old-Curcumin;Old-Placebo;young
Pro258-13C2	ST000076	AN000122	4.320E-6	9.390E-5	Labeling;13C/15N-Gln;13C-Glc;unlabeled
2-LG b	ST000096	AN000154	5.090E-5	9.460E-5	Timepoint;18 hours;4 hours;NA
PC 28:2 (2:0/26:2(5E.9Z)) [M+HCOO]-	ST001111	AN001806	3.500E-5	9.510E-5	Sample;Benign;Cancer;Metastasis
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000713	AN001114	6.100E-6	9.600E-5	malignant transformation;No;yes;Yes
16-Feruloyloxypalmitate	ST000567	AN000871	8.750E-6	9.630E-5	groups;Old-Curcumin;Old-Placebo;young
4-methylcatechol sulfate	ST000899	AN001464	1.190E-5	9.760E-5	Type;Control;Crohn disease;Ulcerative Colitis
phthalate ester	ST000417	AN001448	8.910E-6	9.890E-5	Group;AIR;NO2PM;PM
Corey PG-Lactone Diol	ST000566	AN000870	5.840E-5	9.890E-5	Time point;Post;Pre;Baseline
4-Aminobenzoate / Anthranilate	ST001040	AN001702	8.390E-6	9.900E-5	Sample Type/Matrix;Pooled quality control sample;urine;Water...
D/L N-Acetylgalactosamine / D/L N-Acetylglucosamine / D/L N-Acetylmannosamine	ST001040	AN001702	7.970E-6	9.900E-5	Sample Type/Matrix;Pooled quality control sample;urine;Water...
urea (partial derivative)	ST000092	AN000146	4.290E-5	9.970E-5	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
CMP-N-trimethyl-2-aminoethylphosphonate	ST001202	AN002000	4.700E-5	9.980E-5	treatment_duration_(h);-;1.5;3;6;9
Trifloxystrobin	ST001037	AN001698	3.430E-6	1.010E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000016	AN000033	4.810E-5	1.040E-4	Material;Cells;Media
PC aa C40:3 / PC aa C42:5	ST000545	AN000830	6.050E-5	1.050E-4	Sample Type;Control;Replicate
bOHbutyrate-ALL	ST000114	AN000194	3.010E-6	1.050E-4	Treatment;None;Tetracycline
FA hydroxy(10:0)	ST001202	AN002001	3.990E-5	1.060E-4	treatment_duration_(h);-;1.5;3;6;9
SALICYLATE #2 (M-H)-	ST000842	AN001356	8.540E-5	1.080E-4	Sample type;Muscles;Plasma;Pooled sample
Ala-Thr-Ala-Ser	ST001202	AN002000	5.100E-5	1.080E-4	treatment_duration_(h);-;1.5;3;6;9
d1-piperidine-dicarboxylate	ST000403	AN000642	4.350E-5	1.090E-4	Cell type;Mature erythrocyte;Reticulocyte
Erythrulose 1-phosphate	ST000539	AN000818	3.740E-5	1.090E-4	Cell type;Mature erythrocyte;Reticulocyte
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate) / 3OH-MBP (Mono-(3-hydroxy-n-butyl) phthalate)	ST001048	AN001717	7.600E-5	1.110E-4	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Marinobufagenin	ST000567	AN000871	1.090E-5	1.120E-4	groups;Old-Curcumin;Old-Placebo;young
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	3.950E-5	1.140E-4	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Ala-Leu-Thr-Ala	ST001202	AN002000	5.480E-5	1.150E-4	treatment_duration_(h);-;1.5;3;6;9
2-keto-l-gluconic acid	ST000092	AN000146	8.660E-5	1.220E-4	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
sulfa d18:1 N22:0	ST000362	AN000594	1.910E-5	1.220E-4	Gender;1;2
IS SM 35:1;[M+H]+	ST000661	AN001009	9.830E-5	1.240E-4	Sample type;Plasma;Tissues
cyclo-Dopa-glucuronylglucoside	ST000567	AN000871	1.400E-5	1.250E-4	groups;Old-Curcumin;Old-Placebo;young
N-Oleoyl-L-Serine	ST000566	AN000870	7.520E-5	1.250E-4	Time point;Post;Pre;Baseline
KG M+1	ST000507	AN000776	5.130E-5	1.270E-4	Time (incubation);24 hours;72 hours
N5-acetyl-N5-hydroxy-L-ornithine	ST001201	AN001998	6.110E-5	1.280E-4	cell_type;iRBC;unRBC
PC(16:0/15:1(14))	ST000624	AN000956	1.190E-5	1.290E-4	Condition;Control;Glaucomatous
B-Sulfinyl pyruvate	ST000356	AN000583	5.230E-5	1.300E-4	Diagnosis;breast cancer;control
PC ae C44:5 / PC ae C42:5	ST000545	AN000830	7.720E-5	1.300E-4	Sample Type;Control;Replicate
Histidylproline diketopiperazine	ST000356	AN000583	5.410E-5	1.320E-4	Diagnosis;breast cancer;control
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	2.530E-6	1.330E-4	Race;Black;White;POOLED
OH-monohexcer d18:1 N16:0	ST000362	AN000594	2.520E-5	1.340E-4	Gender;1;2
Imazosulfuron	ST000291	AN000464	7.570E-8	1.350E-4	Treatment ;Baseline urine;Urine after drinking apple juice;U...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	2.280E-6	1.370E-4	Timepoint;T0;T2;Pooled
sulfate	ST000899	AN001464	1.940E-5	1.370E-4	Type;Control;Crohn disease;Ulcerative Colitis
CerH2O(d18:1/24:0)	ST000608	AN000929	1.030E-4	1.390E-4	Sample_Type;blotter;serum
octulose 8-phosphate	ST001202	AN002001	5.470E-5	1.420E-4	treatment_duration_(h);-;1.5;3;6;9
beta-DIHYDROROTENONE	ST000422	AN000667	5.140E-7	1.420E-4	treatment;ND;T1D good glycemic control
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.230E-6	1.430E-4	Timepoint;T0;T2;Pooled
[13C]-ASPARTIC ACID	ST000016	AN000033	1.940E-5	1.430E-4	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
ADMA/SDMA	ST000923	AN001513	9.040E-6	1.450E-4	Diagnosis;CD;nonIBD;UC
Cysteinyl-Hydroxyproline	ST001202	AN002000	1.300E-4	1.460E-4	cell_type;iRBC;unRBC
5-hydroxynorvaline NIST	ST000368	AN000602	7.800E-5	1.500E-4	Organ;Plasma;Serum;Serum or Plasma
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST001205	AN002007	3.820E-6	1.510E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
Fluroxypyr	ST000566	AN000869	6.080E-5	1.530E-4	Time point;Post;Pre;Baseline
Ala-Val-Asp-Ser	ST001202	AN002000	7.590E-5	1.540E-4	treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-D-glucosamine 6-phosphate	ST001201	AN001999	3.920E-6	1.580E-4	treatment;DHA;DMSO;OZ277;OZ439
Arg-Asp-Asp-Gly	ST001202	AN002000	8.010E-5	1.610E-4	treatment_duration_(h);-;1.5;3;6;9
17-phenyl trinor Prostaglandin E2 serinol amide	ST000567	AN000872	8.050E-5	1.660E-4	Time point;Post;Pre;Baseline
cyano-L-alanine	ST000369	AN000603	1.380E-5	1.670E-4	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Pyroglutamylglycine	ST000553	AN000847	1.420E-4	1.670E-4	Sample type;Plasma;Urine
DIHYDROFISSINOLIDE	ST000046	AN000076	6.010E-6	1.680E-4	Cognitive Status;AD;CN;MCI
Ile-Met-Met-Thr	ST000403	AN000642	2.850E-6	1.680E-4	Glucose labelling;C13 glucose;unlabelled
Azaserine	ST000566	AN000870	1.060E-4	1.680E-4	Time point;Post;Pre;Baseline
[FA oxo(8:0)] 3-oxo-octanoic acid	ST000539	AN000819	5.530E-5	1.700E-4	Cell type;Mature erythrocyte;Reticulocyte
(-)-Medicocarpin	ST000539	AN000819	5.600E-5	1.720E-4	Cell type;Mature erythrocyte;Reticulocyte
gamma-CEHC glucuronide*	ST000974	AN001595	2.690E-5	1.720E-4	REGION;AHRI;MRC;SUN
Man6GlcNAc-VI	ST001037	AN001698	7.210E-6	1.770E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Pregnetriol	ST000241	AN000373	1.090E-4	1.780E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Total AC-OH / Total AC	ST000544	AN000827	2.280E-5	1.810E-4	Sample Type;Control;Replicate
Total SM / Total PC	ST000544	AN000827	2.350E-5	1.810E-4	Sample Type;Control;Replicate
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	8.760E-5	1.820E-4	Material;Cells;Media
Ovothiol disulfide	ST000403	AN000642	7.720E-5	1.840E-4	Cell type;Mature erythrocyte;Reticulocyte
o-toluidene2	ST000614	AN000941	9.180E-5	1.840E-4	Diagonsis;Benign;Cancer;Normal
SM (d18:1/17:0) iSTD	ST001211	AN002019	4.140E-5	1.870E-4	Group;Control;Methotrexate
Bile salt	ST001202	AN002001	7.480E-5	1.880E-4	treatment_duration_(h);-;1.5;3;6;9
Aminophosphovaleric acid	ST000614	AN000943	1.460E-4	1.900E-4	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
2-(acetylamino)-1-5-anhydro-2-deoxy-3-O-b-D-galactopyranosyl-D-arabino-Hex-1-enitol	ST001204	AN002004	8.160E-5	1.910E-4	cell_type;iRBC;unRBC
sulfate*	ST000974	AN001595	9.000E-6	1.910E-4	GENDER;F;M
4-hydroxychlorothalonil	ST000899	AN001464	2.970E-5	1.920E-4	Type;Control;Crohn disease;Ulcerative Colitis
ZAPA	ST000539	AN000818	6.880E-5	1.950E-4	Cell type;Mature erythrocyte;Reticulocyte
cis/trans-hydroxyproline	ST001142	AN001875	1.690E-4	1.950E-4	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
creatine major dehydrated TMS3	ST000417	AN001448	2.680E-5	1.950E-4	Group;AIR;NO2PM;PM
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	3.350E-6	1.950E-4	Timepoint;T0;T2;Pooled
Arsenobetaine	ST001202	AN002000	1.750E-4	1.960E-4	cell_type;iRBC;unRBC
N-ACETYL-HEXOSAMINE	ST000956	AN001568	5.580E-5	1.990E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
succinic acid2	ST000417	AN001448	3.390E-5	2.020E-4	Group;AIR;NO2PM;PM
Glucocerebrosides	ST000242	AN000377	3.060E-5	2.020E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Spectinomycin adenylate	ST000242	AN000377	3.160E-5	2.020E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Tiletamine	ST000566	AN000870	1.350E-4	2.060E-4	Time point;Post;Pre;Baseline
acisoga	ST000899	AN001464	3.410E-5	2.170E-4	Type;Control;Crohn disease;Ulcerative Colitis
PC 40:3 (20:0/20:3(5Z.8Z.11Z)) [M-Ac-H]-	ST001111	AN001806	8.690E-5	2.200E-4	Sample;Benign;Cancer;Metastasis
MES	ST001202	AN002000	1.130E-4	2.210E-4	treatment_duration_(h);-;1.5;3;6;9
Asp-Met-Pro-Pro	ST000403	AN000642	9.620E-5	2.270E-4	Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-His	ST000403	AN000642	9.720E-5	2.280E-4	Cell type;Mature erythrocyte;Reticulocyte
Total SM / Total (SM+PC)	ST000544	AN000827	3.260E-5	2.320E-4	Sample Type;Control;Replicate
penem CGP31608	ST001204	AN002004	1.040E-4	2.340E-4	cell_type;iRBC;unRBC
Ganglioside GM3 (d18:0/24:0)	ST000241	AN000373	1.470E-4	2.350E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC 40:3 (20:1(11E)/20:2(11Z.14Z)) [M-Ac-H]-	ST001111	AN001806	9.500E-5	2.390E-4	Sample;Benign;Cancer;Metastasis
maltotriose minor	ST000058	AN000096	2.720E-5	2.390E-4	Treatment;Group 1;Group 2;Group 3;Group 4;Group 5;Group 6;Gr...
O-Acetylneuraminic acid	ST001202	AN002000	1.260E-4	2.430E-4	treatment_duration_(h);-;1.5;3;6;9
cefamandole nafate + 2.0600944	ST000421	AN000663	2.640E-6	2.470E-4	treatment;ND;T1D poor glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanine	ST000421	AN000663	3.170E-6	2.470E-4	treatment;ND;T1D poor glycemic control
2-deoxyglucose-6-phosphate	ST000450	AN000706	1.680E-4	2.490E-4	gender;Female;Male
Kinetensin 4-7	ST000241	AN000373	1.550E-4	2.490E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
(R)-3-Hydroxy-Octadecanoic acid	ST000241	AN000373	1.570E-4	2.500E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
19/20-OH PGE2	ST001214	AN002025	1.550E-4	2.520E-4	BMI group;lean;obese;overweight
Trp-Trp-Tyr-Tyr	ST000403	AN000642	1.080E-4	2.520E-4	Cell type;Mature erythrocyte;Reticulocyte
PIPES	ST001202	AN002001	1.030E-4	2.540E-4	treatment_duration_(h);-;1.5;3;6;9
2-(sulfomethyl)thiazolidine-4-carboxylate	ST000539	AN000819	8.730E-5	2.550E-4	Cell type;Mature erythrocyte;Reticulocyte
Asp-Val-Gly-Ser	ST001202	AN002000	1.340E-4	2.580E-4	treatment_duration_(h);-;1.5;3;6;9
threosphingosine	ST001000	AN001878	4.590E-5	2.590E-4	Diagnosis;CD;Control;UC
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	6.870E-6	2.590E-4	Race;Black;White;POOLED
Cys-Met-Tyr-Tyr	ST000403	AN000642	4.440E-7	2.620E-4	timepoint;1 hour;20 hours
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	4.010E-6	2.630E-4	Tamoxyfen;N;Y;-
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001202	AN002000	1.380E-4	2.650E-4	treatment_duration_(h);-;1.5;3;6;9
PC(16:0/5:0(COOH))	ST000403	AN000642	1.200E-4	2.750E-4	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.100E-6	2.850E-4	TIMEPOINT;3 Month;Baseline;POOLED
Adenosine 35-diphosphate	ST001193	AN001989	1.550E-4	2.860E-4	Plasma;Cord blood;Plasma
5-Deoxy-5-aminoshikimic acid	ST000539	AN000819	1.020E-4	2.940E-4	Cell type;Mature erythrocyte;Reticulocyte
Neomenthyl acetate	ST000567	AN000872	1.590E-4	2.950E-4	Time point;Post;Pre;Baseline
iSTD iSTD Ceramide (d18:1/17:0)	ST000342	AN000554	2.100E-5	2.950E-4	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST000539	AN000819	1.040E-4	2.990E-4	Cell type;Mature erythrocyte;Reticulocyte
2-hydroxymethanesulfonate	ST000403	AN000643	1.240E-4	3.020E-4	Cell type;Mature erythrocyte;Reticulocyte
Diacetylhydrazine	ST000403	AN000642	1.330E-4	3.020E-4	Cell type;Mature erythrocyte;Reticulocyte
3-Methoxyanthranilate	ST000539	AN000818	1.150E-4	3.100E-4	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	5.340E-6	3.110E-4	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
GQ1 d18:1 N20:0	ST000362	AN000594	8.170E-5	3.130E-4	Gender;1;2
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)	ST000105	AN000174	2.380E-5	3.130E-4	Sampling;After SWS onset;Morning fasting
PGF2a ethanolamide	ST000241	AN000373	2.030E-4	3.160E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N-acetyl -D- glucosaminitol	ST000539	AN000818	1.200E-4	3.220E-4	Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitol 2	ST000539	AN000818	1.200E-4	3.220E-4	Cell type;Mature erythrocyte;Reticulocyte
HEPES	ST000403	AN000643	1.340E-4	3.250E-4	Cell type;Mature erythrocyte;Reticulocyte
Cholic acid or similar bile acid	ST000586	AN000901	2.220E-4	3.260E-4	Plasma Volume;0 uL;150 uL;700 uL
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	4.980E-6	3.280E-4	Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.030E-6	3.310E-4	Taxane;N;Y;-
Cotine	ST000614	AN000943	8.500E-5	3.320E-4	Diagonsis;Benign;Cancer;Normal
FMLP	ST000539	AN000818	1.260E-4	3.360E-4	Cell type;Mature erythrocyte;Reticulocyte
3-deoxy-D-galactose	ST001202	AN002001	1.430E-4	3.420E-4	treatment_duration_(h);-;1.5;3;6;9
DIMETHYLXANTHINE	ST000016	AN000033	5.180E-5	3.460E-4	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
FA methyl(6:0)	ST001202	AN002001	1.460E-4	3.470E-4	treatment_duration_(h);-;1.5;3;6;9
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.320E-6	3.500E-4	Chemotherapy;N;Y;POOLED
CL 72:10 (18:2/18:3/18:2/18:3) [M-2H](2-)	ST001111	AN001806	1.460E-4	3.520E-4	Sample;Benign;Cancer;Metastasis
PC(16:0/5:0(CHO))	ST000539	AN000818	1.360E-4	3.590E-4	Cell type;Mature erythrocyte;Reticulocyte
DIMETHYLXANTHINE	ST000016	AN000033	1.790E-4	3.600E-4	Material;Cells;Media
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000741	AN001156	1.660E-5	3.600E-4	subject type;Healthy control;Mild disease;POOLED;Severe dise...
BOC-LYS-OH	ST000043	AN000070	5.680E-5	3.630E-4	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
Arg-Leu-Asn-Asp	ST000403	AN000642	1.640E-4	3.650E-4	Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Cys-Gly	ST000539	AN000818	5.680E-6	3.650E-4	timepoint;1 hour;20 hours
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.580E-6	3.670E-4	CASE_CONTROL;Case;Control;POOLED
14-demethyl-14-dehydrolanosterol	ST000916	AN001492	4.350E-5	3.690E-4	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
MALATE;OXALOACETATE+2H-H	ST000956	AN001569	7.480E-5	3.740E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
L-Glutamic acid dibutyl ester	ST000566	AN000870	2.610E-4	3.750E-4	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	8.590E-6	3.770E-4	Tamoxyfen;N;Y;-
Cys-Met-Met-Phe	ST000403	AN000643	1.590E-4	3.800E-4	Cell type;Mature erythrocyte;Reticulocyte
ketodeoxycholate	ST000923	AN001515	7.390E-5	3.830E-4	Diagnosis;CD;nonIBD;UC
Cys-Leu-Cys-Tyr	ST001202	AN002001	1.660E-4	3.870E-4	treatment_duration_(h);-;1.5;3;6;9
psicoselysine	ST000403	AN000642	8.630E-6	3.920E-4	Glucose labelling;C13 glucose;unlabelled
gamma-glutamyl-2-aminobutyrate	ST000899	AN001462	1.960E-5	3.930E-4	Type;Control;Crohn disease;Ulcerative Colitis
[6]-Paradol	ST001205	AN002007	1.640E-5	3.980E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
D-erythro-L-galacto-Nonulose	ST001202	AN002001	1.740E-4	3.980E-4	treatment_duration_(h);-;1.5;3;6;9
L-Glutamate methylester	ST000403	AN000642	1.830E-4	4.040E-4	Cell type;Mature erythrocyte;Reticulocyte
2-deoxytetronic acid NIST	ST000368	AN000602	2.240E-4	4.050E-4	Organ;Plasma;Serum;Serum or Plasma
GLUCOSE/FRUCTOSE-PHOSPHATE	ST000956	AN001568	1.260E-4	4.070E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
Arg-Leu-Asn-Asp	ST000539	AN000818	1.560E-4	4.090E-4	Cell type;Mature erythrocyte;Reticulocyte
3-Phosphonopyruvate	ST000539	AN000819	1.440E-4	4.100E-4	Cell type;Mature erythrocyte;Reticulocyte
DOCOSADIENOATE	ST000009	AN000024	3.130E-5	4.140E-4	gender;female;male
2-pyrrolidone-5-carboxylic acid	ST000356	AN000582	2.020E-4	4.160E-4	Diagnosis;breast cancer;control
MECPP (Mono-2-ethyl-5-carboxypentyl phthalate)	ST001048	AN001717	3.350E-4	4.180E-4	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Ala-Thr-Ala-Asp	ST001202	AN002000	2.260E-4	4.220E-4	treatment_duration_(h);-;1.5;3;6;9
melibionate	ST001204	AN002005	1.730E-4	4.330E-4	cell_type;iRBC;unRBC
Cycloleucine	ST000567	AN000872	2.700E-4	4.340E-4	Time point;Post;Pre;Baseline
Methyl deoxyadenosine	ST000614	AN000943	1.370E-4	4.440E-4	Diagonsis;Benign;Cancer;Normal
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.180E-5	4.450E-4	Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.180E-5	4.450E-4	Taxane;N;Y;-
2-hydroxybutyrate/2-hydroxyisobutyrate	ST000899	AN001465	3.890E-5	4.480E-4	Type;Control;Crohn disease;Ulcerative Colitis
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001201	AN001998	2.300E-4	4.530E-4	cell_type;iRBC;unRBC
X3.Methylhistidine.	ST000435	AN000685	6.610E-5	4.740E-4	treatment;ND;T1D good glycemic control;T1D poor glycemic con...
Icosatrienoic acid	ST000403	AN000643	2.050E-4	4.810E-4	Cell type;Mature erythrocyte;Reticulocyte
[Fv] Ovalitenin A	ST000403	AN000642	2.200E-4	4.840E-4	Cell type;Mature erythrocyte;Reticulocyte
Erythrotetrofuranose	ST000356	AN000582	2.070E-4	4.870E-4	stage;-;2;3
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.260E-5	4.880E-4	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
Crotanecine	ST001205	AN002006	2.610E-5	4.950E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
DIHEXOSE	ST000106	AN000176	2.710E-5	4.980E-4	Sampling time;0 min;60 min
4-Amino-4-deoxychorismate	ST000403	AN000643	2.190E-4	5.100E-4	Cell type;Mature erythrocyte;Reticulocyte
METHYL7-DESHYDROXYPYROGALLIN-4-CARBOXYLATE	ST000046	AN000078	5.140E-6	5.100E-4	Cognitive Status;AD;CN;MCI
SB N-(eicosanoyl)-sphing-4-enine (d18:1(4E)/20:0) [M-H]-	ST001111	AN001806	2.230E-4	5.180E-4	Sample;Benign;Cancer;Metastasis
N-Acetyl-D-glucosaminate	ST000403	AN000643	2.250E-4	5.210E-4	Cell type;Mature erythrocyte;Reticulocyte
monohexsph	ST000362	AN000594	1.510E-4	5.210E-4	Gender;1;2
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.230E-5	5.390E-4	Drug;Exemestane;Letrozole;POOLED
Ala-Thr-Ala-Ser	ST001205	AN002006	3.240E-5	5.410E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000697	AN001081	1.870E-5	5.430E-4	Cell Type;BS4;HAHA;PAK;POOLED
SARCOSINE/BETA-ALANINE	ST000919	AN001507	9.210E-6	5.430E-4	Gender;Female;Male
P-DPD	ST000403	AN000643	2.360E-4	5.440E-4	Cell type;Mature erythrocyte;Reticulocyte
N-METHYL-L-GLUTAMATE;ALPHA-AMINOADIPATE;L-2-Aminoadipic Acid	ST000956	AN001569	1.210E-4	5.480E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.460E-5	5.490E-4	TIMEPOINT;3 Month;Baseline;POOLED
N-Hydroxy-1-aminonaphthalene	ST000539	AN000819	1.990E-4	5.500E-4	Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxyphenylacetylglycine	ST001202	AN002001	2.500E-4	5.510E-4	treatment_duration_(h);-;1.5;3;6;9
arachidiic acid	ST000416	AN000658	8.170E-5	5.520E-4	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
5?-Androstan-3?-ol-17-one sulfate	ST000567	AN000871	7.010E-5	5.570E-4	groups;Old-Curcumin;Old-Placebo;young
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	3.920E-4	5.590E-4	Volume Urine (µL);100;10;25;50;5
nonulose 9-phosphate	ST001205	AN002007	2.670E-5	5.630E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucoside	ST001202	AN002000	3.120E-4	5.650E-4	treatment_duration_(h);-;1.5;3;6;9
A-Ketoglutaricacidoxime	ST000403	AN000643	2.470E-4	5.660E-4	Cell type;Mature erythrocyte;Reticulocyte
diacetylspermine	ST000923	AN001513	6.100E-5	5.680E-4	Diagnosis;CD;nonIBD;UC
(E)-2-Butenyl-4-methyl-threonine	ST000567	AN000872	3.790E-4	5.730E-4	Time point;Post;Pre;Baseline
3-ethylphenylsulfate	ST000975	AN001596	5.510E-5	5.860E-4	GENDER;F;M
CTAB	ST000539	AN000818	2.340E-4	5.910E-4	Cell type;Mature erythrocyte;Reticulocyte
valerate/isovalerate	ST000923	AN001514	9.270E-5	5.910E-4	Diagnosis;CD;nonIBD;UC
F-Honaucin A	ST000242	AN000376	5.440E-4	5.930E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.350E-5	5.960E-4	CASE_CONTROL;Case;Control;POOLED
HBA	ST000566	AN000870	4.510E-4	6.080E-4	Time point;Post;Pre;Baseline
Glu-Cys-Gly-Ser	ST001205	AN002006	4.260E-5	6.260E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
5-HETrE	ST000916	AN001491	9.860E-5	6.320E-4	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
Gal?1-3Gal?1-4GlcNAc?-Sp	ST000242	AN000377	1.120E-4	6.330E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
cefamandole nafate	ST000421	AN000663	9.560E-6	6.530E-4	treatment;ND;T1D poor glycemic control
DOCOSAPENTAENOATE (*)	ST000105	AN000174	5.380E-5	6.630E-4	Sampling;After SWS onset;Morning fasting
Yamogenin 3-O-neohesperidoside	ST000242	AN000377	1.210E-4	6.640E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Methyl Guanine	ST000614	AN000943	2.730E-4	6.650E-4	Diagonsis;Benign;Cancer;Normal
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acid	ST000403	AN000643	2.930E-4	6.690E-4	Cell type;Mature erythrocyte;Reticulocyte
BOC-LYS-OH	ST000016	AN000033	3.470E-4	6.790E-4	Material;Cells;Media
(-)-jasmonoyl-L-isoleucine	ST000403	AN000642	3.200E-4	6.830E-4	Cell type;Mature erythrocyte;Reticulocyte
butyrate / isobutytare	ST001000	AN001879	1.750E-4	6.880E-4	Diagnosis;CD;Control;UC
Tyr-OEt	ST000539	AN000818	2.780E-4	6.990E-4	Cell type;Mature erythrocyte;Reticulocyte
(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinate	ST000291	AN000464	1.170E-6	6.990E-4	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Ala-Trp-Gly-Gly	ST001202	AN002000	3.980E-4	7.040E-4	treatment_duration_(h);-;1.5;3;6;9
PC 40:5 (20:2(5Z.8Z)/20:3(5Z.8Z.11Z)) [M+HCOO]-	ST001111	AN001806	3.060E-4	7.060E-4	Sample;Benign;Cancer;Metastasis
2-keto-l-gluconic acid	ST000092	AN000146	4.570E-4	7.140E-4	Solution Added;N/A;None;Urease;Water
Phosphonic acid	ST001037	AN001698	5.960E-5	7.300E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
CAI-1	ST000403	AN000643	3.240E-4	7.330E-4	Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Val-Asp	ST000403	AN000642	2.610E-5	7.330E-4	Glucose labelling;C13 glucose;unlabelled
Cys-Lys-Met-Gln	ST000403	AN000642	2.490E-5	7.330E-4	Glucose labelling;C13 glucose;unlabelled
CL 76:12 (18:3/20:3/20:4/18:2) [M-2H](2-)	ST001111	AN001806	3.250E-4	7.440E-4	Sample;Benign;Cancer;Metastasis
4-Nitroestrone-13C0[+QDA adduct]+	ST000148	AN000235	1.460E-6	7.450E-4	Treatment;13C-Glc;unlabeled
FA (14:1) (physeteric acid)	ST001211	AN002019	2.260E-4	7.630E-4	Group;Control;Methotrexate
Icosadienoic acid	ST000403	AN000643	3.440E-4	7.750E-4	Cell type;Mature erythrocyte;Reticulocyte
Decylubiquinol	ST000567	AN000872	5.330E-4	7.870E-4	Time point;Post;Pre;Baseline
4-tert-Octylphenol	ST001037	AN001698	6.700E-5	7.880E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
diacetylspermine	ST001236	AN002054	1.580E-5	8.080E-4	OS_Censor (1 means the time is a censoring time and 0 means ...
indole-3-acetyl-valine	ST000539	AN000819	3.020E-4	8.210E-4	Cell type;Mature erythrocyte;Reticulocyte
tetrahydrogeranylgeranyl-bacteriopheophytin	ST001204	AN002005	3.400E-4	8.270E-4	cell_type;iRBC;unRBC
nonulose 9-phosphate	ST001204	AN002005	3.450E-4	8.310E-4	cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginine	ST000539	AN000818	3.330E-4	8.350E-4	Cell type;Mature erythrocyte;Reticulocyte
DOCOSAHEXAENOYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.350E-4	8.360E-4	Material;Cells;Media
mannose-6-phosphate NIST	ST000379	AN000613	1.780E-4	8.390E-4	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
C8-Ceramide m+11	ST000644	AN000976	1.460E-4	8.430E-4	time;48 hr;0 hr
C8-Ceramide m+13	ST000644	AN000976	1.370E-4	8.430E-4	time;48 hr;0 hr
C8-Ceramide m+15	ST000644	AN000976	1.390E-4	8.430E-4	time;48 hr;0 hr
C8-Ceramide m+9	ST000644	AN000976	1.560E-4	8.430E-4	time;48 hr;0 hr
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000105	AN000173	3.480E-5	8.440E-4	Sampling;After SWS onset;Morning fasting
methanofuran biosynththesis intermediate MF1	ST001205	AN002007	6.960E-5	8.460E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
C8-Ceramide m+7	ST000644	AN000976	1.850E-4	8.470E-4	time;48 hr;0 hr
B-Sulfinyl pyruvate	ST000356	AN000583	3.230E-4	8.510E-4	stage;-;2;3
Asn-Asn-Pro-His	ST000403	AN000642	3.260E-5	8.690E-4	Glucose labelling;C13 glucose;unlabelled
O-Acetylneuraminic acid	ST000403	AN000642	3.390E-5	8.690E-4	Glucose labelling;C13 glucose;unlabelled
Arsenobetaine	ST001202	AN002000	5.080E-4	8.780E-4	treatment_duration_(h);-;1.5;3;6;9
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	1.380E-4	8.810E-4	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
2-O-methyl PAF C16	ST000553	AN000845	7.740E-4	8.890E-4	Sample type;Plasma;Urine
MEVALOLACTONE	ST000016	AN000033	2.130E-4	9.020E-4	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
4aminobenzaldehyde1	ST000614	AN000941	5.580E-4	9.120E-4	Diagonsis;Benign;Cancer;Normal
glycodeoxycholate/glycochenodeoxycholate	ST001237	AN002055	3.790E-4	9.130E-4	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*	ST000975	AN001596	9.970E-5	9.560E-4	GENDER;F;M
N-acetyl-2-aminoctanoate	ST000975	AN001596	1.030E-4	9.590E-4	GENDER;F;M
[13C]-HISTIDINE	ST000016	AN000033	5.170E-4	9.710E-4	Material;Cells;Media
Ala-Thr-Ala-Gly	ST001205	AN002006	7.240E-5	9.780E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
N-acetyl -D- glucosaminitol	ST001201	AN001998	5.380E-4	1.030E-3	cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitol	ST001204	AN002004	4.890E-4	1.030E-3	cell_type;iRBC;unRBC
C8-Ceramide m+8	ST000644	AN000976	2.550E-4	1.050E-3	time;48 hr;0 hr
N2-(D-1-Carboxyethyl)-L-arginine	ST000403	AN000642	5.190E-4	1.070E-3	Cell type;Mature erythrocyte;Reticulocyte
24-Dihydroxyacetophenone	ST001193	AN001989	6.530E-4	1.080E-3	Plasma;Cord blood;Plasma
PC 36:4 (16:0/20:4(5E.8E.11E.14E)) [M+HCOO]-	ST001111	AN001806	4.820E-4	1.080E-3	Sample;Benign;Cancer;Metastasis
Undecanone-13C6[+QDA adduct]+	ST000148	AN000235	3.280E-6	1.080E-3	Treatment;13C-Glc;unlabeled
methiin	ST000539	AN000818	4.420E-4	1.090E-3	Cell type;Mature erythrocyte;Reticulocyte
Dehydrocholic acid	ST001211	AN002017	1.520E-4	1.090E-3	Group;Control;Methotrexate
CL 78:12 (18:1/20:4/18:1/22:6) [M-2H](2-)	ST001111	AN001806	4.880E-4	1.090E-3	Sample;Benign;Cancer;Metastasis
Azelate	ST001048	AN001717	8.970E-4	1.100E-3	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
C8-Ceramide m+17	ST000644	AN000976	2.890E-4	1.100E-3	time;48 hr;0 hr
3-Butynoate	ST000566	AN000870	8.460E-4	1.100E-3	Time point;Post;Pre;Baseline
Ala-Cys-Pro-Ser	ST001204	AN002005	2.030E-5	1.100E-3	treatment_duration_(h);-;3;6;9
His-Met-Trp-Ser	ST000403	AN000643	4.330E-5	1.110E-3	Glucose labelling;C13 glucose;unlabelled
CL 76:11 (18:2/18:2/20:4/20:3) [M-2H](2-)	ST001111	AN001806	5.070E-4	1.110E-3	Sample;Benign;Cancer;Metastasis
CALCIDIOL (M+H)+[-H2O]	ST000818	AN001297	4.040E-4	1.120E-3	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Ala-Glu-Glu-His	ST001205	AN002006	1.030E-4	1.120E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
pyroglutamylphenylalanine*	ST000974	AN001595	2.040E-4	1.120E-3	REGION;AHRI;MRC;SUN
19/20-OH PGF2a	ST001214	AN002025	7.720E-4	1.140E-3	BMI group;lean;obese;overweight
4-Hydroxyphenylacetylglycine	ST001204	AN002005	4.870E-4	1.140E-3	cell_type;iRBC;unRBC
C8-Ceramide m+10	ST000644	AN000976	3.090E-4	1.150E-3	time;48 hr;0 hr
4-Hydroxy-4-methylglutamate	ST000403	AN000642	5.640E-4	1.160E-3	Cell type;Mature erythrocyte;Reticulocyte
D-Alanyl-D-alanine	ST000356	AN000583	5.720E-4	1.170E-3	Diagnosis;breast cancer;control
o-toluidene	ST000614	AN000943	5.980E-4	1.170E-3	Diagonsis;Benign;Cancer;Normal
C8-Ceramide m+1	ST000644	AN000976	3.200E-4	1.170E-3	time;48 hr;0 hr
D-Galacturonate	ST001202	AN002001	5.560E-4	1.170E-3	treatment_duration_(h);-;1.5;3;6;9
citraconic acid major TMS2	ST000420	AN000662	6.740E-4	1.180E-3	Group;nonsmoker;smoker
Tyrphostin B44 (-)	ST000242	AN000375	8.710E-4	1.180E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
A-Ketoglutaricacidoxime	ST001201	AN001999	4.400E-5	1.180E-3	treatment;DHA;DMSO;OZ277;OZ439
Corey PG-Lactone Diol + 6.739769	ST000566	AN000870	9.270E-4	1.190E-3	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000697	AN001081	6.190E-5	1.200E-3	Cell Type;BS4;HAHA;PAK;POOLED
Dimethylallylpyrophosphate	ST000356	AN000583	5.980E-4	1.200E-3	Diagnosis;breast cancer;control
Euparin	ST000567	AN000871	1.910E-4	1.240E-3	groups;Old-Curcumin;Old-Placebo;young
N-hydroxyisoleucine	ST001202	AN002000	7.670E-4	1.240E-3	treatment_duration_(h);-;1.5;3;6;9
ethylpyruvate	ST000539	AN000819	4.670E-4	1.250E-3	Cell type;Mature erythrocyte;Reticulocyte
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	3.110E-4	1.260E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Pro258-13C6	ST000076	AN000122	9.020E-5	1.270E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C0	ST000076	AN000122	8.690E-5	1.270E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
S-(3-hydroxypropyl)mercapturic acid (HPMA)	ST000975	AN001596	1.500E-4	1.300E-3	GENDER;F;M
N-Acetylanthranilate	ST001201	AN001999	6.670E-4	1.310E-3	cell_type;iRBC;unRBC
aminoisobutyric acid/GABA	ST000923	AN001513	2.290E-4	1.310E-3	Diagnosis;CD;nonIBD;UC
p-Toluic acid-M+1	ST001167	AN001930	6.730E-4	1.310E-3	Time points;0.25h;0h;12h;24h;4h;6days
O-6-deoxy-a-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-D-Galactose-13C0[+13CD3 QDA]+	ST000148	AN000235	4.660E-6	1.310E-3	Treatment;13C-Glc;unlabeled
2-acetamidoglucal	ST001201	AN001998	4.220E-5	1.310E-3	treatment;DHA;DMSO;OZ277;OZ439
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	2.220E-4	1.310E-3	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
3-Hydroxyhexdecanedioyl-CoA	ST000241	AN000373	9.070E-4	1.330E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
methylhexadecanoic acid	ST000385	AN000620	2.270E-4	1.340E-3	Gender;F;M;NA
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)	ST001317	AN002193	9.596E-4	1.343E-3	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)	ST001317	AN002193	9.596E-4	1.343E-3	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
alloxanoic acid NIST	ST000392	AN000628	1.380E-4	1.360E-3	Disease State;cancer;control;-
Ala-Met-Asp-Tyr	ST001202	AN002001	6.660E-4	1.360E-3	treatment_duration_(h);-;1.5;3;6;9
GLUCOSAMINE/MANNOSAMINE	ST000475	AN000739	7.440E-4	1.370E-3	Treatment;-;MDH inhib
gamma-CEHC glucuronide	ST000899	AN001464	3.230E-4	1.380E-3	Type;Control;Crohn disease;Ulcerative Colitis
methylnaphthyl sulfate (2)*	ST000975	AN001596	1.670E-4	1.390E-3	GENDER;F;M
Anthranilate / 4-Aminobenzoate	ST001040	AN001703	2.920E-4	1.400E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
N-.alpha.-(tert-Butoxycarbonyl)-L-histidine	ST001211	AN002017	2.130E-4	1.430E-3	Group;Control;Methotrexate
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST001201	AN001999	7.480E-4	1.460E-3	cell_type;iRBC;unRBC
D-Ribose;ALDOPENTOSE	ST000956	AN001568	5.250E-4	1.460E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Phenolsulfonphthalein	ST001202	AN002001	7.220E-4	1.460E-3	treatment_duration_(h);-;1.5;3;6;9
4-hydroxy-3-methylacetophenone	ST000923	AN001513	2.670E-4	1.470E-3	Diagnosis;CD;nonIBD;UC
DL-?-Lipoic Acid	ST000566	AN000870	1.160E-3	1.470E-3	Time point;Post;Pre;Baseline
DIMETHYLXANTHINE	ST000016	AN000033	3.890E-4	1.480E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
iSTD iSTD FA (16:0)-d3	ST000342	AN000554	3.350E-4	1.480E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
3-Ethylmalate	ST001205	AN002006	1.830E-4	1.490E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
2E-methyl-glutaconic acid	ST000567	AN000872	1.040E-3	1.500E-3	Time point;Post;Pre;Baseline
TROMETHAMINE+5.4366517	ST000046	AN000076	6.150E-5	1.540E-3	Cognitive Status;AD;CN;MCI
2-Dehydro-D-xylonate	ST001205	AN002007	1.610E-4	1.540E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
XHWESASXXR*	ST000974	AN001595	2.950E-4	1.540E-3	REGION;AHRI;MRC;SUN
Cotinine-good	ST000614	AN000943	8.400E-4	1.550E-3	Diagonsis;Benign;Cancer;Normal
3-methyl catechol sulfate (2)	ST000974	AN001595	2.990E-4	1.550E-3	REGION;AHRI;MRC;SUN
N-Acetyl Lysine	ST000614	AN000939	1.250E-3	1.560E-3	Diagonsis;Benign;Cancer;Normal
Napthyl amine	ST000614	AN000943	1.280E-3	1.560E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Total AC-DC / Total AC	ST000544	AN000827	2.290E-4	1.570E-3	Sample Type;Control;Replicate
N2-Fructopyranosylarginine	ST001205	AN002006	2.080E-4	1.580E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
2-AG b	ST000096	AN000154	1.340E-3	1.580E-3	Timepoint;18 hours;4 hours;NA
Cys-Gly-Pro-Ser	ST001202	AN002001	8.010E-4	1.580E-3	treatment_duration_(h);-;1.5;3;6;9
2-oxogluconic acid NIST	ST000369	AN000603	2.370E-4	1.590E-3	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	3.480E-5	1.600E-3	Exercise;No;Yes
3-Ethylmalate	ST001201	AN001998	8.810E-4	1.620E-3	cell_type;iRBC;unRBC
2-hydroxyglutarate+Na	ST000956	AN001568	5.930E-4	1.620E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
ethylpyruvate	ST000403	AN000643	7.770E-4	1.640E-3	Cell type;Mature erythrocyte;Reticulocyte
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	1.510E-4	1.640E-3	Sampling;After SWS onset;Morning fasting
ZEATIN [ISTD] (M+H)+	ST000726	AN001139	6.280E-5	1.660E-3	DISEASE_STATE;Control;PCOS
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)	ST000106	AN000176	9.850E-5	1.660E-3	Sampling time;0 min;60 min
BOC-ALA (+NA)	ST000105	AN000173	9.340E-5	1.670E-3	Sampling;After SWS onset;Morning fasting
indole-3-acetyl-valine	ST000403	AN000643	7.980E-4	1.680E-3	Cell type;Mature erythrocyte;Reticulocyte
undecanedicarboxylic acid	ST001000	AN001880	6.110E-4	1.710E-3	Diagnosis;CD;Control;UC
bOHbutyrate-ALL	ST000076	AN000122	1.430E-4	1.710E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Acetylpseudotropine	ST001202	AN002000	1.080E-3	1.710E-3	treatment_duration_(h);-;1.5;3;6;9
methylnaphthyl sulfate (2)*	ST000975	AN001596	1.020E-5	1.730E-3	REGION;MAK;SUN
N-acetyl-isoputrenine*	ST000975	AN001596	1.040E-5	1.770E-3	GROUP;case;control
D5-L-Glutamine iSTD	ST001211	AN002017	2.960E-4	1.770E-3	Group;Control;Methotrexate
16b-Hydroxystanozolol	ST000241	AN000373	1.240E-3	1.770E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-Aminomethylcyclohexane carboxylic acid	ST001037	AN001698	2.420E-4	1.780E-3	Description ;Blank;Reagent Blank;Serum Sample;Solvent
2-deoxytetronic acid NIST	ST000385	AN000620	3.660E-4	1.800E-3	Gender;F;M;NA
6-Acetamido-2-oxohexanoate	ST000403	AN000642	8.680E-5	1.830E-3	Glucose labelling;C13 glucose;unlabelled
2(alpha-D-Mannosyl)-D-glycerate	ST000403	AN000643	8.890E-4	1.850E-3	Cell type;Mature erythrocyte;Reticulocyte
acetophenone NIST	ST000368	AN000602	1.200E-3	1.880E-3	Organ;Plasma;Serum;Serum or Plasma
octulose 8-phosphate	ST001205	AN002007	2.100E-4	1.900E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Hydroxy-6-methylpyran-2-one	ST000567	AN000872	1.370E-3	1.930E-3	Time point;Post;Pre;Baseline
z mstfa artifact	ST000420	AN000662	1.140E-3	1.950E-3	Group;nonsmoker;smoker
Arg-Phe-Phe-Arg	ST001202	AN002001	1.030E-3	1.960E-3	treatment_duration_(h);-;1.5;3;6;9
melibionate	ST001202	AN002001	1.020E-3	1.960E-3	treatment_duration_(h);-;1.5;3;6;9
Bile salt	ST001201	AN001999	1.020E-3	1.970E-3	cell_type;iRBC;unRBC
Gln-Leu-Lys-His	ST000403	AN000642	1.010E-3	1.980E-3	Cell type;Mature erythrocyte;Reticulocyte
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000403	AN000643	1.600E-5	1.980E-3	timepoint;1 hour;20 hours
[FA (8:1)] 2Z-octenoic acid	ST000539	AN000819	7.730E-4	1.990E-3	Cell type;Mature erythrocyte;Reticulocyte
Hydroxyibuprofen	ST000567	AN000871	7.970E-4	2.000E-3	Time point;Post;Pre;Baseline
L-Ala-L-Glu	ST000539	AN000819	7.920E-4	2.010E-3	Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-Glu 2	ST000539	AN000819	7.920E-4	2.010E-3	Cell type;Mature erythrocyte;Reticulocyte
o-cresol sulfate	ST000975	AN001596	2.700E-4	2.040E-3	GENDER;F;M
715929 carbohydrate	ST000369	AN000603	6.670E-4	2.050E-3	Organ;Plasma;Serum
Indanofan	ST000291	AN000464	5.960E-6	2.050E-3	Treatment ;Baseline urine;Urine after drinking apple juice;U...
oleamide NIST	ST000412	AN000652	1.310E-3	2.050E-3	Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
C3 / C4	ST000544	AN000827	3.230E-4	2.070E-3	Sample Type;Control;Replicate
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylate	ST000923	AN001515	5.430E-4	2.080E-3	Diagnosis;CD;nonIBD;UC
Lys-Lys-Met-Pro	ST000403	AN000642	1.020E-4	2.080E-3	Glucose labelling;C13 glucose;unlabelled
indole-3-acetonitrile oxide	ST000403	AN000642	1.100E-3	2.140E-3	Cell type;Mature erythrocyte;Reticulocyte
ethanedisulfonate	ST000403	AN000643	1.050E-3	2.150E-3	Cell type;Mature erythrocyte;Reticulocyte
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	2.450E-4	2.160E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
undecanedionate	ST000923	AN001515	5.970E-4	2.170E-3	Diagnosis;CD;nonIBD;UC
C14:1-OH / C10	ST000545	AN000830	1.390E-3	2.170E-3	Sample Type;Control;Replicate
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATE	ST000956	AN001569	5.770E-4	2.210E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000689	AN001064	2.320E-4	2.250E-3	Construct;-;Control lentivirus;Noxa knockdown
CerH2O(d18:1/24:0);CerH2O(d19:1/23:0)	ST000608	AN000929	4.620E-4	2.250E-3	Factor;case;control
plasmenyl-PE 38:4 (16:0/22:4(7Z.10Z.13Z.16Z)) [M+H]+	ST001111	AN001805	1.570E-3	2.250E-3	Sample;Benign;Cancer;Metastasis
pantothete	ST001000	AN001879	7.050E-4	2.320E-3	Diagnosis;CD;Control;UC
Lys-Lys-Met-Pro	ST000539	AN000818	2.430E-5	2.340E-3	Glucose labelling;C13 glucose;unlabelled
2-Deoxymugineic acid	ST000403	AN000643	1.160E-3	2.350E-3	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	6.260E-5	2.350E-3	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
a Cysteine adduct	ST000539	AN000818	1.010E-3	2.380E-3	Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adduct 2	ST000539	AN000818	1.010E-3	2.380E-3	Cell type;Mature erythrocyte;Reticulocyte
creatine major dehydrated TMS3	ST000416	AN000658	4.400E-5	2.380E-3	Gender;Female;Male
Sulfacetamide sodium anhydrous	ST000292	AN000466	2.570E-5	2.380E-3	Treatment ;Baseline plasma;Plasma after drinking apple juice...
cis-Cyclo[L-ala-L-Pro]	ST000975	AN001596	3.230E-4	2.410E-3	GENDER;F;M
bOHbutyrate-13C4	ST000076	AN000122	2.650E-4	2.430E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
C4 / C0	ST000545	AN000830	1.590E-3	2.470E-3	Sample Type;Control;Replicate
HEPTADECENOATE (*)	ST000044	AN000069	1.050E-5	2.480E-3	Pancreas tissue type;Normal area of the pancreas with tumor;...
C8-Ceramide m0	ST000644	AN000976	8.590E-4	2.490E-3	time;48 hr;0 hr
Ala-Asp-Pro-Ser	ST000539	AN000818	1.070E-3	2.510E-3	Cell type;Mature erythrocyte;Reticulocyte
KINETIN RIBOSIDE	ST000422	AN000668	3.480E-5	2.520E-3	treatment;ND;T1D good glycemic control
Mono-N-depropylprobenecid	ST000422	AN000668	3.300E-5	2.520E-3	treatment;ND;T1D good glycemic control
715929 carbohydrate	ST000386	AN000621	8.300E-4	2.550E-3	Organ;Plasma;Serum
2-Dehydro-3-deoxy-L-rhamnonate	ST000403	AN000642	1.390E-4	2.560E-3	Glucose labelling;C13 glucose;unlabelled
7b-Hydroxydehydroepiandrosterone	ST000356	AN000583	1.060E-3	2.590E-3	stage;-;2;3
Bisnorcholic acid	ST000355	AN000581	3.690E-4	2.610E-3	Stage;1;2;3;4;-
3-(4-Hydroxyphenyl)Pyruvate / Caffeate	ST001040	AN001702	5.800E-4	2.630E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
EPC(d33:1)	ST001202	AN002000	2.410E-3	2.640E-3	cell_type;iRBC;unRBC
pyroglutamylglycine	ST000974	AN001595	5.620E-4	2.640E-3	REGION;AHRI;MRC;SUN
Citrate source fragment (+H and + NH3)	ST000956	AN001568	1.050E-3	2.700E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	8.090E-4	2.710E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Flavonol 3-O-xylosylglycoside-13C23[+QDA adduct]+	ST000148	AN000235	1.610E-5	2.710E-3	Treatment;13C-Glc;unlabeled
lysopalmitoyl monogalactosylglycerol	ST001322	AN002198	6.850E-4	2.740E-3	treatment;expecting 2 month - human breast milk;expecting 2 ...
alloxanoic acid NIST	ST000392	AN000628	8.830E-5	2.740E-3	Gender;F;M;-
6-Acetamido-2-oxohexanoate	ST001201	AN001998	1.130E-4	2.770E-3	treatment;DHA;DMSO;OZ277;OZ439
2-pyrrolidone-5-carboxylic acid	ST000356	AN000582	1.270E-3	2.780E-3	stage;-;2;3
Ammonia	ST000435	AN000685	5.840E-4	2.790E-3	treatment;ND;T1D good glycemic control;T1D poor glycemic con...
N-acetylmannosamine minor	ST000087	AN000139	1.450E-3	2.830E-3	Time Point;18 hours;4 hours
[Fv] Homoflemingin	ST000403	AN000642	1.490E-3	2.860E-3	Cell type;Mature erythrocyte;Reticulocyte
PC 40:4 (18:0/22:4(7Z.10Z.13Z.16Z)) [M-Ac-H]-	ST001111	AN001806	1.430E-3	2.860E-3	Sample;Benign;Cancer;Metastasis
SB N-(9Z-octadecenoyl)-sphinganine (d18:0/18:1(9Z)) [M-H]-	ST001111	AN001806	1.430E-3	2.860E-3	Sample;Benign;Cancer;Metastasis
N-Acetyl Lysine	ST000614	AN000939	2.490E-3	2.870E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
glucose-6-phosphate minor	ST000420	AN000662	1.750E-3	2.890E-3	Group;nonsmoker;smoker
Aminophosphovaleric acid	ST000614	AN000943	1.870E-3	2.920E-3	Diagonsis;Benign;Cancer;Normal
Unknown_742.54(-)@6.25	ST000818	AN001298	1.810E-3	2.940E-3	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000697	AN001081	3.700E-5	2.950E-3	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
Levobunolol glucuronide	ST000566	AN000870	2.450E-3	2.960E-3	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000697	AN001081	6.500E-5	2.970E-3	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
Very low density lipoprotein	ST001038	AN001699	1.480E-3	2.970E-3	Timepoint;15 min;1 hr;24 hr;30 min;<5 min
Furfural diethyl acetal	ST000539	AN000819	1.250E-3	3.030E-3	Cell type;Mature erythrocyte;Reticulocyte
Histidylproline diketopiperazine	ST000356	AN000583	1.260E-3	3.030E-3	stage;-;2;3
6-Acetyl-D-glucose	ST001204	AN002004	1.530E-3	3.040E-3	cell_type;iRBC;unRBC
S-(3-hydroxypropyl)mercapturic acid (HPMA)	ST000975	AN001596	2.290E-5	3.120E-3	GROUP;case;control
9-myristoleate	ST001322	AN002198	8.071E-4	3.127E-3	treatment;expecting 2 month - human breast milk;expecting 2 ...
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	9.840E-4	3.130E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
5b-Pregnediol	ST000241	AN000373	2.240E-3	3.130E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Citrate+Na;CITRATE	ST000956	AN001568	1.270E-3	3.160E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
[13C]-LEUCINE	ST000009	AN000023	1.290E-4	3.200E-3	AFTER_MEAL_TIME;30_MIN;NO_WAIT
IDP-D-mannose	ST001205	AN002006	5.790E-4	3.220E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))	ST001202	AN002001	1.760E-3	3.230E-3	treatment_duration_(h);-;1.5;3;6;9
Picrasin C-13C1[+13CD3 QDA]+	ST000148	AN000235	3.230E-5	3.240E-3	Treatment;13C-Glc;unlabeled
EPC(d37:1)	ST001205	AN002006	5.990E-4	3.250E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
6-diazo-5-oxonorleucine	ST001202	AN002000	2.130E-3	3.250E-3	treatment_duration_(h);-;1.5;3;6;9
Icosatrienoic acid	ST000539	AN000819	1.370E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine	ST000539	AN000819	1.370E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
P-DPD	ST000539	AN000819	1.380E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
methiin	ST000403	AN000642	1.730E-3	3.310E-3	Cell type;Mature erythrocyte;Reticulocyte
UDP-GLCUR-13C0+15N0	ST000076	AN000121	8.720E-6	3.370E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acid	ST000403	AN000643	4.990E-5	3.380E-3	timepoint;1 hour;20 hours
N-acetyl -D- glucosaminitol	ST001202	AN002001	3.110E-3	3.390E-3	cell_type;iRBC;unRBC
2-Pyridylthioamide	ST000566	AN000869	1.730E-3	3.390E-3	Time point;Post;Pre;Baseline
OHPro-ALL	ST000110	AN000185	7.300E-5	3.400E-3	Oxygen Condition;hypoxia;normoxia
saccharic acid	ST000087	AN000139	1.960E-3	3.430E-3	Time Point;18 hours;4 hours
threosphingosine	ST000923	AN001513	8.280E-4	3.460E-3	Diagnosis;CD;nonIBD;UC
Pro258-13C4	ST000076	AN000122	4.200E-4	3.460E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
SB N-(octadecanoyl)-sphing-4-enine (d18:1(4E)/18:0) [M-H]-	ST001111	AN001806	1.790E-3	3.500E-3	Sample;Benign;Cancer;Metastasis
HEPTADECENOATE (*)	ST000105	AN000174	3.780E-4	3.520E-3	Sampling;After SWS onset;Morning fasting
[FA (8:1)] 2Z-octenoic acid	ST000403	AN000643	1.770E-3	3.540E-3	Cell type;Mature erythrocyte;Reticulocyte
Ascorbate 2-sulfate	ST000567	AN000871	7.270E-4	3.540E-3	groups;Old-Curcumin;Old-Placebo;young
BOC-PHE-OH	ST000043	AN000070	6.690E-4	3.550E-3	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
[13C]-PHENYLALANINE	ST000016	AN000033	2.070E-3	3.550E-3	Material;Cells;Media
CPT-I ratio	ST000545	AN000830	2.360E-3	3.580E-3	Sample Type;Control;Replicate
isolinoleic acid NIST	ST000369	AN000603	1.230E-3	3.600E-3	Organ;Plasma;Serum
3-S-cysteinyl-2-methylpropanoate*	ST000974	AN001595	7.790E-4	3.600E-3	REGION;AHRI;MRC;SUN
benzi(ghi)perylene1	ST000614	AN000941	3.600E-3	3.600E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Kyn/Trp	ST001237	AN002055	3.690E-4	3.600E-3	Treatment;EVEROLIMUS;NIVOLUMAB
ALDO/KETO-HEXOSE	ST000475	AN000739	2.150E-3	3.600E-3	Treatment;-;MDH inhib
Galacturonate / Glucuronate	ST001040	AN001702	8.370E-4	3.610E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
alloxanoic acid NIST	ST000392	AN000628	1.370E-4	3.620E-3	Smoking Status;Current;Former;-
isolinoleic acid NIST	ST000386	AN000621	1.270E-3	3.640E-3	Organ;Plasma;Serum
Fummarate M+4	ST000507	AN000776	1.680E-3	3.690E-3	Time (incubation);24 hours;72 hours
C8-Ceramide m+6	ST000644	AN000976	1.390E-3	3.710E-3	time;48 hr;0 hr
Asp-Gly-Pro-Ser	ST000539	AN000818	1.670E-3	3.750E-3	Cell type;Mature erythrocyte;Reticulocyte
Ala-Cys-Pro-Ser	ST001204	AN002005	1.640E-3	3.790E-3	cell_type;iRBC;unRBC
DIMETHYLXANTHINE (*)	ST000105	AN000173	2.400E-4	3.800E-3	Sampling;After SWS onset;Morning fasting
3-hydroxybenzoic acid (likely)	ST000420	AN000662	2.340E-3	3.820E-3	Group;nonsmoker;smoker
4-Hydroxylevamisole Glucuronide	ST000566	AN000869	2.040E-3	3.820E-3	Time point;Post;Pre;Baseline
3-methyl catechol sulfate (1)	ST000899	AN001464	1.130E-3	3.830E-3	Type;Control;Crohn disease;Ulcerative Colitis
400671 carbohydrate	ST000386	AN000621	4.030E-4	3.840E-3	Gender;F;M;NA
Ala-Asp-Asp-His	ST001201	AN001998	2.190E-3	3.850E-3	cell_type;iRBC;unRBC
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	1.220E-3	3.860E-3	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	3.040E-5	3.870E-3	Taxane;N;Y;-
Alpha-acetyllysine	ST001039	AN001712	6.560E-4	3.900E-3	Sample.Matrix;Plasma;Urine
glycol	ST000355	AN000580	8.320E-4	3.950E-3	Stage;1;2;3;4;-
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucose	ST000956	AN001569	1.320E-3	4.000E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Acetylneuraminic acid	ST001039	AN001713	1.180E-3	4.070E-3	Sample.Matrix;Plasma;Urine
C8-Ceramide m+12	ST000644	AN000976	1.550E-3	4.070E-3	time;48 hr;0 hr
4-Hydroxy-4-methylglutamate	ST001205	AN002007	6.090E-4	4.090E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
para-toluidene	ST000614	AN000943	3.050E-3	4.110E-3	Diagonsis;Benign;Cancer;Normal
Casein K	ST000539	AN000818	1.850E-3	4.130E-3	Cell type;Mature erythrocyte;Reticulocyte
Casein K 2	ST000539	AN000818	1.850E-3	4.130E-3	Cell type;Mature erythrocyte;Reticulocyte
Acetyphenylalanine	ST001039	AN001712	9.670E-4	4.130E-3	Sample.Matrix;Plasma;Urine
Pro258-13C5	ST000076	AN000122	5.230E-4	4.150E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
ADMA/SDMA	ST001000	AN001878	1.100E-3	4.170E-3	Diagnosis;CD;Control;UC
Citrate+NH3	ST000956	AN001568	1.870E-3	4.180E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Caffeine-D3	ST000919	AN001507	3.770E-4	4.200E-3	Response;NR;R
(2-Butylbenzofuran-3-yl)(4-hydroxyphenyl)ketone-13C0[+Na]+	ST000142	AN000225	7.120E-4	4.200E-3	Treatment;13C-Glc;unlabeled
PC 40:8 (20:4(5E.8E.11E.14E)/20:4(5E.8E.11E.14E)) [M-Ac-H]-	ST001111	AN001806	2.230E-3	4.250E-3	Sample;Benign;Cancer;Metastasis
Naloxone-3-glucuronide	ST000242	AN000377	9.460E-4	4.330E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Lovastatin Hydroxy Acid	ST000553	AN000845	3.850E-3	4.330E-3	Sample type;Plasma;Urine
lathosterol NIST	ST000369	AN000603	6.010E-4	4.350E-3	Gender;F;M;NA
Taurine Dimer	ST000380	AN000614	2.660E-3	4.350E-3	Time;10min;1hr;24hr;6hr
PC(14:1(9Z)/P-16:0)	ST000241	AN000373	3.180E-3	4.350E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	9.070E-4	4.410E-3	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Cys-Met-Met-Phe	ST000539	AN000819	1.900E-3	4.450E-3	Cell type;Mature erythrocyte;Reticulocyte
Hyppuric Acid	ST000284	AN000452	3.160E-4	4.460E-3	Patient group;CRC;Healthy;Polyp
Phenyl beta-D-glucopyranoside	ST000566	AN000869	1.020E-3	4.490E-3	group;Old-Curcumin;Old-Placebo;young
Dide-O-methylsimmondsin	ST001205	AN002007	7.030E-4	4.530E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000106	AN000175	8.250E-5	4.530E-3	Sampling time;0 min;60 min
N-acetyl-isoputrenine*	ST000974	AN001595	1.960E-4	4.560E-3	TIMEPOINT;BL;M06;M18
glycodeoxycholate/glycochenodeoxycholate	ST001236	AN002054	2.220E-4	4.570E-3	Time point;baseline;week 4;week 9
1-(11Z-octadecenyl)-sn-glycero-3-phosphocholine	ST001204	AN002004	2.430E-3	4.600E-3	cell_type;iRBC;unRBC
Cys-Cys-Pro-Ser	ST001201	AN001998	3.070E-4	4.610E-3	treatment;DHA;DMSO;OZ277;OZ439
D-Alanyl-D-alanine	ST000356	AN000583	2.010E-3	4.650E-3	stage;-;2;3
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+H)+	ST000775	AN001223	2.270E-4	4.790E-3	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
L-Hypoglycin	ST000403	AN000643	2.510E-3	4.820E-3	Cell type;Mature erythrocyte;Reticulocyte
Lys-Lys-Met-Pro	ST000539	AN000818	1.000E-4	4.840E-3	timepoint;1 hour;20 hours
PC 36:2 (18:0/18:2(2E.4E)) [M+HCOO]-	ST001111	AN001806	2.560E-3	4.860E-3	Sample;Benign;Cancer;Metastasis
2-deoxytetronic acid NIST	ST000385	AN000620	7.350E-4	4.860E-3	Smoking Status;Current;Former;NA
1-3-7-trimethylurate	ST000923	AN001514	1.360E-3	4.870E-3	Diagnosis;CD;nonIBD;UC
2-AMINOETHYL DIHYDROGEN PHOSPHATE;ETHANOLAMINE PHOSPHATE	ST000956	AN001569	1.660E-3	4.880E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
N6-carboxymethyllysine	ST000899	AN001462	7.020E-4	4.880E-3	Type;Control;Crohn disease;Ulcerative Colitis
Heptopyranosides	ST001201	AN001999	3.060E-4	4.930E-3	treatment;DHA;DMSO;OZ277;OZ439
Abscisic acid glucose ester	ST000403	AN000643	2.580E-3	4.940E-3	Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adduct	ST000403	AN000642	2.630E-3	4.970E-3	Cell type;Mature erythrocyte;Reticulocyte
plasmenyl-PC 42:1 (18:0/24:1(15Z)) [M+Na]+	ST001111	AN001805	3.640E-3	4.990E-3	Sample;Benign;Cancer;Metastasis
Phenyl beta-D-glucopyranoside	ST000567	AN000871	1.270E-3	5.030E-3	groups;Old-Curcumin;Old-Placebo;young
HWESASXX*	ST000974	AN001595	1.140E-3	5.050E-3	REGION;AHRI;MRC;SUN
Asn-Asn-Gly-His	ST001202	AN002000	3.400E-3	5.060E-3	treatment_duration_(h);-;1.5;3;6;9
2-ethylphenylsulfate	ST000975	AN001596	8.000E-4	5.090E-3	GENDER;F;M
lathosterol NIST	ST000379	AN000613	2.120E-3	5.090E-3	Time;10min;1hr;24hr;6hr
Frctose-6-Phosphate	ST000614	AN000940	3.460E-3	5.100E-3	Diagonsis;Benign;Cancer;Normal
CL 80:14 (18:0/20:4/20:4/22:6) [M-2H](2-)	ST001111	AN001806	2.740E-3	5.110E-3	Sample;Benign;Cancer;Metastasis
OHPro-13C5	ST000076	AN000122	7.330E-4	5.150E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
[13C]-ARGININE	ST000016	AN000033	1.720E-3	5.170E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
heptadecanoic acid NIST	ST000369	AN000603	1.890E-3	5.180E-3	Organ;Plasma;Serum
3-methoxytyramine sulfate	ST000975	AN001596	9.000E-5	5.210E-3	REGION;MAK;SUN
sulfate of piperine metabolite C16H19NO3 (2)*	ST000975	AN001596	7.780E-5	5.210E-3	REGION;MAK;SUN
Cys-Leu-Cys-Tyr	ST001201	AN001999	2.830E-3	5.260E-3	cell_type;iRBC;unRBC
arachidiic acid	ST000417	AN001448	2.230E-3	5.260E-3	Group;AIR;NO2PM;PM
(E)-2-Butenyl-4-methyl-threonine	ST000567	AN000872	3.670E-4	5.310E-3	groups;Old-Curcumin;Old-Placebo;young
Aspidofractine	ST000539	AN000818	2.450E-3	5.340E-3	Cell type;Mature erythrocyte;Reticulocyte
5-hydroxynorvaline NIST	ST000392	AN000628	9.640E-4	5.440E-3	Disease State;cancer;control;-
O-methylcatechol sulfate	ST000899	AN001464	1.740E-3	5.470E-3	Type;Control;Crohn disease;Ulcerative Colitis
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	9.000E-4	5.520E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
L-Leucine-D10	ST000919	AN001506	4.190E-4	5.590E-3	Gender;Female;Male
methylhexadecanoic acid	ST000385	AN000620	1.550E-3	5.630E-3	Health State;Adenocarcinoma;Healthy;NA
Gln-Leu-Lys-Tyr	ST001202	AN002001	3.230E-3	5.630E-3	treatment_duration_(h);-;1.5;3;6;9
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001205	AN002006	1.170E-3	5.670E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
isohexonic acid	ST001211	AN002016	2.390E-3	5.680E-3	Group;Control;Methotrexate
(R)-AMAA	ST000539	AN000819	2.540E-3	5.690E-3	Cell type;Mature erythrocyte;Reticulocyte
4-allylphenol sulfate	ST000975	AN001596	9.110E-4	5.690E-3	GENDER;F;M
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate	ST000539	AN000819	2.340E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate 2	ST000539	AN000819	2.340E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
L-Hypoglycin	ST000539	AN000819	2.270E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
Ala-Leu-Thr-Pro	ST000403	AN000642	3.070E-3	5.730E-3	Cell type;Mature erythrocyte;Reticulocyte
EPC(d37:2)	ST001205	AN002006	1.200E-3	5.780E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
Fummarate M0	ST000507	AN000776	2.780E-3	5.790E-3	Time (incubation);24 hours;72 hours
N-Ace-Asp-13C2	ST001049	AN001864	1.050E-4	5.840E-3	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
plasmenyl-PE 36:2 (18:0/18:2(2E.4E)) [M+H]+	ST001111	AN001805	4.340E-3	5.870E-3	Sample;Benign;Cancer;Metastasis
Putreanine	ST001205	AN002006	1.240E-3	5.890E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	1.010E-3	5.910E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
Galabiosylceramide (d18:1/16:0)	ST000567	AN000872	4.960E-3	5.940E-3	Time point;Post;Pre;Baseline
C3 / C4	ST000545	AN000830	4.040E-3	5.980E-3	Sample Type;Control;Replicate
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-Gluc	ST000241	AN000373	8.810E-4	6.020E-3	Concentration (uM);0;500
benzi(ghi)perylene	ST000614	AN000943	4.790E-3	6.030E-3	Diagonsis;Benign;Cancer;Normal
Pro258-ALL	ST000114	AN000194	3.070E-4	6.100E-3	Treatment;None;Tetracycline
Bisnorcholic acid	ST000355	AN000581	8.200E-4	6.110E-3	Diagnosis;Breast cancer;Control
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	3.040E-4	6.130E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
tetcyclacis	ST001204	AN002005	2.730E-3	6.140E-3	cell_type;iRBC;unRBC
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	3.490E-4	6.160E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Plasmalogen(p18:0/20:4)	ST000450	AN000706	4.610E-3	6.190E-3	gender;Female;Male
sulfa d18:1 N16:0	ST000362	AN000594	2.160E-3	6.220E-3	Gender;1;2
[13C]-LYSINE	ST000016	AN000033	2.160E-3	6.230E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Asn-Asn-Gly-His	ST001201	AN001999	4.500E-4	6.300E-3	treatment;DHA;DMSO;OZ277;OZ439
hydroxyisovaleric acid	ST001000	AN001879	2.200E-3	6.320E-3	Diagnosis;CD;Control;UC
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	1.490E-4	6.320E-3	REGION;MAK;SUN
1_iSTD PG (17:0/17:0)	ST000342	AN000554	2.830E-3	6.330E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
heptadecanoic acid NIST	ST000386	AN000621	2.360E-3	6.380E-3	Organ;Plasma;Serum
ETHYL 3-INDOLE ACETATE	ST000016	AN000033	3.900E-3	6.500E-3	Material;Cells;Media
OH-dihexcer d18:1 N18:0	ST000362	AN000594	2.380E-3	6.540E-3	Gender;1;2
gamma-thiomethyl glutamate	ST001205	AN002006	1.480E-3	6.620E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
[calc GSH-13C]	ST000114	AN000194	5.980E-4	6.620E-3	Treatment;None;Tetracycline
OHPro-13C0	ST000114	AN000194	5.280E-4	6.620E-3	Treatment;None;Tetracycline
OHPro-ALL	ST000114	AN000194	7.080E-4	6.620E-3	Treatment;None;Tetracycline
Pro258-13C1	ST000114	AN000194	7.140E-4	6.620E-3	Treatment;None;Tetracycline
pyroglutamylisoleucine	ST000975	AN001596	7.810E-5	6.650E-3	GROUP;case;control
docosahexaenoylcholine	ST000899	AN001463	2.130E-3	6.650E-3	Type;Control;Crohn disease;Ulcerative Colitis
5-Hydroxycotinine	ST000403	AN000643	3.550E-3	6.670E-3	Cell type;Mature erythrocyte;Reticulocyte
nicotinamide guanine dinucleotide	ST001205	AN002007	1.220E-3	6.750E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d39:1)	ST001205	AN002006	1.580E-3	6.780E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
HYDROXYISOVALERATE (*)	ST000106	AN000176	1.680E-5	6.810E-3	Visit;1;2
iSTD iSTD PE (17:0/17:0)	ST000342	AN000554	3.350E-3	6.870E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
Diphenylmethylphosphineoxide	ST000046	AN000078	2.700E-4	7.070E-3	Cognitive Status;AD;CN;MCI
4-(Trimethylammonio)but-2-enoate	ST001202	AN002000	4.820E-3	7.080E-3	treatment_duration_(h);-;1.5;3;6;9
Deoxydaunorubicin-13C0[+QDA adduct]+	ST000148	AN000235	3.020E-4	7.150E-3	Treatment;13C-Glc;unlabeled
Urethane	ST000539	AN000818	3.420E-3	7.180E-3	Cell type;Mature erythrocyte;Reticulocyte
Urethane 2	ST000539	AN000818	3.420E-3	7.180E-3	Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(9:1)] 4-hydroxy-2-nonenal	ST000403	AN000642	3.890E-3	7.200E-3	Cell type;Mature erythrocyte;Reticulocyte
diacetylspermine	ST001000	AN001878	2.250E-3	7.240E-3	Diagnosis;CD;Control;UC
ADSGEGDFXAEGGGVR*	ST000974	AN001595	1.720E-3	7.270E-3	REGION;AHRI;MRC;SUN
12-OPDA	ST000539	AN000818	3.500E-3	7.280E-3	Cell type;Mature erythrocyte;Reticulocyte
Gentianaine	ST000539	AN000818	3.480E-3	7.280E-3	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000689	AN001063	1.190E-3	7.300E-3	Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000689	AN001063	1.230E-3	7.300E-3	Construct;-;Control lentivirus;Noxa knockdown
4-ethylphenylsulfate	ST000974	AN001595	4.380E-4	7.460E-3	TIMEPOINT;BL;M06;M18
sulfate*	ST000975	AN001596	1.260E-3	7.480E-3	GENDER;F;M
BOC-ASN	ST000010	AN000025	2.440E-3	7.520E-3	FCS;FCS;NO_FCS
DIHEXOSE	ST000106	AN000175	1.620E-4	7.560E-3	Sampling time;0 min;60 min
5?-Androstan-3?-ol-17-one sulfate - 7.5459185	ST000566	AN000869	1.810E-3	7.580E-3	group;Old-Curcumin;Old-Placebo;young
methylhexadecanoic acid	ST000385	AN000620	1.500E-3	7.660E-3	Smoking Status;Current;Former;NA
D-MANNOSAMINE (CAS# 14307-02-9); (M+H)+[-H2O]	ST000689	AN001064	1.520E-3	7.720E-3	Construct;-;Control lentivirus;Noxa knockdown
IDP-D-mannose	ST001201	AN001999	5.750E-4	7.720E-3	treatment;DHA;DMSO;OZ277;OZ439
Gulonolactone	ST001039	AN001713	3.570E-3	7.750E-3	Sample.Matrix;Plasma;Urine
penem CGP31608	ST000539	AN000819	3.680E-3	7.790E-3	Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608 2	ST000539	AN000819	3.680E-3	7.790E-3	Cell type;Mature erythrocyte;Reticulocyte
1-(2-(3-CYCLOHEXENYL)ETHYL)SILATRANE	ST001037	AN001698	1.400E-3	7.830E-3	Description ;Blank;Reagent Blank;Serum Sample;Solvent
N-Acetylanthranilate	ST001201	AN001999	7.360E-5	7.900E-3	treatment_duration_(h);-;0.5;1.5;3
5-hydroxynorvaline NIST	ST000385	AN000620	2.510E-3	7.950E-3	Health State;Adenocarcinoma;Healthy;NA
5-Acetamidopentanoate 2	ST000539	AN000819	3.570E-4	7.970E-3	Glucose labelling;C13 glucose;unlabelled
4-Methylumbelliferyl ?-D-glucuronide	ST000566	AN000869	1.990E-3	7.970E-3	group;Old-Curcumin;Old-Placebo;young
Labriformidin	ST000242	AN000377	1.830E-3	7.970E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
nonulose 9-phosphate	ST001202	AN002001	4.680E-3	7.990E-3	treatment_duration_(h);-;1.5;3;6;9
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000403	AN000643	4.420E-4	8.060E-3	Glucose labelling;C13 glucose;unlabelled
FA methyl(18:0)	ST001202	AN002001	4.770E-3	8.080E-3	treatment_duration_(h);-;1.5;3;6;9
3-deoxy-D-galactose	ST001204	AN002005	1.800E-4	8.080E-3	treatment_duration_(h);-;3;6;9
[PR] 9-Hydroxy-helminthosporol	ST000539	AN000819	3.870E-3	8.130E-3	Cell type;Mature erythrocyte;Reticulocyte
Succcinate	ST001038	AN001699	5.900E-3	8.160E-3	Placenta_Surface;Fetal;Maternal
IS D31-TAG	ST000523	AN000800	1.310E-3	8.170E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Total AC / C0	ST000545	AN000830	5.690E-3	8.170E-3	Sample Type;Control;Replicate
acisoga	ST000975	AN001596	1.420E-4	8.210E-3	GROUP;case;control
Asp-Met-Pro-Pro	ST000539	AN000818	4.020E-3	8.230E-3	Cell type;Mature erythrocyte;Reticulocyte
2-ethylphenylsulfate	ST000975	AN001596	2.360E-4	8.250E-3	REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	2.330E-4	8.250E-3	REGION;MAK;SUN
YM-201636	ST000567	AN000871	2.430E-3	8.260E-3	groups;Old-Curcumin;Old-Placebo;young
3-acetyl pyridine adenine dinucleotide	ST000403	AN000643	4.440E-3	8.280E-3	Cell type;Mature erythrocyte;Reticulocyte
hexadecylglycerol NIST	ST001211	AN002016	3.630E-3	8.280E-3	Group;Control;Methotrexate
phosphinomethylisomalate	ST001205	AN002007	1.600E-3	8.280E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
Gl-OH3P	ST000301	AN000479	4.000E-3	8.300E-3	Cell Line;L229;LN18;Pooled glioblastoma;U-138
N-Acetylphenylalanine / Indole-3-Ethanol	ST001040	AN001703	2.080E-3	8.340E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
methylhexadecanoic acid	ST000369	AN000603	1.480E-3	8.350E-3	Smoker;Current;Former;NA
(R)-AMAA	ST000403	AN000643	4.500E-3	8.360E-3	Cell type;Mature erythrocyte;Reticulocyte
methyl8-[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl]-octanoate	ST000046	AN000078	3.710E-4	8.410E-3	Cognitive Status;AD;CN;MCI
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000818	AN001297	1.960E-3	8.470E-3	Country;Ethiopia;Tanzania;Botswana
PGE2-d4	ST001000	AN001880	3.480E-3	8.480E-3	Diagnosis;CD;Control;UC
[6]-Paradol	ST001202	AN002001	5.060E-3	8.520E-3	treatment_duration_(h);-;1.5;3;6;9
methylhexadecanoic acid	ST000369	AN000603	1.510E-3	8.550E-3	Gender;F;M;NA
3-methyl catechol sulfate (1)	ST000975	AN001596	1.500E-3	8.580E-3	GENDER;F;M
p-Toluic acid-M+3	ST001167	AN001930	1.280E-3	8.600E-3	Cell lines;RWPE1;VCaP
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	8.830E-5	8.600E-3	TIMEPOINT;3 Month;Baseline;POOLED
MEVALOLACTONE	ST000016	AN000033	5.280E-3	8.620E-3	Material;Cells;Media
P-DPD	ST001201	AN001999	6.760E-4	8.700E-3	treatment;DHA;DMSO;OZ277;OZ439
Diethyl Oxalpropionate	ST000566	AN000870	1.670E-4	8.790E-3	group;Old-Curcumin;Old-Placebo;young
A-Ketoglutaricacidoxime	ST001201	AN001999	4.870E-3	8.810E-3	cell_type;iRBC;unRBC
3-sulfopropanoate	ST000539	AN000819	4.220E-3	8.840E-3	Cell type;Mature erythrocyte;Reticulocyte
Mesaconate	ST001205	AN002007	1.740E-3	8.850E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
C16-OH Sulfatide	ST000567	AN000871	2.730E-3	8.860E-3	groups;Old-Curcumin;Old-Placebo;young
N-methylundec-10-enamide	ST000242	AN000377	2.130E-3	8.880E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
uridine-5-diphosphate bromoacetol	ST000403	AN000643	4.900E-3	9.080E-3	Cell type;Mature erythrocyte;Reticulocyte
lathosterol NIST	ST000369	AN000603	1.650E-3	9.080E-3	Smoker;Current;Former;NA
CMP-N-trimethyl-2-aminoethylphosphonate	ST001201	AN001999	7.340E-4	9.090E-3	treatment;DHA;DMSO;OZ277;OZ439
2-oxogluconic acid NIST	ST000369	AN000603	3.590E-3	9.150E-3	Organ;Plasma;Serum
Lactosylceramide (d18:1/12:0)	ST000241	AN000374	2.210E-3	9.300E-3	Concentration (uM);0;500
(R)-2-Ethylmalate	ST001202	AN002000	6.630E-3	9.340E-3	treatment_duration_(h);-;1.5;3;6;9
6-deoxyglucitol NIST	ST000369	AN000603	1.760E-3	9.370E-3	Smoker;Current;Former;NA
Marinobufagenin	ST000566	AN000869	2.490E-3	9.530E-3	group;Old-Curcumin;Old-Placebo;young
furoylglycine NIST	ST000381	AN000615	1.960E-3	9.540E-3	Cohort;CSMC;INHA
[13C]-ASPARTIC ACID	ST000016	AN000033	5.930E-3	9.570E-3	Material;Cells;Media
Bis(2-hydroxypropyl)amine+5.4374814	ST000047	AN000081	9.990E-5	9.760E-3	Cognitive Status;AD;CN;MCI
phosphinomethylmalate	ST000403	AN000643	5.360E-3	9.830E-3	Cell type;Mature erythrocyte;Reticulocyte
5-O-Feruloylquinic acid	ST000566	AN000869	5.700E-3	9.830E-3	Time point;Post;Pre;Baseline
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000689	AN001063	2.330E-3	9.890E-3	Construct;-;Control lentivirus;Noxa knockdown
EPICATECHINPENTAACETATE	ST000047	AN000081	1.410E-4	1.000E-2	Cognitive Status;AD;CN;MCI
Cys-Met-Tyr-Tyr	ST000539	AN000818	2.260E-4	1.010E-2	timepoint;1 hour;20 hours
Arg-Asp-Asp-Gly	ST001201	AN001998	6.120E-3	1.020E-2	cell_type;iRBC;unRBC
(-)-jasmonoyl-L-valine	ST000539	AN000819	4.970E-3	1.030E-2	Cell type;Mature erythrocyte;Reticulocyte
DOPA/Tyr	ST000544	AN000826	2.740E-3	1.030E-2	Sample Type;Control;Replicate
Spermidine / Putrescine	ST000544	AN000826	2.630E-3	1.030E-2	Sample Type;Control;Replicate
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000713	AN001114	8.160E-4	1.040E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000713	AN001114	8.230E-4	1.040E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	2.300E-3	1.040E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
Ovothiol B	ST001204	AN002005	4.840E-3	1.050E-2	cell_type;iRBC;unRBC
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	7.460E-4	1.050E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
2-oxo-4-methylvaleric acid	ST000355	AN000580	2.430E-3	1.070E-2	Diagnosis;Breast cancer;Control
Ala-Ala-Ala-Ser	ST001202	AN002000	7.700E-3	1.070E-2	treatment_duration_(h);-;1.5;3;6;9
L-beta-aspartyl-L-alanine	ST001201	AN001998	6.600E-3	1.080E-2	cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerate	ST000539	AN000818	5.400E-3	1.080E-2	Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylester	ST000539	AN000818	5.450E-3	1.080E-2	Cell type;Mature erythrocyte;Reticulocyte
21-hydroxypregnenolone monosulfate (1)	ST000974	AN001595	2.670E-3	1.080E-2	REGION;AHRI;MRC;SUN
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	6.690E-5	1.090E-2	Drug;Exemestane;Letrozole;POOLED
BOC-SER-OH	ST000044	AN000069	7.750E-4	1.090E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Diethyl adipate	ST000403	AN000643	6.040E-3	1.100E-2	Cell type;Mature erythrocyte;Reticulocyte
Ritodrineglucuronide	ST000046	AN000078	6.490E-4	1.100E-2	Cognitive Status;AD;CN;MCI
Cys-Met-Tyr-Tyr	ST000539	AN000818	1.520E-4	1.100E-2	Glucose labelling;C13 glucose;unlabelled
SELENOCYSTAMINE	ST000016	AN000033	6.950E-3	1.100E-2	Material;Cells;Media
2-oxogluconic acid NIST	ST000386	AN000621	4.190E-3	1.100E-2	Organ;Plasma;Serum
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.570E-4	1.100E-2	Race;Black;White;POOLED
Arg-Cys-Gln-Tyr	ST000539	AN000819	5.430E-3	1.110E-2	Cell type;Mature erythrocyte;Reticulocyte
2-deoxypentitol NIST	ST001211	AN002016	5.250E-3	1.110E-2	Group;Control;Methotrexate
Asn-Lys-Gly-Gly	ST001205	AN002006	3.010E-3	1.110E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	7.460E-4	1.120E-2	KD#2;yes;no;Pooled melanoma
C12 / C8	ST000545	AN000830	7.890E-3	1.120E-2	Sample Type;Control;Replicate
C5-SUGAR ALCOHOL	ST000956	AN001569	4.470E-3	1.120E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
N2-(D-1-Carboxyethyl)-L-arginine	ST001202	AN002000	8.170E-3	1.120E-2	treatment_duration_(h);-;1.5;3;6;9
Frctose-6-Phosphate	ST000614	AN000940	9.140E-3	1.130E-2	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
urea (partial derivative)	ST000092	AN000146	8.150E-3	1.130E-2	Solution Added;N/A;None;Urease;Water
2-(4-sulfophenyl)butyrate	ST001202	AN002000	8.240E-3	1.130E-2	treatment_duration_(h);-;1.5;3;6;9
Hydroxybutyrate3	ST000137	AN000219	1.380E-3	1.140E-2	Sample Group;Control;Patient
Methoxytyramine	ST001039	AN001712	4.730E-3	1.150E-2	Sample.Matrix;Plasma;Urine
deacetylcolchicine	ST001202	AN002000	8.500E-3	1.150E-2	treatment_duration_(h);-;1.5;3;6;9
22:1 (n-9)	ST001098	AN001786	6.750E-4	1.150E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.250E-3	1.160E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
TROMETHAMINE+5.1856112	ST000046	AN000076	6.090E-4	1.160E-2	Cognitive Status;AD;CN;MCI
asparagylisoleucine	ST000974	AN001595	8.020E-4	1.170E-2	TIMEPOINT;BL;M06;M18
urobilin - targeted	ST000923	AN001513	1.270E-3	1.180E-2	sex;Female;Male
glutathione-sulfite	ST000403	AN000643	6.610E-3	1.190E-2	Cell type;Mature erythrocyte;Reticulocyte
N-Hydroxy-1-aminonaphthalene	ST000403	AN000643	6.620E-3	1.190E-2	Cell type;Mature erythrocyte;Reticulocyte
5-(3-Pyridyl)-2-hydroxytetrahydrofuran	ST000567	AN000872	1.020E-3	1.190E-2	groups;Old-Curcumin;Old-Placebo;young
L-beta-aspartyl-L-serine	ST001201	AN001998	1.070E-3	1.190E-2	treatment;DHA;DMSO;OZ277;OZ439
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M+H)+	ST000689	AN001064	2.610E-3	1.200E-2	Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.200E-4	1.210E-2	CASE_CONTROL;Case;Control;POOLED
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000016	AN000033	7.930E-3	1.230E-2	Material;Cells;Media
Sulfoacetate	ST000539	AN000819	6.190E-3	1.240E-2	Cell type;Mature erythrocyte;Reticulocyte
sulfate of piperine metabolite C16H19NO3 (3)*	ST000975	AN001596	3.820E-4	1.240E-2	REGION;MAK;SUN
heptadecanoic acid NIST	ST000385	AN000620	4.730E-3	1.260E-2	Health State;Adenocarcinoma;Healthy;NA
BOC-ASN	ST000009	AN000023	4.370E-3	1.260E-2	SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
C8-Ceramide m+14	ST000644	AN000976	6.370E-3	1.260E-2	time;48 hr;0 hr
creatine major dehydrated TMS3	ST000416	AN000658	4.150E-3	1.270E-2	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
BOC-ASP-OH	ST000043	AN000070	3.020E-3	1.310E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
p-Toluic acid-M+3	ST001167	AN001930	8.090E-3	1.320E-2	Time points;0.25h;0h;12h;24h;4h;6days
Glu-Met-Cys-His	ST000539	AN000819	6.740E-3	1.330E-2	Cell type;Mature erythrocyte;Reticulocyte
bOHbutyrate-13C1	ST000114	AN000194	1.880E-3	1.340E-2	Treatment;None;Tetracycline
2-ketoglucose dimethylacetal NIST	ST000063	AN000101	3.000E-3	1.350E-2	Source;Group 1 - Score 0;Group 2 - Score 50
enolpyruvate NIST	ST000087	AN000139	9.390E-3	1.350E-2	Time Point;18 hours;4 hours
Ovothiol disulfide	ST001204	AN002004	7.590E-3	1.360E-2	cell_type;iRBC;unRBC
3-hydroxyoxyisovaleric acid	ST000355	AN000580	3.400E-3	1.360E-2	Stage;1;2;3;4;-
DMNT	ST000403	AN000642	7.820E-3	1.370E-2	Cell type;Mature erythrocyte;Reticulocyte
Methyltyrosine	ST000356	AN000582	7.610E-3	1.370E-2	Diagnosis;breast cancer;control
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	3.120E-3	1.370E-2	Disease State;cancer;control;-
CPT-I ratio	ST000544	AN000827	2.360E-3	1.370E-2	Sample Type;Control;Replicate
PC(14:1(9Z)/P-16:0)	ST000241	AN000373	2.280E-3	1.380E-2	Concentration (uM);0;500
N-(4-benzenesulfonamide) arachidonoyl amine	ST000242	AN000375	1.130E-2	1.380E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
C9 / C10:2	ST000545	AN000830	9.810E-3	1.380E-2	Sample Type;Control;Replicate
Asn-Val-Gly-Ser	ST001204	AN002004	7.760E-3	1.390E-2	cell_type;iRBC;unRBC
iSTD iSTD MAG (17:0/0:0/0:0)	ST000342	AN000554	7.630E-3	1.390E-2	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
L-Glutamic acid dibutyl ester	ST000566	AN000870	5.570E-4	1.400E-2	group;Old-Curcumin;Old-Placebo;young
glyoxalurea NIST	ST000369	AN000603	3.670E-3	1.410E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
2-HB (2-hydroxybutyric acid)	ST000166	AN000259	4.310E-3	1.410E-2	Group;3M;Control;HF
beta-Homophenylalanine	ST001211	AN002017	3.680E-3	1.410E-2	Group;Control;Methotrexate
5-(3-Pyridyl)-2-hydroxytetrahydrofuran	ST000567	AN000872	1.290E-2	1.410E-2	Time point;Post;Pre;Baseline
tetrahydro-1-methyl-beta-carboline-3-carboxylate	ST000923	AN001514	5.430E-3	1.420E-2	Diagnosis;CD;nonIBD;UC
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)	ST000016	AN000033	9.240E-3	1.430E-2	Material;Cells;Media
1-LG and 2-LG	ST000977	AN001599	7.190E-3	1.440E-2	Group;Healthy Control;NAFLD
Caffeine-D3	ST000956	AN001568	7.430E-3	1.440E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
N-Acetyl-D-glucosaminate	ST001201	AN001999	8.310E-3	1.450E-2	cell_type;iRBC;unRBC
glyoxalurea NIST	ST000386	AN000621	2.410E-3	1.450E-2	Gender;F;M;NA
cytidine-5-monophosphate NIST	ST000087	AN000139	1.030E-2	1.450E-2	Time Point;18 hours;4 hours
[6]-Shogaol-13C0[+H]+	ST000148	AN000235	1.370E-3	1.450E-2	Treatment;13C-Glc;unlabeled
C6H12O6-HEXOSE/KETOSE/INOSITOL	ST000292	AN000467	1.350E-3	1.450E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001202	AN002001	1.350E-2	1.460E-2	cell_type;iRBC;unRBC
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.100E-4	1.460E-2	Chemotherapy;N;Y;POOLED
trimethylbenzene	ST000923	AN001513	4.950E-3	1.460E-2	Diagnosis;CD;nonIBD;UC
Ala-Asp-Asp-His	ST001201	AN001998	1.450E-3	1.460E-2	treatment;DHA;DMSO;OZ277;OZ439
Fisher ratio	ST000545	AN000829	1.970E-4	1.470E-2	Sample Type;Control;Replicate
Sucrose / Trehalose / Lactose	ST001040	AN001702	5.180E-3	1.480E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	3.590E-3	1.480E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
400671 carbohydrate	ST000369	AN000603	4.060E-3	1.500E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
lathosterol NIST	ST000369	AN000603	3.990E-3	1.500E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
4-8dimethylnonanoylcarnitine	ST000403	AN000642	8.670E-3	1.500E-2	Cell type;Mature erythrocyte;Reticulocyte
3-Ethyl-3-methylheptane	ST001037	AN001698	3.560E-3	1.500E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Gulonolactone	ST001193	AN001989	1.130E-2	1.500E-2	Plasma;Cord blood;Plasma
Ala-Leu-Lys-Pro	ST001205	AN002006	4.270E-3	1.510E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
D1-2-Hydroxymethylethisterone-11.471997	ST000046	AN000078	1.030E-3	1.520E-2	Cognitive Status;AD;CN;MCI
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	3.740E-3	1.520E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
OH-monohexcer d18:1 N20:0	ST000362	AN000594	7.590E-3	1.540E-2	Gender;1;2
OH-monohexcer d18:1 N24:0	ST000362	AN000594	7.420E-3	1.540E-2	Gender;1;2
Prunetin or similar isoflavone	ST000586	AN000901	1.230E-2	1.540E-2	Plasma Volume;0 uL;150 uL;700 uL
4-Amino-4-deoxychorismate	ST000539	AN000819	7.990E-3	1.550E-2	Cell type;Mature erythrocyte;Reticulocyte
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE	ST000016	AN000033	5.890E-3	1.560E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Bis(2-hydroxypropyl)amine	ST000047	AN000080	1.650E-4	1.570E-2	Cognitive Status;AD;CN;MCI
3-methyl catechol sulfate (2)	ST000975	AN001596	5.330E-4	1.580E-2	REGION;MAK;SUN
PC 33:3 (15:1(9Z)/18:2(2E.4E)) [M-Ac-H]-	ST001111	AN001806	8.940E-3	1.590E-2	Sample;Benign;Cancer;Metastasis
Fibrinopeptide B (1-11)**	ST000975	AN001596	3.190E-3	1.610E-2	GENDER;F;M
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000044	AN000069	1.670E-3	1.610E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Oleandrosyl-oleandolide-13C0[+QDA adduct]+	ST000148	AN000235	1.650E-3	1.610E-2	Treatment;13C-Glc;unlabeled
[13C]-ARGININE	ST000016	AN000033	4.050E-3	1.610E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	3.290E-3	1.630E-2	Treatment response;No;Yes;Pooled
d1-piperidine-dicarboxylate	ST000539	AN000818	8.580E-3	1.640E-2	Cell type;Mature erythrocyte;Reticulocyte
N-dimethylethanolamine	ST000403	AN000642	9.500E-3	1.640E-2	Cell type;Mature erythrocyte;Reticulocyte
Hexazinone	ST000242	AN000377	4.390E-3	1.650E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Lactosylceramide (d18:1/12:0)	ST000241	AN000374	1.630E-2	1.650E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
hydroxymyristate	ST000923	AN001515	6.220E-3	1.660E-2	Diagnosis;CD;nonIBD;UC
BOC-PHE-OH	ST000105	AN000173	1.410E-3	1.660E-2	Sampling;After SWS onset;Morning fasting
[Fv] Homoflemingin	ST000539	AN000818	4.010E-4	1.660E-2	timepoint;1 hour;20 hours
400671 carbohydrate	ST000369	AN000603	3.670E-3	1.670E-2	Gender;F;M;NA
1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine	ST000445	AN000696	2.320E-3	1.670E-2	Treatment;FSH;LH
10-nonadecenoate	ST000923	AN001515	6.500E-3	1.690E-2	Diagnosis;CD;nonIBD;UC
idonic acid NIST	ST000379	AN000613	5.530E-3	1.690E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Ala-Leu-Lys-Asp	ST001201	AN001998	1.070E-2	1.700E-2	cell_type;iRBC;unRBC
enolpyruvate NIST	ST000381	AN000615	4.500E-3	1.700E-2	Cohort;CSMC;INHA
Ceramide(d18:1/23:0) or Ceramide(d18:1/22:1 OH)	ST000450	AN000705	2.110E-3	1.700E-2	Disease;CFS;Normal
Methylitaconate	ST001205	AN002006	4.840E-3	1.700E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Phorbol butanoate-13C0[+QDA adduct]+	ST000148	AN000235	1.900E-3	1.700E-2	Treatment;13C-Glc;unlabeled
U 0521-13C0[+QDA adduct]+NH4	ST000148	AN000235	1.890E-3	1.700E-2	Treatment;13C-Glc;unlabeled
6-Hydroxy flavin adenine dinucleotide	ST000241	AN000373	1.380E-2	1.700E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acid	ST000567	AN000871	5.870E-3	1.710E-2	groups;Old-Curcumin;Old-Placebo;young
2-Hydroxyphenylalanine;L-TYROSINE	ST000956	AN001568	9.100E-3	1.710E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
beta-mannosylglycerate	ST000368	AN000602	1.210E-2	1.720E-2	Organ;Plasma;Serum;Serum or Plasma
benzi(ghi)perylene1	ST000614	AN000941	1.440E-2	1.730E-2	Diagonsis;Benign;Cancer;Normal
10-oxogeranial	ST000403	AN000643	1.180E-3	1.730E-2	Glucose labelling;C13 glucose;unlabelled
ZEATIN [ISTD] (M+H)+	ST000763	AN001202	3.000E-3	1.730E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
2-oxo-4-methylvaleric acid	ST000355	AN000580	4.490E-3	1.740E-2	Stage;1;2;3;4;-
Ala-Asp-Asp-Cys	ST001201	AN001998	1.110E-2	1.750E-2	cell_type;iRBC;unRBC
heptadecanoic acid NIST	ST000368	AN000602	1.250E-2	1.760E-2	Organ;Plasma;Serum;Serum or Plasma
N-acetylglycine NIST	ST000385	AN000620	8.140E-3	1.770E-2	Gender;F;M;NA
dihydrogeranylgeranyl-bacteriopheophytin	ST001205	AN002007	4.590E-3	1.770E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
5-guanidino-3-methyl-2-oxo-pentanoate	ST000403	AN000642	1.040E-2	1.780E-2	Cell type;Mature erythrocyte;Reticulocyte
threo-sphingosine	ST001236	AN002054	5.220E-4	1.780E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
IS SM 35:1; [M+H]+	ST000523	AN000800	3.810E-3	1.790E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
5-methyluridine NIST	ST001211	AN002016	8.830E-3	1.790E-2	Group;Control;Methotrexate
2(alpha-D-Mannosyl)-D-glycerate	ST001201	AN001999	1.040E-2	1.800E-2	cell_type;iRBC;unRBC
[PC (16:0/3:0)] 1-hexadecanoyl-2-(2E-propionyl)-sn-glycero-3-phosphocholine	ST000539	AN000818	9.610E-3	1.800E-2	Cell type;Mature erythrocyte;Reticulocyte
masilinate	ST000923	AN001515	7.150E-3	1.800E-2	Diagnosis;CD;nonIBD;UC
6-deoxyglucitol NIST	ST000369	AN000603	5.020E-3	1.810E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
1-Methyladenosine B	ST001211	AN002017	4.790E-3	1.810E-2	Group;Control;Methotrexate
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000713	AN001113	2.400E-3	1.810E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
2-oxogluconic acid NIST	ST000386	AN000621	3.650E-3	1.830E-2	Gender;F;M;NA
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)	ST000106	AN000176	1.410E-3	1.840E-2	Sampling time;0 min;60 min
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.890E-4	1.840E-2	Tamoxyfen;N;Y;-
Oxostearate-13C0[+Na]+	ST000148	AN000235	2.370E-3	1.850E-2	Treatment;13C-Glc;unlabeled
Tecomine-13C0[+13CD3 QDA]+NH4	ST000148	AN000235	2.390E-3	1.850E-2	Treatment;13C-Glc;unlabeled
[FA oxo(8:0)] 3-oxo-octanoic acid	ST000403	AN000643	1.410E-3	1.870E-2	Glucose labelling;C13 glucose;unlabelled
N-Butyl-beta-carboline-3-carboxylate	ST001202	AN002001	1.220E-2	1.870E-2	treatment_duration_(h);-;1.5;3;6;9
sulfate of piperine metabolite C16H19NO3 (3)*	ST000974	AN001595	2.710E-4	1.890E-2	GROUP;case;control
Avenic acid A	ST001202	AN002001	1.240E-2	1.890E-2	treatment_duration_(h);-;1.5;3;6;9
methylhexadecanoic acid	ST000369	AN000603	5.670E-3	1.900E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Gln-Leu-Lys-His	ST000539	AN000818	1.030E-2	1.920E-2	Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Asp-Cys	ST001202	AN002000	1.470E-2	1.930E-2	treatment_duration_(h);-;1.5;3;6;9
Furfural diethyl acetal	ST000403	AN000643	1.580E-3	1.940E-2	Glucose labelling;C13 glucose;unlabelled
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	1.980E-3	1.960E-2	Gender;F;M;-
4-oxo-4-(3-pyridyl)-butanoate	ST001205	AN002007	5.280E-3	1.960E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Phenolsulfonphthalein	ST001205	AN002007	5.280E-3	1.960E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
SB N-(docosanoyl)-sphing-4-enine (d18:1(4E)/22:0) [M-H]-	ST001111	AN001806	1.120E-2	1.960E-2	Sample;Benign;Cancer;Metastasis
SALICYLATE #2 (M-H)-	ST000523	AN000799	7.210E-3	1.970E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
N-acetyltheanine	ST000974	AN001595	5.370E-3	1.980E-2	REGION;AHRI;MRC;SUN
DG 37:2 (18:2/19:0/0:0) [M+NH4]+	ST001111	AN001805	1.560E-2	1.990E-2	Sample;Benign;Cancer;Metastasis
N-Acetyl-D-glucosaminate	ST001204	AN002004	1.170E-2	2.010E-2	cell_type;iRBC;unRBC
BOC-ASP-OH	ST000016	AN000033	7.930E-3	2.020E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
3-O-Methyl-myo-inositol	ST000566	AN000870	1.840E-2	2.020E-2	Time point;Post;Pre;Baseline
L-proline amide	ST000403	AN000642	1.520E-3	2.040E-2	Glucose labelling;C13 glucose;unlabelled
Cys-Gly-Pro-Ser	ST001201	AN001999	2.130E-3	2.040E-2	treatment;DHA;DMSO;OZ277;OZ439
Asn-Thr-Asn-Asn	ST001202	AN002000	1.570E-2	2.040E-2	treatment_duration_(h);-;1.5;3;6;9
UDP-GNAc-13C0+15N0	ST000076	AN000121	1.070E-4	2.070E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Cys-Gly-Pro-Ser	ST001204	AN002005	1.040E-2	2.080E-2	cell_type;iRBC;unRBC
AMINOPENTANOIC ACID	ST000044	AN000069	2.560E-3	2.080E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-HIS-OH	ST000016	AN000033	5.310E-3	2.080E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
3-Hydroxyphenytoin	ST000047	AN000083	1.620E-3	2.090E-2	Cognitive Status;AD;CN;MCI
Propionylglycinemethylester	ST000046	AN000077	4.200E-4	2.090E-2	Cognitive Status;AD;CN;MCI
bOHbutyrate-13C2	ST000076	AN000122	4.570E-3	2.100E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
[FA methyl(6:0)] 2-methyl-hexanoic acid	ST000539	AN000819	1.140E-2	2.110E-2	Cell type;Mature erythrocyte;Reticulocyte
octulose 8-phosphate	ST000403	AN000643	1.240E-2	2.110E-2	Cell type;Mature erythrocyte;Reticulocyte
Methylprednisone	ST000567	AN000871	7.540E-3	2.110E-2	groups;Old-Curcumin;Old-Placebo;young
epsilon-caprolactam (likely)	ST000420	AN000662	1.450E-2	2.120E-2	Group;nonsmoker;smoker
[Fv] Desmosdumotin C	ST000403	AN000642	1.260E-2	2.130E-2	Cell type;Mature erythrocyte;Reticulocyte
threo-sphingosine	ST001237	AN002055	1.150E-2	2.130E-2	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
aminoisobutyric acid/GABA	ST000923	AN001513	3.010E-3	2.130E-2	sex;Female;Male
Ala-Thr-Ala-Gly	ST001201	AN001999	2.520E-3	2.130E-2	treatment;DHA;DMSO;OZ277;OZ439
N-Oleoyl-L-Serine	ST000566	AN000870	1.640E-3	2.150E-2	group;Old-Curcumin;Old-Placebo;young
Prunetin or similar isoflavone	ST000589	AN000904	2.090E-2	2.160E-2	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucose	ST000475	AN000740	1.370E-2	2.160E-2	Treatment;-;MDH inhib
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acid	ST000539	AN000819	1.190E-2	2.180E-2	Cell type;Mature erythrocyte;Reticulocyte
trimethylbenzene	ST001000	AN001878	8.220E-3	2.180E-2	Diagnosis;CD;Control;UC
methylhexadecanoic acid	ST000386	AN000621	4.130E-3	2.210E-2	Smoker;Current;Former;NA
uridine-5-diphosphate bromoacetol	ST000539	AN000819	9.140E-5	2.210E-2	timepoint;1 hour;20 hours
ALDO/KETO-HEXOSE	ST000956	AN001568	1.190E-2	2.210E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Dihydroxyacetophenone	ST001039	AN001712	1.280E-2	2.220E-2	Sample.Matrix;Plasma;Urine
FA methyl (8:1)	ST001202	AN002001	1.490E-2	2.220E-2	treatment_duration_(h);-;1.5;3;6;9
Cys-Thr-Ser-Tyr	ST000539	AN000819	1.220E-2	2.230E-2	Cell type;Mature erythrocyte;Reticulocyte
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000539	AN000819	1.220E-2	2.230E-2	Cell type;Mature erythrocyte;Reticulocyte
CAI-1	ST000539	AN000819	3.490E-4	2.230E-2	timepoint;1 hour;20 hours
CL 74:10 (16:0/22:5/20:4/16:1) [M-2H](2-)	ST001111	AN001806	1.320E-2	2.240E-2	Sample;Benign;Cancer;Metastasis
3-S-cysteinyl-2-methylpropanoate*	ST000974	AN001595	1.770E-3	2.240E-2	TIMEPOINT;BL;M06;M18
B-ureidoisobutyric acid	ST000422	AN000667	4.030E-4	2.240E-2	treatment;ND;T1D good glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanine	ST000422	AN000667	4.050E-4	2.240E-2	treatment;ND;T1D good glycemic control
4-(Trimethylammonio)but-2-enoate	ST001205	AN002006	7.230E-3	2.260E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Isocitrate M0	ST000507	AN000776	1.150E-2	2.260E-2	Time (incubation);24 hours;72 hours
Asn-Leu-Pro-Pro	ST001201	AN001998	2.950E-3	2.260E-2	treatment;DHA;DMSO;OZ277;OZ439
6-oxopiperidine-2-carboxylic acid	ST000974	AN001595	1.890E-3	2.280E-2	TIMEPOINT;BL;M06;M18
3-AP	ST001167	AN001929	1.060E-2	2.280E-2	Time points;0.25h;0h;12h;24h;4h;6days
lathosterol NIST	ST000386	AN000621	4.940E-3	2.290E-2	Gender;F;M;NA
Dihydrodaunorubicin-13C0[+13CD3 QDA]+	ST000148	AN000235	3.340E-3	2.300E-2	Treatment;13C-Glc;unlabeled
Mannitol;HEXOSE ALCOHOL	ST000956	AN001569	1.110E-2	2.310E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
N-Acetylanthranilate	ST001201	AN001999	2.880E-3	2.320E-2	treatment;DHA;DMSO;OZ277;OZ439
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-Serine	ST000956	AN001569	1.170E-2	2.330E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
L-4-Hydroxy-3-methoxy-a-methylphenylalanine + 2.0514681	ST000421	AN000663	7.690E-4	2.330E-2	treatment;ND;T1D poor glycemic control
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000763	AN001202	4.600E-3	2.350E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
urobilinogen	ST001237	AN002055	6.100E-3	2.360E-2	Time point;baseline;week 4;week 8
Billirubin	ST000919	AN001507	3.150E-3	2.370E-2	Response;NR;R
N2-(D-1-Carboxyethyl)-L-arginine	ST001201	AN001998	3.440E-3	2.370E-2	treatment;DHA;DMSO;OZ277;OZ439
17a-Ethynylestradiol2-glucuronide	ST000046	AN000079	1.670E-3	2.380E-2	Cognitive Status;AD;CN;MCI
Trihexosylceramide (d18:1/18:0)	ST000241	AN000374	2.380E-2	2.380E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[13C]-GLUTAMATE	ST000016	AN000033	9.460E-3	2.390E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acid	ST000539	AN000819	1.320E-2	2.400E-2	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	4.260E-4	2.410E-2	KD#1;no;yes;Pooled melanoma
Hydroxykynurenamine-13C0[+13CD3 QDA]+	ST000148	AN000235	3.600E-3	2.410E-2	Treatment;13C-Glc;unlabeled
L-Noradrenaline	ST000403	AN000643	1.420E-2	2.420E-2	Cell type;Mature erythrocyte;Reticulocyte
2-hydroxy-3-methylpentanoic acid / leucinic acid	ST001000	AN001879	1.050E-2	2.420E-2	Diagnosis;CD;Control;UC
Source Fragment TRP	ST000919	AN001506	2.580E-3	2.420E-2	Gender;Female;Male
methylhexadecanoic acid	ST000386	AN000621	5.360E-3	2.430E-2	Gender;F;M;NA
Ala-Asp-Asp-Asp	ST001201	AN001998	4.170E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Asn-Pro	ST001201	AN001998	3.900E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-Ser	ST001201	AN001998	4.090E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
BOC-ASN	ST000044	AN000069	3.200E-3	2.440E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
5-hydroxynorvaline NIST	ST000385	AN000620	8.620E-3	2.440E-2	Smoking Status;Current;Former;NA
2-amino-6-methylaminohexanoic acid	ST000355	AN000580	6.670E-3	2.440E-2	Stage;1;2;3;4;-
Geranylgeranylacetone-13C0[+QDA adduct]+	ST000148	AN000235	3.640E-3	2.440E-2	Treatment;13C-Glc;unlabeled
VALERYLSALYCILATE	ST000047	AN000081	6.920E-4	2.450E-2	Cognitive Status;AD;CN;MCI
lathosterol NIST	ST000386	AN000621	4.890E-3	2.460E-2	Smoker;Current;Former;NA
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000974	AN001595	4.970E-4	2.480E-2	GROUP;case;control
ZEATIN [ISTD] (M+CL)-	ST000713	AN001113	2.770E-3	2.480E-2	malignant transformation;No;yes;Yes
o-cresol sulfate	ST000974	AN001595	2.200E-3	2.480E-2	TIMEPOINT;BL;M06;M18
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	1.650E-3	2.490E-2	Condition;no;Pooled melanoma;yes
GUANOSINE 5`-DIPHOSPHO-D-MANNOSE	ST000044	AN000069	3.600E-3	2.500E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Hydroxyhexanone-13C0[+QDA adduct]+	ST000142	AN000225	4.300E-3	2.500E-2	Treatment;13C-Glc;unlabeled
4-Sulfobenzyl alcohol	ST000567	AN000871	9.560E-3	2.530E-2	groups;Old-Curcumin;Old-Placebo;young
[FA methyl(6:0)] 2-methyl-hexanoic acid	ST000403	AN000643	8.260E-4	2.530E-2	timepoint;1 hour;20 hours
beta-hydroxymyristic acid	ST001133	AN001858	4.210E-3	2.540E-2	CENPF;Control;KO
4-Aminobenzoate/Anthranilate	ST001317	AN002192	2.367E-2	2.549E-2	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Aminobenzoate/Anthranilate	ST001317	AN002192	2.367E-2	2.549E-2	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000539	AN000819	1.410E-2	2.550E-2	Cell type;Mature erythrocyte;Reticulocyte
3-methoxycatechol sulfate (2)	ST000899	AN001464	1.040E-2	2.550E-2	Type;Control;Crohn disease;Ulcerative Colitis
3-hydroxybutyroylglycine**	ST000975	AN001596	8.260E-4	2.560E-2	GROUP;case;control
thioproline	ST000899	AN001462	5.610E-3	2.570E-2	Type;Control;Crohn disease;Ulcerative Colitis
Dimethylallylpyrophosphate	ST000356	AN000583	1.380E-2	2.580E-2	stage;-;2;3
Heptopyranosides	ST001201	AN001999	1.570E-2	2.600E-2	cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphate	ST001201	AN001999	1.570E-2	2.600E-2	cell_type;iRBC;unRBC
CL 80:14 (18:0/22:6/18:2/22:6) [M-2H](2-)	ST001111	AN001806	1.550E-2	2.600E-2	Sample;Benign;Cancer;Metastasis
Dipropylene glycol	ST000583	AN000894	3.360E-4	2.620E-2	caries status;caries-active;caries-free
Prostaglandin E2 ethanolamide	ST000241	AN000373	2.180E-2	2.620E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-deoxytetronic acid NIST	ST001118	AN001817	1.340E-2	2.620E-2	Treatment Group;Control;Wilson Disease
DIHYDROMUNDULETONE	ST000046	AN000078	2.240E-3	2.630E-2	Cognitive Status;AD;CN;MCI
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.570E-2	2.640E-2	Cell type;Mature erythrocyte;Reticulocyte
18:3 (n-3)	ST001098	AN001786	6.240E-3	2.650E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
20:3 (n-6)	ST001098	AN001786	3.310E-3	2.650E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
2-C-Methyl-D-erythritol 4-phosphate	ST001201	AN001999	3.590E-3	2.660E-2	treatment;DHA;DMSO;OZ277;OZ439
taurodeoxycholate/taurochenodeoxycholate	ST001000	AN001879	1.200E-2	2.670E-2	Diagnosis;CD;Control;UC
HBA	ST000614	AN000940	2.410E-2	2.670E-2	Diagonsis;Benign;Cancer;Normal
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acid	ST000566	AN000869	8.180E-3	2.670E-2	group;Old-Curcumin;Old-Placebo;young
N-Hydroxymethylnicotinamide	ST000566	AN000870	2.500E-2	2.670E-2	Time point;Post;Pre;Baseline
fumarate/maleate/alpha-ketoisovalerate	ST001142	AN001876	2.320E-2	2.680E-2	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
z dioctylphtalate	ST000417	AN001448	1.470E-2	2.680E-2	Group;AIR;NO2PM;PM
34-Dihydroxymandelic acid	ST001039	AN001713	1.800E-2	2.680E-2	Sample.Matrix;Plasma;Urine
400671 carbohydrate	ST000386	AN000621	5.050E-3	2.690E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
D1-2-Hydroxymethylethisterone	ST000046	AN000078	2.380E-3	2.700E-2	Cognitive Status;AD;CN;MCI
400671 carbohydrate	ST000369	AN000603	7.310E-3	2.700E-2	Smoker;Current;Former;NA
IS Ceramide;[M-H20]+	ST000661	AN001009	2.440E-2	2.710E-2	Sample type;Plasma;Tissues
Ala-Lys-Ala-Ala	ST001201	AN001999	3.880E-3	2.710E-2	treatment;DHA;DMSO;OZ277;OZ439
glycol	ST000355	AN000580	7.010E-3	2.720E-2	Diagnosis;Breast cancer;Control
Sodiumtetradecylsulfate	ST000046	AN000078	2.560E-3	2.730E-2	Cognitive Status;AD;CN;MCI
G3P	ST000302	AN000480	1.210E-2	2.740E-2	Labelint time (hours);0;1;24;3;48;72
3-methyl catechol sulfate (1)	ST000974	AN001595	2.590E-3	2.740E-2	TIMEPOINT;BL;M06;M18
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001205	AN002007	8.180E-3	2.780E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
?-Tocotrienol	ST000553	AN000845	2.520E-2	2.780E-2	Sample type;Plasma;Urine
2-deoxyerythritol NIST	ST000383	AN000618	1.580E-3	2.790E-2	Health Status;diabetic;non-diabetic
Arg/(Arg+Orn)	ST000544	AN000826	8.220E-3	2.790E-2	Sample Type;Control;Replicate
Fisher ratio	ST000544	AN000826	7.830E-3	2.790E-2	Sample Type;Control;Replicate
Trinexapac	ST001037	AN001698	7.790E-3	2.800E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
DIACYL-PHOSPHATIDYLCHOLINE	ST000044	AN000068	8.300E-4	2.810E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Heterocladol	ST000291	AN000465	5.270E-4	2.810E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
trihexcer d18:1 N16:0	ST000362	AN000594	1.510E-2	2.820E-2	Gender;1;2
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000974	AN001595	6.040E-4	2.820E-2	GROUP;case;control
3-AIB (a-amino[1-(14)C]isobutyric acid)	ST000166	AN000259	1.280E-2	2.860E-2	Group;3M;Control;HF
BOC-PHE-OH	ST000044	AN000069	4.540E-3	2.860E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Asn-Asn-Gly-His	ST001201	AN001999	1.760E-2	2.870E-2	cell_type;iRBC;unRBC
FBP	ST000302	AN000480	1.520E-2	2.870E-2	Labelint time (hours);0;1;24;3;48;72
(R)-3-((R)-3-Hydroxybutanoyloxy)butanoate	ST001201	AN001999	1.780E-2	2.890E-2	cell_type;iRBC;unRBC
Furamizole	ST000291	AN000465	5.790E-4	2.890E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
IS d5-DAG	ST000523	AN000800	2.090E-2	2.890E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
NMMA	ST001236	AN002054	1.180E-3	2.900E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
Ovothiol disulfide	ST001201	AN001999	4.270E-3	2.920E-2	treatment;DHA;DMSO;OZ277;OZ439
2-keto-l-gluconic acid	ST000092	AN000146	2.000E-2	2.920E-2	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
4-METHYL-1-PENTENE	ST001037	AN001698	8.270E-3	2.930E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Anaferine-13C0[+13CD3 QDA]+	ST000148	AN000235	4.860E-3	2.940E-2	Treatment;13C-Glc;unlabeled
FA methyl(8:0)	ST001202	AN002001	2.020E-2	2.960E-2	treatment_duration_(h);-;1.5;3;6;9
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	6.450E-3	2.970E-2	GENDER;F;M
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoicacid	ST000047	AN000083	2.510E-3	2.980E-2	Cognitive Status;AD;CN;MCI
c-aconitate-13C5	ST001049	AN001864	1.700E-3	2.980E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C3	ST001049	AN001864	1.710E-3	2.980E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
HBA	ST000614	AN000940	2.500E-2	2.980E-2	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000741	AN001155	9.450E-4	2.990E-2	subject type;Healthy control;Mild disease;POOLED;Severe dise...
Bis(2-hydroxypropyl)amine+5.6003766	ST000046	AN000077	6.660E-4	3.000E-2	Cognitive Status;AD;CN;MCI
Kinetin-9-riboside	ST001037	AN001698	8.900E-3	3.010E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
3-acetyl pyridine adenine dinucleotide	ST000539	AN000819	1.580E-3	3.030E-2	Glucose labelling;C13 glucose;unlabelled
metabolite 1	ST000539	AN000818	1.740E-2	3.050E-2	Cell type;Mature erythrocyte;Reticulocyte
D-Mannose /D-Allose	ST000980	AN001606	1.600E-3	3.060E-2	Classification;Mild;Moderate;Non-allergic;Severe
L-Sorbose/Fructose	ST000980	AN001606	1.860E-3	3.060E-2	Classification;Mild;Moderate;Non-allergic;Severe
Napthyl amine	ST000614	AN000943	2.670E-2	3.060E-2	Diagonsis;Benign;Cancer;Normal
FA hydroxy(18:1)]	ST001205	AN002007	9.210E-3	3.060E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
indole-3-acetonitrile oxide	ST000539	AN000818	1.750E-2	3.070E-2	Cell type;Mature erythrocyte;Reticulocyte
Laudanosine	ST000539	AN000819	1.770E-2	3.090E-2	Cell type;Mature erythrocyte;Reticulocyte
gamma-glutamyllysine	ST000975	AN001596	6.800E-3	3.090E-2	GENDER;F;M
DOCOSADIENOATE (*)	ST000105	AN000174	5.610E-3	3.090E-2	Sampling;After SWS onset;Morning fasting
O-methylcatechol sulfate	ST000974	AN001595	2.970E-3	3.090E-2	TIMEPOINT;BL;M06;M18
Calcium salicylate	ST000292	AN000466	7.670E-4	3.090E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Asn-Leu-Pro-Pro	ST001205	AN002006	1.080E-2	3.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	4.260E-3	3.110E-2	Timepoint;T0;T2;Pooled
Ala-Leu-Thr-Ala	ST001201	AN001998	5.640E-3	3.110E-2	treatment;DHA;DMSO;OZ277;OZ439
pyroglutamylglycine	ST000975	AN001596	4.210E-4	3.140E-2	TIMEPOINT;BL;M06;M18
[13C]-ISOLEUCINE	ST000009	AN000023	9.230E-3	3.150E-2	gender;female;male
4-Amino-4-deoxychorismate	ST001201	AN001999	1.970E-2	3.160E-2	cell_type;iRBC;unRBC
6-(2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL)-1-PHENYL-2-THIOBIUREA-0.88713235	ST000046	AN000078	3.260E-3	3.160E-2	Cognitive Status;AD;CN;MCI
HWESASXX*	ST000974	AN001595	8.140E-4	3.160E-2	GROUP;case;control
sulfate of piperine metabolite C16H19NO3 (2)*	ST000974	AN001595	8.070E-4	3.160E-2	GROUP;case;control
Ala-Thr-Ala-Gly	ST001201	AN001999	1.990E-2	3.180E-2	cell_type;iRBC;unRBC
[13C]-LEUCINE	ST000106	AN000175	1.310E-3	3.210E-2	Sampling time;0 min;60 min
Cys-Met-Pro-His	ST000403	AN000643	2.930E-3	3.230E-2	Glucose labelling;C13 glucose;unlabelled
URSODIOL-2 WATER	ST000691	AN001067	2.780E-2	3.250E-2	Progression;Pooled plasma;Y
Celiprolol	ST000566	AN000870	3.110E-2	3.260E-2	Time point;Post;Pre;Baseline
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000974	AN001595	1.010E-3	3.270E-2	GROUP;case;control
SALICYLATE #2 (M-H)-	ST000841	AN001349	2.830E-3	3.280E-2	Subject group;HIGH-FA;LOW-FA;MID-FA;N/A
AMINOHYDROXYBENZOIC ACID	ST000016	AN000033	2.240E-2	3.290E-2	Material;Cells;Media
fucose + rhamnose	ST000369	AN000603	1.020E-2	3.300E-2	Smoker;Current;Former;NA
Sulfinopyruvate-13C1[+QDA adduct+Na]+	ST000148	AN000235	5.760E-3	3.300E-2	Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+Na]+	ST000148	AN000235	5.820E-3	3.310E-2	Treatment;13C-Glc;unlabeled
Capillone-13C0[+13CD3 QDA]+	ST000148	AN000235	5.810E-3	3.310E-2	Treatment;13C-Glc;unlabeled
IS Ceramide; [M-H2O]+	ST000523	AN000800	1.080E-2	3.330E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Mycalamide A	ST000566	AN000870	3.210E-2	3.330E-2	Time point;Post;Pre;Baseline
nitrocyclohexane	ST000539	AN000818	1.920E-2	3.340E-2	Cell type;Mature erythrocyte;Reticulocyte
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000044	AN000069	5.650E-3	3.340E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Chloroacetoacetanilide-13C1[+QDA adduct+Na]+	ST000148	AN000235	5.920E-3	3.340E-2	Treatment;13C-Glc;unlabeled
C9 / C10:2	ST000544	AN000827	6.450E-3	3.350E-2	Sample Type;Control;Replicate
Prohydrojasmon-13C0[+13CD3 QDA]+	ST000148	AN000235	5.970E-3	3.350E-2	Treatment;13C-Glc;unlabeled
Ala-Lys-Asp-Pro	ST001204	AN002004	5.050E-4	3.360E-2	treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-Pro	ST001204	AN002004	5.180E-4	3.360E-2	treatment;DHA;DMSO;OZ277;OZ439
16:1 (n-7)	ST001098	AN001786	1.380E-2	3.360E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
cyano-L-alanine	ST000369	AN000603	1.060E-2	3.370E-2	Smoker;Current;Former;NA
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	2.990E-3	3.370E-2	Smoking Status;Current;Former;-
alpha-Amylcinnamaldehyde-13C0[+QDA adduct]+	ST000148	AN000235	6.010E-3	3.370E-2	Treatment;13C-Glc;unlabeled
6-Acetamido-2-oxohexanoate	ST000403	AN000642	2.070E-2	3.380E-2	Cell type;Mature erythrocyte;Reticulocyte
Phorbol 12-tiglate 13-decanoate-13C0[+Na]+	ST000148	AN000235	6.110E-3	3.400E-2	Treatment;13C-Glc;unlabeled
NMMA	ST000923	AN001513	1.680E-2	3.420E-2	Diagnosis;CD;nonIBD;UC
L-Asparticacidb-semialdehyde	ST000047	AN000082	1.920E-3	3.430E-2	Cognitive Status;AD;CN;MCI
c-aconitate-13C0	ST001049	AN001864	2.370E-3	3.440E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
CL 74:9 (20:3/18:2/20:4/16:0) [M-2H](2-)	ST001111	AN001806	2.150E-2	3.450E-2	Sample;Benign;Cancer;Metastasis
Diacetylhydrazine	ST000539	AN000818	1.290E-3	3.450E-2	timepoint;1 hour;20 hours
L-proline amide	ST000539	AN000818	1.450E-3	3.450E-2	timepoint;1 hour;20 hours
2-(sulfomethyl)thiazolidine-4-carboxylate	ST000403	AN000643	3.320E-3	3.460E-2	Glucose labelling;C13 glucose;unlabelled
N-ACETYL-D-HEXOSAMINE	ST000011	AN000028	5.990E-3	3.510E-2	COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
Oxodecanoate-13C3[+QDA adduct]+	ST000148	AN000235	6.360E-3	3.510E-2	Treatment;13C-Glc;unlabeled
acetophenone NIST	ST000369	AN000603	9.910E-3	3.520E-2	Gender;F;M;NA
Abscisic acid GLC ester-13C16[+Na]+	ST000148	AN000235	6.410E-3	3.520E-2	Treatment;13C-Glc;unlabeled
IsoquinolineN-oxide	ST000046	AN000079	3.820E-3	3.530E-2	Cognitive Status;AD;CN;MCI
3-(ADP)-glycerate	ST001202	AN002001	3.300E-2	3.540E-2	cell_type;iRBC;unRBC
Fibrinopeptide B (1-9)**	ST000975	AN001596	1.410E-3	3.550E-2	GROUP;case;control
FA methyl(16:1)	ST001202	AN002001	2.460E-2	3.550E-2	treatment_duration_(h);-;1.5;3;6;9
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000763	AN001202	8.610E-3	3.560E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ADMA / Arg	ST000545	AN000829	2.590E-3	3.560E-2	Sample Type;Control;Replicate
DOPA/Tyr	ST000545	AN000829	2.740E-3	3.560E-2	Sample Type;Control;Replicate
Putrescine / Orn	ST000545	AN000829	2.850E-3	3.560E-2	Sample Type;Control;Replicate
Serotonin / Trp	ST000545	AN000829	2.620E-3	3.560E-2	Sample Type;Control;Replicate
SFA (PC)	ST000545	AN000830	2.590E-2	3.560E-2	Sample Type;Control;Replicate
Spermidine / Putrescine	ST000545	AN000829	1.970E-3	3.560E-2	Sample Type;Control;Replicate
Phenylpyruviate-13C1[+13CD3 QDA]+	ST000148	AN000235	6.480E-3	3.560E-2	Treatment;13C-Glc;unlabeled
HEXOSE-DISACCHARIDE	ST000475	AN000739	2.280E-2	3.560E-2	Treatment;-;MDH inhib
Neomenthyl acetate	ST000567	AN000872	6.590E-3	3.570E-2	groups;Old-Curcumin;Old-Placebo;young
BOC-ALA-OH	ST000105	AN000174	6.830E-3	3.570E-2	Sampling;After SWS onset;Morning fasting
Fructoselysine	ST000539	AN000818	2.090E-2	3.580E-2	Cell type;Mature erythrocyte;Reticulocyte
Fructoselysine 2	ST000539	AN000818	2.090E-2	3.580E-2	Cell type;Mature erythrocyte;Reticulocyte
o-cresol sulfate	ST000899	AN001464	1.610E-2	3.580E-2	Type;Control;Crohn disease;Ulcerative Colitis
8-keto-7-aminoperlagonate	ST000403	AN000643	3.650E-3	3.590E-2	Glucose labelling;C13 glucose;unlabelled
isoamylnitrite	ST000046	AN000078	4.440E-3	3.600E-2	Cognitive Status;AD;CN;MCI
Lankamycin-13C0[+Na]+	ST000148	AN000235	6.600E-3	3.600E-2	Treatment;13C-Glc;unlabeled
lathosterol NIST	ST000379	AN000613	1.280E-2	3.620E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST000539	AN000818	2.140E-2	3.630E-2	Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylate 2	ST000539	AN000818	2.140E-2	3.630E-2	Cell type;Mature erythrocyte;Reticulocyte
Ketohexanoate-13C0[+QDA adduct+Na]+	ST000148	AN000235	6.690E-3	3.630E-2	Treatment;13C-Glc;unlabeled
valine ion	ST000975	AN001596	1.670E-3	3.640E-2	GROUP;case;control
3-Oxotetradecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	6.750E-3	3.650E-2	Treatment;13C-Glc;unlabeled
(-)-jasmonoyl-L-isoleucine	ST000539	AN000818	2.170E-2	3.670E-2	Cell type;Mature erythrocyte;Reticulocyte
4-Methylumbelliferylbeta-D-glucuronide	ST000047	AN000082	2.500E-3	3.670E-2	Cognitive Status;AD;CN;MCI
Pro258-13C0	ST000114	AN000194	6.630E-3	3.690E-2	Treatment;None;Tetracycline
Oxodecanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	6.930E-3	3.720E-2	Treatment;13C-Glc;unlabeled
methylsuccinoylcarnitine (1)	ST000975	AN001596	1.820E-3	3.750E-2	GROUP;case;control
BOC-ASN	ST000009	AN000023	1.350E-2	3.750E-2	POST_SURGERY_TIME;12MO;6MO;NO_SURGERY;PRE_SURGERY
methyl-4-hydroxybenzoate sulfate	ST000899	AN001464	1.730E-2	3.780E-2	Type;Control;Crohn disease;Ulcerative Colitis
Diacetylmonoxime	ST000539	AN000818	2.250E-2	3.790E-2	Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonate	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonate 2	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
2-oxosuberate	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
Rimocidine-13C0[+H]+	ST000148	AN000235	7.180E-3	3.810E-2	Treatment;13C-Glc;unlabeled
7-hydroxyTetranorIloprost	ST000047	AN000083	3.810E-3	3.830E-2	Cognitive Status;AD;CN;MCI
gamma-Hydroxyphenylbutazoneglucuronide	ST000047	AN000083	3.820E-3	3.830E-2	Cognitive Status;AD;CN;MCI
400671 carbohydrate	ST000386	AN000621	9.540E-3	3.840E-2	Smoker;Current;Former;NA
cytidine-5-monophosphate NIST	ST000379	AN000613	1.980E-2	3.850E-2	Time;10min;1hr;24hr;6hr
2-Amino-2-methyl-1-propanol+3.3926477	ST000047	AN000080	9.720E-4	3.870E-2	Cognitive Status;AD;CN;MCI
3-(4-Hydroxyphenyl)propionic acid	ST000586	AN000901	3.310E-2	3.870E-2	Plasma Volume;0 uL;150 uL;700 uL
5-alpha-Coprostanol or similar oxysterol	ST000586	AN000901	3.290E-2	3.870E-2	Plasma Volume;0 uL;150 uL;700 uL
[13C]-ARGININE	ST000043	AN000070	1.130E-2	3.880E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
2-Dehydro-3-deoxy-arabinonate-13C0[+Na]+	ST000148	AN000235	7.440E-3	3.890E-2	Treatment;13C-Glc;unlabeled
Manumycin A-13C0[+H]+	ST000148	AN000235	7.440E-3	3.890E-2	Treatment;13C-Glc;unlabeled
Undecanone-13C0[+H]+	ST000148	AN000235	7.430E-3	3.890E-2	Treatment;13C-Glc;unlabeled
t-aconitate-13C0	ST001045	AN001709	1.710E-3	3.910E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Caldarchaeol	ST000445	AN000696	7.930E-3	3.910E-2	Treatment;FSH;LH
2-oxosuberate	ST000403	AN000643	4.130E-3	3.920E-2	Glucose labelling;C13 glucose;unlabelled
B-ureidoisobutyricacid-6.84278	ST000046	AN000079	4.420E-3	3.930E-2	Cognitive Status;AD;CN;MCI
Chloroacetoacetanilide-13C0[+QDA adduct+Na]+	ST000148	AN000235	7.540E-3	3.930E-2	Treatment;13C-Glc;unlabeled
heptadecanoic acid NIST	ST000385	AN000620	1.710E-2	3.940E-2	Smoking Status;Current;Former;NA
N-Acetyl-5-hydroxysulfapyridine	ST000046	AN000079	4.690E-3	3.950E-2	Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoate	ST000046	AN000076	3.660E-3	3.960E-2	Cognitive Status;AD;CN;MCI
Phenylglyoxylate-13C0[+13CD3 QDA]+	ST000148	AN000235	7.610E-3	3.960E-2	Treatment;13C-Glc;unlabeled
Trihexosylceramide (d18:1/18:0)	ST000241	AN000374	1.070E-2	3.970E-2	Concentration (uM);0;500
Sulfinpyrazone sulfone	ST000566	AN000869	2.700E-2	3.970E-2	Time point;Post;Pre;Baseline
L-2-aminobutyric acid	ST000356	AN000582	2.440E-2	3.980E-2	Diagnosis;breast cancer;control
?-Methyltryptamine (AMT)	ST000242	AN000377	1.330E-2	3.980E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Glu-Met-Cys-His	ST000403	AN000643	2.400E-2	3.990E-2	Cell type;Mature erythrocyte;Reticulocyte
5-adenosylhomocysteine	ST001142	AN001875	3.890E-2	4.000E-2	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
N-acetylglycine NIST	ST000392	AN000628	1.590E-2	4.050E-2	Organ;Plasma;Serum;Serum or Plasma
Ala-Cys-Pro-Ser	ST001205	AN002007	1.290E-2	4.050E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Val-Tyr-Val iSTD	ST001211	AN002017	1.190E-2	4.060E-2	Group;Control;Methotrexate
Hydroxyandrosterone-13C0[+Na]+	ST000148	AN000235	7.880E-3	4.060E-2	Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+	ST000148	AN000235	7.890E-3	4.060E-2	Treatment;13C-Glc;unlabeled
Ala-Asp-Asp-Asp	ST001201	AN001998	2.790E-2	4.070E-2	cell_type;iRBC;unRBC
propyl 4-hydroxybenzoate sulfate	ST000899	AN001464	1.910E-2	4.070E-2	Type;Control;Crohn disease;Ulcerative Colitis
2(alpha-D-Mannosyl)-D-glycerate	ST001205	AN002007	1.350E-2	4.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
[PA(18:0)] 1-octadecanoyl-2-sn-glycero-3-phosphate	ST001205	AN002007	1.350E-2	4.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
11-O-Demethylpradimicinone II-13C0[+13CD3 QDA]+	ST000148	AN000235	7.990E-3	4.100E-2	Treatment;13C-Glc;unlabeled
8-HETrE	ST000916	AN001491	1.500E-2	4.110E-2	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
N-Ace-Asp-13C1	ST001049	AN001864	3.090E-3	4.110E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
ZEATIN [ISTD] (M+H)+	ST000711	AN001111	1.470E-3	4.130E-2	NTM pulmonary disease;no;yes
5-6-Dihydrouridine	ST001201	AN001998	8.640E-3	4.140E-2	treatment;DHA;DMSO;OZ277;OZ439
sulfa d18:1 N20:0	ST000362	AN000594	2.350E-2	4.150E-2	Gender;1;2
Triphosphate	ST000241	AN000373	3.510E-2	4.150E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
6-Acetamido-2-oxohexanoate	ST001204	AN002005	2.140E-2	4.160E-2	cell_type;iRBC;unRBC
glyoxalurea NIST	ST000386	AN000621	1.080E-2	4.170E-2	Smoker;Current;Former;NA
C14:1-OH / C10	ST000544	AN000827	8.700E-3	4.180E-2	Sample Type;Control;Replicate
C2 / C0	ST000544	AN000827	8.590E-3	4.180E-2	Sample Type;Control;Replicate
Desmethylnimodipine	ST000047	AN000081	2.020E-3	4.190E-2	Cognitive Status;AD;CN;MCI
Fluoresceinmonoglucuronide	ST000047	AN000081	1.960E-3	4.190E-2	Cognitive Status;AD;CN;MCI
Cys-Met-Tyr-Tyr	ST000403	AN000642	3.830E-3	4.190E-2	Glucose labelling;C13 glucose;unlabelled
1-AG and 2-AG	ST000977	AN001599	2.400E-2	4.200E-2	Group;Healthy Control;NAFLD
20:2 (n-6)	ST001098	AN001786	2.720E-2	4.210E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
Ala-Lys-Lys-Asp	ST001204	AN002004	8.700E-4	4.230E-2	treatment;DHA;DMSO;OZ277;OZ439
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000919	AN001506	6.090E-3	4.240E-2	Gender;Female;Male
cyclo(leu-pro)	ST000974	AN001595	6.000E-3	4.240E-2	TIMEPOINT;BL;M06;M18
valine ion	ST000974	AN001595	5.140E-3	4.240E-2	TIMEPOINT;BL;M06;M18
XHWESASXXR*	ST000974	AN001595	5.480E-3	4.240E-2	TIMEPOINT;BL;M06;M18
Oxododecanoate-13C0[+QDA adduct]+	ST000148	AN000235	8.390E-3	4.250E-2	Treatment;13C-Glc;unlabeled
acetytyrosine	ST001192	AN001986	1.920E-3	4.260E-2	Diet;-;Omnivore;Vegetarian
ZAPA	ST000403	AN000642	3.970E-3	4.260E-2	Glucose labelling;C13 glucose;unlabelled
Trihydroxybutyric acid	ST000980	AN001606	5.570E-3	4.270E-2	Classification;Mild;Moderate;Non-allergic;Severe
z dioctylphtalate	ST000416	AN000658	1.900E-2	4.280E-2	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
CoQ10H2	ST000450	AN000705	2.210E-2	4.300E-2	gender;Female;Male
Undecanone-13C0[+13CD3 QDA]+	ST000148	AN000235	8.510E-3	4.300E-2	Treatment;13C-Glc;unlabeled
5-Dehydro-4-deoxy-D-glucarate	ST000566	AN000869	1.420E-2	4.310E-2	group;Old-Curcumin;Old-Placebo;young
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acid	ST000539	AN000819	8.060E-4	4.320E-2	timepoint;1 hour;20 hours
Hydroxycholesterol Species	ST000465	AN000727	2.030E-3	4.330E-2	Treatment;Control;Englerin (100 nM)
N-acetylglycine NIST	ST000386	AN000621	1.170E-2	4.340E-2	Smoker;Current;Former;NA
N-acetylisoleucine	ST000899	AN001464	2.050E-2	4.340E-2	Type;Control;Crohn disease;Ulcerative Colitis
plasmenyl-PC 19:0; [M+Na]+@2.31	ST000665	AN001017	5.020E-3	4.350E-2	Cell line;HepG2;HuH-7
D-Galacturonate	ST001201	AN001999	2.790E-2	4.350E-2	cell_type;iRBC;unRBC
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000403	AN000643	4.700E-3	4.360E-2	Glucose labelling;C13 glucose;unlabelled
isoamylnitrite	ST000046	AN000076	4.320E-3	4.370E-2	Cognitive Status;AD;CN;MCI
L-beta-aspartyl-L-leucine	ST001204	AN002004	1.920E-3	4.380E-2	treatment_duration_(h);-;3;6;9
4-Aminophenyl 1-thio-beta-D-glucuronide	ST000422	AN000667	1.190E-3	4.380E-2	treatment;ND;T1D good glycemic control
ETHYL 3-UREIDOPROPIONATE (M+H)+	ST000726	AN001139	4.570E-3	4.400E-2	DISEASE_STATE;Control;PCOS
BOC-ALA-OH	ST000044	AN000069	7.820E-3	4.400E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Hydroxynonenal-13C0[+13CD3 QDA]+	ST000148	AN000235	8.770E-3	4.400E-2	Treatment;13C-Glc;unlabeled
GLYCOLITHOCHOLIC ACID ETHYL ESTER	ST000016	AN000033	1.870E-2	4.420E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
3-O-Methyl-myo-inositol	ST000566	AN000870	4.660E-3	4.450E-2	group;Old-Curcumin;Old-Placebo;young
Glu-Met-Met-His	ST000403	AN000643	4.950E-3	4.460E-2	Glucose labelling;C13 glucose;unlabelled
ketoconazol	ST000539	AN000818	2.680E-2	4.470E-2	Cell type;Mature erythrocyte;Reticulocyte
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilane	ST000978	AN001602	7.170E-3	4.470E-2	Cox_RRT;.;N;Y
1-docosapentaenoylglycerophosphocholine (22:5n6)*	ST000975	AN001596	1.060E-2	4.470E-2	GENDER;F;M
ZEATIN [ISTD] (M-H)-	ST000726	AN001138	7.700E-3	4.490E-2	Assay;BC TP;OGTT
desmethylnortriptylineglucuronide	ST000047	AN000083	5.350E-3	4.490E-2	Cognitive Status;AD;CN;MCI
3-propylphosphoenolpyruvate	ST001205	AN002006	1.750E-2	4.490E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
CTAB	ST001205	AN002006	1.750E-2	4.490E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
cis-Cyclo[L-ala-L-Pro]	ST000974	AN001595	6.830E-3	4.490E-2	TIMEPOINT;BL;M06;M18
2-ethylphenylsulfate	ST000974	AN001595	5.410E-3	4.500E-2	GENDER;F;M
Ala-Asn-Asn-Ser	ST001201	AN001998	1.020E-2	4.530E-2	treatment;DHA;DMSO;OZ277;OZ439
Glu-Glu-Gln-His	ST001201	AN001998	1.030E-2	4.530E-2	treatment;DHA;DMSO;OZ277;OZ439
13C-aminoadipic	ST000948	AN001557	3.030E-2	4.540E-2	Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
Isopropenyl oxoheptanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	9.130E-3	4.540E-2	Treatment;13C-Glc;unlabeled
IsoquinolineN-oxide	ST000046	AN000078	6.960E-3	4.550E-2	Cognitive Status;AD;CN;MCI
acetophenone NIST	ST000381	AN000615	1.660E-2	4.550E-2	Cohort;CSMC;INHA
fucose+ rhamnose	ST000390	AN000626	9.210E-3	4.550E-2	Tumor Present;No;Yes;-
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	2.750E-2	4.560E-2	Cell type;Mature erythrocyte;Reticulocyte
isoamylnitrite	ST000047	AN000081	2.660E-3	4.560E-2	Cognitive Status;AD;CN;MCI
4-Methylene-L-glutamate	ST000539	AN000819	2.700E-2	4.570E-2	Cell type;Mature erythrocyte;Reticulocyte
hexanoylglutamine	ST000975	AN001596	2.570E-3	4.570E-2	GROUP;case;control
Total AC / C0	ST000544	AN000827	9.800E-3	4.590E-2	Sample Type;Control;Replicate
C5-SUGAR ALCOHOL	ST000954	AN001564	2.390E-4	4.610E-2	ethnicity;1;2;-
2-Formaminobenzoylacetate	ST000539	AN000819	3.020E-3	4.620E-2	Glucose labelling;C13 glucose;unlabelled
Arg-Met-Asn-His	ST000539	AN000818	2.800E-2	4.630E-2	Cell type;Mature erythrocyte;Reticulocyte
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+HCOO)-	ST000695	AN001075	9.320E-3	4.630E-2	Race;Black;White;POOLED
IBUPROFEN CARBOXYLIC ACID (CAS# 15935-54-3); (M+CL)-	ST000695	AN001075	9.320E-3	4.630E-2	Race;Black;White;POOLED
[6]-Paradol	ST001201	AN001999	3.000E-2	4.640E-2	cell_type;iRBC;unRBC
Diethyl Oxalpropionate	ST000566	AN000870	4.510E-2	4.640E-2	Time point;Post;Pre;Baseline
Hydroxyabscisate-13C0[+Na]+	ST000148	AN000235	9.410E-3	4.640E-2	Treatment;13C-Glc;unlabeled
3-(1-Pyrrolidinyl)-2-pentanone	ST001202	AN002000	3.820E-2	4.640E-2	treatment_duration_(h);-;1.5;3;6;9
Lactosylceramide(d18	ST001202	AN002000	3.820E-2	4.640E-2	treatment_duration_(h);-;1.5;3;6;9
Cys-Thr-Cys-Cys	ST000403	AN000642	4.500E-3	4.660E-2	Glucose labelling;C13 glucose;unlabelled
2-oxogluconic acid NIST	ST000369	AN000603	1.500E-2	4.690E-2	Gender;F;M;NA
8-Amino-7-oxononanoate	ST001201	AN001998	1.160E-2	4.700E-2	treatment;DHA;DMSO;OZ277;OZ439
Asn-Gly-Pro-Pro	ST001201	AN001998	1.140E-2	4.700E-2	treatment;DHA;DMSO;OZ277;OZ439
Sphingosine(18:0)-13C0[+H]+	ST000148	AN000235	9.610E-3	4.710E-2	Treatment;13C-Glc;unlabeled
2-oxogluconic acid NIST	ST000386	AN000621	1.330E-2	4.720E-2	Smoker;Current;Former;NA
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000403	AN000643	5.640E-3	4.790E-2	Glucose labelling;C13 glucose;unlabelled
24-Dihydroxyacetophenone	ST001193	AN001988	3.280E-2	4.810E-2	Plasma;Cord blood;Plasma
Ovothiol disulfide	ST001201	AN001999	3.130E-2	4.820E-2	cell_type;iRBC;unRBC
2-docosanamidoethanesulfonicacid	ST000046	AN000076	5.610E-3	4.820E-2	Cognitive Status;AD;CN;MCI
N-Acetyl-p-benzoquinonimine	ST000047	AN000081	3.000E-3	4.820E-2	Cognitive Status;AD;CN;MCI
acetytyrosine	ST001000	AN001880	2.910E-2	4.820E-2	Diagnosis;CD;Control;UC
2-Oxovalericacid	ST000045	AN000075	2.790E-3	4.820E-2	Treatment;Insulin Withdrawal;Saline Infusion
pyroglutamylglycine	ST000975	AN001596	3.150E-3	4.850E-2	GROUP;case;control
XHWESASXXR*	ST000974	AN001595	2.190E-3	4.850E-2	GROUP;case;control
L-2-Aminoadipate 6-semialdehyde	ST000539	AN000819	3.270E-3	4.870E-2	Glucose labelling;C13 glucose;unlabelled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	8.840E-3	4.870E-2	KD#2;yes;no;Pooled melanoma
OH-monohexcer d18:1 N18:0	ST000362	AN000594	2.120E-3	4.880E-2	Chronic_Bronchitis;1;-
sulfa d18:1 N22:0	ST000362	AN000594	1.450E-3	4.880E-2	Chronic_Bronchitis;1;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	5.200E-3	4.890E-2	KD#1;no;yes;Pooled melanoma
4-ethylphenylsulfate	ST000899	AN001464	2.330E-2	4.890E-2	Type;Control;Crohn disease;Ulcerative Colitis
Pro258-13C3	ST000076	AN000122	1.350E-2	4.900E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
L-Glutamic acid n-butyl ester + 1.5990624	ST000566	AN000870	7.530E-3	4.910E-2	group;Old-Curcumin;Old-Placebo;young
Mycalamide A	ST000566	AN000870	7.440E-3	4.910E-2	group;Old-Curcumin;Old-Placebo;young
4-Hydroxyphenylacetylglycine	ST000403	AN000643	3.040E-2	4.920E-2	Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608	ST000403	AN000643	6.090E-3	4.920E-2	Glucose labelling;C13 glucose;unlabelled
BENZOIC ACID #2 (M-H)-	ST000748	AN001172	4.570E-2	4.930E-2	Sample type;Cells;Culture Media
myo-Inositol 1-phosphate/myo-Inositol 3-phosphate	ST000230	AN000343	6.990E-3	4.930E-2	Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
2-oxindole-3-acetate	ST000899	AN001462	1.320E-2	4.930E-2	Type;Control;Crohn disease;Ulcerative Colitis
FKGK 11	ST000242	AN000377	1.770E-2	4.940E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
cis-Acetylacrylate	ST001205	AN002007	6.270E-4	4.950E-2	treatment_duration_(h);1;5;3
O-PHOSPHONOHEXOPYRANOSE	ST000016	AN000033	1.440E-2	4.970E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
Seratonin	ST000490	AN000756	1.250E-2	4.980E-2	Disease;cardiovascular disease;sleep apnea
Valacyclovir	ST000291	AN000465	1.140E-3	5.000E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Glu-Lys-Lys-Phe	ST001202	AN002001	3.530E-2	5.020E-2	treatment_duration_(h);-;1.5;3;6;9
C24:0 PC	ST001000	AN001881	1.470E-2	5.030E-2	Diagnosis;CD;Control;UC
Phenolsulfonphthalein	ST001204	AN002005	2.650E-2	5.050E-2	cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginine	ST001205	AN002006	2.020E-2	5.050E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
FA hydroxy(18:1)]	ST001204	AN002004	3.160E-2	5.060E-2	cell_type;iRBC;unRBC
FA methyl(14:0)	ST001202	AN002001	3.580E-2	5.060E-2	treatment_duration_(h);-;1.5;3;6;9
Leucomycin A3-13C0[+H]+	ST000148	AN000235	1.050E-2	5.070E-2	Treatment;13C-Glc;unlabeled
Oxodecanoate-13C0[+QDA adduct]+	ST000148	AN000235	1.060E-2	5.080E-2	Treatment;13C-Glc;unlabeled
(R)-3-Hydroxybutanoate	ST000539	AN000819	3.030E-2	5.100E-2	Cell type;Mature erythrocyte;Reticulocyte
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	1.620E-2	5.110E-2	FCS;FCS;NO_FCS
N2-(D-1-Carboxyethyl)-L-arginine	ST001201	AN001998	3.550E-2	5.120E-2	cell_type;iRBC;unRBC
[13C]-TYROSINE	ST000106	AN000175	2.890E-3	5.130E-2	Sampling time;0 min;60 min
L-a-glutamyl-L-Lysine	ST001201	AN001998	1.310E-2	5.130E-2	treatment;DHA;DMSO;OZ277;OZ439
PGP(18:0/18:1(11Z))	ST000241	AN000373	4.490E-2	5.140E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Picrasin C-13C0[+QDA adduct]+	ST000148	AN000235	1.080E-2	5.150E-2	Treatment;13C-Glc;unlabeled
MCOA	ST000301	AN000479	2.950E-2	5.160E-2	Cell Line;L229;LN18;Pooled glioblastoma;U-138
Asn-Thr-Trp-His	ST001205	AN002007	1.840E-2	5.160E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Methyl Caprate	ST000978	AN001602	8.750E-3	5.170E-2	Cox_RRT;.;N;Y
C-glycosyltryptophan*	ST000975	AN001596	1.290E-2	5.210E-2	GENDER;F;M
pyroglutamylisoleucine	ST000974	AN001595	1.570E-2	5.210E-2	REGION;AHRI;MRC;SUN
12-Hydroxynevirapine glucuronide	ST000444	AN000695	2.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
15beta-hydroxycyproterone acetate	ST000444	AN000695	1.560E-2	5.210E-2	Sample Treatment;Bubbled;Control
16-a-Hydroxypregnenolone	ST000444	AN000695	2.600E-2	5.210E-2	Sample Treatment;Bubbled;Control
17a-Ethynylestradiol	ST000444	AN000695	1.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
3-Dechloroethylifosfamide	ST000444	AN000695	1.290E-2	5.210E-2	Sample Treatment;Bubbled;Control
3-Hydroxytetradecanedioic acid	ST000444	AN000695	2.360E-2	5.210E-2	Sample Treatment;Bubbled;Control
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronide	ST000444	AN000695	1.940E-2	5.210E-2	Sample Treatment;Bubbled;Control
6beta-hydroxybudesonide	ST000444	AN000695	2.480E-2	5.210E-2	Sample Treatment;Bubbled;Control
Acitretin	ST000444	AN000695	1.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
b-Dihydrotetrabenazine	ST000444	AN000695	2.090E-2	5.210E-2	Sample Treatment;Bubbled;Control
Buspirone N-oxide	ST000444	AN000695	2.370E-2	5.210E-2	Sample Treatment;Bubbled;Control
CD 1790	ST000444	AN000695	1.270E-2	5.210E-2	Sample Treatment;Bubbled;Control
Cyclopentolate	ST000444	AN000695	1.940E-2	5.210E-2	Sample Treatment;Bubbled;Control
Deoxydihydro-artemisinin	ST000444	AN000695	2.160E-2	5.210E-2	Sample Treatment;Bubbled;Control
Gentamicin	ST000444	AN000695	2.060E-2	5.210E-2	Sample Treatment;Bubbled;Control
Levonorgestrel	ST000444	AN000695	1.840E-2	5.210E-2	Sample Treatment;Bubbled;Control
NNAL-N-glucuronide	ST000444	AN000695	2.440E-2	5.210E-2	Sample Treatment;Bubbled;Control
O-Desmethylverapamil (D-702)	ST000444	AN000695	1.860E-2	5.210E-2	Sample Treatment;Bubbled;Control
Tafluprost free acid	ST000444	AN000695	2.450E-2	5.210E-2	Sample Treatment;Bubbled;Control
5-Nonanol	ST001037	AN001698	1.720E-2	5.230E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Orn / Ser	ST000544	AN000826	1.690E-2	5.230E-2	Sample Type;Control;Replicate
Manumycin A-13C17[+H]+	ST000148	AN000235	1.110E-2	5.230E-2	Treatment;13C-Glc;unlabeled
EthosuximideM7	ST000046	AN000077	1.370E-3	5.240E-2	Cognitive Status;AD;CN;MCI
L-Glutamic acid n-butyl ester	ST000566	AN000870	8.980E-3	5.240E-2	group;Old-Curcumin;Old-Placebo;young
SELENOCYSTAMINE	ST000105	AN000173	5.980E-3	5.240E-2	Sampling;After SWS onset;Morning fasting
metabolite 1	ST000539	AN000819	3.140E-2	5.260E-2	Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Met-His	ST000539	AN000819	3.160E-2	5.270E-2	Cell type;Mature erythrocyte;Reticulocyte
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000016	AN000033	1.540E-2	5.270E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
10-Hydroxy-octadec-12Z-enoate-9-beta-D-glucuronide	ST000444	AN000695	3.150E-2	5.280E-2	Sample Treatment;Bubbled;Control
2-Hydroxy-imipramine glucuronide	ST000444	AN000695	2.950E-2	5.280E-2	Sample Treatment;Bubbled;Control
AFN911	ST000444	AN000695	3.360E-2	5.280E-2	Sample Treatment;Bubbled;Control
Deoxyartemsinin	ST000444	AN000695	3.380E-2	5.280E-2	Sample Treatment;Bubbled;Control
Dibucaine0cinchocaine	ST000444	AN000695	3.420E-2	5.280E-2	Sample Treatment;Bubbled;Control
Dimenhydrinate	ST000444	AN000695	2.990E-2	5.280E-2	Sample Treatment;Bubbled;Control
Edrophonium	ST000444	AN000695	3.230E-2	5.280E-2	Sample Treatment;Bubbled;Control
N-desmethylimatinib	ST000444	AN000695	3.230E-2	5.280E-2	Sample Treatment;Bubbled;Control
Arg-Asp-Asp-Gly	ST001205	AN002006	2.160E-2	5.290E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Sulfoacetate	ST000403	AN000643	3.310E-2	5.340E-2	Cell type;Mature erythrocyte;Reticulocyte
DSGEGDFXAEGGGVR*	ST000974	AN001595	1.620E-2	5.340E-2	REGION;AHRI;MRC;SUN
D1-2-Hydroxymethylethisterone-2.831552	ST000046	AN000079	6.700E-3	5.350E-2	Cognitive Status;AD;CN;MCI
cyclo(L-phe-L-pro)	ST000974	AN001595	8.970E-3	5.360E-2	TIMEPOINT;BL;M06;M18
palmithoylethanolamide	ST000923	AN001516	3.680E-2	5.370E-2	Diagnosis;CD;nonIBD;UC
Decylubiquinol	ST000567	AN000872	1.160E-2	5.370E-2	groups;Old-Curcumin;Old-Placebo;young
GLYCERALDEHYDE 3-PHOSPHATE DIETHYL ACETAL	ST000016	AN000033	3.830E-2	5.380E-2	Material;Cells;Media
Caffeine-D3	ST000919	AN001507	8.000E-3	5.400E-2	Gender;Female;Male
Methyl Caprate	ST000978	AN001602	8.120E-3	5.410E-2	Competitive_RRTvsDeath;.;N;RRT;DEATH
cyclo(L-phe-L-pro)	ST000974	AN001595	6.810E-3	5.410E-2	GENDER;F;M
PYRIDINE CARBOXYLIC ACID	ST000016	AN000033	3.870E-2	5.420E-2	Material;Cells;Media
(Z)-4-Hydroxyphenylacetaldehyde-oxime	ST000403	AN000642	6.210E-3	5.450E-2	Glucose labelling;C13 glucose;unlabelled
4-Aminophenyl1-thio-beta-D-glucuronide	ST000047	AN000081	3.510E-3	5.470E-2	Cognitive Status;AD;CN;MCI
possible sucrose	ST000420	AN000662	3.870E-2	5.480E-2	Group;nonsmoker;smoker
sn-caldarchaeo-1-phosphoethanolamine	ST000445	AN000696	1.410E-2	5.500E-2	Treatment;FSH;LH
4-(1-methyl-5-hydroxy-2-pyrrolidinyl)-3-oxobutanoate methyl ester	ST000403	AN000642	6.450E-3	5.520E-2	Glucose labelling;C13 glucose;unlabelled
12-OPDA	ST000403	AN000642	6.590E-3	5.550E-2	Glucose labelling;C13 glucose;unlabelled
[PS(18:1)] 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine	ST001205	AN002007	2.030E-2	5.570E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
N-Ace-Asp-13C4	ST001049	AN001864	5.390E-3	5.570E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Dityrosine	ST000444	AN000695	3.680E-2	5.570E-2	Sample Treatment;Bubbled;Control
N-ACETYL-HEXOSAMINE	ST000956	AN001569	3.130E-2	5.580E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
2-amino-2-deoxy-isochorismate	ST001201	AN001999	3.640E-2	5.590E-2	cell_type;iRBC;unRBC
VALERYLSALYCILATE	ST000047	AN000080	1.530E-3	5.600E-2	Cognitive Status;AD;CN;MCI
Betaine / L-Valine/ Norvaline	ST001040	AN001702	2.750E-2	5.600E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000539	AN000819	3.390E-2	5.620E-2	Cell type;Mature erythrocyte;Reticulocyte
c-aconitate-13C1	ST001049	AN001864	5.670E-3	5.620E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Casein K	ST000403	AN000642	1.660E-3	5.620E-2	timepoint;1 hour;20 hours
Ala-Thr-Ala-Ser	ST001201	AN001998	1.470E-2	5.630E-2	treatment;DHA;DMSO;OZ277;OZ439
cytidine-5-monophosphate NIST	ST000390	AN000626	1.290E-2	5.640E-2	Tumor Present;No;Yes;-
Ala-Asp-Gly-Arg	ST001201	AN001998	1.490E-2	5.670E-2	treatment;DHA;DMSO;OZ277;OZ439
2-Dehydro-D-xylonate	ST000539	AN000819	3.460E-2	5.700E-2	Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonate 2	ST000539	AN000819	3.460E-2	5.700E-2	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000763	AN001201	1.410E-2	5.720E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
tartrazine	ST001202	AN002001	4.130E-2	5.740E-2	treatment_duration_(h);-;1.5;3;6;9
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000697	AN001082	8.540E-3	5.750E-2	Cell Type;BS4;HAHA;PAK;POOLED
Undecanone-13C0[+QDA adduct]+	ST000148	AN000235	1.250E-2	5.750E-2	Treatment;13C-Glc;unlabeled
Methyltyrosine	ST000356	AN000582	3.220E-2	5.800E-2	stage;-;2;3
D-Allose	ST000980	AN001606	2.470E-2	5.820E-2	Classification;Mild;Moderate;Non-allergic;Severe
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000016	AN000033	2.630E-2	5.870E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
N-BOC-D-GLUCOSAMINE	ST000016	AN000033	2.640E-2	5.870E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000465	AN000726	1.640E-3	5.870E-2	Treatment;Control;Englerin (100 nM)
6-deoxy-5-ketofructose-1-phosphate	ST001201	AN001998	1.700E-2	5.890E-2	treatment;DHA;DMSO;OZ277;OZ439
Ala-Val-Asp-Ser	ST001201	AN001998	1.720E-2	5.890E-2	treatment;DHA;DMSO;OZ277;OZ439
Isohomovanillic acid	ST000356	AN000583	4.110E-2	5.910E-2	Diagnosis;breast cancer;control
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000919	AN001506	9.240E-3	5.910E-2	Gender;Female;Male
Ala-Asp-Cys-Ser	ST001202	AN002000	4.930E-2	5.930E-2	treatment_duration_(h);-;1.5;3;6;9
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000403	AN000643	3.080E-3	5.960E-2	timepoint;1 hour;20 hours
1-Naphthoicacidglucuronide	ST000046	AN000078	1.070E-2	5.990E-2	Cognitive Status;AD;CN;MCI
D-Galacturonate	ST001205	AN002007	2.240E-2	5.990E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
butylamine NIST	ST000379	AN000613	2.450E-2	6.030E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
acisoga	ST000975	AN001596	1.600E-2	6.040E-2	GENDER;F;M
nornorcapsaicin	ST000403	AN000642	7.390E-3	6.060E-2	Glucose labelling;C13 glucose;unlabelled
8-Amino-7-oxononanoate	ST001201	AN001998	4.280E-2	6.080E-2	cell_type;iRBC;unRBC
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000818	AN001297	3.340E-2	6.130E-2	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
5-guanidino-3-methyl-2-oxo-pentanoate	ST000539	AN000818	3.400E-3	6.160E-2	timepoint;1 hour;20 hours
octulose 8-phosphate	ST000403	AN000643	8.110E-3	6.180E-2	Glucose labelling;C13 glucose;unlabelled
Ala-Leu-Thr-Pro	ST000539	AN000818	3.910E-2	6.190E-2	Cell type;Mature erythrocyte;Reticulocyte
HYDROXYISOVALERATE (*)	ST000044	AN000069	1.340E-2	6.190E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
tocopherol beta NIST	ST000061	AN000099	2.000E-2	6.190E-2	Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
acetophenone NIST	ST000386	AN000621	1.780E-2	6.200E-2	Smoker;Current;Former;NA
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C0[+Na]+	ST000148	AN000235	1.390E-2	6.240E-2	Treatment;13C-Glc;unlabeled
Capillone-13C1[+QDA adduct]+	ST000148	AN000235	1.390E-2	6.250E-2	Treatment;13C-Glc;unlabeled
3-AP	ST001167	AN001929	3.220E-2	6.260E-2	Cell lines;RWPE1;VCaP
iodoacetate	ST001204	AN002005	3.360E-2	6.260E-2	cell_type;iRBC;unRBC
Thujaplicin-13C0[+13CD3 QDA]+	ST000142	AN000225	1.090E-2	6.280E-2	Treatment;13C-Glc;unlabeled
PC(O-12:0/O-1:0)	ST000624	AN000956	1.470E-2	6.320E-2	Condition;Control;Glaucomatous
GAB-ALL	ST000110	AN000185	2.400E-2	6.370E-2	Oxygen Condition;hypoxia;normoxia
His-Thr-OH	ST000242	AN000377	2.520E-2	6.370E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	3.190E-3	6.400E-2	REGION;MAK;SUN
t-aconitate-ALL	ST000076	AN000122	1.850E-2	6.410E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Cys-Gly-Pro-Ser	ST001201	AN001999	4.240E-2	6.440E-2	cell_type;iRBC;unRBC
FA methyl(16:1)	ST001205	AN002007	2.440E-2	6.440E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
PYRIDINE CARBOXYLIC ACID	ST000044	AN000069	1.420E-2	6.450E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
N-acetyltheanine	ST000975	AN001596	1.740E-2	6.460E-2	GENDER;F;M
Methyl butenal-13C0[+13CD3 QDA]+	ST000148	AN000235	1.460E-2	6.480E-2	Treatment;13C-Glc;unlabeled
BOC-HIS-OH	ST000016	AN000033	2.970E-2	6.510E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Unknown_742.54(-)@5.61	ST000818	AN001298	4.970E-2	6.530E-2	Country;Ethiopia;Tanzania;Botswana
alpha-Methylstyrene	ST000403	AN000642	4.350E-2	6.580E-2	Cell type;Mature erythrocyte;Reticulocyte
idonic acid NIST	ST000379	AN000613	3.670E-2	6.590E-2	Time;10min;1hr;24hr;6hr
3-HB (3-hydroxybutyric acid)	ST000166	AN000259	3.850E-2	6.650E-2	Group;3M;Control;HF
3-nitro-2-pentanol	ST000539	AN000818	4.330E-2	6.750E-2	Cell type;Mature erythrocyte;Reticulocyte
5-hydroxymethyl-2-furoylcarnitine*	ST000974	AN001595	8.990E-3	6.750E-2	GENDER;F;M
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfate	ST000046	AN000079	9.910E-3	6.760E-2	Cognitive Status;AD;CN;MCI
N-(3-pyridyl)-Indomethacin amide	ST000242	AN000377	2.820E-2	6.760E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
[FA hydroxy(9:1)] 4-hydroxy-2-nonenal	ST000539	AN000818	3.970E-3	6.760E-2	timepoint;1 hour;20 hours
L-proline amide	ST000539	AN000818	4.370E-2	6.770E-2	Cell type;Mature erythrocyte;Reticulocyte
inositol 1-phosphate (I1P)	ST000974	AN001595	3.390E-3	6.770E-2	GROUP;case;control
ETHYL 3-UREIDOPROPIONATE (M+H)+	ST000726	AN001139	3.190E-2	6.770E-2	Timepoint;-;270;120;30;90
Oxidized Latia luciferin-13C10[+QDA adduct]+	ST000148	AN000235	1.550E-2	6.770E-2	Treatment;13C-Glc;unlabeled
Hydroxyproline/Aminolevulinate	ST000284	AN000452	9.630E-3	6.800E-2	Patient group;CRC;Healthy;Polyp
N-acetylglycine NIST	ST000062	AN000100	1.190E-2	6.800E-2	Source;Group 1 - Score 0;Group 2 - Score 50
CIS-4-NONENE	ST001037	AN001698	2.340E-2	6.810E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
SC-514	ST000567	AN000871	2.900E-2	6.810E-2	groups;Old-Curcumin;Old-Placebo;young
saccharic acid	ST000369	AN000603	3.350E-2	6.820E-2	Organ;Plasma;Serum
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+Cl)-	ST000818	AN001296	4.020E-2	6.850E-2	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
2-hydroxyoctanoate	ST000899	AN001464	3.400E-2	6.860E-2	Type;Control;Crohn disease;Ulcerative Colitis
(3-sulfo)Galbeta-Cer(d18:0/18:0(2OH))	ST000445	AN000696	2.270E-2	6.880E-2	Treatment;FSH;LH
cyclo(leu-pro)	ST000974	AN001595	3.560E-3	6.900E-2	GROUP;case;control
(R)-piperidine-3-carboxylate	ST001205	AN002006	3.010E-2	6.900E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
DMGV	ST001236	AN002054	1.350E-2	6.930E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
Arg-Phe-Phe-Arg	ST001201	AN001999	1.290E-2	6.940E-2	treatment;DHA;DMSO;OZ277;OZ439
MES	ST001201	AN001999	1.270E-2	6.940E-2	treatment;DHA;DMSO;OZ277;OZ439
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfate	ST000046	AN000078	1.290E-2	6.950E-2	Cognitive Status;AD;CN;MCI
2-oxogluconic acid NIST	ST000369	AN000603	2.660E-2	6.950E-2	Smoker;Current;Former;NA
Cys-Phe-Trp-Gly	ST001201	AN001998	2.090E-2	6.980E-2	treatment;DHA;DMSO;OZ277;OZ439
t-aconitate-13C4	ST000076	AN000122	2.050E-2	7.010E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
glyoxalurea NIST	ST000369	AN000603	2.850E-2	7.030E-2	Smoker;Current;Former;NA
isolinoleic acid NIST	ST000369	AN000603	2.760E-2	7.030E-2	Smoker;Current;Former;NA
acetytyrosine	ST000923	AN001515	3.560E-2	7.040E-2	Diagnosis;CD;nonIBD;UC
Texanol	ST000583	AN000894	3.330E-3	7.050E-2	caries status;caries-active;caries-free
Ala-Cys-Pro-Ser	ST001201	AN001999	1.360E-2	7.050E-2	treatment;DHA;DMSO;OZ277;OZ439
PIPES	ST001201	AN001999	1.380E-2	7.050E-2	treatment;DHA;DMSO;OZ277;OZ439
saccharic acid	ST000386	AN000621	3.400E-2	7.070E-2	Organ;Plasma;Serum
2-deoxycytidine	ST000923	AN001513	4.660E-2	7.100E-2	Diagnosis;CD;nonIBD;UC
2-Formaminobenzoylacetate	ST000539	AN000819	4.390E-2	7.140E-2	Cell type;Mature erythrocyte;Reticulocyte
3-dimethylsulfoniopropionaldehyde	ST000403	AN000643	4.350E-3	7.140E-2	timepoint;1 hour;20 hours
sodium dodecyl sulfate	ST000403	AN000643	4.350E-3	7.140E-2	timepoint;1 hour;20 hours
diacetylspermine	ST001237	AN002055	2.190E-2	7.140E-2	Time point;baseline;week 4;week 8
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	1.720E-2	7.160E-2	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
1-deoxyxylonojirimycin	ST001205	AN002006	3.170E-2	7.170E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
L-Noradrenaline	ST000539	AN000819	4.470E-2	7.200E-2	Cell type;Mature erythrocyte;Reticulocyte
Pyrazinoicacid	ST000047	AN000081	5.710E-3	7.210E-2	Cognitive Status;AD;CN;MCI
D-2-Amino-hexano-6-lactam	ST000539	AN000818	4.690E-2	7.220E-2	Cell type;Mature erythrocyte;Reticulocyte
BOC-HIS-OH	ST000105	AN000174	1.700E-2	7.220E-2	Sampling;After SWS onset;Morning fasting
L-Noradrenaline	ST001205	AN002007	2.790E-2	7.230E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
t-aconitate-13C2	ST000076	AN000122	2.250E-2	7.270E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Monoethyl phthalate (mEP)	ST000954	AN001565	3.160E-3	7.280E-2	daily_dose;2;3;4;1
[13C]-LYSINE	ST000105	AN000173	1.080E-2	7.280E-2	Sampling;After SWS onset;Morning fasting
DIMETHYLXANTHINE	ST000105	AN000173	1.060E-2	7.280E-2	Sampling;After SWS onset;Morning fasting
Capillone-13C0[+QDA adduct]+	ST000148	AN000235	1.700E-2	7.280E-2	Treatment;13C-Glc;unlabeled
LACTATE-dimer	ST000956	AN001569	4.590E-2	7.280E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Pro258-13C2	ST000114	AN000194	1.470E-2	7.290E-2	Treatment;None;Tetracycline
6-Dehydrotestosterone glucuronide	ST000355	AN000581	2.430E-2	7.300E-2	Stage;1;2;3;4;-
L-2-Aminoadipate 6-semialdehyde	ST000403	AN000643	1.040E-2	7.310E-2	Glucose labelling;C13 glucose;unlabelled
2-methylcitrate/homocitrate	ST000899	AN001464	3.670E-2	7.320E-2	Type;Control;Crohn disease;Ulcerative Colitis
Uscharidin-13C0[+QDA adduct+Na]+	ST000148	AN000235	1.720E-2	7.330E-2	Treatment;13C-Glc;unlabeled
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATE	ST000583	AN000895	4.180E-3	7.350E-2	time;12-weeks;baseline
Laudanosine	ST000539	AN000819	5.220E-3	7.360E-2	Glucose labelling;C13 glucose;unlabelled
N-acetylisoleucine	ST000974	AN001595	1.340E-2	7.360E-2	TIMEPOINT;BL;M06;M18
7-Deoxyadriamycinone	ST000422	AN000668	1.670E-3	7.360E-2	treatment;ND;T1D good glycemic control
SALICYLATE #2 (M-H)-	ST000523	AN000799	2.090E-2	7.390E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Isohomovanillic acid	ST000356	AN000583	4.490E-2	7.390E-2	stage;-;2;3
1-5-diazabicyclononane	ST000539	AN000818	5.240E-3	7.400E-2	timepoint;1 hour;20 hours
1-5-diazabicyclononane 2	ST000539	AN000818	5.240E-3	7.400E-2	timepoint;1 hour;20 hours
metabolite 2	ST000539	AN000818	5.140E-3	7.400E-2	timepoint;1 hour;20 hours
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+13CD3 QDA]+	ST000148	AN000235	1.730E-2	7.400E-2	Treatment;13C-Glc;unlabeled
L-Glutamate methylester	ST000539	AN000818	5.380E-3	7.420E-2	timepoint;1 hour;20 hours
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	5.650E-3	7.440E-2	timepoint;1 hour;20 hours
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholine	ST000539	AN000818	5.660E-3	7.440E-2	timepoint;1 hour;20 hours
O-glucosyl-tomatidine	ST001204	AN002005	4.060E-2	7.460E-2	cell_type;iRBC;unRBC
2-hydroxyoctanoate	ST000974	AN001595	2.400E-2	7.490E-2	REGION;AHRI;MRC;SUN
BOC-ALA-OH (CAS# 15761-38-3); (M-H)-	ST000697	AN001081	9.200E-3	7.550E-2	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
NVP-BEZ235	ST000567	AN000871	3.280E-2	7.570E-2	groups;Old-Curcumin;Old-Placebo;young
Ala-Glu-Glu-His	ST001201	AN001998	2.310E-2	7.580E-2	treatment;DHA;DMSO;OZ277;OZ439
Kynurenine / Trp	ST000545	AN000829	9.110E-3	7.600E-2	Sample Type;Control;Replicate
Met-SO / Met	ST000545	AN000829	8.730E-3	7.600E-2	Sample Type;Control;Replicate
Oxidized Latia luciferin-13C0[+13CD3 QDA]+	ST000148	AN000235	1.810E-2	7.610E-2	Treatment;13C-Glc;unlabeled
Fibrinopeptide A (4-15)**	ST000975	AN001596	6.060E-3	7.640E-2	GROUP;case;control
hydroxy-CMPF	ST000975	AN001596	7.060E-3	7.640E-2	GROUP;case;control
thioproline	ST000975	AN001596	6.910E-3	7.640E-2	GROUP;case;control
deschlorobenzoylIndomethacin	ST000046	AN000076	1.330E-2	7.650E-2	Cognitive Status;AD;CN;MCI
D-Phenyllacticacid	ST000046	AN000078	1.510E-2	7.650E-2	Cognitive Status;AD;CN;MCI
N5-formyl-N5-hydroxy-L-ornithine	ST001201	AN001999	1.570E-2	7.650E-2	treatment;DHA;DMSO;OZ277;OZ439
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000105	AN000173	3.920E-3	7.680E-2	Gender;Female;Male
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	4.230E-3	7.690E-2	Gender;Female;Male
cytidine-5-monophosphate NIST	ST000379	AN000613	3.410E-2	7.700E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
GAB-ALL	ST001045	AN001709	7.970E-3	7.720E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroGlu-13C3	ST001045	AN001709	7.170E-3	7.720E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Pro258-13C0	ST000076	AN000122	2.440E-2	7.760E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
2-deoxycytidine	ST000923	AN001513	2.430E-2	7.810E-2	sex;Female;Male
L-thiazolidine-4-carboxylate	ST000403	AN000642	3.460E-3	7.850E-2	timepoint;1 hour;20 hours
Lys-Lys-Met-Pro	ST000403	AN000642	3.330E-3	7.850E-2	timepoint;1 hour;20 hours
Icosadienoic acid	ST000539	AN000819	4.930E-2	7.860E-2	Cell type;Mature erythrocyte;Reticulocyte
BOC-ALA (+NA)	ST000043	AN000070	2.620E-2	7.870E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
ZEATIN [ISTD] (M+Cl)-	ST000523	AN000799	3.330E-2	7.870E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000539	AN000819	4.970E-2	7.880E-2	Cell type;Mature erythrocyte;Reticulocyte
lathosterol NIST	ST000386	AN000621	2.010E-2	7.890E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
phenol red	ST000974	AN001595	2.570E-2	7.900E-2	REGION;AHRI;MRC;SUN
Bile salt	ST001201	AN001999	1.230E-3	7.900E-2	treatment_duration_(h);-;0.5;1.5;3
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	2.170E-2	7.920E-2	GENDER;F;M
2(alpha-D-Mannosyl)-D-glycerate	ST000403	AN000643	1.240E-2	7.960E-2	Glucose labelling;C13 glucose;unlabelled
12-(2-Cyclopenten-1-yl)-2-dodecanone-13C10[+QDA adduct]+	ST000148	AN000235	1.930E-2	7.980E-2	Treatment;13C-Glc;unlabeled
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.260E-2	8.030E-2	Glucose labelling;C13 glucose;unlabelled
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000742	AN001158	4.600E-2	8.070E-2	Species;Homo sapiens;Mus musculus;-
D-2-Amino-hexano-6-lactam	ST000539	AN000818	6.490E-3	8.070E-2	timepoint;1 hour;20 hours
cyclo(L-phe-L-pro)	ST000974	AN001595	2.640E-2	8.080E-2	REGION;AHRI;MRC;SUN
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000742	AN001158	4.760E-2	8.080E-2	Species;Homo sapiens;Mus musculus;-
6-deoxy-mannose	ST000355	AN000580	3.100E-2	8.090E-2	Stage;1;2;3;4;-
Bifemelane(M4)	ST000046	AN000079	1.480E-2	8.110E-2	Cognitive Status;AD;CN;MCI
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	3.390E-2	8.170E-2	Hours;72;0;12;24;2
cytidine-5-monophosphate NIST	ST000061	AN000099	3.150E-2	8.210E-2	Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
6-deoxy-5-ketofructose-1-phosphate	ST001205	AN002006	3.900E-2	8.240E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Methoxycinnamaldehyde-13C0[+QDA adduct]+	ST000148	AN000235	2.010E-2	8.250E-2	Treatment;13C-Glc;unlabeled
N-Ace-Asp-13C5	ST001049	AN001864	1.010E-2	8.270E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Oxostearate-13C2[+QDA adduct]+	ST000142	AN000225	1.450E-2	8.270E-2	Treatment;13C-Glc;unlabeled
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	2.350E-2	8.290E-2	GENDER;F;M
D/L Glucosamine / D/L Galactosamine	ST001040	AN001702	4.560E-2	8.310E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
3alpha-HYDROXY-3-DEOXYANGOLENSICACIDMETHYLESTER	ST000047	AN000083	1.220E-2	8.350E-2	Cognitive Status;AD;CN;MCI
4-hydroxy-3-methylacetophenone	ST000923	AN001513	2.930E-2	8.360E-2	sex;Female;Male
OHPro-13C5	ST001045	AN001709	1.080E-2	8.410E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
D1-2-Hydroxymethylethisterone	ST000422	AN000668	2.670E-3	8.430E-2	treatment;ND;T1D good glycemic control
DIHYDROSPATHELIACHROMENE	ST000422	AN000668	3.650E-3	8.430E-2	treatment;ND;T1D good glycemic control
EDOXUDINE	ST000422	AN000668	3.500E-3	8.430E-2	treatment;ND;T1D good glycemic control
Furfuryl alcohol	ST000292	AN000466	3.370E-3	8.440E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Mono-N-depropylprobenecid	ST000046	AN000079	1.600E-2	8.450E-2	Cognitive Status;AD;CN;MCI
9-myristoleate	ST001322	AN002198	1.094E-2	8.480E-2	group;OB;NW
fucose + rhamnose	ST000369	AN000603	3.300E-2	8.530E-2	Gender;F;M;NA
glyoxalurea NIST	ST000369	AN000603	3.250E-2	8.530E-2	Gender;F;M;NA
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE	ST000009	AN000024	4.230E-2	8.560E-2	SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
ZEATIN [ISTD] (M+CL)-	ST000711	AN001110	1.380E-3	8.610E-2	NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M-H)-	ST000711	AN001110	1.930E-3	8.610E-2	NTM pulmonary disease;no;yes
DMGV	ST001237	AN002055	1.350E-2	8.630E-2	Prior antiangiogenic regimens (≥2);FALSE;TRUE
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000106	AN000176	9.850E-3	8.650E-2	Sampling time;0 min;60 min
AMINOHYDROXYBUTANOIC ACID	ST000044	AN000069	2.110E-2	8.660E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
7-Hexadecenoic acid methyl ester	ST001000	AN001881	2.870E-2	8.680E-2	Diagnosis;CD;Control;UC
c181hexcerum	ST000433	AN000683	1.480E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
c241hexcerum	ST000433	AN000683	3.160E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
cer160	ST000433	AN000683	2.120E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
cer200	ST000433	AN000683	2.870E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
4-Amino-4-deoxychorismate	ST001205	AN002007	3.380E-2	8.690E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Ile-Ala/Leu-Ala	ST000230	AN000344	6.890E-3	8.710E-2	Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
Disialyllacto-N-tetraose	ST000241	AN000373	1.770E-2	8.770E-2	Concentration (uM);0;500
Deamino-alpha-keto-demethylphosphinothricin-13C0[+QDA adduct]+	ST000142	AN000225	1.550E-2	8.770E-2	Treatment;13C-Glc;unlabeled
t-aconitate-ALL	ST000114	AN000194	2.400E-2	8.780E-2	Treatment;None;Tetracycline
BOC-ALA-OH	ST000043	AN000070	3.090E-2	8.790E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	9.700E-3	8.800E-2	GROUP;case;control
3-Methyglutarate	ST001040	AN001703	4.200E-2	8.820E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
tthyl hexadecenoate	ST001000	AN001878	4.950E-2	8.890E-2	Diagnosis;CD;Control;UC
BOC-HIS-OH	ST000106	AN000175	6.650E-3	8.940E-2	Sampling time;0 min;60 min
trans-Hexadec-2-enoyl carnitine	ST000355	AN000581	3.230E-2	8.950E-2	Stage;1;2;3;4;-
Oxononanoate-13C1[+QDA adduct]+	ST000148	AN000235	2.240E-2	9.000E-2	Treatment;13C-Glc;unlabeled
7-hydroxyTetranorIloprost	ST000046	AN000079	1.780E-2	9.010E-2	Cognitive Status;AD;CN;MCI
Sulfate	ST000046	AN000079	1.770E-2	9.010E-2	Cognitive Status;AD;CN;MCI
L-Glutamic-13C3[-H+]-	ST000367	AN000601	1.940E-2	9.070E-2	Tissue type;nontumor;tumor
L-Glutamic-13C4[-H+]-	ST000367	AN000601	1.210E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C2[-H+]-	ST000367	AN000601	1.530E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C3[-H+]-	ST000367	AN000601	1.950E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C4[-H+]-	ST000367	AN000601	1.280E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C5[-H+]-	ST000367	AN000601	1.430E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C6[-H+]-	ST000367	AN000601	1.320E-2	9.070E-2	Tissue type;nontumor;tumor
N-Acetylglutamic-13C7[-H+]-	ST000367	AN000601	1.510E-2	9.070E-2	Tissue type;nontumor;tumor
SucroseAndDischarrides-13C11[-H+]-	ST000367	AN000601	1.830E-2	9.070E-2	Tissue type;nontumor;tumor
SucroseAndDischarrides-13C6[-H+]-	ST000367	AN000601	1.500E-2	9.070E-2	Tissue type;nontumor;tumor
SucroseAndDischarrides-13C9[-H+]-	ST000367	AN000601	2.450E-2	9.070E-2	Tissue type;nontumor;tumor
bOHbutyrate-13C0	ST000076	AN000122	3.090E-2	9.100E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Ketohexanoate-13C1[+QDA adduct+Na]+	ST000148	AN000235	2.270E-2	9.100E-2	Treatment;13C-Glc;unlabeled
p-Hydroxyphenylbutazoneglucuronide	ST000046	AN000079	1.880E-2	9.110E-2	Cognitive Status;AD;CN;MCI
Celiprolol	ST000566	AN000870	1.790E-2	9.110E-2	group;Old-Curcumin;Old-Placebo;young
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	2.880E-2	9.120E-2	Sex;F;M;nan
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000697	AN001082	6.590E-3	9.120E-2	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
4-Hydroxypyridine+4.290232	ST000047	AN000081	8.250E-3	9.130E-2	Cognitive Status;AD;CN;MCI
succite	ST001000	AN001879	4.890E-2	9.130E-2	Diagnosis;CD;Control;UC
Gln-Phe-Gln-His	ST001205	AN002007	3.580E-2	9.130E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
alpha-(Methylenecyclopropyl)glycine	ST000403	AN000643	1.470E-2	9.150E-2	Glucose labelling;C13 glucose;unlabelled
D9-Choline iSTD	ST001211	AN002017	3.110E-2	9.160E-2	Group;Control;Methotrexate
Sulfinopyruvate-13C0[+QDA adduct+Na]+	ST000148	AN000235	2.290E-2	9.160E-2	Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C0[+QDA adduct]+	ST000148	AN000235	2.300E-2	9.170E-2	Treatment;13C-Glc;unlabeled
2-Aceto-2-hydroxybutanoate	ST000292	AN000466	3.760E-3	9.180E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
N-acetyl-2-aminoctanoate	ST000974	AN001595	3.110E-2	9.200E-2	REGION;AHRI;MRC;SUN
TROMETHAMINE	ST000047	AN000081	8.710E-3	9.240E-2	Cognitive Status;AD;CN;MCI
Asn-Lys-Gly-Pro	ST001201	AN001998	2.910E-2	9.250E-2	treatment;DHA;DMSO;OZ277;OZ439
methylhexadecanoic acid	ST000386	AN000621	2.410E-2	9.270E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
(R)-3-Hydroxybutanoate	ST000403	AN000643	1.580E-2	9.310E-2	Glucose labelling;C13 glucose;unlabelled
uridine-5-diphosphate bromoacetol	ST000403	AN000643	1.600E-2	9.310E-2	Glucose labelling;C13 glucose;unlabelled
Oleoylglycerone phosphate-13C0[+H]+	ST000148	AN000235	2.350E-2	9.320E-2	Treatment;13C-Glc;unlabeled
Oxononanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	2.360E-2	9.330E-2	Treatment;13C-Glc;unlabeled
18-Hydroxycorticosterone	ST000355	AN000581	3.980E-2	9.380E-2	Stage;1;2;3;4;-
6-deoxyglucitol NIST	ST000369	AN000603	3.790E-2	9.390E-2	Gender;F;M;NA
N-acetyl-isoputrenine*	ST000974	AN001595	1.420E-2	9.430E-2	GENDER;F;M
Hydroxynonenal-13C5[+QDA adduct]+	ST000148	AN000235	2.390E-2	9.450E-2	Treatment;13C-Glc;unlabeled
Oxytetracycline hydrochloride-13C0[+13CD3 QDA]+	ST000148	AN000235	2.400E-2	9.470E-2	Treatment;13C-Glc;unlabeled
Bergamottin	ST001037	AN001698	3.460E-2	9.520E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
D-Alanyl-D-alanine	ST000539	AN000819	2.630E-3	9.520E-2	timepoint;1 hour;20 hours
glutathione-sulfite	ST000539	AN000819	2.660E-3	9.520E-2	timepoint;1 hour;20 hours
Met-Met-Pro-Tyr	ST000403	AN000643	1.660E-2	9.540E-2	Glucose labelling;C13 glucose;unlabelled
8-Amino-7-oxononanoate	ST000047	AN000081	9.230E-3	9.580E-2	Cognitive Status;AD;CN;MCI
MBzP	ST001040	AN001703	4.790E-2	9.580E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
Oxodecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	2.450E-2	9.600E-2	Treatment;13C-Glc;unlabeled
Picrasin C-13C0[+13CD3 QDA]+	ST000148	AN000235	2.450E-2	9.610E-2	Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C5[+QDA adduct]+	ST000148	AN000235	2.460E-2	9.630E-2	Treatment;13C-Glc;unlabeled
N-Acetylglutamic-13C1[-H+]-	ST000367	AN000601	2.830E-2	9.640E-2	Tissue type;nontumor;tumor
C-glycosyltryptophan*	ST000974	AN001595	6.170E-3	9.670E-2	GROUP;case;control
cyclo(L-phe-L-pro)	ST000974	AN001595	6.490E-3	9.670E-2	GROUP;case;control
Hydroxyprolyl-Asparagine	ST001205	AN002006	4.760E-2	9.690E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Aminofructose 6-phosphate/Glucosamine 6-phosphate-13C3[-H+]-	ST000367	AN000601	3.030E-2	9.720E-2	Tissue type;nontumor;tumor
pyroGlu-13C4	ST001049	AN001864	1.430E-2	9.730E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Mono-N-depropylprobenecid	ST000047	AN000083	1.520E-2	9.740E-2	Cognitive Status;AD;CN;MCI
L-Glutamic-13C2[-H+]-	ST000367	AN000601	3.160E-2	9.800E-2	Tissue type;nontumor;tumor
3-Oxotetradecanoate-13C0[+QDA adduct]+	ST000148	AN000235	2.540E-2	9.830E-2	Treatment;13C-Glc;unlabeled
4-Hydroxypyridine	ST000046	AN000077	6.890E-3	9.840E-2	Cognitive Status;AD;CN;MCI
Propionylglycinemethylester+6.2598743	ST000046	AN000077	6.910E-3	9.840E-2	Cognitive Status;AD;CN;MCI
Xanthoxin-13C0[+QDA adduct]+	ST000148	AN000235	2.540E-2	9.840E-2	Treatment;13C-Glc;unlabeled
hydroxy-CMPF*	ST000975	AN001596	5.210E-3	9.850E-2	REGION;MAK;SUN
hydroxy-CMPF*	ST000975	AN001596	1.210E-2	9.890E-2	GROUP;case;control
[FA (8:1)] 2Z-octenoic acid	ST000403	AN000643	1.770E-2	9.900E-2	Glucose labelling;C13 glucose;unlabelled
Cyclo(deltaAla-L-Val)	ST000539	AN000818	9.080E-3	9.920E-2	timepoint;1 hour;20 hours
IS D31-TAG	ST000523	AN000800	2.920E-2	9.930E-2	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
4-Methyl-5-thiazoleethanol?	ST001211	AN002017	3.480E-2	9.980E-2	Group;Control;Methotrexate
UDP-GLCUR-13C13+15N0	ST000076	AN000121	7.780E-4	1.000E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Aminodipic Acid	ST000876	AN001413	8.870E-3	1.000E-1	L-serine (mg/kg/day);100;200;300;400;50;-
pyroGlu-13C5	ST001049	AN001864	1.670E-2	1.000E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilane	ST000978	AN001602	1.970E-2	1.010E-1	Competitive_RRTvsDeath;.;N;RRT;DEATH
Source Fragment TRP	ST000954	AN001564	3.170E-3	1.020E-1	race;1;2
Cit / Arg	ST000544	AN000826	3.430E-2	1.020E-1	Sample Type;Control;Replicate
3-S-cysteinyl-2-methylpropanoate*	ST000975	AN001596	2.430E-3	1.020E-1	TIMEPOINT;BL;M06;M18
cefamandole nafate	ST000422	AN000667	3.310E-3	1.020E-1	treatment;ND;T1D good glycemic control
Digoxigenin bisdigitoxoside	ST000242	AN000377	4.600E-2	1.030E-1	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
1-octadecanoyl-rac-glycerol+2.8676724	ST000047	AN000081	1.030E-2	1.040E-1	Cognitive Status;AD;CN;MCI
Ne-Acetyllysine	ST001037	AN001698	3.850E-2	1.040E-1	Description ;Blank;Reagent Blank;Serum Sample;Solvent
N-ACETYL-D-HEXOSAMINE	ST000011	AN000028	2.410E-2	1.050E-1	gender;male;female
OHPro-13C0	ST001045	AN001709	1.610E-2	1.050E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OH-dihexcer d18:1 N16:0	ST000362	AN000594	7.700E-3	1.060E-1	Chronic_Bronchitis;1;-
C-GLYCOSYLTRYPTOPHAN (*)	ST000106	AN000175	2.100E-3	1.060E-1	Constitution;Lean;Obese
N-ACETYL-D-HEXOSAMINE	ST000106	AN000175	1.970E-3	1.060E-1	Constitution;Lean;Obese
10-nonadecenoate	ST001192	AN001986	9.500E-3	1.060E-1	Diet;-;Omnivore;Vegetarian
L-Hypoglycin	ST000403	AN000643	1.940E-2	1.060E-1	Glucose labelling;C13 glucose;unlabelled
Fibrinopeptide B (1-13)**	ST000974	AN001595	3.670E-2	1.060E-1	REGION;AHRI;MRC;SUN
methylnaphthyl sulfate (2)*	ST000974	AN001595	3.680E-2	1.060E-1	REGION;AHRI;MRC;SUN
Total DMA / Arg	ST000545	AN000829	1.410E-2	1.060E-1	Sample Type;Control;Replicate
5-guanidino-3-methyl-2-oxo-pentanoate	ST000403	AN000642	4.850E-3	1.060E-1	timepoint;1 hour;20 hours
Lorazepamglucuronide	ST000046	AN000076	2.070E-2	1.070E-1	Cognitive Status;AD;CN;MCI
Cycloleucine	ST000567	AN000872	2.790E-2	1.070E-1	groups;Old-Curcumin;Old-Placebo;young
N-Ace-Asp-13C0	ST001049	AN001864	2.190E-2	1.070E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Ergine	ST000242	AN000377	4.900E-2	1.070E-1	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
sodium dodecyl sulfate	ST000539	AN000819	4.740E-3	1.070E-1	timepoint;1 hour;20 hours
isodeoxytetronic acid	ST000396	AN000633	1.340E-2	1.080E-1	Age Group;45-49;50-54;55-59;60-64;65-69;70-74
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	2.250E-2	1.080E-1	Condition;no;Pooled melanoma;yes
glycodeoxycholate/glycochenodeoxycholate	ST001237	AN002055	2.950E-2	1.080E-1	Treatment;EVEROLIMUS;NIVOLUMAB
ketodeoxycholate	ST001192	AN001986	1.590E-2	1.090E-1	Diet;-;Omnivore;Vegetarian
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000106	AN000175	8.680E-3	1.090E-1	Sampling time;0 min;60 min
nonulose 9-phosphate	ST001204	AN002005	6.030E-3	1.090E-1	treatment_duration_(h);-;3;6;9
[13C]-ASPARTIC ACID	ST000106	AN000175	2.650E-3	1.100E-1	Constitution;Lean;Obese
ZEATIN [ISTD] (M-H)-	ST000726	AN001138	1.260E-2	1.100E-1	DISEASE_STATE;Control;PCOS
Apionicacid	ST000046	AN000079	2.520E-2	1.110E-1	Cognitive Status;AD;CN;MCI
thioproline	ST000974	AN001595	8.090E-3	1.110E-1	GROUP;case;control
[Fv] Desmosdumotin C	ST000403	AN000642	5.260E-3	1.110E-1	timepoint;1 hour;20 hours
Dihydrogenphosphate	ST001204	AN002005	6.660E-3	1.110E-1	treatment_duration_(h);-;3;6;9
BOC-ASN	ST000010	AN000025	4.940E-2	1.120E-1	Hours;72;0;12;24;2
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE (*)	ST000105	AN000173	1.830E-2	1.120E-1	Sampling;After SWS onset;Morning fasting
7-Hydroxyprochlorperazineglucuronide	ST000045	AN000073	2.450E-2	1.120E-1	Treatment;Insulin Withdrawal;Saline Infusion
SALICYLURIC GLUCURONIDE (*)	ST000105	AN000174	2.870E-2	1.130E-1	Sampling;After SWS onset;Morning fasting
4-Oxocyclohexanecarboxylate-13C0[+QDA adduct]+	ST000148	AN000235	3.020E-2	1.130E-1	Treatment;13C-Glc;unlabeled
Bis(2-hydroxypropyl)amine+5.586841	ST000047	AN000081	1.320E-2	1.140E-1	Cognitive Status;AD;CN;MCI
2-Isopropyl-5-methyl-1-heptanol	ST000978	AN001602	2.580E-2	1.140E-1	Cox_RRT;.;N;Y
Methyl Docosanoate	ST000978	AN001602	2.600E-2	1.140E-1	Cox_RRT;.;N;Y
Diacetylmonoxime	ST000403	AN000642	1.660E-2	1.140E-1	Glucose labelling;C13 glucose;unlabelled
GAB-13C0	ST001045	AN001709	2.550E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-ALL	ST001045	AN001709	2.640E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroGlu-ALL	ST001045	AN001709	2.330E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C1	ST001045	AN001709	2.270E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C4	ST001045	AN001709	2.400E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Oxooctanoate-13C0[+QDA adduct+Na]+	ST000148	AN000235	3.030E-2	1.140E-1	Treatment;13C-Glc;unlabeled
[13C]-GLUTAMATE	ST000043	AN000070	4.580E-2	1.150E-1	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000081	1.360E-2	1.150E-1	Cognitive Status;AD;CN;MCI
O-PHOSPHONOHEXOPYRANOSE	ST000044	AN000069	3.050E-2	1.150E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
gama-Aminobutyrate	ST000284	AN000452	2.130E-2	1.150E-1	Patient group;CRC;Healthy;Polyp
SucroseAndDischarrides-13C12[-H+]-	ST000367	AN000601	4.690E-2	1.150E-1	Tissue type;nontumor;tumor
6C-SUGAR ALCOHOL	ST000954	AN001564	2.490E-3	1.160E-1	ethnicity;1;2;-
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+	ST000775	AN001223	1.510E-2	1.160E-1	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
aOHglutarate-13C0	ST001049	AN001864	2.580E-2	1.160E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C0	ST001049	AN001864	2.510E-2	1.160E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000105	AN000174	3.010E-2	1.160E-1	Sampling;After SWS onset;Morning fasting
17beta-Hydroxy-5alpha-androst-2-ene-2-carboxaldehyde-13C1[+QDA adduct]+	ST000148	AN000235	3.130E-2	1.160E-1	Treatment;13C-Glc;unlabeled
Benzoquinoneacetate-13C0[+QDA adduct]+	ST000148	AN000235	3.130E-2	1.160E-1	Treatment;13C-Glc;unlabeled
Kynorenate	ST000284	AN000452	2.580E-2	1.170E-1	Patient group;CRC;Healthy;Polyp
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)	ST000016	AN000033	4.220E-2	1.170E-1	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
glyoxalurea NIST	ST000386	AN000621	3.250E-2	1.180E-1	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
2-hydroxyoctanoate	ST000974	AN001595	1.910E-2	1.180E-1	GENDER;F;M
N-acetyl-2-aminoctanoate	ST000974	AN001595	1.990E-2	1.180E-1	GENDER;F;M
Khellol glucoside-13C0[+13CD3 QDA]+	ST000142	AN000225	2.100E-2	1.180E-1	Treatment;13C-Glc;unlabeled
Oxododecanoate-13C1[+QDA adduct]+	ST000148	AN000235	3.210E-2	1.180E-1	Treatment;13C-Glc;unlabeled
cis-3-Hexenyllactate	ST000355	AN000580	4.660E-2	1.190E-1	Diagnosis;Breast cancer;Control
BOC-MET-OH	ST000105	AN000174	3.100E-2	1.190E-1	Sampling;After SWS onset;Morning fasting
TROMETHAMINE+5.9955096	ST000046	AN000076	2.480E-2	1.200E-1	Cognitive Status;AD;CN;MCI
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000106	AN000175	1.070E-2	1.200E-1	Sampling time;0 min;60 min
CCCP	ST000292	AN000466	5.680E-3	1.200E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000726	AN001138	6.390E-3	1.210E-1	AGE;12;13;14;15;16;17
cyclohexylammonium+5.197659	ST000046	AN000076	2.730E-2	1.210E-1	Cognitive Status;AD;CN;MCI
6-deoxyglucitol NIST	ST000386	AN000621	3.660E-2	1.210E-1	Gender;F;M;NA
3-acetyl pyridine adenine dinucleotide	ST000403	AN000643	2.310E-2	1.210E-1	Glucose labelling;C13 glucose;unlabelled
6-bromotryptophan	ST000975	AN001596	1.590E-2	1.210E-1	GROUP;case;control
Albendazole sulfone	ST001204	AN002005	8.950E-3	1.210E-1	treatment_duration_(h);-;3;6;9
2-Amino-2-methyl-1-propanol	ST000421	AN000663	5.550E-3	1.210E-1	treatment;ND;T1D poor glycemic control
Diglycolicacid	ST000046	AN000078	3.180E-2	1.220E-1	Cognitive Status;AD;CN;MCI
N-Hydroxymethylnicotinamide	ST000566	AN000870	3.130E-2	1.220E-1	group;Old-Curcumin;Old-Placebo;young
Mannopine	ST000292	AN000466	6.160E-3	1.220E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
TRIDESACETOXYKHIVORIN	ST000046	AN000078	3.260E-2	1.230E-1	Cognitive Status;AD;CN;MCI
Desmethylmianserin glucuronide	ST000566	AN000870	3.270E-2	1.230E-1	group;Old-Curcumin;Old-Placebo;young
2-Formaminobenzoylacetate	ST000539	AN000819	7.680E-3	1.230E-1	timepoint;1 hour;20 hours
Abscisic acid glucose ester	ST000403	AN000643	8.620E-3	1.230E-1	timepoint;1 hour;20 hours
Cys-Thr-Ser-Tyr	ST000539	AN000819	7.860E-3	1.230E-1	timepoint;1 hour;20 hours
Methyl 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-p-toluate	ST000539	AN000819	7.630E-3	1.230E-1	timepoint;1 hour;20 hours
Oxononanoate-13C0[+QDA adduct]+	ST000148	AN000235	3.360E-2	1.230E-1	Treatment;13C-Glc;unlabeled
diacetylspermine	ST001237	AN002055	3.880E-2	1.240E-1	Treatment;EVEROLIMUS;NIVOLUMAB
cyclohexylammonium	ST000046	AN000077	1.260E-2	1.250E-1	Cognitive Status;AD;CN;MCI
asparagylisoleucine	ST000974	AN001595	9.860E-3	1.250E-1	GROUP;case;control
IS Ceramide; [M-H2O]+	ST000523	AN000800	3.850E-2	1.250E-1	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
Oxidized Latia luciferin-13C1[+13CD3 QDA]+	ST000148	AN000235	3.430E-2	1.250E-1	Treatment;13C-Glc;unlabeled
OH-dihexcer d18:1 N18:0	ST000362	AN000594	1.690E-2	1.260E-1	Chronic_Bronchitis;1;-
sulfa d18:1 N20:0	ST000362	AN000594	1.660E-2	1.260E-1	Chronic_Bronchitis;1;-
Meradimate	ST000047	AN000080	5.080E-3	1.260E-1	Cognitive Status;AD;CN;MCI
Manumycin A-13C16[+H]+	ST000148	AN000235	3.460E-2	1.260E-1	Treatment;13C-Glc;unlabeled
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.630E-2	1.260E-1	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
hydroxy-CMPF	ST000975	AN001596	7.240E-3	1.270E-1	REGION;MAK;SUN
CerP 21:0; [M-H]-@2.12	ST000775	AN001224	4.770E-2	1.270E-1	Treatment response;No;Yes;Pooled
2-Amino-2-methyl-1-propanol+5.1998544	ST000046	AN000077	1.370E-2	1.280E-1	Cognitive Status;AD;CN;MCI
N-Acetyl-5-aminosalicylicacid-3.4608338	ST000046	AN000079	3.460E-2	1.280E-1	Cognitive Status;AD;CN;MCI
SAPPANONEA7-METHYLETHER	ST000046	AN000079	3.370E-2	1.280E-1	Cognitive Status;AD;CN;MCI
BOC-ALA-OH	ST000041	AN000063	6.680E-3	1.280E-1	Group;Control;NAFLD
THYMIDINE-5`-DIPHOSPHO-ALPHA-D-GLUCOSE	ST000044	AN000069	3.580E-2	1.290E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
1-PHENYLETHANOL (CAS# 1445-91-6); (M+H)+[-H2O]	ST000741	AN001156	2.640E-2	1.290E-1	subject type;Healthy control;Mild disease;POOLED;Severe dise...
OBTUSAQUINONE	ST000422	AN000668	7.150E-3	1.290E-1	treatment;ND;T1D good glycemic control
5-Formiminotetrahydrofolic acid	ST000566	AN000870	3.830E-2	1.300E-1	group;Old-Curcumin;Old-Placebo;young
perchlorate	ST000403	AN000643	9.390E-3	1.300E-1	timepoint;1 hour;20 hours
monohexsph	ST000362	AN000594	2.510E-2	1.310E-1	Chronic_Bronchitis;1;-
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000046	AN000076	3.020E-2	1.310E-1	Cognitive Status;AD;CN;MCI
aOHglutarate-13C4	ST001049	AN001864	3.170E-2	1.310E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
PO4-ALL	ST001049	AN001864	3.270E-2	1.310E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
C6H12O6-HEXOSE/KETOSE/INOSITOL	ST000919	AN001507	3.200E-2	1.310E-1	Response;NR;R
GemfibrozilM2	ST000046	AN000078	3.700E-2	1.320E-1	Cognitive Status;AD;CN;MCI
N-BOC-L-Tryptophan	ST000954	AN001564	6.870E-3	1.320E-1	race;1;2
Methyl Linocerate	ST000978	AN001602	3.630E-2	1.330E-1	Cox_RRT;.;N;Y
Trimethylsilyl 3-((trimethylsilyl)thio)propanoate	ST000978	AN001602	3.630E-2	1.330E-1	Cox_RRT;.;N;Y
(3-Arylcarbonyl)-alanine	ST000291	AN000465	3.910E-3	1.330E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
inositol allo-	ST000396	AN000633	2.180E-2	1.340E-1	Age Group;45-49;50-54;55-59;60-64;65-69;70-74
4-Hydroxybenzylcyanide+6.609466	ST000046	AN000076	3.280E-2	1.340E-1	Cognitive Status;AD;CN;MCI
saccharic acid	ST000412	AN000652	4.560E-2	1.340E-1	Collection Time;1 Hr;2 Hr;3 Hr;-
3-CMPFP**	ST000975	AN001596	1.910E-2	1.340E-1	GROUP;case;control
bOHbutyrate-13C0	ST001049	AN001864	3.500E-2	1.340E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Hexose Pool	ST000465	AN000726	2.410E-2	1.340E-1	Treatment;Control;Englerin (100 nM)
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.260E-2	1.350E-1	Chemotherapy;N;Y;POOLED
Propionylglycinemethylester	ST000046	AN000079	3.800E-2	1.350E-1	Cognitive Status;AD;CN;MCI
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	1.990E-2	1.350E-1	GROUP;case;control
Corey PG-Lactone Diol	ST000566	AN000870	4.120E-2	1.350E-1	group;Old-Curcumin;Old-Placebo;young
4-hydroxy-3-methylacetophenone	ST001236	AN002054	3.760E-2	1.350E-1	OS_Censor (1 means the time is a censoring time and 0 means ...
DIMETHYLCAFFEIC ACID	ST000422	AN000668	8.490E-3	1.350E-1	treatment;ND;T1D good glycemic control
SDMA / Arg	ST000545	AN000829	2.180E-2	1.360E-1	Sample Type;Control;Replicate
Ala-Asp-Cys-Ser	ST001201	AN001998	4.550E-2	1.360E-1	treatment;DHA;DMSO;OZ277;OZ439
8-Amino-7-oxononanoate	ST000047	AN000080	6.930E-3	1.370E-1	Cognitive Status;AD;CN;MCI
Pyrazinoicacid	ST000046	AN000077	1.610E-2	1.370E-1	Cognitive Status;AD;CN;MCI
isoamylnitrite	ST000046	AN000077	1.770E-2	1.380E-1	Cognitive Status;AD;CN;MCI
o-Toluenesulfamide	ST000046	AN000077	1.780E-2	1.380E-1	Cognitive Status;AD;CN;MCI
HEXANESULFONIC ACID-Sulfate	ST000957	AN001571	1.270E-2	1.380E-1	Milk fraction;fat;skim;whole
[13C]-LYSINE	ST000044	AN000068	1.640E-2	1.380E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000726	AN001138	4.060E-2	1.400E-1	Assay;BC TP;OGTT
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	3.350E-2	1.400E-1	Race;Black;White;POOLED
Cit / Orn	ST000544	AN000826	4.950E-2	1.400E-1	Sample Type;Control;Replicate
Maleylpyruvate-13C0[+QDA adduct+Na]+	ST000142	AN000225	2.510E-2	1.400E-1	Treatment;13C-Glc;unlabeled
Hydroxycholesterol species	ST000450	AN000705	3.440E-2	1.410E-1	Disease;CFS;Normal
2-oxo-3-methylvaleric acid	ST000566	AN000870	4.700E-2	1.410E-1	group;Old-Curcumin;Old-Placebo;young
HYDROXYISOVALERATE (*)	ST000105	AN000174	2.580E-3	1.410E-1	PCOS;No PCOS;PCOS
AMINOHYDROXYBUTANOIC ACID	ST000106	AN000176	1.840E-2	1.410E-1	Sampling time;0 min;60 min
PC(16:0/5:0(COOH))	ST000539	AN000818	1.410E-2	1.410E-1	timepoint;1 hour;20 hours
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000539	AN000819	1.190E-2	1.410E-1	timepoint;1 hour;20 hours
3-deoxy-D-galactose	ST001205	AN002006	8.310E-4	1.410E-1	treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-Pro	ST001205	AN002006	1.660E-3	1.410E-1	treatment;DHA;DMSO;OZ277;OZ439
Chloramphenicolalcohol	ST000047	AN000081	1.910E-2	1.420E-1	Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000082	2.130E-2	1.420E-1	Cognitive Status;AD;CN;MCI
threo-Isocitricacid-1.0347548	ST000047	AN000082	2.220E-2	1.420E-1	Cognitive Status;AD;CN;MCI
Oxidized Latia luciferin-13C1[+QDA adduct]+	ST000148	AN000235	4.030E-2	1.420E-1	Treatment;13C-Glc;unlabeled
Phosphoagmatine	ST000291	AN000464	2.910E-3	1.420E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
cyclohexylammonium+2.7358363	ST000046	AN000076	3.610E-2	1.430E-1	Cognitive Status;AD;CN;MCI
arachidiic acid	ST000416	AN000658	3.710E-2	1.430E-1	Gender;Female;Male
aOHglutarate-13C1	ST001049	AN001864	3.790E-2	1.430E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Oxooctanoate-13C1[+QDA adduct]+	ST000148	AN000235	4.060E-2	1.430E-1	Treatment;13C-Glc;unlabeled
EPIAFZELECHINTRIMETHYLETHER	ST000046	AN000079	4.100E-2	1.440E-1	Cognitive Status;AD;CN;MCI
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000698	AN001083	3.690E-2	1.440E-1	KD#2;yes;no;Pooled melanoma
O-Desmethyloxotolrestatsulfate	ST000045	AN000072	1.840E-2	1.440E-1	Treatment;Insulin Withdrawal;Saline Infusion
ORTHOTHYMOTINICACID	ST000047	AN000082	2.320E-2	1.450E-1	Cognitive Status;AD;CN;MCI
5-Dehydro-4-deoxy-D-glucarate	ST000403	AN000643	1.070E-2	1.450E-1	timepoint;1 hour;20 hours
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000403	AN000643	1.100E-2	1.450E-1	timepoint;1 hour;20 hours
Undecanone-13C2[+QDA adduct]+	ST000148	AN000235	4.130E-2	1.450E-1	Treatment;13C-Glc;unlabeled
Glu-Met-Met-His	ST000539	AN000819	1.250E-2	1.460E-1	timepoint;1 hour;20 hours
Oxodecanoate-13C1[+QDA adduct]+	ST000148	AN000235	4.170E-2	1.460E-1	Treatment;13C-Glc;unlabeled
Asn-Leu-Lys-Asp	ST001201	AN001998	4.940E-2	1.460E-1	treatment;DHA;DMSO;OZ277;OZ439
Propoxyphene	ST000421	AN000663	7.470E-3	1.460E-1	treatment;ND;T1D poor glycemic control
cyclo(leu-pro)	ST000974	AN001595	2.700E-2	1.470E-1	GENDER;F;M
Hydroxynonenal-13C1[+QDA adduct]+	ST000148	AN000235	4.190E-2	1.470E-1	Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	4.190E-2	1.470E-1	Treatment;13C-Glc;unlabeled
8-hydroxymianseringlucuronide	ST000047	AN000082	2.420E-2	1.480E-1	Cognitive Status;AD;CN;MCI
GLUCARIC/GULARIC/SACCHARIC ACID	ST000041	AN000063	9.810E-3	1.500E-1	Group;Control;NAFLD
Cyanidin-3-rhamnoglucoside chloride-13C0[+Na]+	ST000142	AN000225	2.710E-2	1.500E-1	Treatment;13C-Glc;unlabeled
3-(a-Naphthoxy)lacticacid	ST000047	AN000083	2.790E-2	1.510E-1	Cognitive Status;AD;CN;MCI
URSINICACID	ST000046	AN000076	3.870E-2	1.510E-1	Cognitive Status;AD;CN;MCI
t-aconitate-13C2	ST001045	AN001709	4.310E-2	1.510E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
4-Hydroxypyridine+1.305617	ST000046	AN000076	3.990E-2	1.530E-1	Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000083	2.960E-2	1.530E-1	Cognitive Status;AD;CN;MCI
Fumaric	ST000284	AN000452	4.470E-2	1.530E-1	Patient group;CRC;Healthy;Polyp
GAB-13C3	ST001046	AN001710	5.330E-3	1.530E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
CAI-1-13C0[+13CD3 QDA]+	ST000148	AN000235	4.410E-2	1.530E-1	Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	4.430E-2	1.530E-1	Treatment;13C-Glc;unlabeled
Monodehydroascorbate	ST000292	AN000466	9.390E-3	1.530E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
VD2716	ST000045	AN000075	2.890E-2	1.530E-1	Treatment;Insulin Withdrawal;Saline Infusion
Ivermectin B1a	ST000421	AN000665	5.140E-3	1.530E-1	treatment;ND;T1D poor glycemic control
N-(6-Quinolinyl)phthalimide	ST000978	AN001602	4.770E-2	1.540E-1	Cox_RRT;.;N;Y
3-methoxytyramine sulfate	ST000975	AN001596	2.370E-2	1.540E-1	GROUP;case;control
pyroglutamylphenylalanine*	ST000975	AN001596	2.330E-2	1.540E-1	GROUP;case;control
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST001201	AN001999	3.730E-2	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
Asn-Lys-Gly-Pro	ST001204	AN002004	8.160E-3	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
Cys-Leu-Cys-Tyr	ST001201	AN001999	3.810E-2	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
4-oxoproline;5-OXO-L-PROLINE	ST000954	AN001565	1.260E-2	1.550E-1	race;1;2
2-oxogluconic acid NIST	ST000386	AN000621	5.000E-2	1.560E-1	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
1-octadecanoyl-rac-glycerol	ST000046	AN000077	2.210E-2	1.560E-1	Cognitive Status;AD;CN;MCI
2-docosanamidoethanesulfonicacid	ST000046	AN000077	2.300E-2	1.560E-1	Cognitive Status;AD;CN;MCI
[13C]-VALINE	ST000044	AN000068	2.020E-2	1.560E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000954	AN001564	1.080E-2	1.560E-1	race;1;2
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000708	AN001100	4.240E-2	1.570E-1	GROUP;POOLED;Standard;VLED
[13C]-ISOLEUCINE	ST000044	AN000068	2.100E-2	1.570E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
pyroGlu-13C1	ST001049	AN001864	4.350E-2	1.570E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Prohydrojasmon-13C0[+13CD3 QDA]+	ST000142	AN000225	2.850E-2	1.570E-1	Treatment;13C-Glc;unlabeled
ZEATIN [ISTD] (M+H)+	ST000763	AN001202	4.600E-2	1.570E-1	Type;Cath;Non-invasive
Fenoterolsulfate	ST000047	AN000082	2.930E-2	1.590E-1	Cognitive Status;AD;CN;MCI
(R)-3-Methyl-2-oxobutanoate	ST000047	AN000082	2.820E-2	1.590E-1	Cognitive Status;AD;CN;MCI
[13C]-TYROSINE	ST000044	AN000068	2.150E-2	1.590E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
4-Hydroxytacrine	ST000047	AN000082	3.010E-2	1.600E-1	Cognitive Status;AD;CN;MCI
ANHYDROBRAZILICACID	ST000046	AN000078	4.840E-2	1.600E-1	Cognitive Status;AD;CN;MCI
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	2.530E-2	1.600E-1	GROUP;case;control
Ac-Tyr-OEt	ST000539	AN000818	1.990E-2	1.600E-1	timepoint;1 hour;20 hours
EB1213	ST000047	AN000081	2.270E-2	1.610E-1	Cognitive Status;AD;CN;MCI
isobutene glycol NIST	ST000910	AN001480	1.540E-2	1.610E-1	Diagnosis;MECFS;MS;ND
NMMA	ST001237	AN002055	4.480E-2	1.610E-1	Prior antiangiogenic regimens (≥2);FALSE;TRUE
PC(16:0/5:0(COOH))	ST000403	AN000642	8.610E-3	1.610E-1	timepoint;1 hour;20 hours
8-Hydroxypromazine	ST000046	AN000077	2.480E-2	1.620E-1	Cognitive Status;AD;CN;MCI
Ala-Leu-Thr-Pro	ST000403	AN000642	2.700E-2	1.620E-1	Glucose labelling;C13 glucose;unlabelled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+QDA adduct]+	ST000148	AN000235	4.770E-2	1.620E-1	Treatment;13C-Glc;unlabeled
Oxononanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	4.760E-2	1.620E-1	Treatment;13C-Glc;unlabeled
OH-monohexcer d18:1 N16:0	ST000362	AN000594	3.460E-3	1.630E-1	GoldStage;3;4;2;1;-
Benzoquinoneacetate-13C1[+QDA adduct+Na]+	ST000142	AN000225	2.960E-2	1.630E-1	Treatment;13C-Glc;unlabeled
[13C]-LEUCINE	ST000044	AN000068	2.260E-2	1.640E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Gentianaine	ST000539	AN000818	2.270E-2	1.640E-1	timepoint;1 hour;20 hours
Isobutyrylglycinemethylester	ST000047	AN000083	3.350E-2	1.650E-1	Cognitive Status;AD;CN;MCI
Casein K	ST000539	AN000818	2.340E-2	1.650E-1	timepoint;1 hour;20 hours
Casein K 2	ST000539	AN000818	2.340E-2	1.650E-1	timepoint;1 hour;20 hours
AC1MIY4G	ST000770	AN001217	3.410E-2	1.660E-1	Timepoint;T0;T55
4-8dimethylnonanoylcarnitine	ST000403	AN000642	2.870E-2	1.680E-1	Glucose labelling;C13 glucose;unlabelled
Asn-Gln-Tyr-His	ST000403	AN000643	3.710E-2	1.680E-1	Glucose labelling;C13 glucose;unlabelled
Chloramphenicolalcohol	ST000046	AN000077	3.050E-2	1.690E-1	Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.7465215	ST000046	AN000077	3.070E-2	1.690E-1	Cognitive Status;AD;CN;MCI
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000105	AN000174	1.150E-2	1.690E-1	Gender;Female;Male
IS D31-TAG	ST000669	AN001025	1.050E-2	1.690E-1	Matrix;Plasma;SRF;CB
[13C]-PROLINE	ST000044	AN000068	2.360E-2	1.690E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
(3-Arylcarbonyl)-alanine	ST000291	AN000464	4.050E-3	1.690E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Sulfate - 1.053629	ST000422	AN000668	1.240E-2	1.690E-1	treatment;ND;T1D good glycemic control
L-gamma-Cyano-gamma-aminobutyricacid+1.2438003	ST000046	AN000077	3.220E-2	1.700E-1	Cognitive Status;AD;CN;MCI
Methyl Docosanoate	ST000978	AN001602	4.640E-2	1.700E-1	Competitive_RRTvsDeath;.;N;RRT;DEATH
D1-2-Hydroxymethylethisterone - 1.9729741	ST000421	AN000664	5.170E-3	1.710E-1	treatment;ND;T1D poor glycemic control
N-Acetyl-5-hydroxysulfapyridine	ST000421	AN000664	3.640E-3	1.710E-1	treatment;ND;T1D poor glycemic control
SAPPANONE A 7-METHYL ETHER	ST000421	AN000664	3.590E-3	1.710E-1	treatment;ND;T1D poor glycemic control
Abscisic acid glucose ester	ST000403	AN000643	3.810E-2	1.720E-1	Glucose labelling;C13 glucose;unlabelled
[13C]-THREONINE	ST000044	AN000068	2.450E-2	1.720E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Ala-Glu-Glu-His	ST001204	AN002004	1.000E-2	1.720E-1	treatment;DHA;DMSO;OZ277;OZ439
Diacetylmonoxime	ST000539	AN000818	5.930E-3	1.730E-1	Glucose labelling;C13 glucose;unlabelled
O-Acetylneuraminic acid	ST000539	AN000818	5.740E-3	1.730E-1	Glucose labelling;C13 glucose;unlabelled
4-Hydroxybenzyl cyanide	ST000421	AN000664	1.040E-2	1.730E-1	treatment;ND;T1D poor glycemic control
ANGOLENSIN (R)	ST000421	AN000664	8.540E-3	1.730E-1	treatment;ND;T1D poor glycemic control
[13C]-GLUTAMATE	ST000044	AN000068	2.600E-2	1.740E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Valproate	ST000150	AN000237	5.750E-3	1.740E-1	Patient;Patient 1;Patient 2;Patient 3;Patient 4
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+	ST000741	AN001156	3.950E-2	1.740E-1	subject type;Healthy control;Mild disease;POOLED;Severe dise...
iSTD iSTD Ceramide (d18:1/17:0)	ST000346	AN000562	2.790E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD FA (16:0)-d3	ST000346	AN000562	1.590E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD MAG (17:0/0:0/0:0)	ST000346	AN000562	1.900E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PC (12:0/13:0)	ST000346	AN000562	1.900E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PG (17:0/17:0)	ST000346	AN000562	1.470E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
[13C]-ARGININE	ST000044	AN000068	2.660E-2	1.750E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Ala-Leu-Trp-Ser	ST001204	AN002004	1.080E-2	1.750E-1	treatment;DHA;DMSO;OZ277;OZ439
BOC-ASN	ST000011	AN000027	4.770E-2	1.770E-1	COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
cyclo(pro-arg)*	ST000975	AN001596	1.400E-2	1.770E-1	REGION;MAK;SUN
2-OG b	ST000096	AN000154	4.760E-2	1.770E-1	Sample Type;Adipocyte ;Co-culture ;Control ;Media blank
DMGV	ST001192	AN001984	1.280E-2	1.780E-1	Diet;-;Omnivore;Vegetarian
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.650E-2	1.780E-1	Taxane;N;Y;-
IS Ceramide;[M-H20]+	ST000669	AN001025	2.230E-2	1.790E-1	Matrix;Plasma;SRF;CB
Pinacidil-N-Oxide	ST000047	AN000080	1.680E-2	1.800E-1	Cognitive Status;AD;CN;MCI
cefamandolenafate	ST000047	AN000081	3.000E-2	1.810E-1	Cognitive Status;AD;CN;MCI
Mesaconate	ST000539	AN000819	1.660E-2	1.810E-1	Glucose labelling;C13 glucose;unlabelled
Ala-Leu-Trp-Ser	ST001204	AN002004	1.300E-2	1.810E-1	treatment_duration_(h);-;3;6;9
N-acetylglycine NIST	ST001131	AN001856	4.320E-2	1.810E-1	Treatment;Healthy;Trauma
Methyl Caprate	ST000978	AN001602	2.930E-2	1.820E-1	Cox_Composite_DeathRRT;.;N;Y
N-ACETYL-HEXOSAMINE	ST000954	AN001564	2.640E-2	1.820E-1	race;1;2
hexanoylglutamine	ST000974	AN001595	3.820E-2	1.830E-1	GENDER;F;M
Dinoterb (herbicide)	ST000583	AN000895	3.410E-2	1.830E-1	time;12-weeks;baseline
nornorcapsaicin	ST000403	AN000642	1.090E-2	1.830E-1	timepoint;1 hour;20 hours
1-(14 or 15-methyl)palmitoyl-GPC (a17:0 or i17:0)*	ST000974	AN001595	1.840E-2	1.840E-1	GROUP;case;control
3-(ADP)-2-phosphoglycerate	ST000539	AN000818	2.700E-2	1.840E-1	timepoint;1 hour;20 hours
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.790E-2	1.850E-1	CASE_CONTROL;Case;Control;POOLED
Dicyclohexyl phthalate	ST000583	AN000894	2.620E-2	1.850E-1	time;12-weeks;baseline
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.910E-2	1.850E-1	TIMEPOINT;3 Month;Baseline;POOLED
D-Alanyl-D-alanine	ST000539	AN000819	1.950E-2	1.860E-1	Glucose labelling;C13 glucose;unlabelled
metabolite 1	ST000539	AN000819	1.910E-2	1.860E-1	Glucose labelling;C13 glucose;unlabelled
2-Formaminobenzoylacetate	ST000403	AN000643	4.460E-2	1.870E-1	Glucose labelling;C13 glucose;unlabelled
3-S-cysteinyl-2-methylpropanoate*	ST000975	AN001596	3.230E-2	1.870E-1	GROUP;case;control
n-acetyl-d-hexosamine	ST001322	AN002198	4.466E-2	1.870E-1	group;OB;NW
DIHYDROSPATHELIACHROMENE	ST000047	AN000080	2.210E-2	1.880E-1	Cognitive Status;AD;CN;MCI
AMINOPENTANOIC ACID	ST000106	AN000176	3.120E-2	1.880E-1	Sampling time;0 min;60 min
Cys-Met-Pro-His	ST000539	AN000819	2.080E-2	1.890E-1	Glucose labelling;C13 glucose;unlabelled
Aspidofractine	ST000403	AN000642	3.540E-2	1.900E-1	Glucose labelling;C13 glucose;unlabelled
N-Acetyl-ala-ala-ala-methylester	ST000403	AN000642	3.510E-2	1.900E-1	Glucose labelling;C13 glucose;unlabelled
PYRIDINE CARBOXYLIC ACID	ST000044	AN000068	3.110E-2	1.900E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
gamma-Hydroxyphenylbutazone glucuronide	ST000421	AN000666	1.940E-3	1.900E-1	treatment;ND;T1D poor glycemic control
nicotinamide guanine dinucleotide	ST001201	AN001999	4.910E-2	1.910E-1	treatment;DHA;DMSO;OZ277;OZ439
Carboxyibuprofen	ST000421	AN000663	1.410E-2	1.910E-1	treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.9674853	ST000421	AN000663	1.360E-2	1.910E-1	treatment;ND;T1D poor glycemic control
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.530E-2	1.920E-1	timepoint;1 hour;20 hours
CAI-1-13C0[+13CD3 QDA]+	ST000142	AN000225	3.540E-2	1.920E-1	Treatment;13C-Glc;unlabeled
DMGV	ST001236	AN002054	1.870E-2	1.940E-1	Nivolumab Dose (mg/kg);0.3;10;2
[13C]-ASPARTIC ACID	ST000044	AN000068	3.640E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-PHENYLALANINE	ST000044	AN000068	3.630E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASN	ST000044	AN000068	3.800E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
N-ACETYL-HEXOSAMINE	ST000583	AN000895	3.780E-2	1.940E-1	time;12-weeks;baseline
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000708	AN001100	4.270E-2	1.940E-1	VISIT;POOLED;visit 1;visit 2
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000080	2.490E-2	1.950E-1	Cognitive Status;AD;CN;MCI
penem CGP31608	ST000539	AN000819	2.340E-2	1.950E-1	timepoint;1 hour;20 hours
penem CGP31608 2	ST000539	AN000819	2.340E-2	1.950E-1	timepoint;1 hour;20 hours
BOC-ASP-OH	ST000041	AN000063	1.730E-2	1.960E-1	Group;Control;NAFLD
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000957	AN001570	2.940E-2	1.960E-1	Milk fraction;fat;skim;whole
2-Amino-2-methyl-1-propanol	ST000047	AN000081	3.460E-2	1.970E-1	Cognitive Status;AD;CN;MCI
N-Amidino-L-glutamate	ST000292	AN000466	1.550E-2	1.970E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*	ST000974	AN001595	4.400E-2	1.980E-1	GENDER;F;M
AMINOHYDROXYBUTANOIC ACID	ST000044	AN000068	3.960E-2	1.980E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Bifemelane (M4)	ST000421	AN000664	1.340E-2	1.980E-1	treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.4680848	ST000421	AN000663	1.530E-2	1.980E-1	treatment;ND;T1D poor glycemic control
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000106	AN000176	3.550E-2	1.990E-1	Sampling time;0 min;60 min
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+NA)+	ST000744	AN001163	7.070E-3	2.000E-1	Gender;female;male
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	4.190E-3	2.000E-1	OSA;Negative;Positive
Bis(2-hydroxypropyl)amine+5.481559	ST000046	AN000077	4.150E-2	2.020E-1	Cognitive Status;AD;CN;MCI
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE	ST000011	AN000028	3.150E-2	2.020E-1	ETHNICITY_ASSIGNED;AMHARA;ARGOBBA;MURSI;SABUE;WEYTO;HADZABE;...
Aspidofractine	ST000539	AN000818	3.250E-2	2.020E-1	timepoint;1 hour;20 hours
3-(Methylthio)propanoate	ST000292	AN000466	1.610E-2	2.020E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
7-Hydroxyfluphenazine glucuronide	ST000422	AN000668	1.580E-2	2.020E-1	treatment;ND;T1D good glycemic control
5-hydroxynorvaline NIST	ST000390	AN000626	3.570E-2	2.040E-1	Diagnosis;adenocarcinoma;adenocarcinoma w/ BAC;adenocarcinom...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000698	AN001083	3.690E-2	2.040E-1	KD#1;no;yes;Pooled melanoma
2(alpha-D-Mannosyl)-D-glycerate	ST000539	AN000819	2.740E-2	2.040E-1	timepoint;1 hour;20 hours
3-dimethylsulfoniopropionaldehyde	ST000539	AN000819	2.700E-2	2.040E-1	timepoint;1 hour;20 hours
[13C]-HISTIDINE	ST000044	AN000068	4.280E-2	2.050E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
4-Maleylacetoacetate	ST000292	AN000466	1.680E-2	2.050E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	3.770E-2	2.060E-1	Tamoxyfen;N;Y;-
5-Guanidino-3-methyl-2-oxopentanoate	ST000292	AN000466	1.840E-2	2.060E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
2-Amino-2-methyl-1-propanol+5.204487	ST000047	AN000081	4.200E-2	2.080E-1	Cognitive Status;AD;CN;MCI
2-hexacosanamidoethanesulfonicacid	ST000047	AN000081	4.190E-2	2.080E-1	Cognitive Status;AD;CN;MCI
Meradimate+2.886999	ST000047	AN000081	4.090E-2	2.080E-1	Cognitive Status;AD;CN;MCI
[13C]-PROLINE	ST000105	AN000173	4.410E-2	2.080E-1	Sampling;After SWS onset;Morning fasting
Fibrinopeptide B (1-9)**	ST000975	AN001596	8.510E-3	2.080E-1	TIMEPOINT;BL;M06;M18
N-Didesethylquinagolide glucuronide	ST000421	AN000663	1.930E-2	2.080E-1	treatment;ND;T1D poor glycemic control
3-hydroxybutyroylglycine**	ST000976	AN001597	3.130E-3	2.090E-1	GROUP;case;control
4-Hydroxypyridine+1.305617	ST000046	AN000077	4.540E-2	2.100E-1	Cognitive Status;AD;CN;MCI
3-ethylphenylsulfate	ST000974	AN001595	4.770E-2	2.100E-1	GENDER;F;M
4-PIOL	ST000539	AN000818	3.430E-2	2.110E-1	timepoint;1 hour;20 hours
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	9.170E-3	2.120E-1	Glucose labelling;C13 glucose;unlabelled
1-docosapentaenoylglycerophosphocholine (22:5n6)*	ST000976	AN001597	5.960E-3	2.130E-1	GENDER;F;M
URSINICACID	ST000046	AN000077	4.750E-2	2.140E-1	Cognitive Status;AD;CN;MCI
16a-hydroxy DHEA 3-sulfate	ST000974	AN001595	4.900E-2	2.140E-1	GENDER;F;M
2-Oxovaleric acid	ST000421	AN000663	2.090E-2	2.140E-1	treatment;ND;T1D poor glycemic control
2-Amino-2-methyl-1-propanol	ST000047	AN000080	2.970E-2	2.150E-1	Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoate+4.7958198	ST000047	AN000080	3.040E-2	2.150E-1	Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine	ST000047	AN000081	4.630E-2	2.150E-1	Cognitive Status;AD;CN;MCI
fluphenazineenanthate	ST000047	AN000081	4.610E-2	2.150E-1	Cognitive Status;AD;CN;MCI
cis-Cyclo[L-ala-L-Pro]	ST000975	AN001596	1.800E-2	2.150E-1	REGION;MAK;SUN
GPEtnNMe(16:0/18:1(9Z))	ST000421	AN000664	1.840E-2	2.150E-1	treatment;ND;T1D poor glycemic control
crustecdysone	ST001192	AN001986	4.370E-2	2.160E-1	Diet;-;Omnivore;Vegetarian
4-Hydroxybenzylcyanide	ST000046	AN000077	4.890E-2	2.170E-1	Cognitive Status;AD;CN;MCI
ZEATIN [ISTD] (M+CL)-	ST000726	AN001138	4.170E-2	2.170E-1	DISEASE_STATE;Control;PCOS
O-Acetyl-L-homoserine 2	ST000539	AN000819	3.040E-2	2.170E-1	timepoint;1 hour;20 hours
1-deoxynojirimycin	ST000403	AN000642	4.330E-2	2.180E-1	Glucose labelling;C13 glucose;unlabelled
Sodium ortho-phenylphenate	ST000292	AN000466	2.050E-2	2.180E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
sodium chlorovulone III	ST000422	AN000668	1.810E-2	2.180E-1	treatment;ND;T1D good glycemic control
8R-hydroxy-9Z-octadecenoic acid	ST000421	AN000666	1.260E-2	2.190E-1	treatment;ND;T1D poor glycemic control
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000106	AN000176	4.300E-2	2.210E-1	Sampling time;0 min;60 min
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	9.620E-3	2.220E-1	TGF;NO_TGF;TGF
L-ARGININE-(GUANIDINEIMINO-15N2) [ISTD] (CAS# ); (M+H)+	ST000695	AN001076	6.260E-3	2.270E-1	Taxane;N;Y;-
Glutamate semialdehyde-13C0[+13CD3 QDA]+	ST000142	AN000225	4.230E-2	2.280E-1	Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+13CD3 QDA]+	ST000142	AN000225	4.260E-2	2.290E-1	Treatment;13C-Glc;unlabeled
Diethyl adipate	ST000403	AN000643	2.170E-2	2.300E-1	timepoint;1 hour;20 hours
tetrahydrogeranylgeranyl-bacteriopheophytin	ST001204	AN002005	2.040E-2	2.300E-1	treatment_duration_(h);-;3;6;9
Gln-Leu-Lys-His	ST000403	AN000642	4.890E-2	2.310E-1	Glucose labelling;C13 glucose;unlabelled
acetyl-galactosamine	ST001236	AN002054	3.910E-2	2.310E-1	Nivolumab Dose (mg/kg);0.3;10;2
(S)-Methylmalonate semialdehyde	ST000539	AN000819	3.550E-2	2.310E-1	timepoint;1 hour;20 hours
Diacetylmonoxime	ST000539	AN000818	4.010E-2	2.330E-1	timepoint;1 hour;20 hours
TRIDESACETOXYKHIVORIN	ST000421	AN000666	2.190E-2	2.330E-1	treatment;ND;T1D poor glycemic control
Phenylalanine-HCOOH	ST000954	AN001564	4.390E-2	2.340E-1	race;1;2
Delphinidin 3-O-glucoside-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.350E-2	2.340E-1	Treatment;13C-Glc;unlabeled
N-Acetyl-D-glucosaminate	ST001204	AN002004	1.570E-2	2.340E-1	treatment;DHA;DMSO;OZ277;OZ439
7-DEACETOXY-7-OXOKHIVORIN	ST000047	AN000080	3.540E-2	2.350E-1	Cognitive Status;AD;CN;MCI
nitrocyclohexane	ST000539	AN000818	1.060E-2	2.350E-1	Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-Tyr	ST000539	AN000818	4.320E-2	2.360E-1	timepoint;1 hour;20 hours
(R)-AMAA	ST000539	AN000819	3.740E-2	2.360E-1	timepoint;1 hour;20 hours
25-hydroxyvitaminD225-(beta-glucuronide)/25hydroxyergocalciferol25-(beta-glucuronide)	ST000045	AN000072	4.260E-2	2.380E-1	Treatment;Insulin Withdrawal;Saline Infusion
Oxprenolol	ST000421	AN000663	2.480E-2	2.380E-1	treatment;ND;T1D poor glycemic control
1-monoheptadecanoyl glyceride NIST	ST000910	AN001480	3.330E-2	2.390E-1	Diagnosis;MECFS;MS;ND
SALICYLURIC GLUCURONIDE (*)	ST000105	AN000174	1.260E-2	2.400E-1	PCOS;No PCOS;PCOS
Spermine / Spermidine	ST000545	AN000829	4.900E-2	2.400E-1	Sample Type;Control;Replicate
3-methyl catechol sulfate (1)	ST000976	AN001597	8.690E-4	2.400E-1	TIMEPOINT;BL;M06
PC(16:0/5:0(COOH))	ST000539	AN000818	1.170E-2	2.410E-1	Glucose labelling;C13 glucose;unlabelled
2-Phospho-D-glycerate	ST001205	AN002007	6.090E-3	2.410E-1	treatment_duration_(h);1;5;3
octulose 8-phosphate	ST000539	AN000819	2.980E-2	2.420E-1	Glucose labelling;C13 glucose;unlabelled
carboxyibuprofen	ST000923	AN001515	2.940E-2	2.430E-1	sex;Female;Male
ETHYL 3-INDOLE ACETATE	ST000105	AN000173	2.080E-2	2.440E-1	Gender;Female;Male
deschlorobenzoyl Indomethacin	ST000422	AN000668	2.090E-2	2.440E-1	treatment;ND;T1D good glycemic control
hydroxy-CMPF*	ST000976	AN001597	1.760E-2	2.450E-1	GENDER;F;M
BOC-PRO-OH	ST000106	AN000175	3.100E-2	2.460E-1	Sampling time;0 min;60 min
Sulfoacetate	ST000403	AN000643	2.480E-2	2.460E-1	timepoint;1 hour;20 hours
Pentazocinetransacid	ST000047	AN000080	3.910E-2	2.470E-1	Cognitive Status;AD;CN;MCI
Hydroxyabscisate-13C1[+H]+	ST000142	AN000225	4.640E-2	2.470E-1	Treatment;13C-Glc;unlabeled
Ketohexanoate-13C5[+QDA adduct]+	ST000142	AN000225	4.640E-2	2.470E-1	Treatment;13C-Glc;unlabeled
ZEATIN [ISTD] (M+H)+	ST000721	AN001127	4.380E-2	2.480E-1	Gender;Male;Female
HECOGENINACETATE	ST000047	AN000080	4.150E-2	2.500E-1	Cognitive Status;AD;CN;MCI
PEUCENIN	ST000047	AN000080	4.500E-2	2.500E-1	Cognitive Status;AD;CN;MCI
PEUCENIN+7.86186	ST000047	AN000080	4.280E-2	2.500E-1	Cognitive Status;AD;CN;MCI
ORTHOTHYMOTINIC ACID	ST000421	AN000664	2.480E-2	2.520E-1	treatment;ND;T1D poor glycemic control
IS D31-TAG	ST000669	AN001025	9.210E-3	2.530E-1	Disease;AS-Control-P;AS-Control-S;Coats;JB-Coats-P
6-Acetyl-D-glucose	ST001204	AN002004	2.470E-2	2.530E-1	treatment_duration_(h);-;3;6;9
BOC-ASN	ST000009	AN000023	4.560E-2	2.550E-1	AFTER_MEAL_TIME;30_MIN;NO_WAIT
N-(6-Aminohexanoyl)-6-aminohexanoate	ST000292	AN000466	2.960E-2	2.550E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Sphinganine-phosphate	ST000612	AN000937	2.330E-2	2.560E-1	Condition;Control;Glaucomatous
Gln-Leu-Lys-His	ST000539	AN000818	4.790E-2	2.570E-1	timepoint;1 hour;20 hours
Pro258-ALL	ST000113	AN000191	1.940E-2	2.590E-1	Treatment;None;Tetracycline
Xanthumin-13C0[+Na]+	ST000142	AN000225	4.910E-2	2.600E-1	Treatment;13C-Glc;unlabeled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	4.090E-2	2.620E-1	Drug;Exemestane;Letrozole;POOLED
AMINOHYDROXYBUTANOIC ACID	ST000106	AN000175	3.410E-2	2.620E-1	Sampling time;0 min;60 min
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000539	AN000819	3.480E-2	2.630E-1	Glucose labelling;C13 glucose;unlabelled
Pro258-13C5	ST000114	AN000194	3.210E-2	2.630E-1	Oxygen Condition;hypoxia;normoxia
Myxalamid D	ST001204	AN002004	1.890E-2	2.630E-1	treatment;DHA;DMSO;OZ277;OZ439
4-Aminophenyl 1-thio-beta-D-glucuronide + 2.6188798	ST000421	AN000663	3.120E-2	2.630E-1	treatment;ND;T1D poor glycemic control
URETHANE	ST000421	AN000663	3.130E-2	2.630E-1	treatment;ND;T1D poor glycemic control
UDP-GNAc-13C6+15N0	ST000076	AN000121	4.360E-3	2.640E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Dicyclohexyl phthalate	ST000583	AN000894	3.340E-2	2.650E-1	caries status;caries-active;caries-free
N-Acetyl-O-acetylneuraminate	ST001204	AN002004	2.660E-2	2.650E-1	treatment_duration_(h);-;3;6;9
3-(a-Naphthoxy)lactic acid	ST000422	AN000668	2.420E-2	2.680E-1	treatment;ND;T1D good glycemic control
FAMPRIDINE	ST000422	AN000668	2.430E-2	2.680E-1	treatment;ND;T1D good glycemic control
L-proline amide	ST000403	AN000642	2.030E-2	2.720E-1	timepoint;1 hour;20 hours
Arg-Lys-Asp-Asp	ST001204	AN002005	2.760E-2	2.760E-1	treatment_duration_(h);-;3;6;9
HYDROLYSIS PRODUCT OF BUSSEIN	ST000421	AN000664	3.080E-2	2.780E-1	treatment;ND;T1D poor glycemic control
N-acetyphenylalanine	ST001192	AN001984	3.390E-2	2.800E-1	Diet;-;Omnivore;Vegetarian
phenylalanine-d8	ST001192	AN001984	2.550E-2	2.800E-1	Diet;-;Omnivore;Vegetarian
gamma-glutamyllysine	ST000976	AN001597	2.510E-2	2.830E-1	GENDER;F;M
hydroxy-CMPF	ST000976	AN001597	2.800E-2	2.830E-1	GENDER;F;M
(R)-AMAA	ST000539	AN000819	3.850E-2	2.830E-1	Glucose labelling;C13 glucose;unlabelled
Fibrinopeptide B (1-12)**	ST000975	AN001596	1.710E-2	2.840E-1	TIMEPOINT;BL;M06;M18
VGAHAGEYGAEALER*	ST000093	AN000149	4.500E-2	2.860E-1	condition;FFA affected ;FFA unaffected ;Scalp biopsy normal
VGAHAGEYGAEALER*	ST000093	AN000149	4.500E-2	2.860E-1	location;frontal scalp;occipital scalp;NA
3-hydroxykynurenate	ST001192	AN001985	2.210E-2	2.870E-1	Diet;-;Omnivore;Vegetarian
URIDINE 5`-DIPHOSPHOGLUCURONIC ACID	ST000010	AN000026	2.450E-2	2.870E-1	TGF;NO_TGF;TGF
LACTATE-dimer	ST000954	AN001565	3.750E-2	2.880E-1	race;1;2
methylhexadecanoic acid	ST000389	AN000625	3.350E-2	2.910E-1	Group;Benign;Cancer
C-GLYCOSYLTRYPTOPHAN (*)	ST000105	AN000173	1.140E-2	2.920E-1	OSA;Negative;Positive
trans-OH-Pro	ST000783	AN001239	1.570E-3	2.920E-1	RACE;AA;EA
3-CMPFP**	ST000975	AN001596	2.750E-2	2.930E-1	REGION;MAK;SUN
P-Hydroxydesmethylgliquidone	ST000422	AN000668	2.860E-2	2.930E-1	treatment;ND;T1D good glycemic control
N-acetylisoleucine	ST000976	AN001597	1.110E-2	2.940E-1	TIMEPOINT;BL;M06
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylate	ST000923	AN001515	4.560E-2	2.960E-1	sex;Female;Male
GLUCOSE/FRUCTOSE-PHOSPHATE	ST000424	AN000673	1.540E-2	2.970E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
psicoselysine	ST000539	AN000818	1.800E-2	2.970E-1	Glucose labelling;C13 glucose;unlabelled
ETHYL 3-INDOLE ACETATE	ST000105	AN000173	2.330E-2	2.990E-1	PCOS;No PCOS;PCOS
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000106	AN000175	4.190E-2	3.060E-1	Sampling time;0 min;60 min
Creatine-D3	ST000424	AN000673	4.250E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
GLUCOSAMINE/MANNOSAMINE	ST000424	AN000673	3.280E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
HEXOSE-DISACCHARIDE	ST000424	AN000673	2.170E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
L-Leucine-D10	ST000424	AN000673	4.180E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
6-bromotryptophan	ST000976	AN001597	4.050E-2	3.080E-1	GENDER;F;M
N2-(D-1-Carboxyethyl)-L-arginine	ST001204	AN002004	3.940E-2	3.080E-1	treatment_duration_(h);-;3;6;9
2-Amino-3-methyl-1-butanol + 5.2393837	ST000421	AN000663	4.020E-2	3.090E-1	treatment;ND;T1D poor glycemic control
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000617	AN000946	3.450E-2	3.110E-1	Treatment;CFS;Control
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (POSSIBLY)	ST000041	AN000063	3.420E-2	3.160E-1	Group;Control;NAFLD
4-methylhexanoylglutamine	ST000975	AN001596	3.080E-2	3.160E-1	REGION;MAK;SUN
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000954	AN001564	2.960E-2	3.180E-1	ethnicity;1;2;-
deschlorobenzoyl Indomethacin	ST000422	AN000667	1.500E-2	3.190E-1	treatment;ND;T1D good glycemic control
3-OH-DL-KYNURENINE	ST000876	AN001413	4.390E-2	3.200E-1	L-serine (mg/kg/day);100;200;300;400;50;-
BOC-PHE-OH	ST000105	AN000174	2.480E-2	3.250E-1	PCOS;No PCOS;PCOS
N-acetylalliin	ST000975	AN001596	3.290E-2	3.250E-1	REGION;MAK;SUN
Tolmetin sodium	ST000292	AN000466	4.660E-2	3.250E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Tos-Lys-CH2Cl	ST000292	AN000466	4.730E-2	3.250E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
L-Aspartic acid b-semialdehyde	ST000422	AN000668	3.450E-2	3.260E-1	treatment;ND;T1D good glycemic control
Sulfadoxine suflate	ST000421	AN000664	4.070E-2	3.270E-1	treatment;ND;T1D poor glycemic control
Sulfite	ST000421	AN000664	4.380E-2	3.270E-1	treatment;ND;T1D poor glycemic control
Acetominophen	ST000913	AN001483	1.360E-2	3.310E-1	Diagnosis;MECFS;MS;ND
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000768	AN001215	4.840E-2	3.320E-1	Media;3N media;E8 media
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000105	AN000174	2.690E-2	3.320E-1	PCOS;No PCOS;PCOS
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000768	AN001215	4.840E-2	3.320E-1	Type;neurons;stem cells
Mesaconate	ST000403	AN000643	4.440E-2	3.340E-1	timepoint;1 hour;20 hours
L-2-Aminoadipate 6-semialdehyde	ST000403	AN000643	4.560E-2	3.380E-1	timepoint;1 hour;20 hours
Oleoyl amine + 12.276432	ST000421	AN000665	1.480E-2	3.420E-1	treatment;ND;T1D poor glycemic control
CerP(t39:1)[M+H]+	ST000992	AN001621	4.140E-2	3.460E-1	Metabolic syndrome;No;Yes
UDP-GNAc-13C13+15N0	ST000076	AN000121	7.600E-3	3.500E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
[13C]-PROLINE	ST000105	AN000173	3.130E-2	3.500E-1	PCOS;No PCOS;PCOS
PYRIDINE CARBOXYLIC ACID	ST000105	AN000174	4.260E-2	3.540E-1	Gender;Female;Male
OHPro-13C2	ST001046	AN001710	1.700E-2	3.540E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
URSINIC ACID	ST000422	AN000668	4.300E-2	3.560E-1	treatment;ND;T1D good glycemic control
BOC-ASP-OH	ST000106	AN000176	1.850E-2	3.570E-1	Visit;1;2
IBUPROFEN CARBOXYLIC ACID (M-H)-	ST000721	AN001128	3.070E-2	3.590E-1	CT findings;Abnormal only;Normal
6-oxopiperidine-2-carboxylic acid	ST000975	AN001596	3.800E-2	3.590E-1	REGION;MAK;SUN
C8-Ceramide m0	ST000644	AN000976	2.290E-2	3.600E-1	group ID;PHGDH;PSAT;PSPH
C8-Ceramide m+14	ST000644	AN000976	2.560E-2	3.600E-1	group ID;PHGDH;PSAT;PSPH
Gentianaine	ST000539	AN000818	2.400E-2	3.640E-1	Glucose labelling;C13 glucose;unlabelled
2-hydroxydecanoate	ST000976	AN001597	1.470E-2	3.710E-1	GROUP;case;control
3-CMPFP**	ST000976	AN001597	1.350E-2	3.710E-1	GROUP;case;control
thymine-d4	ST001192	AN001985	4.910E-2	3.720E-1	Diet;-;Omnivore;Vegetarian
7-Deoxyloganetin	ST000291	AN000464	1.200E-2	3.760E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Fibrinopeptide A (3-15)**	ST000975	AN001596	2.810E-2	3.780E-1	TIMEPOINT;BL;M06;M18
O-methylcatechol sulfate	ST000975	AN001596	2.800E-2	3.780E-1	TIMEPOINT;BL;M06;M18
3-methyl catechol sulfate (1)	ST000975	AN001596	4.800E-2	3.890E-1	REGION;MAK;SUN
CocamidopropylBetaine	ST000913	AN001483	2.650E-2	3.990E-1	Diagnosis;MECFS;MS;ND
6-oxopiperidine-2-carboxylic acid	ST000975	AN001596	3.330E-2	3.990E-1	TIMEPOINT;BL;M06;M18
Lys-Lys-Trp-Pro	ST001204	AN002005	4.690E-2	4.030E-1	treatment_duration_(h);-;3;6;9
BOC-PRO-OH	ST000105	AN000173	3.830E-2	4.040E-1	Gender;Female;Male
alpha-Methylstyrene	ST000403	AN000642	3.800E-2	4.040E-1	timepoint;1 hour;20 hours
bOHbutyrate-13C1	ST001046	AN001710	2.510E-2	4.100E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Arg-Met-Asn-His	ST000539	AN000818	3.400E-2	4.110E-1	Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-Tyr	ST000403	AN000642	4.000E-2	4.140E-1	timepoint;1 hour;20 hours
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000954	AN001564	4.450E-2	4.160E-1	ethnicity;1;2;-
L-Leucine-D10	ST000954	AN001564	4.560E-2	4.160E-1	ethnicity;1;2;-
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000105	AN000174	1.790E-2	4.190E-1	OSA;Negative;Positive
AMINOPENTANOIC ACID	ST000105	AN000174	2.210E-2	4.190E-1	OSA;Negative;Positive
ATP-H2O-13C2+15N0	ST000076	AN000121	1.130E-2	4.230E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C11+15N0	ST000076	AN000121	1.270E-2	4.230E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Asp-Leu-Lys-Asp	ST001204	AN002004	4.380E-2	4.260E-1	treatment;DHA;DMSO;OZ277;OZ439
[Fv] Desmosdumotin C	ST000539	AN000818	3.850E-2	4.280E-1	Glucose labelling;C13 glucose;unlabelled
Acetominophen	ST000913	AN001483	2.550E-2	4.280E-1	Sex;FEMALE;MALE
12-OPDA	ST000403	AN000642	4.810E-2	4.280E-1	timepoint;1 hour;20 hours
Diacetylhydrazine	ST000403	AN000642	5.000E-2	4.280E-1	timepoint;1 hour;20 hours
Cerebroside C	ST000421	AN000665	2.360E-2	4.280E-1	treatment;ND;T1D poor glycemic control
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000106	AN000175	1.330E-2	4.280E-1	Visit;1;2
PYRIDINE CARBOXYLIC ACID	ST000106	AN000175	5.350E-3	4.280E-1	Visit;1;2
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+	ST000823	AN001307	7.090E-3	4.330E-1	Dysplasia;LGD;N/A
ZEATIN [ISTD] (M+H)+	ST000823	AN001307	2.670E-2	4.330E-1	Dysplasia;LGD;N/A
Mannitol;HEXOSE ALCOHOL	ST000954	AN001565	5.860E-3	4.360E-1	ethnicity;1;2;-
ZEATIN [ISTD] (M+H)+	ST000744	AN001163	3.470E-2	4.360E-1	Gender;female;male
GAB-ALL	ST000113	AN000191	2.400E-2	4.370E-1	Oxygen Condition;hypoxia;normoxia
1-octadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	2.120E-2	4.380E-1	treatment_duration_(h);1;5;3
Ganglioside GA1 (d18:1/24:1(15Z))	ST001205	AN002006	2.300E-2	4.380E-1	treatment_duration_(h);1;5;3
L-a-glutamyl-L-Lysine	ST001205	AN002006	1.920E-2	4.380E-1	treatment_duration_(h);1;5;3
DIMETHYLXANTHINE (*)	ST000105	AN000173	4.790E-2	4.390E-1	Gender;Female;Male
H2S2O3	ST001201	AN001999	1.230E-2	4.390E-1	treatment_duration_(h);-;0.5;1.5;3
Chlordiazepoxide	ST000913	AN001483	3.440E-2	4.400E-1	Sex;FEMALE;MALE
1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	2.440E-2	4.400E-1	treatment_duration_(h);1;5;3
3-Butynoate	ST001205	AN002006	2.720E-2	4.400E-1	treatment_duration_(h);1;5;3
L-beta-Homoleucine	ST000913	AN001483	4.910E-2	4.480E-1	Diagnosis;MECFS;MS;ND
3-(a-Naphthoxy)lactic acid glucuronide	ST000421	AN000665	2.860E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Allotetrahydrocortisol	ST000421	AN000665	4.870E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Arachidonyl lysolecithin + 10.70548	ST000421	AN000665	3.160E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Gemeprost	ST000421	AN000665	4.710E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Gemeprost + 11.412178	ST000421	AN000665	4.410E-2	4.500E-1	treatment;ND;T1D poor glycemic control
isoamyl nitrite	ST000421	AN000665	4.000E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Ivermectin B1a + 11.394018	ST000421	AN000665	3.750E-2	4.500E-1	treatment;ND;T1D poor glycemic control
N-HISTIDYL-2-AMINONAPHTHALENE (betaNA)	ST000421	AN000665	3.690E-2	4.500E-1	treatment;ND;T1D poor glycemic control
L-2-Amino-4-(hydroxymethylphosphinyl)butanoate	ST000291	AN000464	1.550E-2	4.620E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
[13C]-VALINE	ST000106	AN000175	3.790E-2	4.680E-1	Constitution;Lean;Obese
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-Serine	ST000954	AN001565	2.210E-2	4.710E-1	ethnicity;1;2;-
3-phosphoglucarate	ST001201	AN001999	1.500E-2	4.840E-1	treatment_duration_(h);-;0.5;1.5;3
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000721	AN001128	1.570E-2	4.850E-1	GOSE;4;5;6;7;8;NA
[13C]-HISTIDINE	ST000042	AN000064	1.660E-2	4.910E-1	Condition;Acute lung injury;Healthy
A-Ketoglutaricacidoxime	ST001201	AN001999	1.790E-2	4.950E-1	treatment_duration_(h);-;0.5;1.5;3
beta-mannosylglycerate	ST000389	AN000625	2.360E-2	5.000E-1	Emphysema/COPD;No;Yes
N-acetylglycine NIST	ST000389	AN000625	1.480E-2	5.000E-1	Emphysema/COPD;No;Yes
UDP-GNAc-13C15+15N0	ST000076	AN000121	1.700E-2	5.030E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
BOC-ASP-OH	ST000105	AN000174	3.820E-2	5.090E-1	OSA;Negative;Positive
BOC-HIS-OH	ST000105	AN000174	3.690E-2	5.090E-1	OSA;Negative;Positive
BOC-MET-OH	ST000105	AN000174	4.610E-2	5.090E-1	OSA;Negative;Positive
1-tetradecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	4.020E-2	5.090E-1	treatment_duration_(h);1;5;3
L-Glutamate methylester	ST000539	AN000818	4.780E-2	5.120E-1	Glucose labelling;C13 glucose;unlabelled
BOC-ASN	ST000106	AN000176	4.560E-2	5.150E-1	Visit;1;2
BOC-ASN-OH	ST000106	AN000176	4.660E-2	5.150E-1	Visit;1;2
DOCOSAPENTAENOATE (*)	ST000106	AN000176	4.330E-2	5.150E-1	Visit;1;2
Arachidonyl lysolecithin	ST000422	AN000667	3.640E-2	5.290E-1	treatment;ND;T1D good glycemic control
Ala-Leu-Trp-Ser	ST001201	AN001998	3.270E-2	5.330E-1	treatment_duration_(h);-;0.5;1.5;3
[13C]-ARGININE	ST000105	AN000173	3.130E-2	5.450E-1	CPAP;No CPAP;After CPAP
BOC-ALA (+NA)	ST000105	AN000173	3.360E-2	5.450E-1	CPAP;No CPAP;After CPAP
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000725	AN001137	2.680E-3	5.560E-1	gender;Female;Male
AMINOHYDROXYBUTANOIC ACID	ST000105	AN000173	4.980E-2	5.620E-1	CPAP;No CPAP;After CPAP
C16 / C16:1	ST000405	AN000645	3.390E-2	5.630E-1	Vaginal Bleeding;N;UNK;Y;-
Cit / Orn	ST000405	AN000645	3.130E-3	5.630E-1	Vaginal Bleeding;N;UNK;Y;-
16a-hydroxy DHEA 3-sulfate	ST000976	AN001597	4.340E-2	5.670E-1	GROUP;case;control
4-Amino-4-deoxychorismate	ST001205	AN002007	2.570E-2	5.810E-1	treatment_duration_(h);1;5;3
IBUPROFEN CARBOXYLIC ACID (M-H)-	ST000743	AN001160	2.820E-2	5.870E-1	Gender;female;male
D1-2-Hydroxymethylethisterone - 13.49303	ST000422	AN000670	1.610E-2	5.900E-1	treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone - 14.2670965	ST000422	AN000670	2.860E-2	5.900E-1	treatment;ND;T1D good glycemic control
Tetrahydrothiophene sulfoxide	ST000422	AN000667	4.530E-2	5.950E-1	treatment;ND;T1D good glycemic control
CBS 113A	ST000291	AN000464	2.240E-2	5.970E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
UDP-GNAc-13C7+15N0	ST000076	AN000121	2.410E-2	5.980E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
S-Methyl-5-thio-D-ribose 1-phosphate	ST001204	AN002005	2.440E-2	5.980E-1	treatment;DHA;DMSO;OZ277;OZ439
C12 / C12:1	ST000405	AN000645	1.850E-2	5.990E-1	Group;No PA;PA;PoolAll
PC aa C28:1 / PC aa C40:2	ST000405	AN000645	4.470E-2	5.990E-1	Group;No PA;PA;PoolAll
Total DMA / Arg	ST000405	AN000645	2.220E-2	5.990E-1	Group;No PA;PA;PoolAll
ATP-H2O-13C0+15N0	ST000076	AN000121	4.080E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C12+15N0	ST000076	AN000121	2.840E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C5+15N0	ST000076	AN000121	4.290E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Bis (2-hydroxypropyl) amine + 5.4315743	ST000422	AN000667	4.990E-2	6.020E-1	treatment;ND;T1D good glycemic control
BOC-ASP-OH	ST000105	AN000174	1.640E-2	6.040E-1	CPAP;No CPAP;After CPAP
N5-acetyl-N5-hydroxy-L-ornithine	ST001201	AN001998	3.930E-2	6.150E-1	treatment_duration_(h);-;0.5;1.5;3
z dioctylphtalate	ST000417	AN001448	2.800E-2	6.220E-1	Collection Time;24HRPOST;Post;Pre
BOC-MET-OH	ST000105	AN000174	3.930E-2	6.250E-1	CPAP;No CPAP;After CPAP
sulfa d18:1 N22:0	ST000362	AN000594	4.230E-2	6.260E-1	Severe_Exacerbations;1;2;3;5;-
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000992	AN001618	2.150E-2	6.470E-1	Smoker;No;Yes
Lactose+K	ST000954	AN001564	3.380E-2	6.520E-1	daily_dose;2;3;4;1
Ferrous lactate	ST000291	AN000465	3.460E-2	6.800E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
2-Phospho-D-glycerate	ST001201	AN001999	3.020E-2	6.950E-1	treatment_duration_(h);-;0.5;1.5;3
Nitro-Tyr1)	ST000783	AN001239	3.570E-2	7.020E-1	RACE;AA;EA
N-Acetylanthranilate	ST001205	AN002007	4.490E-3	7.090E-1	treatment;DHA;DMSO;OZ277;OZ439
M1	ST000291	AN000464	3.330E-2	7.190E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
16-Oxo-palmitate	ST000248	AN000392	2.740E-2	7.260E-1	Cell population;Fast-cycling cells;Slow-cyling cells
4-keto pentadecanoic acid	ST000248	AN000392	4.080E-2	7.260E-1	Cell population;Fast-cycling cells;Slow-cyling cells
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+	ST000823	AN001307	3.450E-2	7.330E-1	Diagnosis;IPMN;MCN;SCA
Caffeine-D3	ST000424	AN000673	3.630E-2	7.400E-1	SEX;F;M
Phenolsulfonphthalein	ST001201	AN001999	3.910E-2	7.400E-1	treatment_duration_(h);-;0.5;1.5;3
AMINOHYDROXYBUTANOIC ACID	ST000041	AN000063	3.160E-2	7.450E-1	Visit;1;2;3;4;5;6;7
Asn-Leu-Pro-Pro	ST001202	AN002000	3.860E-3	7.780E-1	treatment;DHA;DMSO;OZ277;OZ439
Creatine-D3	ST000954	AN001564	1.800E-2	7.810E-1	diplotype;1;2
Dichlorophen	ST000291	AN000464	4.080E-2	8.100E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
iodoacetate	ST001204	AN002005	4.410E-2	8.320E-1	treatment;DHA;DMSO;OZ277;OZ439
bOHbutyrate-13C00	ST000951	AN001560	2.720E-2	9.040E-1	cell_type;CD8_T_memory;CD8_T_naive;NK
O-Acetyl-Lcarnitine:HCl (N-methyl-D3)	ST000552	AN000843	3.230E-2	9.420E-1	VTE;no;yes
monohexsph	ST000362	AN000594	2.420E-2	9.440E-1	SmokingStatus;-;1
lathosterol NIST	ST000383	AN000618	2.330E-2	9.680E-1	UCP-3 Polymorphism;g/a;g/g
Ala-Ala-Ala-Ser	ST001205	AN002006	4.320E-2	9.990E-1	treatment;DHA;DMSO;OZ277;OZ439
cis-Acetylacrylate	ST001205	AN002007	3.440E-2	1.000E+0	treatment;DHA;DMSO;OZ277;OZ439
2-Propylisonicotinic acid	ST000422	AN000669	2.590E-2	1.000E+0	treatment;ND;T1D good glycemic control
isoamyl nitrite	ST000422	AN000669	1.970E-2	1.000E+0	treatment;ND;T1D good glycemic control

( Species:Human)
List of studies, analyses, submitted metabolite names, experimental conditions and RSD values

Replicate numbers reflect the number of replicates for each experimental condition where the measured value was not null

Name	Study_id	Analysis_id	Factors	Range(RSD)	Replicates